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 Abstract 
L'invecchiamento è associato ad una progressiva diminuzione della capacità delle β-
cellule del pancreas a secernere insulina. Con l'invecchiamento, inoltre, la densità dei recettori 
adrenergici β (βARs), in particolare il β2AR, diminuisce. Per valutare il ruolo dei β2AR nel 
rilascio di insulina e nell'omeostasi del glucosio sono stati condotti degli esperimenti in vivo, in 
topi con delezione del β2AR (β2AR-/-) a diverse età, ex vivo, in insulae isolate e in vitro, in β-
cellule di insulinoma di ratto silenziate (shRNA) per il β2AR.  
Si è dimostrato per la prima volta che la densità del β2AR a livello del pancreas 
diminuisce nel tempo negli animali wild-type (β2AR+/+). Inoltre, gli animali β2AR-/- a 6 mesi di 
età evidenziano una ridotta produzione di insulina ed un’intolleranza al glucosio. Tali 
caratteristiche sono evidenziabili anche in β2AR+/+ anziani (20 mesi). Questi risultati sono stati 
confermati anche ex vivo ed in vitro. È interessante notare inoltre, che l'infezione adenovirale di 
β2AR in animali knock-out per il β2AR è in grado di ripristinare il normale rilascio di insulina. È 
evidente, quindi, che i risultati ottenuti indicano che il β2AR gioca un ruolo fondamentale nel 
rilascio di insulina. I topi β2AR-/-, riproducendo le caratteristiche metaboliche degli animali 
β2AR+/+ anziani, rappresentano un modello di invecchiamento utile per lo studio del diabete 
mellito. 
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Introduzione 
La compromissione del metabolismo del glucosio e l’invecchiamento rappresentano 
fattori determinanti per lo sviluppo del diabete mellito. Sebbene i processi fisiopatologici alla 
base di questo fenomeno non siano ancora completamente noti, si ipotizza che alla base vi sia una 
concomitanza di cause piuttosto che un unico meccanismo coinvolto (1; 2). L'invecchiamento è 
già di per sé associato ad una diminuzione del rilascio di insulina (3; 4). Infatti, l’incidenza 
dell'età sul rilascio dell’insulina è tale da aumentare la probabilità di intolleranza al glucosio ed 
infine di diabete (2; 5). Questo fenomeno è comune a diverse specie, in quanto è stato osservato 
sia nel ratto (6; 7) che negli esseri umani (5; 8; 9). Nonostante ciò, il motivo di una ridotta 
secrezione insulinica da parte delle cellule β-pancreatiche, legata all’avanzare dell'età, non è 
ancora noto. 
Le catecolamine rappresentano un fine regolatore dell'attività del pancreas endocrino, mediante i 
recettori α e β adrenergici (ARs) (10; 11). Per di più, la stretta connessione tra il sistema 
adrenergico e l'insulina è testimoniata da numerosi studi che mostrano la regolazione reciproca di 
questi due sistemi (12-14). Questa ipotesi è supportata da recenti lavori che mostrano che i topi 
con delezione dei tre geni conosciuti per i βARs, vale a dire β1, β2 e β3AR, presentano un fenotipo 
caratterizzato da ridotta tolleranza al glucosio (15). Studi con agonisti del β2AR suggeriscono, 
inoltre, che esso possa svolgere un ruolo importante nella regolazione della secrezione insulinica 
(16). Diversi polimorfismi del gene umano β2AR sono stati associati ad alti livelli di insulina a 
digiuno (17). Tuttavia, l’impatto del sottotipo β2AR sulla tolleranza al glucosio e la secrezione 
insulinica non è del tutto chiaro. 
È interessante notare che anche il signaling AR è influenzato negativamente dall’invecchiamento 
(18-21), ma i precisi meccanismi coinvolti sono tuttora sconosciuti. In particolar modo il 
signaling βAR appare alterato con l'avanzare dell’età, con dei cambiamenti nell'espressione dei 
componenti molecolari coinvolti nel signaling (22-25). Si è quindi ipotizzato che le alterazioni 
dovute all’invecchiamento abbiano un ruolo negativo sul βAR ed il rilascio dell’insulina. Per 
verificare tale ipotesi si è analizzata la secrezione insulinica in animali β2AR knock-out e si è 
indagato il ruolo dell’invecchiamento sulla tolleranza al glucosio.  
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Materiali e metodi 
 
Studi in vivo 
Animali 
Sono stati studiati topi maschi C57BL/6J con delezione omozigote del gene β2AR (β2AR-/-). 
I founders di tali animali sono stati gentilmente forniti da Brian Kent Kobilka, Stanford 
University, Stanford, CA, USA (26). I wild-type (β2AR+/+) sono stati utilizzati come controlli. Gli 
animali sono stati collocati in una stanza ad una temperatura di 22°C con un ciclo luce/buio 
12/12h in conformità con la Guida per la Cura di animali da laboratorio pubblicato dal National 
Institute of Health negli Stati Uniti (NIH Publication N. 85 - 23, riveduta nel 1996) e approvato 
dal Comitato Etico dell'Università “Federico II” di Napoli. I pancreas sono stati asportati 
rapidamente dopo eutanasia degli animali. I campioni sono stati processati, fissati per immersione 
in paraformaldeide al 4% per l'istologia, omogeneizzati per la determinazione del contenuto 
totale di insulina e glucagone o congelati in azoto liquido e conservati a -80°C per successive 
analisi (10; 27). 
Test di tolleranza al glucosio (GTT) e valutazione della secrezione di insulina 
Il GTT è stato eseguito come descritto in precedenza (28). I topi sono stati tenuti a 
digiuno durante la notte e al mattino è stata effettuata un’iniezione intraperitoneale di glucosio (2 
g/kg). La glicemia è stata misurata mediante prelievo di sangue dalla coda (Glucose Analyzer II, 
Beckman Coulter, Brea, CA, USA) ai tempi indicati. La valutazione della secrezione di insulina è 
stata eseguita come descritto in precedenza (27; 28). L’insulina nel siero è stata valutata su 
sangue prelevato dalla vena mandibolare mediante test radio-immunologici (RIA, Millipore, 
Billerica, MA, USA).  
Determinazione della sensibilità insulinica (clamp) 
 Il clamp euglicemico-iperinsulinemico è stato eseguito mediante infusione endovenosa 
(catetere impiantato in giugulare) di insulina (velocità costante) e di glucosio (velocità variabile) 
in modo da mantenere costanti (clampare) livelli euglicemici. L’infusione di insulina consente di 
raggiungere elevate concentrazioni ematiche dell’ormone in grado di sopprimere la produzione 
epatica di glucosio; in tali condizioni l’unica fonte di glucosio è rappresentata dall’infusione 
esogena, che viene regolata sulla base di frequenti determinazioni glicemiche, in modo da 
mantenere costante la glicemia. Le misurazioni dei livelli ematici di glucosio e traccianti sono 
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state eseguite su sangue arterioso prelevato da una cannula precedentemente impiantata in 
carotide destra. Gli interventi chirurgici di cateterizzazione di giugulare sinistra e carotide destra, 
con successiva dorsalizzazione subcutanea delle cannule, sono stati eseguiti almeno cinque giorni 
prima dell’effettuazione del clamp. Abbiamo quindi misurato i seguenti parametri: produzione 
epatica di glucosio (PEG), velocità di infusione del glucosio (VIG), indicativa dell’azione 
dell’insulina sull’intero organismo, velocità di eliminazione del glucosio (VEG), essenzialmente 
legato all’uptake periferico. 
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Studi ex vivo 
 
Analisi istologica  
L’immunoistochimica è stata effettuata su sezioni in paraffina probate con anticorpi 
specifici per insulina (H38 rabbit) e glucagone (N-17 goat) (entrambi da Santa Cruz 
Biotechnology, Santa Cruz, CA, USA; diluizione 1:200). L’anti-rabbit (made in goat) legato a 
perossidasi (Immunotech, Marsiglia, Francia) è stato usato come anticorpo secondario. Dopo 
l'esposizione all’anticorpo primario, le sezioni sono state incubate con immunoglobuline G anti-
rabbit e anti-goat biotinilate e con perossidasi-streptavidina (Dako Corporation; Danimarca). 
Tutte le reazioni sono state rivelate con diaminobenzidina (29). Le sezioni sono state colorate con 
ematossilina e montate (30). 
Isolamento di insulae pancreatiche e valutazione della secrezione di insulina.      
L’isolamento di insulae pancreatiche murine è stato ottenuto mediante digestione con 
collagenasi P (Roche Applied Sciences, Penzberg, Germania) a 37°C agitando la preparazione 
per 5-8 minuti (27; 31; 32). Le insulae sono state raccolte e poi coltivate a 37°C con 95% di O2 e 
il 5% di CO2 in mezzo Roswell Park Memorial Institute (RPMI 1640), integrato con 5% di siero 
fetale bovino, 1 mmol/L di sodio piruvato, 50 µmol/L 2-mercaptoetanolo, 2mMol/L glutammina, 
10mmol/L HEPES, 100 U/ml penicillina e 100 µg/ml di streptomicina (tutti da Sigma-Aldrich, 
Milano, Italia), come descritto (28; 32). 
Le insulae isolate sono state preincubate a 37°C per 30 minuti in Krebs-Ringer bicarbonato 
(KRBB: 120mMol/L di NaCl, 4.7 mmol/L di KCl, 1.2 mmol/L MgSO4, 1.2 mmol/L KH2PO4, 2.4 
mMol/LCaCl2, 20 mMol/LNaHCO3) integrate con 10 mmol/L HEPES e 0,2% di albumina sierica 
bovina e ossigenate con una miscela di 95% O2 e 5% CO2 contenente 2 mmol/L di glucosio. Le 
insulae sono state incubate per 1 ora a 37°C con 500 µl di KRBB contenente glucosio 2,8 
mmol/L o 16,7 mmol o 33mMol/L KCl. Le insulae sono state poi centrifugate (9000g, 2 minuti, 
4°C) per valutare la secrezione di insulina (32). 
Reinstallazione di β2AR in vivo ed ex vivo (gene delivery) 
I topi β2AR+/+ di 20 mesi sono stati anestetizzati con isoflurano (4%) e mantenuti in 
anestesia mediante ventilazione in maschera (isofluorano 1,8%) (29). In seguito a minima 
laparotomia, si è identificato e immobilizzato il pancreas ed e’ stata effettuata una iniezione 
intraduttale di adenovirus (7 × 1010 pfu) utilizzando un ago 33 Gauge. Sono stati impiegati 
8 
 
adenovirus esprimenti il β2AR umano (Adβ2AR) o, come controllo, una cassetta di espressione 
vuota derivata da pcDNA3.2/V5/GW/D-mouse (AdEmpty), per gentile dono di Walter J. Koch, 
Temple University, Philadelphia, PA, USA (33; 34). Infine, l’incisione addominale è stata chiusa 
a strati utilizzando fili di sutura di seta 3/0 e gli animali sono stati osservati e monitorati fino al 
recupero. 
Le insulae isolate sono state infettate con Adβ2AR o AdEmpty. A seguito di tre ore di 
incubazione con l'adenovirus (12 × 104 pfu/insula), le insulae pancreatiche sono state poste in 
mezzo fresco in condizioni normossiche (95% di O2, 5% CO2) a 37°C per 24 ore. 
  
9 
 
Studi in vitro  
Le cellule INS-1E, derivate e selezionate dalla linea parentale di insulinoma di ratto INS-
1, sono state poste in coltura monostrato in RPMI-1640 come sopra descritto per gli esperimenti 
ex vivo. Per i test di secrezione di insulina, le cellule sono state piastrate ad una densità di 5x105 
cellule/cm2 almeno 96 ore prima dell'uso (28). La trasfezione del cDNA codificante per PPARγ e 
il plasmide di controllo vuoto sono state eseguite utilizzando Lipofectamine 2000 (Life 
Technologies, Norwalk, CT, USA), come descritto (33). 
Short hairpin RNA (shRNA): progettazione, produzione e trasfezione  
Sono stati disegnati degli shRNA specifici per il β2AR, poi sintetizzati da Life 
Technolgies (Norwalk, CT, USA). Le cellule INS-1E sono state transfettate con 100 nmol/L sh-
RNA β2AR o sh-RNA scramble utilizzando Lipofectamine 2000 secondo le istruzioni del 
produttore (Life Technologies, Norwalk, CT, USA). Dopo 20 minuti di incubazione, la miscela di 
trasfezione è stata aggiunta alle cellule in 6 piastre contenenti 2 ml di mezzo RPMI-1640 fresco, 
privo di siero. Le cellule sono state quindi incubate per 5 ore a 37°C, 5% CO2, ed il mezzo di 
trasfezione è stato sostituito con il mezzo condizionato. Tutti i test successivi sono stati effettuati 
almeno 3 giorni dopo la trasfezione del shRNA. 
Radioligand binding assay 
Su frazioni di membrana di tessuto pancreatico, insulae isolate e cellule INS-1E sono stati 
utilizzati radioligandi per studi di binding utilizzando una quantità saturante dell’antagonista βAR 
[125I]-Cyanopindolol (PerkinElmer, Monza, Italia), come descritto in precedenza (35; 36).  
Quantitative real-time RT-PCR e immunoblotting 
L’RNA cellulare totale è stato isolato da insulae pancreatiche e campioni di tessuto, 
utilizzando il kit RNasy (Qiagen, Hilden, Germania) in base alle istruzioni del produttore (28). I 
valori di PCR sono stati analizzati utilizzando platinum SYBR green (Life Technologies, 
Norwalk, CT, USA). Le reazioni sono state eseguite in triplicato (30) utilizzando iCycler IQ Real 
Time PCR Detection System (Biorad, Hercules, CA, USA). La ciclofilina è stata utilizzata come 
standard interno (32; 37). Il western blot è stato effettuato come descritto in precedenza (35; 36). 
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Analisi statistica  
Tutti i dati sono presentati come media±errore standard (ES). Le differenze statistiche 
sono state determinate mediante test ANOVA a una o due vie, seguito da test di Bonferroni ove 
applicabile. Un valore di p inferiore a 0,05 è stato considerato significativo. Tutte le analisi 
statistiche e la valutazione dei dati sono state eseguite utilizzando GraphPad Prism versione 6.00 
(GraphPad Software, San Diego, CA, USA). 
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Risultati  
Fenotipo metabolico di animali privi del β2AR-/- 
Per studiare in vivo il ruolo del gene codificante per il β2AR nella regolazione della 
secrezione di insulina, si sono confrontati i fenotipi metabolici di topi adulti (6-mesi) β2AR-/- e 
β2AR+/+. Da questa comparazione si è evinto che la concentrazione di glucosio nel sangue è 
significativamente più alta nei topi in cui il gene è deleto rispetto ai wild type, sia a digiuno che 
in condizioni di alimentazione random. Inoltre, nei topi β2AR-/ - i livelli di insulina plasmatica a 
digiuno sono significativamente ridotti. I dati dagli esperimenti di carico di glucosio (GTT) 
riportano che i topi β2AR-/- mostrano una marcata riduzione della tolleranza al glucosio e dei 
livelli sierici di insulina (Fig. 1A-D). Inoltre è ridotto il rapporto tra picco di insulina/picco di 
glucosio (Fig. 1E), ciò indica un’alterata funzione β-cellulare. Il clamp iperinsulinemico 
euglicemico mostra che l’animale KO ha un’elevata sensibilità all’insulina (VIG: β2AR+/+ 
12±4mg/kg/min vs β2AR-/-31±6mg/kg/min; VEG: β2AR+/+ 92±7 mg/kg/min vs β2AR-/- 
66±5mg/kg/min). I valori registrati a livello epatico (PEG: β2AR+/+ 74±5mg/kg/min vs β2AR-/- 
45±3mg/kg/min) suggeriscono un ruolo chiave per il β2AR anche nel fegato. Ulteriori studi sono 
attualmente in corso nei nostri laboratori per approfondire questo aspetto. 
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Figura 1 
 
FIG. 1. Profilo metabolico di topi β2AR-/-. 
Topi di sei mesi β2AR-/- e β2AR+/+ a seguito di 16 ore di digiuno, sono stati sottoposti a carico di glucosio intraperitoneale (2g/kg 
peso corporeo). AD: I livelli di glicemia (A, B) e i livelli sierici di insulina (C, D) sono stati monitorati per 120 e 30 minuti, 
rispettivamente, dopo somministrazione di glucosio (n = 12-16 animali per gruppo). Visualizzazione dell’intolleranza al glucosio 
(A) e della ridotta secrezione di insulina (C) nei topi β2AR-/-. Abbiamo calcolato l'AUC dal glucosio (B), e le curve di escursione 
insulinica (D). E: il rapporto picco di insulina/picco di glucosio rappresenta la funzione β-cellulare. *: P <0,05 vs β2AR+/+; le barre 
rappresentano la media±ES; AUC indica l'area sotto la curva. 
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L’istologia delle insulae pancreatiche non ha mostrato alcuna differenza significativa tra questi 
topi (Fig. 2A), e la concentrazione di insulina e glucagone è simile negli animali wild-type e nei 
knock-out (Fig. 2B-C). 
Un ulteriore quesito è se l'ulteriore riduzione della secrezione di insulina che si osserva nei topi 
β2AR-/- in vivo sia dovuta ad una conseguenza diretta della mancanza del β2AR a livello delle β-
cellule pancreatiche o se sia indirettamente mediato da altri fattori di regolazione. Per rispondere 
a questa domanda, si è analizzato ex vivo l’effetto del glucosio su insulae pacreatiche isolate dai 
topi β2AR-/-. Come mostrato in fig. 2D, queste insulae rispondono in maniera non ottimale al 
glucosio rispetto alle insulae prelevate dai topi wild-type, ma restano sensibili alla 
depolarizzazione KCl-mediata.  
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Figura 2  
 
FIG. 2. Morfologia e funzionalità di isole pancreatiche β2AR+/+ e β2AR-/- 
A: L’analisi Immunoistochimica delle isole è stata effettuata su sezioni di paraffina con insulina (colonna a sinistra) 
o glucagone (colonna di destra). Le microfotografie sono rappresentative di immagini ottenute da sezioni di pancreas 
di cinque topi β2AR+/+ (riga superiore) o β2AR-/- (fila inferiore). B, C: contenuto di insulina (B) e glucagone (C) in 
insulae da topi β2AR+/+ (n = 10) o β2AR-/- (n = 13). D: La secrezione di insulina in risposta a glucosio (16,7 mmol/L) 
o KCl (33 mmol/L) è stata misurata in insulae da topi β2AR+/+ (barre bianche) e β2AR-/- (barre nere). Le barre 
rappresentano la media±ES di dati provenienti da dieci topi per gruppo. *: P <0,05 vs β2AR+/+; test di Bonferroni 
post hoc.  
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Profilo di espressione genica nelle β-cellule con delezione del β2AR-/- 
Per ottenere una visione più completa del meccanismo alla base della ridotta secrezione 
insulinica in topi privi del β2AR, si sono valutati i profili di espressione di diversi geni rilevanti 
per la regolazione delle β-cellule pancreatiche mediante real-time RT-PCR (mRNA) e western-
blot (proteine). Come mostrato in Fig. 3, i livelli PDX-1 che di GLUT2, due geni coinvolti nella 
funzione delle β cellule, sono diminuiti del 75 e del 60% nelle insulae dei topi β2AR-/- . Inoltre, i 
livelli di PPARγ sono diminuiti del 54% rispetto ai topi wild-type.  
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Figura 3 
 
FIG.3 Profilo di espressione genica in insulae isolate da topi β2AR+/+ e β2AR-/-. 
Livelli di mRNA (A-C) e proteine (D, E) per PDX-1, GLUT 2 e PPARγ. L’abbondanza di mRNA è stata determinata 
mediante real-time RT-PCR di RNA totale, utilizzando ciclofilina come standard interno. I livelli di mRNA in topi 
β2AR-/- sono relativi a quelli degli animali di controllo. Ogni banda rappresenta la media±ES di quattro esperimenti 
indipendenti in ciascuno dei quali le reazioni sono state eseguite in triplicato utilizzando il pool di RNA totale da 
cinque topi/genotipo. *: P <0,05 vs β2AR+/+; AU rappresenta unità arbitrarie.  
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Si è quindi cercato di comprendere se queste anomalie nell'espressione genica siano direttamente 
causate dall’assenza del β2AR. Per perseguire questo obiettivo, si è silenziato con uno specifico 
shRNA il gene β2AR in linee cellulari INS-1E (INS-1Eshβ2AR, Fig. 4A and B). Come mostrato in 
fig. 4C, la secrezione insulinica glucosio-indotta è ridotta del 58% nelle cellule silenziate rispetto 
alle cellule di controllo. Coerentemente con i nostri risultati ex vivo, le cellule INS-1Eshβ2AR 
mostrano una riduzione dei livelli di mRNA dei geni PDX-1, GLUT2 e PPARγ (Fig. 4D-F). È 
interessante notare che le cellule INS-1Eshβ2AR trasfettate in seguito con cDNA codificante per 
PPARγ aumentano transitoriamente la secrezione insulinica glucosio-indotta rispetto alle cellule 
di controllo (Fig. 4C). Inoltre, l'overespressione di PPARγ evita la down-regulation di PDX-1 e 
GLUT2 in cellule INS-1Eshβ2AR (Fig. 4D ed E). 
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Figura 4 
 
 
FIG. 4. Livelli del β2AR,  secrezione insulinica glucosio-indotta e profilo di espressione genica in β-cellule 
β2AR silenziate. 
Il trattamento con uno specifico β2AR-shRNA diminuisce significativamente la densità (da 73,7%, A) e i livelli di 
mRNA (da 59,1%, B) di β2AR in β-cellule INS-1E. β2AR-shRNA inibisce la risposta secretoria insulinica a 16,7 
mmol/L di glucosio, che viene ripristinata dalla overespressione di PPARγ (C). Il rilascio di insulina KCl indotto (C) 
non e’ significativamente differente tra i gruppi studiati. β2AR-shRNA determina anche una significativa riduzione 
del livello di mRNA di PDX-1 (D), GLUT2 (E) e PPAR (F), che non e’ piu’ presente dopo overespressione di 
PPARγ. L’espressione genica e’ stata inoltre valutata a livello proteico (G, H). Le barre rappresentano la media±ES. 
4-5 esperimenti indipendenti in ciascuno dei quali le reazioni sono state effettuate in triplicato (  : controllo, i.e. 
cellule INS-1E non trattate;  : sh-scramble;  : sh-scramble+empty vector;  : sh-β2AR;  : sh-β2AR+PPARγ; 
*: p <0,05 vs controllo; basale indica glucosio 2,8 mmol/L). 
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Questi risultati mostrano che l’assenza del β2AR è responsabile, attraverso un meccanismo 
mediato almeno in parte da PPARγ, della diminuita secrezione di insulina età-dipendente (Fig. 
4D-F). 
L’overespressione del β2AR ex vivo ripristina l’alterato rilascio di insulina 
L'espressione del β2AR risulta significativamente diminuita nelle insulae di topi β2AR+/+ di 20 
mesi rispetto a quelle isolate da topi di 6 mesi sia in esperimenti di binding recettoriale che alla 
real-time RT-PCR (Fig. 5A and B). A livello delle insulae pancreatiche di topi β2AR+/+ anziani i 
livelli di espressione di PDX-1, GLUT2 and PPARγ sono ridotti cosi come è ridotta la secrezione 
insulinica glucosio-indotta, mentre non è ridotta quella mediata dalla depolarizzazione indotta dal 
KCl (Fig. 5C-F).  
Questi dati suggeriscono una ridotta espressione del β2AR a livello delle insulae pancreatiche in 
questi animali. Per dimostrare questa ipotesi, le insule sono state trattate ex vivo con un 
adenovirus esprimente il β2AR umano (Adβ2AR). In questo modo, si ottiene un miglioramento 
significativo della secrezione di insulina glucosio-indotta, fino a livelli paragonabili a quelli di 
insulae di animali adulti di 6 mesi (Fig. 5C), cosi come sono ripristinate le espressioni di PDX-1, 
GLUT2 e PPARγ (Fig. 5D-F).  
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Figura 5 
 
FIG. 5. Il gene delivery del β2AR ripristina il deterioramento età-dipendente della funzione β-cellulare. 
Densità (A) e livelli di mRNA (B) di β2AR sono stati valutati sulle membrane delle cellule di isole isolate da topi 
β2AR+/+. Il rilascio di insulina (C) è stato determinato a seguito di esposizione alla concentrazione indicata di 
glucosio o di KCl. I livelli di mRNA di PDX-1 (D), GLUT2 (E) e PPAR (F) sono stati determinati mediante Real-
time RT-PCR utilizzando il pool di RNA totale da cinque topi/gruppo con ciclofilina come standard interno. 
L’espressione genica è stata inoltre valutata a livello proteico (G, H). AdEmpty: insulae infettate con un adenovirus 
di controllo; Adβ2AR: insulae infettate con un adenovirus che codifica per il gene β2AR umano. Ogni barra 
rappresenta la media ± ES di cinque esperimenti indipendenti in ciascuno dei quali le reazioni sono state eseguite in 
triplicato. (  : 6 mesi;  : 20 mesi;  : 20 mesi Adempty; : 20 mesi Adβ2AR; *: p <0,05 vs 6 mesi; 
basale indica glucosio 2,8 mmol/L).*: p <0,05 vs β2AR+/+6 mos; mos indica mesi di età. 
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Effetti dell’iniezione intrapancreatica dell’Adenovirus Adβ2AR sull’omeostasi del glucosio 
I topi β2AR+/+ di 20 mesi di età mostrano una significativa riduzione dei livelli sierici di insulina 
a digiuno accompagnata da ridotta tolleranza al glucosio e ridotta risposta insulinica dopo GTT 
(Fig. 6A-E). Si è quindi ideato un protocollo di terapia genica per dimostrare il concetto che 
queste anomalie possano essere corrette mediante il ripristino della densità β2AR. Di 
conseguenza, dopo aver infettato il pancreas di topi mediante iniezione intraduttale di Adβ2AR, si 
è ripristinata l’espressione di β2AR nel tessuto pancreatico, che è tornata a livelli paragonabili a 
quella di topi di 6 mesi. L'effetto è evidenziabile anche con un significativo miglioramento della 
tolleranza al glucosio e della secrezione di insulina a seguito di GTT (Fig. 6A-E). 
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Figura 6 
 
FIG. 6. Il trasferimento genico del β2AR adenovirus-mediato nel pancreas ripristina la riduzione della 
tolleranza al glucosio legata all'età. 
Livelli di glucosio nel sangue (A) e livelli sierici di insulina (C) dopo 120 e 30 minuti dalla somministrazione di 
glucosio, rispettivamente (n = 12-16 animali per gruppo). Sono state calcolate le AUC del glucosio (B) e 
dell’insulina (D). i topi β2AR+/+ di 20 mesi di età hanno mostrato intolleranza al glucosio (A, B), ridotta secrezione di 
insulina (C, D) e anche un’alterata funzione β-cellulare, valutata misurando il rapporto picco di insulina / picco di 
glucosio (E). Tutti questi parametri sono stati ripristinati dopo infezione del Adβ2AR in vivo. *: p <0,05 vs β2AR+/+ 6 
mos; mos indica mesi di età; AUC indica l'area sotto la curva.  
23 
 
I livelli di insulina a digiuno sono aumentati, raggiungendo valori simili a quelli misurati in topi 
di 6 mesi, sottolineando ulteriormente l'importanza della funzione del β2AR per consentire un 
adeguata risposta all’iperglicemia a livello delle β-cellule pancreatiche.  
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Discussione 
Nel presente elaborato di tesi, si mostra che l’assenza del gene β2AR provoca la riduzione del 
rilascio di insulina glucosio-indotta da parte delle β-cellule pancreatiche. Questo fenotipo ricorda 
quello osservato nei topi con delezione del gene Gas a livello delle β-cellule pancreatiche (27). In 
questi topi, però, sono evidenti gravi anomalie delle insulae pancreatiche. È interessante notare 
che, a livello delle insulae di β2AR-/-, i livelli di espressione di PPARγ sono significativamente 
down-regulati insieme ad una ridotta espressione di PDX-1 e GLUT2, due geni fondamentali per 
la funzionalità delle β-cellule pancreatiche (31; 38; 39). Questi meccanismi, oltre ad essere stati 
dimostrati nell’animale KO per il gene β2AR sono stati supportati anche da studi in vitro condotti 
sulle β-cellule pancreatiche INS-1E. Tali studi mostrano che il silenziamento del β2AR altera la 
risposta al glucosio e inibisce l’espressione di PPARγ riducendo anche i livelli di PDX-1 e 
GLUT2. Questi dati indicano che β2AR controlla la secrezione di insulina, almeno in parte 
attraverso questo pathway. A riprova di ciò, in questa tesi si è dimostrato che l'overespressione di 
PPARγ nelle β-cellule INS-1E silenziate per il β2AR porta al recupero dei livelli di PDX-
1/GLUT2 e della secrezione di insulina stimolata dal glucosio. A supporto di questa visione, 
numerose evidenze suggeriscono un’interconnessione tra β2AR e PPAR γ (38; 40-42), un 
elemento chiave nel processo di secrezione di insulina, recentemente studiato anche 
nell'invecchiamento (39; 43).  
Se e in che misura il knock-out del gene β2AR nel fegato e nei tessuti periferici colpisca 
l’omeostasi del glucosio deve essere ancora approfondito. Infatti, variazioni a livello del locus 
β2AR sono state associate a resistenza insulinica nei pazienti diabetici tipo 2 (17). Tuttavia, come 
mostrato in questo elaborato di tesi, l’alterata tolleranza al glucosio degli animali β2AR-/- appare 
essere essenzialmente dovuta a una disfunzione delle β-cellule. 
Negli esseri umani, la tolleranza al glucosio diminuisce con l'età, con una conseguente elevata 
prevalenza di diabete mellito e di ridotta tolleranza al glucosio nella popolazione anziana (2; 9). 
Come la tolleranza al glucosio peggiori nel tempo a livello individuale rimane poco chiaro, ma è 
probabilmente determinato da molteplici fattori tra cui la diminuzione della secrezione di insulina 
(3; 4; 8). Nei modelli animali e nell'uomo, è stato documentato un progressivo deterioramento 
della funzione β-cellulare con l'età (5; 6). Similmente a risultati evidenziati in diversi tessuti 
umani (19-22; 44-46), a questi cambiamenti si accompagnano livelli ridotti del β2AR in insulae 
pancreatiche murine da noi riscontrati.  
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La diminuzione dell’espressione del β2AR in insulae di animali anziani ricapitola gli stessi 
meccanismi che portano alla compromissione della secrezione insulinica registrata in roditori 
privi del β2AR. Ciò indica ancora una volta che vi è una correlazione tra l’invecchiamento e la 
compromissione della tolleranza al glucosio. Infatti, esperimenti sia in vivo che ex vivo di terapia 
genica attuata mediante trasferimento del β2AR hanno rivelato che il recupero di livelli normali 
del β2AR ripristina il rilascio di insulina e la tolleranza al glucosio negli animali anziani. Così, nel 
modello murino il progressivo declino dell’espressione del β2AR a livello delle insulae sembra 
contribuire alla riduzione della tolleranza al glucosio che accompagna l'invecchiamento. Se lo 
stesso meccanismo sia applicabile anche negli esseri umani è attualmente in corso di studio. 
 
Conclusioni 
Il β2AR regola fisiologicamente la secrezione di insulina da parte delle β-cellule pancreatiche 
modulando la funzione PPARγ/PDX-1/GLUT2. L’espressione ridotta del β2AR contribuisce 
all’alterazione età-dipendente della tolleranza al glucosio.  
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Age-Related Impairment in Insulin Release
The Essential Role of b2-Adrenergic Receptor
Gaetano Santulli,1,2 Angela Lombardi,3,4 Daniela Sorriento,1 Antonio Anastasio,1 Carmine Del
Giudice,1 Pietro Formisano,4 Francesco Béguinot,4 Bruno Trimarco,1 Claudia Miele,4 and
Guido Iaccarino5
In this study, we investigated the signiﬁcance of b2-adrenergic
receptor (b2AR) in age-related impaired insulin secretion and
glucose homeostasis. We characterized the metabolic phenotype
of b2AR-null C57Bl/6N mice (b2AR
2/2) by performing in vivo and
ex vivo experiments. In vitro assays in cultured INS-1E b-cells
were carried out in order to clarify the mechanism by which
b2AR deﬁciency affects glucose metabolism. Adult b2AR
2/2 mice
featured glucose intolerance, and pancreatic islets isolated from
these animals displayed impaired glucose-induced insulin release,
accompanied by reduced expression of peroxisome proliferator–
activated receptor (PPAR)g, pancreatic duodenal homeobox-1
(PDX-1), and GLUT2. Adenovirus-mediated gene transfer of hu-
man b2AR rescued these defects. Consistent effects were
evoked in vitro both upon b2AR knockdown and pharmacologic
treatment. Interestingly, with aging, wild-type (b2AR
+/+) littermates
developed impaired insulin secretion and glucose tolerance. More-
over, islets from 20-month-old b2AR
+/+ mice exhibited reduced
density of b2AR compared with those from younger animals, par-
alleled by decreased levels of PPARg, PDX-1, and GLUT2. Over-
expression of b2AR in aged mice rescued glucose intolerance and
insulin release both in vivo and ex vivo, restoring PPARg/PDX-1/
GLUT2 levels. Our data indicate that reduced b2AR expression
contributes to the age-related decline of glucose tolerance in
mice. Diabetes 61:692–701, 2012
Impairment of glucose metabolism with age repre-sents a major determinant of type 2 diabetes epi-demics within the elderly population. The molecularmechanisms underlying these changes have not been
fully elucidated and are likely attributable to multiple
causes (1,2). Aging per se is associated with a continuous
decrease in basal insulin release (3). The size of this effect
is sufﬁcient to increase the likelihood of developing ab-
normalities in glucose tolerance and even overt diabetes
(2,4). The consequence of aging on glucose tolerance
occurs in different species, having been identiﬁed in rats
(5,6) as well as in humans (4,7,8). However, why insulin
secretion deteriorates with aging remains a moot point.
The noradrenergic system provides ﬁne-tuning to the
endocrine pancreas activity through the function of a- and
b-adrenergic receptors (ARs) (9,10). The reciprocal regu-
lation exerted by insulin and the adrenergic system has
been well documented through a large number of studies
(11–13). More recent evidence shows that mice with si-
multaneous deletion of the three known genes encoding
the bARs (b1, b2, and b3) present a phenotype character-
ized by impaired glucose tolerance (14). Studies with b2AR
agonists further suggest that the b2AR may play an im-
portant role in regulating insulin secretion (15). In addition,
different human polymorphisms in the b2AR gene have been
associated with higher fasting insulin levels (16). Never-
theless, the impact of the b2AR subtype on glucose toler-
ance and insulin secretion is still unclear.
Similar to glucose tolerance, bAR function and respon-
siveness deteriorate with aging (17–20), but the precise
mechanisms involved are unknown. However, current evi-
dence indicates that aging may downregulate bAR signaling,
b2AR in particular, by decreasing the expression of molecular
components of the adrenergic signaling machinery (21–24).
We have therefore hypothesized that age-dependent alter-
ations in bAR function impair glucose-regulated insulin
release by the pancreatic b-cells and may contribute to
deterioration of glucose tolerance. To test this hypothesis,
we explored the consequences of b2AR knockout on insulin
secretion in mice and investigated the signiﬁcance of the
age-related changes in b2AR function with regard to glucose
tolerance.
RESEARCH DESIGN AND METHODS
In vivo studies. We studied male mice with a homozygous deletion of the
b2AR gene (b2AR
2/2) and backcrossed .12 generations onto C57Bl/6N
background. Founders were provided by Brian Kobilka (Stanford University,
Stanford, CA) (25). Wild-type littermates (b2AR
+/+) were used as controls. The
animals were housed in a temperature-controlled (22°C) room with a 12-h
light/dark cycle in accordance with the Guide for the Care and Use of Labo-
ratory Animals published by the National Institutes of Health (NIH publica-
tion no. 85-23, revised 1996), and experiments were approved by the ethics
committee of the Federico II University. Mice were killed by cervical dislo-
cation. Pancreata were excised and collected rapidly after mice were killed.
Samples were weighted, ﬁxed by immersion in 4% paraformaldehyde for
histology, homogenized for determination of total insulin content, or snap-
frozen in liquid nitrogen and stored at –80°C for subsequent analyses. For
determination of insulin or glucagon content, pancreatic tissue was homog-
enized in acid ethanol and extracted at 4°C overnight. The acidic extracts
were dried by vacuum, reconstituted, and subjected to insulin and glucagon
measurements.
Glucose tolerance test and assessment of insulin secretion. Glucose
tolerance test (GTT) was performed as previously described (9,26). Brieﬂy,
mice were fasted overnight and then injected with glucose (2 g/kg i.p.). Blood
glucose was measured by tail bleeding (Glucose Analyzer II; Beckman Coulter,
Brea, CA) at indicated time points. The assessment of insulin secretion before
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and during glucose challenge was performed as previously described (9,27).
Blood from the mandibular vein of overnight-fasted mice was collected at the
indicated time for serum insulin assessment. The evaluation of glucagon se-
cretion was performed by collecting blood from the mandibular vein of random-
fed mice before and after injection of insulin (0.75 IU/kg i.p.). Serum insulin and
plasma glucagon were assayed by radioimmunoassay (Millipore, Billerica, MA).
Histological analysis. Immunohistochemistry was carried out on parafﬁn
sections using the H38 rabbit insulin antibody or the N-17 goat glucagon anti-
body (1:200 dilution; both from Santa Cruz Biotechnology, Santa Cruz, CA).
Goat anti-rabbit serum coupledwith peroxidase (Immunotech,Marseille, France)
was used as secondary antibody. After primary antibody exposure, slides
were incubated with biotinylated anti-rabbit or anti-goat IgG and peroxidase-
labeled streptavidin (Dako Corporation). All reactions were revealed with
diaminobenzidine. Sections were counterstained with hematoxylin and
mounted (28,29).
Ex vivo studies
Isolation of mouse pancreatic islets. Islets of Langerhans were isolated by
collagenase digestion (26,30). In brief, mice were killed as described above,
the fur was soaked with ethanol, and the abdomen was opened to locate and
excise the pancreas. Digestion was completed with collagenase P (Roche
Applied Sciences, Penzberg, Germany) in a shaking water bath (37°C) for 5–8
min. The digested pancreas was treated with DNase I (New England BioLabs,
Ipswich, MA). The islets were hand-picked under a stereomicroscope using a
syringe with a 25-gauge needle and cultured at 37°C with 95% air and 5% CO2
in complete RPMI-1640 supplemented with 5% heat-inactivated FBS, 1 mmol/L
sodium pyruvate, 50 mmol/L 2-mercaptoethanol, 2 mmol/L glutamine, 10 mmol/L
HEPES, 100 units/mL penicillin, and 100 mg/mL streptomycin (all from Sigma-
Aldrich, Saint Louis, MO) as previously described (31,32).
Evaluation of insulin secretion. Isolated islets were preincubated at 37°C
for 30 min in Krebs-Ringer bicarbonate buffer (120 mmol/L NaCl, 4.7 mmol/L
KCl, 1.2 mmol/L MgSO4, 1.2 mmol/L KH2PO4, 2.4 mmol/L CaCl2, and 20 mmol/L
NaHCO3) supplemented with 10 mmol/L HEPES and 0.2% BSA and gassed
with a mixture of 95% O2 and 5% CO2 containing 2 mmol/L glucose. Twenty
size-matched islets collected in each tube were incubated for 1 h in a 37°C
water bath with 500 mL Krebs-Ringer bicarbonate buffer medium containing
2.8 mmol/L glucose, 16.7 mmol glucose, or 2.8 mmol/L glucose plus 33 mmol/L
KCl. Islets were then pelleted by centrifugation (9,000g, 2 min, 4°C), and
supernatants were collected for insulin secretion. Insulin concentrations were
determined using radioimmunoassay (31).
Adenovirus-mediated reinstallation of b2AR in vivo and ex vivo.
Twenty-month-old b2AR
+/+ mice were anesthetized by isoﬂurane (4%) inha-
lation and maintained by mask ventilation (isoﬂurane 1.8%) (28). After lapa-
rotomy, we identiﬁed and mobilized the distal pancreas and we performed two
injections (50 mL each) of adenovirus (7 3 1010 plaque-forming units [pfu]/
mouse) using a 30-gauge needle. Given the high homology between the human
and mouse b2AR (33) and the validated use of the adenoviruses expressing the
human b2AR (Adb2AR) for in vivo gene transfer (34–36), we used the human
Adb2AR or, as control, an empty expression cassette derived from pcDNA3.2/
V5/GW/D-TOPO (AdEmpty), kindly provided by Walter J. Koch, Jefferson
University (Philadelphia, PA). Finally, abdominal incision was quickly closed
in layers using 3–0 silk suture, and animals were observed and monitored until
recovery. Isolated islets were infected (12 3 104 pfu/islet) with Adb2AR or
AdEmpty. After 3 h incubation with the adenoviruses, pancreatic islets were
incubated with fresh medium and under normoxic conditions (95% air, 5%
CO2) at 37°C for 24 h.
In vitro studies. The INS-1E b-cells (provided by P. Maechler, University of
Geneva, Geneva, Switzerland), derived and selected from the parental rat
insulinoma INS-1 b-cell line, were maintained in monolayer culture in RPMI-
1640 medium as described above for the ex vivo experiments. For the insulin
secretion assays, cells were seeded at a density of 53 105 cells/cm2 for at least
96 h before use (31). Transient transfection of the PPARg cDNA and control
empty plasmid was performed using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) (37). We also tested the effects of the speciﬁc pharmacological b2AR
antagonist ICI 118.551 (0.1 mmol/L) or agonist (1 mmol/L fenoterol) (both from
Sigma-Aldrich) (36).
Short hairpin RNA design, generation, and transfection and radioligand-
binding assay. Stealth short hairpin (sh)RNA oligoribonucleotides against
b2AR and scramble were designed (sequences and efﬁciency shown in Sup-
plementary Table 1 and Supplementary Fig. 2, respectively) and then syn-
thesized by Invitrogen. The shRNA hairpin conﬁguration is cleaved by the
cellular machinery into small interfering RNA, which is then bound to the
RNA-induced silencing complex. This complex binds to and cleaves mRNAs
that match the small interfering RNA that is bound to it. We transfected INS-1E
b-cells with 100 nmol/L sh-b2AR RNA or sh-scramble RNA using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions. Assays were
performed at least 3 days after shRNA transfection. Membrane fractions
from pancreatic tissue, isolated islets, and INS-1E b-cells were used for
radioligand-binding studies to assess the density of ARs as previously de-
scribed and validated (35,36,38,39).
Real-time RT-PCR analysis. Total cellular RNA was isolated from INS-1E
b-cells, isolated islets, and pancreatic tissue samples with the RNeasy kit (Qiagen,
Germantown, MD), according to the manufacturer’s instructions, as previously
described (31,40). PCRs were analyzed using SYBR Green mix (Invitrogen).
Reactions were performed in triplicate using Platinum SYBR Green qPCR
Super-UDG by means of an iCycler IQ multicolor Real Time PCR Detection
system (Bio-Rad, Hercules, CA). Cyclophilin was used as an internal standard.
Primer sequences are reported in Supplementary Table 2.
Immunoblotting. Immunoblot analysis was performed as previously de-
scribed (31,37). Blots were probed with mouse monoclonal antibodies against
adenylate cyclase type VI (AC-VI) (Abcam, Cambridge, MA), pancreatic and
duodenal homeobox (PDX)-1, GLUT2, peroxisome proliferator–activated re-
ceptor (PPAR)g, G-protein–coupled receptor (GRK)2, G protein as (Gas),
clathrin heavy chain, and actin (Santa Cruz Biotechnology). Experiments were
performed in triplicate to ensure reproducibility. Membrane extracts were
obtained as previously described (29,38). Data are presented as arbitrary units
using actin as internal control (clathrin heavy chain for membrane extracts) as
indicated.
Measurement of cAMP production in vitro and ex vivo. Intracellular
content of cAMP was determined using a cAMP 125I-scintillation proximity
assay (GE Healthcare, Piscataway, NJ) according to the manufacturer’s in-
structions. Brieﬂy, we used 20 size-matched islets (for the ex vivo assays) and
4,000 cells/well INS-1E (for the in vitro assays). Islets and b-cells were washed
once and preincubated at 37°C in HEPES-buffered Krebs-Ringer solution con-
taining 1 mmol/L glucose and 0.5 mmol/L isobutylmethylxanthine (a phospho-
diesterase inhibitor) for 1 h and incubated for another 15 min in the same buffer
with or without 100 mmol/L forskolin (MP Biomedicals, Solon, OH), 3 mmol/L
NaF (Thermo Fisher Scientiﬁc, Pittsburgh, PA), or 1 mmol/L isoproterenol
(Tocris Bioscience, Ellisville, MO). The reaction was stopped by addition of 50
mmol/L HCl and neutralized with NaOH. The cAMP levels were normalized to
the protein concentration.
Statistical analysis. All data are presented as means 6 SE. Statistical dif-
ferences were determined by one-way or two-way ANOVA as appropriate, and
Bonferroni post hoc testing was performed when applicable. A P value ,0.05
was considered signiﬁcant. Statistical analysis was performed using GraphPad
Prism (version 5.01; GraphPad Software Inc., San Diego, CA).
RESULTS
Metabolic phenotype of b2AR
2/2 mouse. To investigate
in vivo the relevance of the b2AR gene in the regulation of
insulin secretion, we compared the metabolic phenotype
of adult (6 months old) b2AR
2/2 and b2AR
+/+ mice. Blood
glucose was signiﬁcantly higher in the null mice compared
with that in their wild-type littermates both upon fasting
and under random feeding conditions (Table 1). In addition,
their fasting serum insulin levels were signiﬁcantly reduced
(Table 1). Upon glucose loading (GTT), the b2AR
2/2 mice
displayed a marked reduction in glucose tolerance (Fig. 1A
and B). In b2AR
+/+ mice, we observed a threefold increase
in insulin secretion 3 min after intraperitoneal glucose in-
jection, presumably corresponding with the peak of ﬁrst-
phase insulin release. This was followed by a decrease at 10
TABLE 1
Metabolic characteristics of adult (6 months old) wild-type and
knockout mice
b2AR
+/+ b2AR
2/2
n 15 14
Body weight (g) 29.6 6 1.1 28.2 6 0.7
Food intake (g/day) 3.1 6 0.6 3.1 6 0.8
Water intake (mL/day) 5.8 6 0.6 6.3 6 0.9*
Random-fed blood glucose (mg/dL) 170.1 6 12.3 198.4 6 11.1*
Fasting blood glucose (mg/dL) 75.7 6 8.2 135.3 6 11.5*
Fasting serum insulin (ng/mL) 0.41 6 0.03 0.30 6 0.07*
Data are means 6 SE unless otherwise indicated. *P , 0.05 vs.
b2AR
+/+.
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FIG. 1. Metabolic proﬁle of b2AR
2/2mice. Six-month-old b2AR
2/2mice and their wild-type littermates (b2AR
+/+) were fasted for 16 h and subjected
to intraperitoneal glucose loading (2 g/kg body weight). Blood glucose (A and B) and serum insulin (C and D) were monitored for 120 min after
glucose administration (n = 14–18 animals per group). b2AR
2/2 mice displayed glucose intolerance (A) and impaired insulin secretion (C). We
calculated the AUC from glucose (B) and insulin excursion (D) curves. Peak insulin–to–peak glucose ratio (E) represents b-cell function, as better
described in RESEARCH DESIGN AND METHODS. Bars represent means 6 SE. *P < 0.05 vs. b2AR
+/+, Bonferroni post hoc test. AUC, area under the curve.
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min and then a gradual increase over 30 min that may in-
dicate a second-phase response (27,41).
In b2AR
2/2 mice, the early phase of insulin secretory
response to glucose was reduced by more than twofold. The
late response was also signiﬁcantly impaired in the b2AR
2/2
compared with b2AR
+/+ mice (Fig. 1C and D). The peak
insulin–to–peak glucose ratio was also decreased (Fig. 1E),
further indicating impaired insulin response to hyperglyce-
mia in the null mice.
To investigate whether the alterations in glucose toler-
ance identiﬁed in the b2AR
2/2 mice were contributed by
deranged glucagon release, we further measured blood
glucose and plasma glucagon levels 30 min after insulin
administration. Indeed, insulin administration determines a
fall in blood glucose and a counterregulatory rise in plasma
glucagon (2,30). However, b2AR
2/2 and b2AR
+/+ mice ex-
hibited comparable glucose and glucagon responses to
insulin administration (Supplementary Fig. 1A and B).
Pancreatic islet histology also did not show any signiﬁcant
difference in these mice (Fig. 2A), similar to total insulin and
glucagon pancreatic content (Fig. 2B and C).
We then posed the further question of whether the re-
duced glucose insulin secretion observed in the b2AR
2/2
mice in vivo may represent the direct consequence of the
b2AR
2/2 lack in the b-cells or whether it is indirectly me-
diated by other regulatory factors. To answer this question,
we analyzed glucose effect on islets isolated from the null
mice. As shown in Fig. 2D, these islets responded poorly to
increased glucose concentration in the culture medium
compared with the islets from their wild-type littermates but
were fully responsive to KCl depolarization.
Islets and b-cell proﬁling after b2AR deletion. To gain
further insight into the mechanism leading to impaired in-
sulin secretion in mice lacking b2AR, we proﬁled the ex-
pression of different genes relevant to b-cell regulation by
real-time RT-PCR of islet mRNA. As shown in Fig. 3A and B,
mRNA levels of both PDX-1 and GLUT2, two major genes
involved in b-cell function, were decreased in islets from
b2AR
2/2 mice by 75 and 60%, respectively. Also, mRNA
levels of the PDX-1/GLUT2 upstream regulator PPARg
were decreased by 54% compared with islets from wild-
type mice (Fig. 3C). Reliable results were obtained in
FIG. 2. Comparison of b2AR
+/+ and b2AR
2/2 pancreatic islets. Immunoistochemical analysis (A) of the islets was carried out on parafﬁn sections
using insulin (left panel) or glucagon (right panel) antibodies. Microphotographs are representative of images obtained from pancreas sections
of ﬁve 6-month-old b2AR
+/+ (upper panel) or b2AR
2/2 (lower panel) mice. Insulin (B) and glucagon (C) content in isolated islets from b2AR
+/+
(n = 10) or b2AR
2/2 (n = 13) mice. Insulin secretion in response to basal (2.8 mmol/L) or high (16.7 mmol/L) glucose concentration and to KCl (33
mmol/L) was measured in isolated islets from b2AR
+/+ (□) and b2AR
2/2 (■) mice (D). Bars represent means 6 SE of data from 10 mice per group.
*P < 0.05 vs. b2AR
+/+, Bonferroni post hoc test. (See also Supplementary Fig. 1.) (A high-quality digital representation of this ﬁgure is available in
the online issue.)
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immunoblotting experiments (Fig. 3D and E). PDX-1 and
GLUT2 mRNAs were also reduced to a similar extent in
total pancreatic tissue from the b2AR
2/2 mice (data not
shown).
We then sought to demonstrate whether these abnor-
malities in gene expression were directly caused by b2AR
silencing. To pursue this objective, we silenced with a
speciﬁc shRNA (Supplementary Fig. 2) the b2AR gene in
the glucose-responsive INS-1E b-cell line (INS-1Eshb2AR)
(Fig. 4A and B). As shown in Fig. 4C, this speciﬁc knock-
down impaired glucose-induced insulin secretion by 58% in
these cells. A similarly sized effect was achieved by treat-
ment with the speciﬁc b2AR antagonist ICI, while the b2AR
agonist fenoterol showed an opposite action (Supplemen-
tary Fig. 3A). Consistent with our ex vivo results, the INS-
1Eshb2AR displayed a reduction in PDX-1, GLUT2, and
PPARg mRNA (Fig. 4D–F) and protein levels (Fig. 4G and
H). Interestingly, transient transfection of a PPARg cDNA in
INS-1Eshb2AR b-cells increased glucose-induced insulin se-
cretion compared with the wild-type INS1-E control b-cells
(Fig. 4C). In addition, overexpression of PPARg prevented
the downregulation of both PDX-1 and GLUT2 occurring in
the INS-1Eshb2AR b-cells (Fig. 4D–H). Consistently, treatment
of INS-1E b-cells with ICI decreased PDX-1 and GLUT2
mRNA and protein levels, while PPARg overexpression
completely prevented the effect of ICI (Supplementary Fig.
3B–D), suggesting that b2AR controls insulin secretion
through a PPARg/PDX-1–mediated mechanism.
To better deﬁne the b2AR downstream mechanism lead-
ing to PPARg activation, we assessed the cAMP levels in
these cells, observing an impaired production of cAMP in
INS-1Eshb2AR b-cells both in basal condition and after stim-
ulation with the bAR agonist isoproterenol (Supplementary
Fig. 4A). Accordingly, to rule out possible involvement of
other components of b2AR signaling machinery, we assessed
the protein level of AC-VI, GRK2, and Gas, and we found
no signiﬁcant difference (Supplementary Fig. 4B and C).
Parallel results were obtained in ex vivo experiments,
performed to investigate the possible age-related alter-
ations in the b2AR transduction pathway, comparing
pancreatic islets isolated from adult (6 months old) and
old (20 months old) b2AR
+/+ mice (Supplementary Fig. 4D
and E).
b2AR overexpression rescued the age-related impairment
in insulin release. Based on radioligand binding and real-
time RT-PCR analysis, the expression of both b2AR protein
and mRNA was signiﬁcantly decreased in islets from aged
(20 months old) b2AR
+/+ mice compared with those isolated
from adult (6 months old) mice (Fig. 5A and B). PDX-1,
GLUT2, and PPARg expression (both in terms of mRNA
and protein level) was also reduced, and insulin release
in response to glucose, though not that evoked by KCl de-
polarization, was impaired in islets from the aged mice (Fig.
5C–H), suggesting that the reduced b2AR density constrains
islet glucose response in these animals. To prove this hy-
pothesis, we used an adenoviral construct driving over-
expression of human b2AR in mouse islets. Interestingly,
infection of islets isolated from wild-type old mice with this
construct induced a twofold increase in b2AR expression
(Fig. 5A and B) and returned glucose-induced insulin secre-
tion to levels comparable with those of islets from 6-month-
old mice (Fig. 5C) accompanied by restored expression of
PDX-1, GLUT2, and PPARg (Fig. 5D–H).
In the in vivo setup, 20-month-old b2AR
+/+ mice exhibited
a signiﬁcant reduction in fasting serum insulin levels
(Table 2) accompanied by impaired glucose tolerance and
FIG. 3. Gene expression proﬁle in isolated Langerhans islets from b2AR
+/+ and b2AR
2/2mice. The abundance of mRNAs for PDX-1 (A), GLUT2 (B),
and PPARg (C) was determined by real-time RT-PCR analysis of total RNA, using cyclophilin as internal standard. The mRNA levels in b2AR
2/2 mice
are relative to those in control animals. Each bar represents means6 SE of four independent experiments in each of which reactions were performed
in triplicate using the pooled total RNAs from ﬁve mice/genotype. Proteins from aWestern blot representative of three independent experiments were
quantiﬁed by densitometry (D and E). *P < 0.05 vs. b2AR
+/+, Bonferroni post hoc test. AU, arbitrary units.
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insulin response upon GTT (Fig. 6A–E). We have therefore
designed a gene therapy protocol aimed to prove that
these abnormalities can be corrected by restoring b2AR
density. Accordingly, we infected the pancreas of aged
mice by Adb2AR injection. This injection effectively res-
cued b2AR expression in the pancreatic tissue, returning it
to levels comparable with those of 6-month-old mice (Sup-
plementary Fig. 5A and B), and restored the expression of
PDX-1, GLUT2, and PPARg (Supplementary Fig. 5C–E).
Injections in the distal pancreas did not induce b2AR ex-
pression in other tissues, such as the liver (Supplementary
Fig. 6A and B) or the skeletal muscle (Supplementary Fig.
6C and D).
These effects were paralleled by signiﬁcant improve-
ment in glucose tolerance and insulin secretion during
GTT (Fig. 6A–E). Fasting insulin levels also increased,
reaching values similar to those measured in 6-month-old
mice (Table 2), further underlining the relevance of b2AR
function in enabling adequate pancreatic b-cell response
to hyperglycemia.
DISCUSSION
In the present work, we provide evidence that b2AR gene
deletion in mice causes reduction of glucose-stimulated
insulin release by pancreatic b-cells. This phenotype is
reminiscent of that observed in mice with targeted b-cell
disruption of the Gas gene (30). In these mice, however,
the impairment of Gas prevented response to multiple Gas-
related receptors, causing a severe phenotype, with gross
abnormalities in pancreatic islets. Interestingly, in islets
from b2AR
2/2 mice, PPARg expression was reduced by
50%, leading to repression of the PPARg downstream mol-
ecules PDX-1 and GLUT2, two key effectors of b-cell
function (26,42,43). This downregulation resulted in a clear
impairment in insulin release, though islet architecture and
insulin content were not affected by the b2AR gene de-
letion.
Rosen et al. (44) showed that islets from mice with
targeted elimination of PPARg in b-cells were approxi-
mately twice as large as those from control mice. Thus, we
can speculate that in our model the 50% reduction in
FIG. 4. b2AR levels, glucose-stimulated insulin secretion, and gene expression proﬁle in silenced INS-1E b-cells. Treatment with a speciﬁc b2AR-
shRNA signiﬁcantly decreased the density (by 73.7% [A]) and mRNA levels (by 59.1% [B]) of b2AR in INS-1E b-cells. b2AR-shRNA inhibited the
insulin secretory response to 16.7 mmol/L glucose, which was rescued by the overexpression of PPARg (C). KCl-induced insulin release (C) was
not signiﬁcantly different among the studied groups. b2AR-shRNA also determined a signiﬁcant reduction in mRNA level of PDX-1 (D), GLUT2 (E),
and PPARg (F) that was prevented by the overexpression of PPARg. Bars represent means6 SE from four to ﬁve independent experiments in each
of which reactions were performed in triplicate ( , control, i.e. untreated INS-1E b-cells; , sh-scramble; , sh-scramble+empty vector; ,
sh-b2AR; , sh-b2AR+PPARg; *P < 0.05 vs. control, Bonferroni post hoc test; basal is glucose 2.8 mmol/L. Equal amount of proteins from three
independent experiments was analyzed by Western blotting and quantiﬁed by densitometry (G and H ). *P < 0.05 vs. sh-scramble. AU, arbitrary
units. (See also Supplementary Figs. 2–4.)
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PPARg levels is sufﬁcient to restrain b-cell function with-
out altering islet mass.
The mechanistic signiﬁcance of b2AR gene knockout
was further sustained by in vitro studies in the INS-1E
pancreatic b-cells, showing that the silencing of the b2AR
as well as the pharmacological treatment with a speciﬁc
b2AR antagonist impaired glucose response and down-
regulated PPARg expression, reducing both PDX-1 and
GLUT2 levels. No alteration of aARs was observed instead
(data not shown). In addition, treatment with the b2AR
agonist fenoterol activated PPARg/PDX-1/GLUT2 signal-
ing, indicating that, at least in part, b2AR controls insulin
secretion through this pathway. Indeed, in this study we
show that exogenous PPARg expression in INS-1E b-cells
silenced for b2AR led to recovery of PDX-1/GLUT2 levels
and glucose-stimulated insulin secretion. This ﬁnding is
supported by recent evidence that directly relates b2AR to
PPARg (42,45–47), a key element in the process of insulin
FIG. 5. b2AR ex vivo infection rescued age-dependent impairment of b-cell function. Density (A) and mRNA levels (B) of b2AR were evaluated on
cell membranes of islets isolated from b2AR
+/+ mice. Insulin release (C) was determined upon exposure to the indicated concentration of glucose or
KCl as described in RESEARCH DESIGN AND METHODS. mRNA levels of PDX-1 (D), GLUT2 (E), and PPARg (F) were determined by real-time RT-PCR using
the pooled total RNAs from ﬁve mice/group with cyclophilin as internal standard. Each bar represents means6 SE of ﬁve independent experiments in
each of which reactions were performed in triplicate. Islets isolated from b2AR
+/+ mice were solubilized and aliquots of the lysates were blotted with
PDX-1, GLUT2, and PPARg antibodies. Actin was used as loading control. The autoradiographs shown (G) are representative of three independent
experiments, which are quantiﬁed in H. , age 6 months (mos); , 20 months; , 20 months AdEmpty; , 20 months Adb2AR. *P < 0.05 vs.
b2AR
+/+ 6 months, Bonferroni post hoc test.
TABLE 2
Metabolic effects of b2AR overexpression in aged (20 months old) b2AR
+/+ mice
20 months old 6 months old
Untreated AdEmpty Adb2AR Untreated
n 10 6 8 15
Body weight (g) 38.4 6 1.7* 38.1 6 2.4* 38.6 6 2.1* 29.6 6 1.1
Food intake (g/day) 4.0 6 1.1* 4.2 6 1.8* 3.9 6 1.5* 3.1 6 0.6
Water intake (mL/day) 6.8 6 1.2* 6.9 6 1.7* 6.6 6 1.8* 5.8 6 0.6
Random-fed blood glucose (mg/dL) 176.5 6 8.6 178.4 6 12.7 173.2 6 10.4 170.1 6 12.3
Fasting blood glucose (mg/dL) 84.2 6 10.4 83.6 6 11.9 77.7 6 11.7 75.7 6 8.2
Fasting serum insulin (ng/mL) 0.32 6 0.04* 0.33 6 0.05* 0.42 6 0.1 0.41 6 0.03
Data are means 6 SE unless otherwise indicated. *P , 0.05 vs. adult (6 months old) b2AR
+/+ mice.
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FIG. 6. Adenoviral vector-mediated b2AR gene transfer in the mouse pancreas rescued age-related reduction in glucose tolerance. Blood glucose
levels (A) and serum insulin (C) after 120 min of glucose administration (n = 14–18 animals per group). We calculated the AUC from glucose (B)
and insulin excursion (D) curves. Twenty-month-old b2AR
+/+ mice showed glucose intolerance (A and B), impaired insulin secretion (C and D), and
also an impairment in b-cell function, evaluated measuring the peak insulin–to–peak glucose ratio (E). All of these parameters were restored after
Adb2AR in vivo infection. *P < 0.05 vs. b2AR
+/+ at 6 months (mos) of age, Bonferroni post hoc test. (See also Supplementary Figs. 5 and 6.)
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secretion that has also recently been investigated in aging
(43,48). Our results are consistent with these observations,
sustaining also the hypothesis that cAMP levels could act
as a connecting link through which b2AR signaling leads to
activation of PPARg (49,50). Moreover, the cAMP assays,
performed both in INS-1Eshb2AR pancreatic b-cells and in
islets isolated from aged mice, showed an impairment in
basal conditions and after stimulation with isoproterenol,
while the responses to NaF and forskolin were not affected.
Also, Gas and AC-VI protein levels were not signiﬁcantly
different among the explored settings. This combination of
events is usually observed in models of b2AR gene deletion
or impaired b2AR signaling (18,34).
Whether and to what extent b2AR gene knockout in liver
and peripheral tissues affects glucose homeostasis in the
b2AR
2/2 mice remain to be conclusively addressed. In-
deed, variations at the b2AR locus have also been reported
to associate with insulin resistance in type 2 diabetic patients
(16). However, as shown in this work, the impaired glu-
cose tolerance of b2AR
2/2mice is likely contributed by the
defective b-cell function, as indicated by the major effect
of b2AR lack on glucose-evoked insulin secretion.
In humans, glucose tolerance declines with age, result-
ing in a high prevalence of type 2 diabetes and impaired
glucose tolerance in the elderly population (2,8). How, at
the individual level, glucose tolerance declines remains
unclear, but it is likely determined by multiple factors in-
cluding diminished insulin secretion (3,7). In rat models
and in humans, a progressive decline in b-cell activity with
age has been documented (4,6). In the present work, we
show that the same occurs in the C57Bl/6N mouse and is
paralleled by the development of abnormal glucose toler-
ance. Similar to previous ﬁndings in several human tissues
(18–21,24), our results show that these changes are ac-
companied by reduced b2AR levels in mouse pancreatic
islets. The decreased b2AR density in islets from aged mice
recapitulates the mechanisms leading to the insulin se-
cretory defect occurring in b2AR-null mice, indicating that
it may contribute to the age-related impairment in glucose
tolerance. Indeed, both in vivo and ex vivo experiments of
b2AR gene transfer revealed that recovery of normal b2AR
levels rescued insulin release and glucose tolerance in
aged mice. Thus, in the mouse model progressive decline
of islet b2AR density appears to contribute to the reduction
in glucose tolerance that accompanies aging. Whether the
same also occurs in humans needs to be clariﬁed and is
currently under investigation in our laboratory.
In conclusion, we have shown that b2AR physiologically
regulates pancreatic b-cell insulin secretion by modulating
PPARg/PDX-1/GLUT2 function. Reduced b2AR expression
contributes to the age-dependent deterioration of glucose
tolerance.
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Supplementary Table 1. shRNA sequences 
 
  5’- 3’ 
shRNA scramble GCUGACGUAUCCUUAAUGUGUAAUA 
shRNA β2AR CCACAAGCAAGCCAUCGACUGUUAU 
shRNA β2AR (x) GGGAGGAAACUGUAACACAAACGACU 
shRNA β2AR (y) GAAGGUCCUCCAAAGUUCUGCUUGAA 
 
 
 
 
Supplementary Table 2. Real Time RT-PCR primer sequences (5’- 3’) 
 
 Forward Reverse 
β2AR (rat) ACGAGGATGGGAGGAGCGGG GGTTGGCCCGGATGACGTGG 
β2AR (mouse) GAGTGTGCAGGACGCACCCC CTGTCGTTCCCGTGTGGCCC 
PDX-1 (rat and mouse) AAAACCGTCGCATGAAGTGG CCCGCTACTACGTTTCTTATCT 
GLUT2 (rat and mouse) ACAGTCACACCAGCATAC ACCCACCAAAGAATGAGG 
PPARγ (mouse) ACGGGGTCTCGGTTGAGGGG AGTTGGTGGGCCAGAATGGCA 
PPARγ (rat) AAGGTGCTCCAGAAGATGACA TCAGCGACTGGGACTTTTCT 
Cyclophilin (rat and mouse) GCAGACAAAGTTCCAAAGACAG CACCCTGGCACATGAATCC 
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Supplementary Figure 1. Blood glucose and plasma glucagon assessed after intraperitoneal insulin 
administration. Blood glucose (A) and plasma glucagon (B), evaluated in basal (random fed) conditions 
and 30 minutes after intraperitoneal administration of insulin (0.75 IU/Kg), were not significantly 
different among the two studied groups of adult (6-month-old) mice. Each bar represents the mean±SE 
of eight independent experiments. *:p<0.05 vs basal condition; Bonferroni post hoc test. 
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Supplementary Figure 2. β2AR silencing in pancreatic INS-1E β-cells.  
To silence the expression of β2AR in INS-1E β-cells, we designed (sequences are shown in 
Supplementary Table 1) three shRNA, namely sh-β2AR, sh-β2AR(x), sh-β2AR(y). We decide to use the 
first one, which showed the best effectiveness, inducing a 73.7% decrease in the membrane density of 
β2AR, also better than the pooled mix of the three sh-β2AR. Each bar represents mean±SE from five 
independent experiments in each of whom reactions were performed in triplicate. *:p<0.05 vs control; 
Bonferroni post hoc test). 
 
 
 
 
 
 
 
 
 
 
 
SUPPLEMENTARY DATA 
 
©2011 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1027/-/DC1 
 
Supplementary Figure 3. Pharmacological modulation of β2AR.  
INS-1E pancreatic β-cells were incubated (1 hour) with the β2AR selective agonist fenoterol (1 µMol/l) 
or antagonist ICI 118.551 (ICI, 0.1 µMol/l). This latter inhibited the insulin secretory response to 16.7 
mMol/l glucose, that was completely rescued by overexpression of PPARγ (A). Neither fenoterol nor 
ICI determined significant changes in KCl-induced insulin release. Each bar represents the mean±SE 
from five independent experiments in each of whom reactions were performed in triplicate. (*:p<0.05 vs 
control, i.e. untreated INS-1E β-cells; Bonferroni post hoc test; basal is glucose 2.8 mMol/l). Fenoterol 
treatment caused a marked rise in mRNA level of PDX-1 (by 76%), GLUT2 (by 53%) and PPARγ (by 
80.5%). On the contrary, ICI determined a significant decrease in mRNA level of the same genes: PDX-
1 (by 37%), GLUT2 (by 48%) and PPARγ (by 53%), compared to untreated INS-1E β-cells (B). Bars 
represent the mRNA levels in treated cells and are relative to those in control cells; data are expressed as 
mean±SE of triplicate reactions for total RNA from each group in four independent experiments. 
Reliable results were obtained from western blot analysis (C-D); representative images (C) of triplicate 
experiments are shown; actin was used as loading control; bar graph in panel D show densitometry. 
*:p<0.05 vs control, i.e. untreated INS-1E cells; Bonferroni post hoc test; : control, i.e. untreated 
INS-1E cells; : fenoterol; : ICI 118.551; : ICI 118.551 + PPARγ). 
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Supplementary Figure 4. Assessment of β2AR downstream. 
In vitro (A-C) and ex vivo (D-F) experiments were performed to investigate cAMP production and β2AR 
downstream. cAMP levels (A, D) were measured in basal condition and after stimulation with 
isoproterenol (1 μMol/l), NaF (3 mMol/l) and forskolin 100 μMol/l, as described in RESEARCH DESIGN 
AND METHODS. Each bar represents the mean±SE of four independent experiments in each of whom 
reactions were performed in triplicate. We found an impaired cAMP production in basal conditions and 
after stimulation with isoproterenol both in INS-1Eshβ2AR β-cells (A, *:p<0.05 vs unstimulated INS-1E β-
cells; #:p<0.05 vs control) and in islets of Langerhans isolated from 20-month-old β2AR+/+ mice (D, 
*:p<0.05 vs unstimulated islets; #:p<0.05 vs β2AR+/+ 6 mos). We assessed by Western blot (B,E) protein 
levels of adenylate cyclase type VI (AC-VI), GRK2 and Gαs on membrane extracts, using chlatrin heavy 
chain (chlatrin HC) as loading control. Representative images of three independent experiments are 
shown. We quantified blots by densitometry in INS-1E pancreatic β-cells (B,  : sh-scramble;  : sh-
β2AR; *:p<0.05 vs sh-scramble) and in isolated islets (E, : 6 mos, : 20 mos; *:p<0.05 vs β2AR+/+ 6 
mos). Control indicates INS-1E β-cells not treated with shRNA; AU indicates arbitrary units; mos is 
months of age. 
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Supplementary Figure 5. Efficacy of β2AR in vivo infection. 
Assessment of β2AR expression on cell membranes of pancreatic tissue from 2AR+/+ mice after β2AR 
overexpression in vivo. β2AR density (A) was evaluated by radioligand assay. mRNA levels of β2AR 
(B), PDX-1 (C), GLUT2 (D) and PPARγ (E) were determined by Real-time RT-PCR using the pooled 
total RNAs from four mice/group, using cyclophilin as internal standard. AdEmpty: Pancreata infected 
with a control adenovirus; Adβ2AR: Pancreata infected with an adenovirus encoding for the human 
β2AR gene. Each bar represents the mean±SE of four independent experiments in each of whom 
reactions were performed in triplicate; : 6 mos, : 20 mos, : 20 mos Adempty, : 20 mos 
Adβ2AR; *:p<0.05 vs β2AR+/+ 6 mos; Bonferroni post hoc test; mos is months of age. 
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Supplementary Figure 6. Effect of Adβ2AR pancreatic injection on liver and muscle. 
The localized injections in the distal pancreas do not induce β2AR expression in other tissues. Density 
(A, C) and mRNA levels (B, D) of β2AR were evaluated on cell membranes of liver and quadriceps 
muscle (C, D) from 2AR+/+ mice. mRNA levels were determined by Real-time RT-PCR using the 
pooled total RNAs from four mice/group with cyclophilin as internal standard. Each bar represents the 
mean±SE of five independent experiments in each of whom reactions were performed in triplicate. : 
20 mos, : 20 mos Adempty, : 20 mos Adβ2AR; AdEmpty: Mice infected with a control 
adenovirus; Adβ2AR: Mice infected with an adenovirus encoding for the human β2AR gene; mos is 
months of age. 
 
 
LETTERS
Coronary Heart Disease Risk Factors andMortality
To the Editor: Dr Canto and colleagues1 found that hospi-
tal mortality increased as the number of cardiovascular risk
factors declined. This inverse relationship is perplexing and
the potential explanations discussed by the authors appear
not completely satisfactory.
The authors just considered the number of risk factors,
whereas the severity of each factor was not evaluated. Blood
pressure, plasma glucose, and lipids are continuous, not dis-
creet, variables that exert a dose-dependent effect on car-
diovascular risk.2 It would be of interest to see the results
of the analysis conducted considering these parameters,
which also would help to clarify the still controversial as-
sociation of themetabolic syndrome andmortality aftermyo-
cardial infarction (MI).3
It also would be interesting to know if the inverse corre-
lation is still present after correction for one of themost im-
portant predictors of mortality after acute coronary syn-
drome,4 the baseline infarct size.
Last, traditional cardiovascular risk factors do not fully
explain the pathophysiological process of atherothrombo-
sis in acute ischemic heart disease. Several studies have iden-
tified a series of emerging biomarkers reflecting thrombo-
sis, inflammation, and oxidative stress.5 Do the authors have
any data about this issue?
Gaetano Santulli, MD
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To the Editor: The study by Dr Canto and colleagues1
provides an example of an epidemiological phenomenon
that deserves wider recognition. Differential selection
from an underlying population cohort into a study data
set can reverse the direction of observed associations,
making a deleterious factor appear protective. It is well-
known that conditioning on a variable that is affected by
both an exposure and outcome can produce a distortion
known as selection bias.2 Admission into the analysis
data set in this study was a function of both the exposure
(number of cardiovascular risk factors) and the outcome
(all-cause, in-hospital, or 30-day mortality) because
deaths occurring before hospitalization and patients with
existing cardiovascular disease diagnoses were excluded.
Approximately 30% of MIs lead to death prior to hospi-
talization.3 In the study, 75% of those who were admitted
to the hospital after their MI were excluded (1.62 million
of 2.16 million; Figure 1 in the article).
The combined effect of these 2 selection mechanisms
means that individuals with more cardiovascular risk fac-
tors were more likely to be excluded. If an increased num-
ber of risk factors accelerate mortality so that more events
occur in the prehospital window rather than during hospi-
talization or 30-day follow-up, risk factors will appear to be
protective.4 The study results are therefore understandable
in terms of selection bias and require no elaborate specu-
lation about pathophysiological processes1 or “novel but as-
yet uncharacterized and deadly CVD [cardiovascular dis-
ease] risk factors.”5
Hailey R. Banack, MA
Sam Harper, PhD
Jay S. Kaufman, PhD
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In Reply: Our study challenges conventional wisdom that
patients with more coronary heart disease (CHD) risk fac-
tors haveworse outcomes following their firstMI.We found
that patients withmultiple CHD risk factors presentedmuch
earlier in life withMI and had lower hospital mortality than
patients with fewer or no risk factors. We confirmed that
the high prevalence of risk factor exposure in patients with
MI was consistent with the prior literature.
Dr Santulli seeks additional information that may en-
hance our study, such as the influence of a dose-dependent
effect of CHD risk factors, presence of the metabolic syn-
drome, other novel risk markers, and infarct size. Unfortu-
nately, these factors were not available in the National Reg-
istry ofMyocardial Infarction. Although baseline infarct size
was not recorded, the finding of an inverse relationship be-
tween the number of CHD risk factors and mortality was
consistently observed among patients with low-, interme-
diate-, and high-risk features using 2 well-validated mea-
sures of infarct severity (Killip classification and TIMI Risk
Index).
Ms Banack and colleagues suggest that bias in the selec-
tion of our study cohort could have reversed the direction
of observed associations, making a deleterious factor ap-
pear protective. An MI cohort with no previous cardiovas-
cular disease represents amore uniform population to study
given the differences inmanagement and treatment after ath-
erosclerosis is manifest. Excluding patients with previous
cardiovascular disease simply presents findings generaliz-
able only to patients without previous disease. When our
analysis was rerun using only an MI cohort with previous
cardiovascular disease (N=630 210), our results did not
change appreciably (TABLE).
Banack et al also raise the possibility that patients with
multiple CHD risk factors might have died disproportion-
ately before hospitalization. This is merely speculative.
No prior study has examined the relationship between
the number of CHD risk factors and mortality among
patients with suspected MI who died prior to hospital
arrival, perhaps due to the challenges of confirming MI in
the prehospital setting.
In the discussion of our findings, we devoted 4 para-
graphs to methodological issues that may have limited gen-
eralizability and inferences of causality, including risk fac-
tor misclassification, bias with case ascertainment, residual
confounding, healthy survivor bias, and index event bias.1
Index event bias (also known as reverse epidemiology or
collider stratification bias) may affect research that exam-
ines disease progression and severity when there are mul-
tiple risk factors for progression or for severity that are also
risk factors for having the disease in the first place.1We also
present biologically plausible alternative interpretations of
our findings, including receipt of more aggressive treat-
ments and follow-up care among patientswithmultipleCHD
risk factors.
In summary, we report an unexpected and possibly con-
troversial association that, like all observational findings,
should be considered hypothesis-generating and further ex-
plored in terms of health care provided to patients who reach
the hospital alive with first MI.
John G. Canto, MD, MSPH
Catarina I. Kiefe, MD, PhD
Philip Greenland, MD
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Urinary SodiumExcretion andCardiovascular Events
To the Editor: Dr O’Donnell and colleagues, in their study
on urinary sodium excretion and risk of cardiovascular
events,1 reached the counterintuitive conclusion that so-
dium restriction increased the risk of cardiovascular events,
which runs counter to the consistent evidence that, in in-
dividuals with hypertension, decreased sodium intake re-
duces blood pressure and improves the effectiveness of treat-
ment with antihypertensive agents.2-4
Table. Crude Hospital Mortality of Patients With Myocardial Infarction (MI) and Previous Cardiovascular Diseasea
No. of Risk Factors at Presentationb
0 1 2 3 4 5
No. (%)
MI (N = 630 210) 83 978 (13.3) 195 238 (31.0) 205 224 (32.6) 111 384 (17.7) 30 893 (4.9) 3493 (0.6)
Crude hospital mortality 15 790 (18.8) 30 825 (15.8) 25 894 (12.6) 10 336 (9.3) 2293 (7.4) 220 (6.3)
aData are from the National Registry of Myocardial Infarction, 1994-2006. Excluded patients without prior cardiovascular disease, those who had been transferred, and those with
missing data.
bFive major risk factors: smoking, diabetes, dyslipidemia, hypertension, and family history of coronary heart disease.
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CaMK4 Gene Deletion Induces Hypertension
Gaetano Santulli, MD; Ersilia Cipolletta, MD; Daniela Sorriento, PhD; Carmine Del Giudice, MS; Antonio Anastasio, MS; Sara Monaco, PhD;
Angela Serena Maione, BS; Gianluigi Condorelli, MD, PhD; Annibale Puca, MD, PhD; Bruno Trimarco, MD; Maddalena Illario, MD, PhD;
Guido Iaccarino, MD, PhD
Background-—The expression of calcium/calmodulin-dependent kinase IV (CaMKIV) was hitherto thought to be conﬁned to the
nervous system. However, a recent genome-wide analysis indicated an association between hypertension and a single-nucleotide
polymorphism (rs10491334) of the human CaMKIV gene (CaMK4), which suggests a role for this kinase in the regulation of
vascular tone.
Methods and Results-—To directly assess the role of CaMKIV in hypertension, we characterized the cardiovascular phenotype of
CaMK4/ mice. They displayed a typical hypertensive phenotype, including high blood pressure levels, cardiac hypertrophy,
vascular and kidney damage, and reduced tolerance to chronic ischemia and myocardial infarction compared with wild-type
littermates. Interestingly, in vitro experiments showed the ability of this kinase to activate endothelial nitric oxide synthase.
Eventually, in a population study, we found that the rs10491334 variant associates with a reduction in the expression levels of
CaMKIV in lymphocytes from hypertensive patients.
Conclusions-—Taken together, our results provide evidence that CaMKIV plays a pivotal role in blood pressure regulation through
the control of endothelial nitric oxide synthase activity. ( J Am Heart Assoc. 2012;1:e001081 doi: 10.1161/JAHA.112.001081)
Key Words: angiogenesis • arrhythmia • endothelium • hypertension • hypertrophy
A growing body of evidence bears out the rising interest inthe function of calcium/calmodulin-dependent kinases
(CaMKs) in cardiovascular pathophysiology. In particular,
although it is now established that CaMKII is an important
player in the regulation of cardiac responses, both in terms of
electrophysiology and of cardiac myocyte hypertrophy,1–4 less
is known about the role of other members of the CaMK family,
such as CaMKIV, in the cardiovascular system.5
The recent genome-wide analysis of the Framingham Heart
Study 100K Project6 showed an association between elevated
diastolic blood pressure (BP) and the rs10491334 T/C
single-nucleotide polymorphism (SNP) of the human CaMKIV
gene (CaMK4). Such a ﬁnding suggests that this kinase, the
expression of which once was thought to be conﬁned to the
nervous tissue,7–10 has a yet unidentiﬁed role in the control of
vascular tone.
We therefore hypothesized that CaMKIV could affect
endothelial functions, such as the control of vascular
resistance, and that changes in its level of expression or
activity in endothelial cells (ECs) might alter the ﬁne regulation
of vascular responses, causing hypertension. To ascertain
whether CaMKIV signaling is involved in endothelial
dysfunction, a hallmark of the hypertensive state,11–14 we used
a murine model of genetic deletion of CaMK4. Finally, a
population study was carried out in normotensive and
hypertensive patients to investigate the effects of the CaMK4
rs10491334 SNP in humans.
Methods
In Vivo Studies
Animals
All animal procedures were performed in accordance with the
policies and guidelines of the “Position of the American Heart
Association on Research Animal Use”15 and were approved by
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Medicine and Surgery, University of Salerno, Salerno, Italy (A.P., G.I.).
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the Ethics Committee of the “Federico II” University. The
European Commission Directive 2010/63/EU was followed.
We studied male mice with global homozygous deletion of the
CaMK4 gene (CaMK4/), backcrossed >12 generations onto
a C57Bl/6J background. The mice were kindly provided by
Anthony Means (Duke University, Durham, NC).9 Age-matched
wild-type littermates (CaMK4+/+) were used as controls. The
animals were housed in a 22°C room with a 12-hour light/
dark cycle and were allowed food and tap water ad libitum.
Two groups of mice (CAMK4+/+ and CAMK4/) were
subjected to a long-term furosemide treatment (0.35 mg/kg
per day) from the age of 3 months until 6 or 18 months. The
drug was added directly to the drinking water. The develop-
ment of the typical target-organ damage (vascular, cardiac,
and kidney damage)16–18 was evaluated in 18-month-old
mice. Longitudinal survival observation on CAMK4+/+ and
CAMK4/ mice was performed over a period of 24 months.
Genotypes were determined by polymerase chain reaction
ampliﬁcation of tail DNA. The individual performing all
experiments was blinded to the mouse genotype until all
data were fully analyzed.
Invasive Arterial BP Measurement
Mice were anesthetized by isoﬂurane (4%) inhalation and
maintained by mask ventilation (isoﬂurane 1.8%). Direct BP
and heart rate measurements were performed with the use of
a 1.0F Mikro-Tip catheter (SPR1000, Millar Instruments,
Houston, TX), which was advanced through the right external
carotid artery and placed in the descending aorta. After
implantation, the catheter was connected to a transducer
(Gould Instruments Systems, Cleveland, OH) to record BP and
heart rate for 15 minutes. The pressure catheter then was
advanced through the aortic valve into the left ventricle (LV).
Subsequent ofﬂine evaluation provided the ﬁrst derivative of
the LV pressure curve (maximum and minimum dP/dt). All
data were analyzed with dedicated software (PowerLab-Chart
7.1, ADInstruments, Sydney, Australia).
Echocardiography
Transthoracic echocardiography was performed with a small-
animal high-resolution imaging system (VeVo770, VisualSon-
ics, Inc, Toronto, Canada) equipped with a 30-MHz transducer
(Real-Time Micro Visualization, RMV-707B). The mice, anes-
thetized as described previously for BP measurement, were
placed in a shallow left lateral decubitus position, with strict
thermoregulation (37±1°C) to optimize physiological condi-
tions and reduce hemodynamic variability. Fur was removed
from the chest by application of a cosmetic cream (Veet,
Reckitt Benckiser, Milan, Italy) to gain a clear image. LV end-
diastolic and LV end-systolic diameters were measured at the
level of the papillary muscles from the parasternal short-axis
view.19,20 Intraventricular septal and LV posterior wall thick-
ness were estimated at end diastole. LV fractional shortening
was calculated as follows: LVFS = [(LVEDD  LVESD)/
LVEDD] 9 100, where LVFS indicates LV fractional shorten-
ing; LVEDD, LV end-diastolic diameter; and LVESD, LV
end-systolic diameter. LV ejection fraction was calculated
automatically by the echocardiography system. All measure-
ments were averaged on 10 consecutive cardiac cycles
per experiment and were analyzed by one experienced
investigator.
Electrocardiography
Electrocardiography (ECG) was performed under isoﬂurane
(1.5%) anesthesia. Mice were placed on a thermocontrolled
plate (37±1°C) and were given 10 minutes to acclimate
before ECG recording. Signal-averaged ECG tracings were
obtained by subcutaneous placement of 27-gauge steel
needle electrodes in each limb, secured with tape. ECG was
recorded for 60 minutes with the PowerLab Chart 7.1 system
(ADInstruments, Sydney, Australia) and then was analyzed
ofﬂine.
Angiogenic Response After Peripheral Chronic
Ischemia
Peripheral chronic ischemia was induced in 6-month-old mice
by means of surgical ligation and excision of the right
common femoral artery. We have published a detailed
description of the procedure.21–23 The angiogenic response
was assessed on postoperative days 3, 7, 14, and 21 by laser
Doppler (Perimed Instruments, Järfälla, Sweden).22 Further-
more, 3 weeks after surgery, we performed (1) ultrasound
Doppler analysis of the posterior tibial artery with a VeVo770
imaging system equipped with a 20- to 60-MHz scanhead
(VisualSonics, Inc, Toronto, Canada), (2) dyed-microbead
assay on the gastrocnemius muscle, and (3) histological
analysis of the anterior tibial muscle.
Myocardial Infarction
Reproducible infarcts of the anterior LV wall were imposed on
6-month-old mice by cryogeny with a 6-mm2 cryoprobe.
Brieﬂy, after isoﬂuorane (2%) anesthesia, a thoracotomy was
performed through the fourth left intercostal space, the
pericardium was opened, and the heart was exposed.
Cryoinfarction was produced by applying the cryoprobe to
the anterior LV free wall, followed by freezing for 10 seconds.
The exact position of the probe was set carefully by using the
left atrium and pulmonary artery as anatomic landmarks.
Rinsing with room-temperature saline was performed to allow
nontraumatic detachment of the probe from the LV wall after
freezing. Cardiac ultrasound analysis was performed 8 weeks
after the lesion was created.
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Urinary Protein Excretion
As a marker of renal damage,16 we assessed urinary protein
excretion nephelometry (bicinchoninic acid method; Pierce,
Rockford, IL) by placing the mice (n=12 in each group) in
metabolic cages (Tecniplast, Buguggiate, Italy) for 24 hours.
Ex Vivo Studies
Vascular Reactivity
Aortic rings (6 to 9 mm) from 6-month-old mice were
suspended in isolated tissue baths (Radnoti Glass Technology,
Monrovia, CA) ﬁlled with 25 mL Krebs-Henseleit solution (in
mmol/L: NaCl 118.3, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4
1.2, NaHCO3 25, and glucose 5.6) continuously bubbled with a
mixture of 5% CO2 and 95% O2 (pH 7.38 to 7.42) at 37°C,
according to the protocol used in our laboratory.23 Vasorelax-
ation was assessed in vessels preconstricted with phenyleph-
rine (1 lmol/L) in response to isoproterenol, acetylcholine, or
nitroprusside, all from 10 nmol/L to 10 lmol/L, freshly
prepared on the day of experiment.23 Endothelium-indepen-
dent vasorelaxation also was tested after incubation
(10 lmol/L, 15 minutes) with NG-nitro-L-arginine methyl ester
(Sigma-Aldrich, Milan, Italy), a competitive inhibitor of endo-
thelial nitric oxide synthase (eNOS). Concentrations are
reported as the ﬁnal molar value in the organ bath.
Histology
Samples (hearts, kidneys, muscles) were ﬁxed in 10% buffered
formalin and processed for parafﬁn embedding.24 Slides were
stained with hematoxylin and eosin for architectural analysis
or with Masson’s trichrome to assess the presence and extent
of interﬁber interstitial ﬁbrosis.19,24,25 Percent collagen was
calculated from high-resolution, color-calibrated digital
images of Masson’s trichrome–stained sections with the use
of dedicated software (NIH ImageJ64), as described.19 To
measure myocyte cross-sectional area (lm2) we used
ﬂuorescence-tagged wheat germ agglutinin staining
(5.0 lg/mL; with samples incubated in the dark for 10 min-
utes at 37°C). Images were recorded at 494-nm excitation
and 518-nm emission and were evaluated with ImageJ64.
Lectin immunohistochemical staining was performed on
myocardial and skeletal muscle.21,26
Quantiﬁcation of Atherosclerotic Lesions
Atherosclerotic lesions in 18-month-old mice were detected
by staining with the neutral lipid-targeting lysochrome
Oil Red O (Sigma-Aldrich, Milan, Italy). Each aorta was rinsed
ﬁrst in distilled water and then quickly in 60% isopropyl
alcohol. Subsequently, vessels were stained for 25 minutes
(in a solution of 15 g Oil Red O, 30 mL isopropyl alcohol, and
20 mL distilled water, freshly prepared and ﬁltered) and then
were washed. The Oil Red O–stained areas of the inner aortic
surfaces were quantiﬁed using the free software Fiji. The
extent of atherosclerosis was assessed on longitudinally
opened aorta and expressed as the percentage of the lipid-
accumulating lesion area to the total aortic area analyzed.
Acquisition of images and analysis of lesions were performed
in a blinded fashion.
In Vitro Assays
Cell Culture
Murine aortic ECs were isolated from 3-month-old CaMK4/
and CaMK4+/+ animals as previously described.27 Bovine
aortic ECs and human embrionic kidney (HEK293) cells were
purchased from Lonza (Basel, Switzerland) and American Type
Culture Collection (ATCC; Manassas, VA), respectively. Cells
were cultured in Dulbecco’s modiﬁed Eagle medium (Sigma-
Aldrich, Milan, Italy) as described.19 All experiments were
performed in triplicate to ensure reproducibility. We used
ionomycin (1 lmol/L; Sigma-Aldrich) as activator and KN93
(5 lmol/L; Seikagaku Corporation, Tokyo, Japan) as inhibitor
of CaMK.5,28
Immunoprecipitation and Immunoblotting
Immunoblot analysis was performed as previously described
and validated.21 Blots were probed with mouse monoclonal
antibodies against eNOS, phospho-eNOS (peNOS Ser1177),
CaMKIV (BD Bioscience, Franklin Lakes, NJ), peNOS Ser114,
peNOS Ser615 (Millipore, Billerica, MA), peNOS Thr495,
pCaMKIV, CaMKII, pCaMKII, and actin (Santa Cruz Biotech-
nology, Santa Cruz, CA). Images then were digitalized and
densitometry was assessed with dedicated software (Image
Quant, GE Healthcare, Piscataway, NJ). Data are presented as
arbitrary units after normalization for the total corresponding
protein or actin as loading control, as indicated.
eNOS Activity Assay
eNOS activity was detected in CaMK4/ and CaMK4+/+
murine aortic ECs and in bovine aortic ECs by measuring
the conversion of L-[3H]arginine to L-[3H]citrulline at 37°C
for 30 minutes with the eNOS assay kit (Calbiochem-Nova
Biochem, San Diego, CA), according to the manufacturer’s
instructions. Unlabeled L-arginine was added to L-[3H]
arginine (speciﬁc activity, 60 Ci/mmol/L) at a ratio of
3:1. Mouse cerebellum extracts, containing elevated
amounts of neuronal NOS, were used as positive controls,
whereas samples incubated in the presence of NG-nitro-L-
arginine methyl ester (1 mmol/L) were used to determine
nonspeciﬁc activity.
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CaMKIV Activity Assay
The CaMKIV activity assay consisted of 2 reaction steps.
Brieﬂy, in the ﬁrst step, active recombinant full-length CaMKIV
(Millipore, Billerica, MA) was incubated at 30°C for 30 min-
utes with 0.5 mmol/L CaCl2 and 1 lmol/L CaM in 25 lL of a
reaction mixture (25 mmol/L 4-[2-hydroxyethyl]-1-piperazi-
neethanesulfonic acid [HEPES], pH 7.5, 0.5 mmol/L MgCl2,
1 mmol/L dithiothreitol, 0.5 mg/L BSA, 1 mmol/L sodium
orthovanadate, 0.1 mmol/L cold adenosine triphosphate
(ATP), and H2O 0.01% Tween 20). In the second step, a 20-
lL aliquot from the ﬁrst reaction mixture containing active
CaMKIV was incubated in 50 lL of a solution containing
0.1 IU of eNOS (Calbiochem-Nova Biochem, San Diego, CA)
as substrate and 1 mmol/L EGTA, 0.5 lL [32P]-cATP (3000
Ci/mmol/L) for 30 minutes at 30°C. The reactions were
stopped by the addition of sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (SDS-PAGE) sample loading buffer,
and the whole reaction mixes were separated on 4% to 12%
SDS-PAGE (Life Technologies, Grand Island, NY). Then, the gel
was dried and peNOS was visualized by phosphorImager (GE
Healthcare, Piscataway, NJ).
Alternatively, a partially modiﬁed protocol was performed
without the use of radioactive ATP. In this case, after PAGE,
proteins were blotted on nitrocellulose, and eNOS
phosphorylation by CaMKIV was also assessed by Western
blot by using the previously mentioned antibodies.
Overlay Blot Assay
Twenty nanograms of CaMKIV and 0.1 IU of eNOS-puriﬁed
proteins were subjected to SDS-PAGE and transferred on
nitrocellulose. The membranes were incubated 2 hours at
room temperature in 5% blocking solution. At this time, the
ﬁlters were incubated with CaMKIV or eNOS-puriﬁed protein
in phosphorylation solution (ﬁnal concentrations: 20 lmol/L
ATP, 1 mmol/L CaCl2, 20 mmol/L MgCl2, and 4 mmol/L
Tris, pH 7.5). After 1 hour of incubation at room temperature,
the blots were cooled rapidly on ice; washed twice with NaCl,
Tris, and 0.1% Tween 20; and then ﬁxed with 0.5% formal-
dehyde for 10 minutes. The ﬁlters were washed 3 times with
2% glycine and once with NaCl, Tris, and 0.1% Tween 20.
CaMKIV or eNOS-bound proteins were detected by chemilu-
minescence.29
Human Association Study
Study participants were consecutive hypertensive patients
referred to the Hypertension Diagnosis and Care Outpatient
Clinic of “Federico II” University of Naples. Age-matched
unaffected controls were recruited from a database of
normotensive blood donors. The matching design was
accounted for in the statistical analyses. All subjects were
white and born within the Campania region in Southern Italy.
We had access to a digital archive for each participant.30
Enrollment criteria for hypertensive status were an age of 18
to 80 years and a conﬁrmed diagnosis of essential hyperten-
sion. We considered the average systolic and diastolic BP
values, according to European guidelines.16
Analysis of the rs10491334 SNP of CaMK4 was performed
on peripheral blood DNA by restriction fragment length
polymorphism.30 Genetic analyses were performed by
laboratory personnel blinded to sample identity. Patients’
lymphocytes were extracted by means of phicoll puriﬁcation
with HISTOPAQUE-1077 (Sigma-Aldrich) from a 20-mL blood
sample, which had been anticoagulated with ethylenediamine-
tetraacetic acid.31
Data Presentation and Statistical Analysis
Data are presented as mean ± standard error (SE) unless
otherwise mentioned. To determine the statistical signiﬁcance
of the results, we used 1-way ANOVA or Kruskal-Wallis test,
as appropriate (nonparametric analysis was used when a large
number of tests increased the risk of a type a error). Survival
curves were compared with the log-rank test.
To assess signiﬁcant differences between genotype classes
in the human studies, we used the Student t test for continuous
variables and the Fisher exact test for categorical variables. The
association between the SNP and hypertension was adjusted
for age, sex, heart rate, and body mass index. Statistical
signiﬁcancewas set at P<0.05. All the analyses were performed
with GraphPad Prism version 5.01 (GraphPad Software, San
Diego, CA), Systat 13 (Systat software, Inc, Chicago, IL), and
Statistical Package for Social Sciences software version 20.0.0
(IBM SPSS Inc, Armonk, NY).
Results
BP, Organ Damage, and Survival
CaMK4/ mice developed higher systolic and diastolic BP
levels than did CaMK4+/+ littermates, as shown in Table 1.
We decided to assess BP-dependent phenotypes, such as
target-organ damage, in homozygous mice only. At
6 months, cardiac ultrasound analysis showed that
CaMK4/ mice displayed concentric25,31,32 LV hypertrophy
(LVH) due to increased septum and posterior wall thickness,
with no signiﬁcant changes in internal diameter, as depicted
in Table 1. At gross analysis, CAMK4/ hearts were larger
both as absolute values (163.1±4.5 versus 136.8±3.1 mg,
Figure 1A) and after correction by either body weight
(Figure 1B) or tibial length (Figure 1C). Histological analysis
showed increased cell size of CAMK4/ cardiomyocytes
(Figure 1D and 1E) and augmented interstitial ﬁbrosis
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Figure 1. LVH in CaMK4/ mice. CaMK4/ 6-month-old mice present cardiac hypertrophy, as determined by an increase in heart weight (A),
normalized by body weight (B) or tibial length (C). Fluorescence-tagged wheat germ agglutinin, which binds to saccharides of cellular membranes,
showed increased cardiac myocyte cross-sectional area in CaMK4/ mice (D and E; magniﬁcation 9200, scale bar = 15 lm). Masson’s
trichrome staining (F; magniﬁcation 9300, scale bar = 15 lm; interstitial and perivascular collagen deposition indicated by black arrows and
yellow arrowheads, respectively) also revealed an increase in ﬁbrosis, quantiﬁed as described in Methods (G). Blue bars are CaMK4+/+ mice; red
bars, CaMK4/ mice. *P<0.05 vs CaMK4+/+.
Table 1. Systemic and LV Hemodynamics in CAMK4+/+ and CAMK4/ Mice
CaMK4+/+
(n=12)
CaMK4/
(n=13)
CaMK4+/+
(n=14)
CaMK4/
(n=16)
CaMK4+/+
(n=12)
CaMK4/
(n=13)
3-Month-Old Mice 6-Month-Old Mice 18-Month-Old Mice
HR, bpm 492±28 486±36 486±18 474±16 460±32 468±28
SBP, mm Hg 111±1.3 113±1.8 110±0.6 123±0.7* 111±1.1 124±1.3*
DBP, mm Hg 81±0.9 82±1.1 81±0.3 90±0.3* 86±0.8 93±0.9*
LVEDD, mm 3.71±0.42 3.73±0.35 3.85±0.32 3.74±0.29 3.89±0.37 4.36±0.3*
LVESD, mm 2.08±0.26 2.15±0.28 2.19±0.27 2.37±0.28 2.22±0.3 3.02±0.46*
IVS, mm 0.72±0.04 0.73±0.05 0.72±0.03 0.88±0.02* 0.82±0.04 0.89±0.03*
LVPW, mm 0.71±0.03 0.72±0.04 0.69±0.02 0.89±0.03* 0.78±0.03 0.92±0.04*
LVFS, % 43.4±4.8 42.6±5.5 42.4±4.5 36.2±6.1* 37.2±5.8 30.2±7.2*
LVEF, % 66.8±8.2 66.3±9.1 64.8±8.6 59.6±7.8 56.4±9.4 50.1±9.8*
+dP/dt, mm Hg/s 6334±602 6211±522 6237±531 5681±498* 6004±582 5014±578*
dP/dt, mm Hg/s 6420±542 6322±508 6302±504 5702±486* 6080±682 5112±606*
Data are mean±SE. HR indicates heart rate; SBP, systolic BP; DBP, diastolic BP; LVEDD, LV end-diastolic diameter; LVESD, LV end-systolic diameter; IVS, interventricular septum; LVPW,
LV posterior wall; LVFS, LV fractional shortening; and LVEF, LV ejection fraction.
*P<0.05 comparing CaMK4/ to CaMK4+/+at each time point; otherwise, P not signiﬁcant.
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(Figure 1F and 1G), 2 common elements of hypertension-
induced LVH.19 In older mice (18 months old), cardiac
damage evolved toward dilatation and dysfunction (Table 1)
complicated by arrhythmias, as shown by ECG (Figure 2A
through 2C), according to the natural history of untreated
hypertension.33 Indeed, LVH is associated with alterations in
the dispersion of repolarization34 and prolongation of
ventricular action potentials.35 These effects result in
electrical instability and increase the propensity to develop
arrhythmias. When an antihypertensive treatment with
furosemide was initiated at 3 months of age, the develop-
ment of both hypertension and LVH was prevented (Table 2).
Figure 2. Organ damage in 18-month-old mice. Old CaMK4/ mice displayed a dilatation of the LV (see also Table 1) and exhibited several
spontaneous ventricular arrhythmias (A; representative ECG records at different heart rates). These data are quantiﬁed in B and C (n=10 per
group; *P<0.05). Of note, heart rate among mutated animals did not signiﬁcantly differ (see Table 1). D and E, Lipid deposition in vessels of
CaMK4+/+ and CaMK4/ mice (n=12 per group). Representative pictures of oil red O–stained ascending aortas (D; white bar = 600 lm); areas
of atherosclerotic lesions were quantiﬁed using the free software Fiji and are represented as percentage of lesion area to total aortic area (E;
*P<0.05 vs CaMK4+/+). Kidneys (F) from the CaMK4/ group exhibited increased glomerulosclerosis, inﬂammatory cell inﬁltration, and
tubulointerstitial ﬁbrosis compared with CaMK4+/+ mice (n=8 per group; representative pictures of hematoxylin and eosin or Masson’s trichrome
staining; magniﬁcation 960; green bar = 100 lm). Moreover, 18-month-old CaMK4/ mice presented another typical feature of the
hypertensive phenotype (G), showing greater proteinuria than CaMK4+/+ mice (n=12 per group; *P<0.05 vs CaMK4+/+). In all histograms, blue
bars are CaMK4+/+ mice; red bars, CaMK4/ mice. Notably, compared with CaMK4+/+ mice, CaMK4-null mice displayed signiﬁcantly (*P<0.05)
impaired survival, as well (Kaplan-Meier curves; H). Blue line indicates CaMK4+/+ mice; red dotted line, CaMK4/ mice.
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Along with increased heart size, CAMK4/ mice over
time developed hypertensive vascular damage, as assessed
by Oil Red O staining (Figure 2D), which revealed larger
atherosclerotic lesions in aortas from 18-month-old
CaMK4/ mice versus CaMK4+/+ mice (Figure 2E). We
also found renal damage, another typical feature of the
hypertensive phenotype,16 inasmuch as CaMK4/ mice
displayed increased glomerulosclerosis, inﬂammatory cell
inﬁltration, and tubulointerstitial ﬁbrosis compared with
CaMK4+/+ mice (Figure 2F). The functional correlate to this
histological alteration is increased proteinuria in 18-month-
old CaMK4/ mice (Figure 2G). Furosemide-treated
CaMK4/ mice still presented proteinuria (Figure 2G),
although they had normal BP levels.
Eventually, CaMK4/ mice showed signiﬁcantly reduced
lifespan compared with CAMK4+/+ littermates (Figure 2H).
Assessment of Endothelium-Dependent
Phenotypes
Endothelium-dependent vasodilation in ex vivo experiments
was assessed on isolated aortic rings. After vasoconstriction
obtained through 1 lmol/L phenylephrine (Figure 3A), aortic
rings from CaMK4/ mice showed impaired endothelial-
dependent vasodilation both to the b-adrenergic agonist
isoproterenol and to the muscarinic agonist acetylcholine,
which is consistent with our hypothesis of endothelial
dysfunction (Figure 3B and 3C), a known hallmark of the
hypertensive state.13 Moreover, there was no difference in the
vascular smooth muscle cell–mediated response to the nitric
oxide donor nitroprusside (Figure 3D), and experiments
performed after NG-nitro-L-arginine methyl ester incubation
conﬁrmed intact endothelium-independent vasodilation in
both CaMK4/ and CaMK4+/+ vessels (Figure 3E and 3F).
Additionally, we assessed in vivo the angiogenic response
to ischemia after femoral artery removal, a phenotype that is
largely under the control of the endothelium.21,23,36
CaMK4/ mice displayed impaired angiogenesis after
21 days of peripheral ischemia, as assessed by laser Doppler
(Figure 4A and 4B), Doppler ultrasound (Figure 4C), dyed
microbeads (Figure 4D), and capillary density (Figure 4E
and 4F).
Development of Heart Failure After Myocardial
Infarction
Increased BP and reduced angiogenesis are expected to
precipitate the evolution of the heart failure phenotype after
myocardial damage.17,37 Indeed, 8 weeks after myocardial
cryoinfarction, CaMK4/ mice presented larger LV dilatation
and a greater decrease in cardiac function than did CAMK4+/+
mice, as shown in both Table 3 and Figure 5A. This feature
also was accompanied by reduced capillary density in the
peri-infarct area (Figure 5B and 5C).
Interaction Between CaMKIV and eNOS
Because endothelium dysfunction can be mimicked by altered
production or removal of nitric oxide, we assessed the effect
of CaMK4 knockout on eNOS activation. Indeed, calcium-
induced eNOS phosphorylation on Ser1177 is impaired in
CaMK4/ ECs. (Figures 6A and 7A through 7C). This
Table 2. Effect of Long-Term Diuretic Treatment on Systemic and LV Hemodynamics in CAMK4+/+ and CAMK4/ Mice
CaMK4+/+ (n=11) CaMK4/ (n=16) CaMK4+/+ (n=10) CaMK4/ (n=14)
6-Month-Old Mice Treated (3 Months) With Furosemide 18-Month-Old Mice Treated (15 Months) With Furosemide
HR, bpm 498±46 492±38 483±52 488±41
SBP, mm Hg 107±6.8 114±1.8 103±6.6 104±1.3
DBP, mm Hg 74±8.5 83±1.1 75±5.9 78±1.2
LVEDD, mm 3.82±0.9 3.83±0.4 3.9±0.8 3.95±0.7
LVESD, mm 2.21±0.8 2.23±0.3 2.26±0.9 2.28±0.5
IVS, mm 0.71±0.08 0.76±0.04 0.78±0.09 0.8±0.05
LVPW, mm 0.69±0.07 0.77±0.05 0.76±0.08 0.79±0.06
LVFS, % 41.6±8.8 39.2±7.3 36.9±8.6 36.5±7.1
LVEF, % 62.8±9.7 62.5±8.4 55.4±8.1 55.1±8.9
+dP/dt, mm Hg/s 6126±684 6088±642 5522±528 5876±627
dP/dt, mm Hg/s 6188±747 6104±594 5596±639 5892±582
Data are mean±SE. HR indicates heart rate; SBP, systolic BP; DBP, diastolic BP; LVEDD, LV end-diastolic diameter; LVESD, LV end-systolic diameter; IVS, interventricular septum; LVPW, LV
posterior wall; LVFS, LV fractional shortening; and LVEF, LV ejection fraction.
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impairment associates with a reduction in CaMKIV expression
and activity in CaMK4/ EC, whereas activation of CaMKII
remains unaffected (Figure 6A). This ﬁnding also is endorsed
by a reduction in eNOS activity (Figure 8). Interestingly,
transgenic restoration of CaMKIV expression in CaMK4/
ECs also corrects calcium-induced eNOS activation (Fig-
ures 6B, 7D, and 7E). CaMKIV and eNOS can
coimmunoprecipitate in either naïve or overexpressing cells
(Figures 6C and 9). The physical interaction between the 2
proteins can be replicated in an overlay assay with the use of
puriﬁed CaMKIV and eNOS, which indicates that the
interaction is not mediated by a third component (Figure 6D).
The result of this physical interaction is the incorporation in
eNOS of 32P (Figure 6E). Also, in vitro, puriﬁed CaMKIV can
phosphorylate eNOS directly on Ser1177 and Ser615, 2
phosphorylation sites that are regulatory for enzyme activity,
but not on other phosphorylation sites of eNOS, namely
Ser114 and Thr495 (Figures 6F and 7F through 7I).
Role of rs10491334 T/C Polymorphism of
Human CaMK4 Gene in Hypertensive Patients
The results gained in the CaMK4/ mouse show a role for
this kinase in the setup of hypertension. To conﬁrm the
possible relevance of this ﬁnding in humans, we studied the
frequencies of the rs10491334 T/C SNP.6 This polymorphism
associates with a reduction in the cellular expression of the
kinase.38 We studied 2 populations of normotensive (n=457)
and hypertensive subjects (n=730). Clinical characteristics
of these individuals are reported in Table 4. We found a higher
occurrence of the polymorphism among the hyperten-
sive patients that fell short of statistical signiﬁcance
Figure 3. Vascular responses on isolated aortic rings from 6-month-old mice. Vasoconstriction to a1-adrenergic agonist phenylephrine was
similar in CaMK4+/+ and CaMK4/ mice (A). Endothelium-dependent vasorelaxation induced by the b-adrenergic agonist isoproterenol (B) or by
the muscarinic agonist acetylcholine (C) was blunted in CaMK4/ vessels, whereas endothelium-independent vasodilation to nitroprusside was
not different between CaMK4+/+ and CaMK4/ (D). To better explore the role of nitric oxide in endothelial responses, we also evaluated vascular
responses in the presence (10 lmol/L) of the speciﬁc eNOS inhibitor NG-nitro-L-arginine methyl ester (E and F). *P<0.05 vs CaMK4+/+.
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(normotensive patients: 31.32%; hypertensive patients:
41.64%; P=0.0594, Pearson v2 analysis). Thus, we dichoto-
mized our hypertensive population according to European
Guidelines into categories of severe (Grade 2/3) and not-severe
(Grade 1) diastolic hypertension (cutoff: diastolic BP=100 mm
Hg)16 and found a signiﬁcantly larger frequency of the T variant
of the rs10491334 SNP in patients with severe hypertension
than in patients with diastolic BP<100 mm Hg (54.42%
versus 38.41%; P<0.05, Pearson v2 analysis), as shown in
Table 5. Intriguingly, hypertensive patients homozygous
for the polymorphic T allele showed reduced expression levels
of CaMKIV in circulating peripheral blood lymphocytes
(Figure 10).
Discussion
In the present study, we provide compelling evidence for a
fundamental and previously unrecognized role of CaMKIV in
the regulation of vascular function. Indeed, the phenotype of
the CaMK4/ mouse indicates that this kinase is extremely
important for endothelial function. A paramount ﬁnding of this
Figure 4. Decreased neoangiogenic responses in CaMK4/ mice during chronic ischemia in vivo (n=6 per group). Determination of laser
Doppler blood ﬂow (A and B) on postoperative days 3, 7, 14, and 21 showed a deﬁcit in ischemic hindlimb perfusion, compared with the
contralateral hindlimb, that was signiﬁcantly increased in CaMK4/ vs CaMK4+/+ mice (*P<0.05, repeated measurements, ANOVA; laser
Doppler blood ﬂow data are expressed as percent of ischemic to nonischemic limb). Ultrasound Doppler ﬂowmetry of posterior tibial artery (C),
performed 3 weeks after femoral artery removal, conﬁrmed the attenuated blood ﬂow restoration in CaMK4/ mice (*P<0.05 vs CaMK4+/+).
This result was mirrored by the dyed-bead perfusion analysis (D; *P<0.05 vs CaMK4+/+). Lectin staining of capillaries in the ischemic hindlimb
(E; magniﬁcation 920, black bar = 100 lm) showed that chronic ischemia produced a greater rarefaction of the capillary density, evaluated as
number of capillaries corrected for the number of muscle ﬁbers (F), in CaMK4/ compared with CaMK4+/+ mice (*P<0.05). In all histograms,
blue bars are CaMK4+/+ mice; red bars, CaMK4/ mice.
Table 3. Systemic and LV Hemodynamics in CAMK4+/+ and
CAMK4/ Mice 8 Weeks After Myocardial Infarction
CaMK4+/+
(n=12)
CaMK4/
(n=14)
HR, bpm 498±20 482±18
SBP, mm Hg 100±0.5 108±0.6*
DBP, mm Hg 74±0.3 82±0.4*
LVEDD, mm 4.16±0.12 4.6±0.11*
LVESD, mm 3.15±0.08 3.71±0.13*
IVS, mm 0.66±0.04 0.85±0.05*
LVPW, mm 0.68±0.03 0.86±0.03*
LVFS, % 24.74±2.9 17.8±2.3*
LVEF, % 49.02±4.8 35.8±3.4*
+dP/dt, mm Hg/s 3784±402 3004±382*
dP/dt, mm Hg/s 3918±386 3128±394*
Data are mean±SE. Mice were 8 months old (myocardial infarction was induced in 6-
month-old animals). HR indicates heart rate; SBP, systolic BP; DBP, diastolic BP; LVEDD,
LV end-diastolic diameter; LVESD, LV end-systolic diameter; IVS, interventricular septum;
LVPW, LV posterior wall; LVFS, LV fractional shortening; and LVEF, LV ejection fraction.
*P<0.05; otherwise, P not signiﬁcant.
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Figure 5. Cardiac evaluation after cryoinjury. Changes in echocardiographic parameters (A) 8 weeks after myocardial infarction. (LVEDD
indicates LV end-diastolic diameter; LVFS, LV fractional shortening; and LVEF, LV ejection fraction. n=12 per group. *P<0.05 vs CaMK4+/+).
Immunohistochemical analysis (B; lectin staining, magniﬁcation 960, black bar = 30 lm) of myocardium in mice 8 weeks after infarction. The
peri-infarct area demonstrated lower capillary density, as conﬁrmed by quantitative analysis (C); blue bars are CaMK4+/+ mice; red bars, CaMK4/
mice. *P<0.05 vs CaMK4+/+.
Figure 6. Interaction between CaMKIV and eNOS. eNOS phosphorylation (Ser1177) is enhanced by ionomycin, echoing the phosphorylation of
CaMKIV, and is prevented by the CaMK inhibitor KN93 (A). Notably, eNOS activation was less evident in CaMK4/ MAEC, where CaMK4 was not
expressed (A). Transgenic restoration of CaMKIV expression in CaMK4/ ECs corrected calcium-induced eNOS activation (B). The interaction
between CaMKIV and eNOS was demonstrated by performing immunoprecipitation (IP) experiments in different cellular settings, both in basal
conditions and after stimulation with ionomycin (C). Such interaction is shown in BAEC and CaMK4+/+ MAEC but not in CaMK4/ MAEC. In a
nonendothelial cell type, HEK293, we conﬁrmed the interaction after reconstituting the system by using a plasmid encoding CaMKIV and a plasmid
encoding eNOS linked to GFP (C; rat cerebellum was used as CaMKIV-positive control). The input protein levels are shown in Figure 8. Overlay assay
with puriﬁed CaMKIV (left blot) or eNOS (right blot) as bait (D). CaMKIV induced eNOS [32P]-cATP incorporation (E). Puriﬁed CaMKIV induced eNOS
phosphorylation on Ser1177 and Ser615 but not on Ser114 and Thr495 (F). *P<0.05 vs eNOS, *P<0.05 vs CaMKIV; representative images from triplicate
experiments are shown. Densitometric analyses are reported in Figure 7. MAEC indicates murine aortic ECs; BAEC, bovine aortic ECs.
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study is that the loss of CaMK4 results in the development of
hypertension, accompanied by its typical hallmarks: endothe-
lial dysfunction, target-organ damage, and reduced survival
rate.16,32 Interestingly, furosemide-treated mice did not
display LVH, which suggests that LVH is indeed the result
of increased BP rather than being genetically determined by
CaMK4 gene removal.13 We used a loop diuretic to obtain an
effective BP decrease with minimum effect on vascular
function.16 Moreover, other diuretics, such as thiazides, have
metabolic implications not present in furosemide treatment16
that could confuse the cardiovascular phenotype of our
CaMK4/ mice further. In our model, endothelial dysfunc-
tion could be either primitive to hypertension or, alternatively,
secondary to the hypertensive state of CaMK4/ mice. We
rule out this second hypothesis on the basis of 2 pieces of
evidence: First, diuretic treatment resulted in normalization of
Figure 7. Quantiﬁcation of blot results presented in Figure 6. Relative protein quantiﬁcation levels for Figure 6A (A–C) and Figure 6B (D–E).
Blue bars are CaMK4+/+; red bars, CaMK4/. *P<0.05 vs untreated cells; #P<0.05 vs MAEC CaMK4+/+. MAEC indicates murine aortic ECs.
Densitometric analyses for Figure 6F (F–H) showing CaMKIV-mediated eNOS phosphorylation on Ser1177 and Ser615 but not on Ser114 and Thr495.
Red bars indicate eNOS; black bars, CaMKIV; and blue bars, eNOS and CaMKIV. *P<0.05 vs eNOS.
Figure 8. eNOS activity in ECs. eNOS activity, assessed by
arginine–citrulline conversion, after stimulation by ionomycin
(1 lmol/L) was blunted in CaMK4/ MAEC. *P<0.05 vs basal;
#P<0.05 vs CaMK4+/+. MAEC indicates murine aortic ECs; CPM,
counts per minute.
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hemodynamic-dependent LVH but did not correct proteinuria,
which is a characteristic of endothelial dysfunction.39 Second,
in a hemodynamic-independent setup36 (ie, in isolated ECs),
CaMK4 removal causes endothelial dysfunction as assessed
by reduction of eNOS activity, which is corrected only after
gene replacement. Endothelial dysfunction is known to induce
hypertension, as demonstrated in eNOS/ mice, which show
absent endothelial-dependent vasorelaxation and increased
BP.13
Our study is the ﬁrst to demonstrate the interaction of
CaMKIV and eNOS. Previous reports had suggested the impor-
tance of CaMKs in endothelium-dependent relaxation.40–42 In
addition, 2 independent groups had provided evidence that a
nonselective CaMK inhibitor could signiﬁcantly decrease
bradykinin-induced eNOS activity12 and prevent eNOS phos-
phorylation28 in rat and porcine aortic ECs, respectively. Our
study characterizes the close relationship between CaMKIV and
eNOS in the endothelium. Indeed, CaMKIV can phosphorylate
eNOS directly in Ser1177 and Ser615, 2 sites that are known to
induce eNOS activation. Although we have not investigated all
Figure 9. Input Western blots of immunoprecipitation assay rep-
resented in Figure 6C. To conﬁrm that equal amounts of proteins
were present in the cell lysates used for immunoprecipitation as
depicted in Figure 6C, we performed Western blotting on 30 lg of
proteins of corresponding cell lysates with the same antibodies used
in the experiment represented in Figure 6C, raised respectively
against CaMKIV and eNOS. Furthermore, actin was detected to
conﬁrm equal amount of proteins.
Table 4. Characteristics of the Normotensive and
Hypertensive Populations
Normotensive
Subjects
(n=457)
Hypertensive
Subjects
(n=730)
Age, y 52.91±3.4 55.84±2.9
Sex (male/female), n 288/169 452/278
HR, bpm 76.8±9.3 72.8±8.2
SBP, mm Hg 131.67±0.84 147.7±0.72*
DBP, mm Hg 77.06±0.51 96.69±0.48*
Body mass index, kg/m2 26.03±0.27 27.19±0.21
Smoking (current or former), % 53.6 54.1
Glycemia, mmol/L 4.8±0.72 5.2±0.88
Diabetes, % 4.7 5.9
Total cholesterol, mmol/L 4.35±0.12 4.98±0.18
High-density lipoprotein
cholesterol, mmol/L
1.24±0.11 1.21±0.14
Low-density lipoprotein
cholesterol, mmol/L
2.96±0.13 3.25±0.19
Triglycerides, mmol/L 1.46±0.09 1.53±0.11
Dyslipidemia, % 37.8 41.2
LV mass index, g/m2 92.6±4.5 115.34±4.8*
CaMK4 rs10491334
polymorphism
(T-allele frequency), %
31.32 41.64
Data are mean±SE; n, or %, as indicated. HR indicates heart rate; SBP, systolic BP; and
DBP, diastolic BP.
*P<0.05; otherwise, P not signiﬁcant.
Table 5. Characteristics of the Hypertensive Patients,
Subdivided Into 2 Populations According to a DBP Cutoff of
100 mm Hg
Patients With
DBP <100 mm
Hg
(n=583)
Patients With
DBP  100 mm
Hg
(n=147)
Age, y 54.9±3.6 56.2±3.8
Sex, male/female, n 371/212 81/66
HR, bpm 71.6±9.6 72.2±11.3
SBP, mm Hg 142.86±1.58 154.46±1.42*
DBP, mm Hg 91.89±0.74 108.69±0.86*
Body mass index, kg/m2 26.85±0.63 27.71±1.74
Smoking (current or former), % 55.4 53.3
Glycemia, mmol/L 5.4±0.77 5.1±0.98
Diabetes (%) 5.7 6.1
Total cholesterol, mmol/L 4.77±0.22 5.01±0.28
High-density lipoprotein
cholesterol, mmol/L
1.22±0.15 1.17±0.19
Low-density lipoprotein
cholesterol, mmol/L
3.32±0.17 3.05±0.23
Triglycerides, mmol/L 1.52±0.13 1.55±0.16
Dyslipidemia, % 43.1 39.8
LV mass index, g/m2 112.6±4.5 116.86±7.3
CaMK4 rs10491334
polymorphism
(T-allele frequency), %
38.41 54.42*
Data are mean±SE; n, or %, as indicated. HR indicates heart rate; SBP, systolic BP; and
DBP, diastolic BP.
*P<0.05; otherwise, P not signiﬁcant.
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phosphorylation sites of eNOS, these 2 appear to be relevant for
the described mechanism.
It is remarkable that CaMKII does not seem to supersede
CaMKIV loss. Although CaMKIV and CaMKII often are
considered mutually exchangeable, these 2 kinases present
differences in tissue distribution and regulation43,44 and
cannot be considered isoforms.5 For the present study, we
used mice generated in the Means’ laboratory in the 1990s.9
The cardiovascular phenotype of this mouse was never before
investigated as extensively as we have in the present report. A
hint of the higher BP of CaMK4/ mice can be found in the
article of Colomer and colleagues,4 showing that after
constriction of the thoracic aorta, BP gradients were higher
in CaMK4-null than in wild-type mice. Other reports have
failed to describe cardiovascular parameters of these mice.
Interestingly, though, CaMK4/ mice present cognitive
disorders that are typical of patients in the advanced phases
of untreated hypertension,45 such as erasure of long-term
memory.10 This phenotype has been ascribed to the loss of
CaMK4 signaling in neurons of CaMK4/ mice but also can
be worsened by chronic exposure to increased BP levels.
To ﬁnd a correlation between our observations in this
genetically modiﬁed mouse and the human condition, we took
advantage of the DNA Bank associated with the Campania
Salute database of >5000 hypertensive patients.30 Previously,
the Framingham study had identiﬁed an association marker
for high diastolic BP in the rs10491334 SNP of the human
Figure 10. Expression levels of CaMKIV in circulating lymphocytes
of hypertensive patients. Western blot analysis of CaMKIV on
peripheral blood lymphocytes showed that CaMKIV levels were
higher in subjects with the CaMK4 wild-type genotype (1, 2, 3, and 4
represent samples from 4 different individuals) than in subjects
homozygous for the polymorphic CaMK4 rs10491334 variant (A, B,
C, and D represent samples from 4 different individuals). Rat
cerebellum was used as CaMKIV-positive control. Data from
immunoblots (IB; representative images from 5 experiments are
shown) were quantiﬁed by densitometric analysis. CaMKIV levels
were normalized to actin densitometry. *P<0.05 vs CaMK4+/+. AU
indicates arbitrary units.
CaMK4 gene.6 Our study conﬁrms this ﬁnding: We performed
an association analysis with a candidate gene approach and
found a signiﬁcant correlation between the rs10491334 SNP
and diastolic BP levels among hypertensive patients. Further-
more, in the present work, we show that this polymorphism
associates with a reduction in the cellular expression levels of
CaMKIV, similar to that observed in other populations.38
These data are highly suggestive of the intrinsic regulatory
nature of CaMKIV in hypertension.
Our study follows the groove of the identiﬁcation of the
physiological implications of CaMKs in the cardiovascular
system.1–3 Some authors have investigated the effects of
CaMKIV in the heart by overexpressing it in cardiomyocytes,
leading to cardiac hypertrophy.46 This notion was challenged
by a more recent study showing that mice null for CaMK4
still developed LVH.4 Our data reconcile these opposing
views by suggesting that dysfunctional CaMKIV, albeit not
expressed in the heart, might partake in cardiac organ
damage in the context of the hypertensive state.
Conclusion
Our ﬁndings establish that CaMKIV plays a relevant role in the
regulation of the vascular tone by a mechanism that involves
eNOS activation through phosphorylative events. Impairment
of CaMK-mediated activation of eNOS, as in CaMK4 gene
deletion, induces hypertension, as demonstrated by the fact
that CAMK4/ mice display a hypertensive phenotype that
leads to typical organ damage. Extending our observations to
the clinical scenario, we show that in hypertensive patients a
CaMK4 polymorphism that causes reduced expression of the
protein identiﬁes a subset of patients with higher BP levels.
Altogether, our results point to CaMKIV as a novel potential
biological target for therapeutic interventions in hypertension.
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CORRESPONDENCE
Atrial remodelling in
echocardiographic
super-responders to cardiac
resynchronization therapy
To the Editor In a recent issue of Heart,
Steffel et al1 showed in an elegant retro-
spective study that patients with an excep-
tionally good echocardiographic response to
cardiac resynchronisation therapy (CRT) are
highly likely to experience a favourable
outcome after CRT. We feel that this paper is
worthy of comment. The study is well
designed and represents an outstanding ‘real
world’ experience. However, we do have
several issues. The authors present much
echocardiographic data regarding the
ventricular function, but there is no infor-
mation concerning atrial dimensions and
function. Given the rising interest about the
impact of CRT on atrial function,2 3 we
believe that such information may be of
value to the readers, especially from a popu-
lation of ‘super-responders’ with a long-term
follow-up. These data about atrial remodel-
ling could be also useful to clarify the role of
CRT response in the development of atrial
ﬁbrillation.2 3 Indeed, in the paper, there is
only the baseline percentage of patients with
atrial ﬁbrillation without any result of the
follow-up. Another moot point2 4 that the
authors can elucidate is the impact of
the aetiology of cardiomyopathy (ischaemic
vs non-ischaemic) on the response to CRT.
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The Authors’ reply We are thankful for the
interest of Santulli et al1 in our recent
manuscript published in Heart.2 We will
gladly respond to their comments.
An increasing body of evidence is implying
a beneﬁcial effect of cardiac resynchronisa-
tion therapy (CRT) on atrial remodelling and
the occurrence of atrial tachyarrhythmias.3 4
In our study, we indeed looked at the effect
of super-responder status on atrial size, but
did not include the results in the original
paper due to inconsistent ﬁndings. While no
signiﬁcant effect of responder status as
deﬁned by an increase in ejection fraction
(EF) >10% or a decrease in EDVI >30% was
observed, we did ﬁnd an atrial size reduction
of borderline signiﬁcance (48.767.5e4568.9,
p¼0.0573) when super-responders were
deﬁned by a decrease in end-systolic volume
index (ESVI) >20%. Due to these inconsis-
tencies, we believe that in our cohort we do
not have sufﬁcient evidence to postulate an
effect of CRT on atrial reverse remodelling.
Furthermore, due to the retrospective design
of our study, only incomplete data on left
atrial volumes, a more robust parameter of
atrial size, were available making analysis of
changes in left atrial volumes impossible.
Similarly, we did not ﬁnd an association of
Super-Responder Status (according to any of
the deﬁnitions) on the occurrence of atrial
ﬁbrillation (data not shown). This may be
due to the inclusion of a more heterogeneous
population in this ‘real world’ cohort as
compared with clinical trials, which may
have diluted a potentially beneﬁcial effect.
Hence, further research is warranted to
address these two issues in real world
patients with CRT.
In contrast, and as expected, we did ﬁnd
an impact of underlying coronary artery
disease, indicating that super-responders
deﬁned by a reduction in ESVI >30%
(p<0.02) and EDVI reduction >20%
(p¼0.09) were less likely to suffer from
coronary artery disease. These results are
included in the manuscript (tables 4e6).
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Endothelium
Endothelial Cells Are Able to Synthesize and Release
Catecholamines Both In Vitro and In Vivo
Daniela Sorriento, Gaetano Santulli, Carmine Del Giudice, Antonio Anastasio,
Bruno Trimarco, Guido Iaccarino
See Editorial Commentary, pp 12–14
Abstract—Recently it has been demonstrated that catecholamines are produced and used by macrophages and mediate
immune response. The aim of this study is to verify whether endothelial cells (ECs), which are of myeloid origin,
can produce catecholamines. We demonstrated that genes coding for tyrosine hydroxylase, Dopa decarboxylase,
dopamine  hydroxylase (DH), and phenylethanolamine-N-methyl transferase, enzymes involved in the synthesis
of catecholamines, are all expressed in basal conditions in bovine aorta ECs, and their expression is enhanced in
response to hypoxia. Moreover, hypoxia enhances catecholamine release. To evaluate the signal transduction
pathway that regulates catecholamine synthesis in ECs, we overexpressed in bovine aorta ECs either protein kinase
A (PKA) or the transcription factor cAMP response element binding, because PKA/cAMP response element
binding activation induces tyrosine hydroxylase transcription and activity in response to stress. Both cAMP
response element binding and PKA overexpression enhance DH and phenylethanolamine-N-methyl transferase
gene expression and catecholamine release, whereas H89, inhibitor of PKA, exerts the opposite effect, evidencing
the role of PKA/cAMP response element binding transduction pathway in the regulation of catecholamine release
in bovine aorta ECs. We then evaluated by immunohistochemistry the expression of tyrosine hydroxylase, Dopa
decarboxylase, DH, and phenylethanolamine-N-methyl transferase in femoral arteries from hindlimbs of C57Bl/6
mice 3 days after removal of the common femoral artery to induce chronic ischemia. Ischemia evokes tyrosine
hydroxylase, Dopa decarboxylase, DH, and phenylethanolamine-N-methyl transferase expression in the endo-
thelium. Finally, the pharmacological inhibition of catecholamine release by fusaric acid, an inhibitor of DH,
reduces the ability of ECs to form network-like structures on Matrigel matrix. In conclusion, our study
demonstrates for the first time that ECs are able to synthesize and release catecholamines in response to ischemia.
(Hypertension. 2012;60:129-136.) ● Online Data Supplement
Key Words: catecholamines  ischemia  endothelium  angiogenesis
Endothelial cells (ECs) cover the interior surface of bloodvessels throughout the entire circulatory system, and they
are involved in many aspects of vascular biology.1–4 Indeed,
angiogenesis is a phenomenon intimately associated with EC
migration and proliferation during embryonic development.5
Similarly, ECs play major roles in immune and inflammatory
reactions by regulating lymphocyte and leukocyte migration
into tissues by means of direct interaction with ECs.6 More-
over, ECs have an important role in the regulation of the
vascular tone by releasing vasoactive agents controlling
smooth muscle cell proliferation and contractility.
Indeed, ECs are known to release both vasodilators
(NO) and vasoconstrictors (thromboxane, platelet-derived
growth factor, and endothelin 1) in response to local and
circulating stimuli.7–14 To this purpose, the endothelium is
regulated in a fine way by a series of receptors that are
expressed on its surface, including adrenergic receptors
(ARs), such as 1 and 2AR.15,16 Circulating cat-
echolamines are thought to be the natural agonist of these
receptors, giving the fact that ECs are not reached by
sympathetic innervation.1
The endothelium derives from the embrional mesenchimal
sheet, so it does the population of myeloid lineage-restricted
bone marrow progenitors.17 The common features between
the 2 lineages are suggested by the observation that endothe-
lial progenitors are released in the bloodstream from bone
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marrow myelocytic progenitors.18 This finding is consistent
with results from several laboratories that have reported
circulating cells with myeloid features contributing to human
angiogenesis.19–22
Circulating catecholamines, dopamine, norepinephrine
(NE), and epinephrine (EPI), regulate vascular tone via AR
activation, leading to vasoconstriction in most systemic
arteries and veins. They are synthesized from the amino acid
precursor l-tyrosine. Tyrosine hydroxylase (TH) is the first
rate-limiting enzyme in catecholamine synthesis that cata-
lyzes the conversion of tyrosine to l-dihydroxyphenylalanine.
This latter is converted to dopamine by Dopa decarboxylase
(DDC). On turn, dopamine is converted to NE by dopamine
 hydroxylase (DH), and NE is converted to EPI by
phenylethanolamine-N-methyl transferase (PNMT).23–26
Once released, catecholamines are quickly inactivated by 2
enzymes that are responsible for their catabolism, catechol-
oxymethyltransferase and monoamine oxidase.27,28 Mono-
amine oxidase catalyzes the oxidative deamination of amines,
and catechol-oxymethyltransferase methylates the hydroxyl
group meta to the side chain of catecholamines.29 Until a few
years ago, catecholamines were considered mainly as con-
ventional neurotransmitters and neuroendocrine mediators,
synthesized in the adrenal medulla. However, it has been
demonstrated recently that they are also produced and used
by cells of the immune system.30–36 Indeed, catecholamines
are actively produced by macrophages and have the capacity
to act in an autocrine way on ARs to regulate macrophage
production of interleukin 1, which has a key role in the
inflammatory response.37
Giving the common myeloid origin of ECs and macro-
phages and the ability of cells of the immune system to
produce catecholamines, the aim of this study was to verify
whether ECs were also able to autonomously synthesize and
release catecholamines for signaling purposes.
Materials and Methods
All of the experiments were performed as described previously.38
Extended details of Methods are described in the online-only Data
Supplement.
Results
ECs Produce Catecholamines
To assess the ability of ECs to synthesize catecholamines, we
first evaluated the expression of genes coding for the en-
zymes involved in the synthesis of catecholamines by real-
time RT-PCR both in basal conditions and in response to
hypoxia. We performed a time course experiment evaluating
enzyme gene expression at 1, 3, 6, 16, and 24 hours of
hypoxia (Figure 1A). Hypoxia-induced TH, DDC, DH, and
PNMT gene expressions respect to basal conditions in a
time-dependent manner. At 16 hours of hypoxia, we found
the maximum expression of these enzymes, and then cells
start to die. Based on such data, we chose to incubate cells in
hypoxic conditions for 16 hours, because it is an intermediate
time between enzyme maximum expression and cell death.
We confirmed this result by Western blot analysis. Figure 1B
shows that hypoxia increased protein levels of TH, DDC,
DH, and PNMT in whole cell lysates. Total lysate from
mouse adrenal glands and spleens were used, respectively, as
positive and negative controls. We also verified enzyme
expression in bovine aorta ECs by immunohistochemistry.
TH, DDC, DH, and PNMT were all expressed in basal
condition, and their expression was enhanced by hypoxic
stimulus (Figure S1, available in the online-only Data Sup-
plement). Immunohistochemistry shows that DDC, DH, and
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response to hypoxia. A, RNA from bovine aorta endothelial cells
(BAECs) was converted to cDNA and analyzed by real-time PCR
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release. *P0.05 vs normoxia. Results are the mean of 5 inde-
pendent experiments. e, normoxia; , hypoxia.
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PNMT presented a cytosolic and perinuclear localization,
whereas TH was mainly localized in the nucleus. Finally, to
confirm the ability of bovine aorta ECs (BAECs) to produce
catecholamines, we analyzed NE and EPI release in the
culture medium by ELISA assay (Figure 1C). Hypoxia
enhanced both NE and EPI release with respect to normoxia.
Hypoxia Regulates Catecholamine Synthesis in EC
by Activation of Protein Kinase A/cAMP Response
Element Binding Signaling
To assess the signal transduction pathway that regulates
catecholamine synthesis in ECs, we evaluated protein kinase
A (PKA) signaling, because it is known that PKA/cAMP
response element binding (CREB) activation induces TH
transcription and activity in response to stress.39,40 We first
analyzed by Western blot the effect of hypoxia on the
activation of CREB and PKA. Figure 2A shows that hypoxia
induces the expression of the phosphorylated and activated
forms of both CREB and PKA, confirming that, also in
BAECs, hypoxia regulates PKA/CREB signaling. Based on
such data, we evaluated whether hypoxia-induced PKA/
CREB activation regulates catecholamine synthesis in
BAECs. In these experiments, we focused on DH and
PNMT expression, being the key enzymes for NE and EPI
synthesis. To assess whether this signaling was involved in
the regulation of catecholamine synthesis, we pharmacolog-
ically inhibited PKA/CREB signaling using a selective inhib-
itor of PKA, H89. This latter inhibited hypoxia induced DH
and PNMT gene expression (DH, 73.70.03% and
PNMT, 75.20.04% versus hypoxia; Figure 2B) and pre-
vented hypoxia-evoked increase of DH and PNMT protein
levels (Figure 2C). To further confirm these data, we used a
peptidic inhibitor of PKA (PKA-I), which is more specific
and selective respect to H89. PKA-I reduced both DH and
PNMT protein levels in response to hypoxia (Figure 2D).
These data demonstrate that, in BAECs, hypoxia induces
PKA/CREB signaling, and the activation of this pathway
regulates catecholamine synthesis. To confirm these results,
we overexpressed in BAECs both PKA and CREB by means
of transient transfection. Both CREB and PKA overexpres-
sion enhanced DH (CREB, 2.10.09; PKA, 62.01-
fold of basal) and PNMT (CREB, 9.80.3; PKA,
5.61.7-fold of basal) gene expression in basal conditions
(Figure 2E). PKA overexpression further enhanced the re-
sponse to hypoxia (DH 160.6 and PNMT 9.60.2
versus hypoxia; Figure 2E). Accordingly, Western blot anal-
ysis showed that CREB and PKA overexpression increased
DH and PNMT protein levels, and PKA overexpression
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further increased the response to hypoxia (Figure 2F). More-
over, PKA/CREB signaling also regulated catecholamine
release in the culture medium (Figure S2). Indeed, H89
inhibited hypoxia-induced NE (Figure S2A) and EPI (Figure
S2B) release. CREB overexpression caused NE (Figure S2C)
and EPI (Figure S2D) release. In these conditions, hypoxia
was no longer able to induce further accumulation (Figure
S2C and S2D). Also, PKA overexpression increased cate-
cholamine release (Figure S2C and S2D), and in these cells
hypoxia was still able to induce a modest increase of
catecholamine release. These data indicate that hypoxia-
induced activation of the PKA/CREB signaling transduction
pathway regulates catecholamine synthesis and release in
BAECs.
Endothelium Produces Catecholamines In Vivo
To confirm in vitro data, we evaluated in vivo by immuno-
histochemistry the expression of TH, DDC, DH, and PNMT
in superficial femoral arteries from hindlimbs of C57Bl/6
mice 3 days after surgery. Ischemia induced DDC, DH, and
PNMT expression in the endothelium of femoral arteries
(Figure 3A) and in capillaries, highlighted in the femoral
muscle by lectin staining (Figure 3B). On the contrary, TH
was maximally expressed in the cytoplasm of muscle cells,
although a higher magnification also revealed an endothelial
localization. Negative control with secondary antibody only was
shown in Figure S3.
Endothelium-Dependent Catecholamine Release
Has a Key Role in Angiogenesis In Vitro
To evaluate the physiopathological role of endothelium-
dependent catecholamine release in vitro, we evaluated the
ability of BAECs to form network-like structures on Matrigel
matrix in the presence or absence of a selective inhibitor of
DH, fusaric acid (FA). Figure S4 shows that hypoxia
induced vascular network formation and FA inhibited the
response to hypoxia (Figure S4A). To confirm that the effect
of FA on angiogenesis is ascribed to its ability to inhibit
catecholamine release, we evaluated NE and EPI release in
the culture medium by ELISA assay (Figure S4B and S4C).
A
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Hypoxia
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Hypoxia
TH DβHDDC PNMTLectin
TH DβHDDC PNMTLectin
Figure 3. Endothelial cell (EC) produce catecholamines in vivo. Immunohistochemical analysis of tyrosine hydroxylase (TH), Dopa
decarboxylase (DDC), dopamine  hydroxylase (DH), and phenylethanolamine-N-methyl transferase (PNMT) expression was performed
in superficial femoral arteries from hindlimbs of C57/black mice 3 days after removal of the common femoral artery. Ischemia induces
TH, DDC, DH, and PNMT expression in the endothelium of femoral arteries (A) and in capillaries (B), evidenced in the femoral muscle
by lectin staining. The expression of TH in endothelium is just evident at a higher magnification. TH is also expressed in the muscle tis-
sue, and its expression is enhanced in response to ischemia (B). Scale bar is 20 m. Images are representative of 3 independent
experiments.
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FA inhibited hypoxia-dependent catecholamine release (NE,
321.7%; EPI, 372.1% versus hypoxia). These data
suggest that ECs autonomously produce catecholamines
that have a key role in the regulation of EC proangiogenic
responses. To avoid the possibility that FA-dependent
inhibition of angiogenesis in vitro was attributed to a toxic
effect of the drug, we performed a proliferation assay using
different dosages of FA. FA turned out to be not toxic for
cells at doses from 10 nmol/L to 500 mol/L (data not
shown).
2AR Is Involved in Catecholamine-Induced
Angiogenesis in BAECs
We have demonstrated previously that 2AR has a key role in
angiogenesis both in vitro and in vivo.16,41 In particular, we
demonstrated in vivo that 2AR regulates angiogenesis in vivo
in response to ischemia, because angiogenesis is impaired in
2AR knockout mice and is ameliorated by reinstatement of
2AR. Here we tested this effect also on hypoxia-induced
angiogenesis in BAECs. To this aim we performed a real-time
PCR analysis to evaluate the effect of 2AR inhibition by the
selective inhibitor ICI 118.551 on vascular endothelial growth
factor gene expression. Our data show that 2AR blockade
is able to reduce vascular endothelial growth factor ex-
pression induced by hypoxia (Figure 4A), suggesting a key
role for this receptor in catecholamine-induced angiogenesis
in response to hypoxia. Furthermore, we evaluated whether
catecholamine-induced 2AR-dependent angiogenesis could,
in turn, be regulated by 2AR itself. To this aim, we
performed a real-time PCR experiment to evaluate DH and
PNMT gene expression in cells with selective blockade of
2AR by ICI 118.551. The blockade of 2AR inhibited both
DH (Figure 4B) and PNMT (Figure 4C) gene expression in
response to hypoxia. These data suggest that catecholamines
from ECs could promote their own synthesis in a paracrine
positive feedback manner by means of 2AR activation.
Discussion
We report here, for the first time, that ECs are capable of
synthesizing catecholamines because they have the complete
intracellular machinery for the generation and release of NE
and EPI. In vitro, ECs expressed all of the enzymes involved
in the synthesis of catecholamines in basal conditions, and
this expression is enhanced in response to hypoxia. We also
identified the molecular mechanism that regulates this phe-
nomenon. Indeed, we demonstrated that hypoxia-induced
catecholamine release in the culture medium is regulated by
the activation of PKA/CREB signaling, which is already
known to regulate most important endothelial functions, such
as endothelial NO synthase gene transcriptional activation.42
These results are paralleled by data from an in vivo model of
chronic ischemia, where we demonstrate that TH, DDC,
DH, and PNMT are expressed in the endothelium of the
femoral artery. TH expression in endothelium, despite the
other enzymes, is difficult to detect at low magnification and
needs a higher enlargement. This is because of the nuclear
localization of TH in BAECs, as demonstrated by immuno-
histochemical analysis (Figure S1), which is difficult to detect
in vivo in capillaries. Moreover, the nuclear staining is
masked by hematoxylin counterstain. This nuclear localiza-
tion of TH is suggested also by other reports, in human
epidermal melanocytes43 and in perikarya of rat ventral
tegmental area.44 Our in vivo results also show that TH is
localized in the cytoplasm of muscle cells, and it was never
described before. However, further experiments are needed to
clarify this aspect.
ECs play a critical role in the control of vascular function
because they participate in all aspects of vascular homeostasis
but also in physiological or pathological processes like
vascular wall remodeling, inflammation, or thrombosis. In
particular, they have a key role in angiogenesis, in coagula-
tion and fibrinolysis, and in the regulation of vascular tone, as
well as in inflammatory reactions and in tumor neoangiogen-
esis.45–50 ECs are capable of synthesizing and releasing a
variety of substances that may exert autocrine, paracrine, or
endocrine effects. Indeed, they contribute to the regulation of
blood pressure and blood flow by releasing vasodilators such
as NO and prostacyclin, as well as vasoconstrictors, including
endothelin and platelet-activating factor, in response to stim-
uli.14,51,52 Given the evidence that ischemia enhances plasma
levels of NE,53 it has been shown recently that cat-
echolamines contribute to arteriogenesis and angiogenesis in
pathological conditions such as hindlimb ischemia54 and that
they contribute to angiogenesis in the wound-healing pro-
cess.55 Based on our and previous data, we hypothesize that
the ability of ECs to synthesize and release catecholamines is
an autoregulatory physiological mechanism in response to
hypoxia to induce neovascularization. Indeed, the inhibition
of catecholamine release by FA reduced the proangiogenic
phenotype of ECs in vitro. This finding puts the ARs on ECs
in a different perspective. Indeed, the lack of terminal
innervations on ECs has sustained the concept that circulating
catecholamines are the natural stimulants to endothelial ARs.
Our data allow for the promoting of a new scenario in which
ECs produce catecholamines that act in a paracrine way to
sustain proangiogenic phenotypes in conditions such as isch-
emia (Figure 4D). Furthermore, these data are well in
agreement with previous reports showing the ability of ECs to
produce catecholamine catabolism enzymes, such as mono-
amine oxidase and catechol-oxymethyltransferase.56
We have identified previously the 2AR as the adrenergic
receptor involved in the regulation of angiogenesis in
ECs.16,41 Here we demonstrated that 2AR is activated by
catecholamines released by ECs to induce angiogenesis, and
it, in turn, regulates catecholamines release. A future direc-
tion of research will address the signaling linking hypoxia
and PKA/CREB activation given the potential role of this
pathway in the activation of the endothelium. In conclusion,
our study demonstrates for the first time the ability of ECs to
synthesize and release catecholamines in response to hypoxia
(in vitro) and ischemia (in vivo) and the involvement of this
phenomenon in the regulation of angiogenesis.
Perspectives
Our data indicate ECs as a source of catecholamine synthesis
and release. This is a further advance in the understanding of
endothelial function and physiology that could be useful to
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determine targeted therapies for many diseases, including
cancer, cardiovascular disease, and inflammatory conditions.
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growth factor (VEGF; A), dopamine  hydroxylase (DH; B), and phenylethanolamine-N-methyl transferase (PNMT; C) in response
to hypoxia. All of the enzymes are expressed in basal conditions, and hypoxia enhanced their expression. ICI inhibits basal gene
expression and reduces the response to hypoxia; *P0.05 vs normoxia, #P0.05 vs hypoxia. Results are the mean of 5 indepen-
dent experiments. e, control (CTRL); , hypoxia. D, Schematic summary of our results: in endothelial cells, ischemia activates induced
protein kinase A (PKA)/cAMP response element binding (CREB) signaling inducing the transcription of genes coding for tyrosine
hydroxylase (TH), Dopa decarboxylase (DDC), DH, and PNMT. All of these enzymes participate in catecholamine synthesis. Norepi-
nephrine (NE) and epinephrine (EPI) are then released and act in a paracrine way on 2 adrenergic receptors to promote VEGF produc-
tion and angiogenesis. The enzymes catechol-oxymethyltransferase (COMT) and monoamine oxidase (MAO) regulate catecholamine
catabolism.
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Novelty and Significance
What Is New?
● ECs respond to stress-releasing catecholamines. These catecholamines
stimulate receptors on EC accelerating regenerating processes, such as
angiogenesis.
What Is Relevant?
● Endothelial dysfunction seen in hypertension might alter the ability of
ECs to release catecholamines in response to stress. This impairment
alters the ability of ECs to adapt to conditions such as ischemia or
inflammation.
Summary
We demonstrate that ECs present the enzymes to produce and
release NE and EPI, in response to ischemia. These substances, in
turn, further sustain the activation of endothelial function, such as
angiogenesis.
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Supplemental Methods 
 
Cell Culture 
Bovine aorta EC (BAEC), purchased from Lonza, were cultured in Dulbecco’s MEM (DMEM) 
supplemented with 10% foetal bovine serum (FBS) at 37°C in 95% air and 5% CO2. 
Plasmids 
p-CREB and p-PKA were purchased from Stratagene; p-PKA-I was a kind gift of Prof. Antonio 
Feliciello (Federico II University of Naples). Transient transfection of these plasmids was 
performed using Lipofectamine 2000 (Invitrogen) in 70% confluent BAEC, accordingly to 
manufacturer instructions.  
Hypoxia 
24 hours after transient transfection, culture medium was replaced with hypoxia-medium (116 mM 
NaCl, 5.4 mM KCl, 0.8 mM MgSO4, 26.2 mM NaHCO3, 1 mM NaH2PO4, 1.8 mM CaCl2, 0.01 
mM glycine and 0.001 (% w/v) phenol red), previously saturated for 10 min at 1 atm with 95% N2 
and 5% CO2 mixture. In some plates H89 (10-6M, Sigma Aldrich), a selective inhibitor of PKA, 
was added to the culture medium for 30 minutes and then plates were incubated at 37°C in an 
anaerobic chamber (hypoxia chamber) filled with the same gas mixture for 16 hours.  
Western Blot  
BAEC were lysed in RIPA/SDS buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-
40, 0, 25% deoxycholate, 9,4 mg/50 ml sodium orthovanadate, 20% SDS]. Protein concentration 
was determined by using BCA assay kit (Pierce). Total extracts were electrophoresed by 
SDS/PAGE and transferred to nitrocellulose. Endogenous pCREB, pPKA, TH (Cell signaling), 
Actin, DDC, DβH and PNMT (Santacruz) were visualized by specific antibodies, anti-rabbit HRP-
conjugated secondary antibody (Santa Cruz) and standard chemiluminescence (Pierce). 
 
Immunocytochemistry and Immunohistochemistry 
Transfected cells were grown in chamber slides (Nunc, LabTek). Cells were then fixed with -20°C 
cold methanol and permeabilized with 0.01% Triton X-100 in PBS. Primary antibodies incubation 
with anti-TH, anti-DDC, anti-DbH and anti-PNMT (Santacruz) at a 1:50 dilution were performed at 
room temperature for two hours. Specific secondary antibodies (Santacruz) at a 1:100 dilution were 
incubated at room temperature for 1 hour. The peroxidase was revealed in presence of 0,03% 
hydrogen peroxide and of an electron donor, 2,5% diaminobenzidine, which becomes visible as a 
brown precipitate. Cells were then counterstained with hematoxylin, then dehydradated, cleared 
with histolemon and coverslipped. For immunohistochemistry, femoral muscles and arteries were 
fixed in formaline, embedded in paraffin and sectioned at 5 µm with a rotary microtome. Sections 
were dewaxed, rehydrated and immunostaining was performed by the peroxidase anti-peroxidase 
(PAP) method as described above. Images were taken by using an Eclipse E1000 Fluorescence 
Microscope (Nikon) and acquired by using Sigma Scan Pro software (Jandel). Images were 
optimized for contrast in Adobe PhotoShop, but no further manipulations were made.  
Real Time RT-PCR 
Total RNA was isolated using Trizol reagent (Invitrogen) and cDNA was synthetized by means of 
Thermo-Script RT-PCR System (Invitrogen), following the manufacturer instruction. After reverse 
transcription reaction, real-time quantitative polymerase chain reaction (PCR) was performed with 
the SYBR Green Real Time PCR master mix kit (Applied Biosystems). The reaction was visualized 
by SYBR Green Analysis (Applied Biosystem) on StepOne instrument (Applied Biosystem). 
Primers for gene expression analysis were as follows: 
TH:   FOR 5'AGCCTGGCCTTCCGCGTGTTCCAG3' 
REV 5'CTACGCCTCCCGCATCCAGCGCCC3'  
DDC:   FOR, 5'CCAGAGACATTTGAGGCCAT3' 
REV 5'TCCAGCCAGAAACGCCTCT3',  
DBH:   FOR 5'GAACATCAGCTATGCGCAGGA3'  
REV 5' AAAAGGCCTCTTGAAGAGCAG3'  
PNMT:  FOR 5'TACCTCCGCAACAACTACGC3' 
REV 5' CTGTATACGCTCCAGTCGAA3’  
18S:   FOR 5'GTAACCCGTTGAACCCCATT3'   
REV 5'CCATCCAATCGGTAGTAGCG3' 
VEGF:            FOR 5'CAGGCTGTCGTAACGATGAA3' 
                        REV 5'TTTCTTGCGCTTTCGTTTTT3' 
 
All values obtained were normalized to the values obtained with the 18S primers (endogenous 
control) and relative to the reference sample (basal control) using the formula 2-ΔΔCt. Obtained 
results are expressed as relative quantification (RQ). 
ELISA assay 
The release of catecholamines in the culture medium was analyzed by ELISA assay (Pantec), 
accordingly to the manufacturer instructions. Cell were transfected and incubated in the hypoxia 
chamber for 16 hours as described above. In some experiments Fusaric Acid (Sigma, 10µM) was 
added to the culture medium before hypoxic stimulus to inhibit catecholamines release. Culture 
medium was collected and used for the ELISA assay. 
Angiogenesis in vitro 
Angiogenesis in vitro was performed on Matrigel matrix as previously described 1. 
In Vivo Study.  
Experiments were carried out, in accordance to Federico II University guidelines and to 
the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals, on 12-
week-old C57Bl/6 mice, which had access to food and water ad libitum. The model of unilateral 
hindlimb (HL) ischemia was prepared as described previously 1. Briefly, anesthesia was performed 
with an intramuscular injection of a mixture of tiletamine (50 mg/kg) and zolazepam (50 mg/kg); 
the right common femoral artery was exposed, isolated and permanently closed after the emergence 
from the inguinal ligament with a non-reabsorbable suture (5–0 silk, Ethicon) whereas the femoral 
vein was clamped. Afterwards, the common femoral artery was removed and the wound closed in 
layers. After 3 days, femoral muscles and arteries were extracted from both legs of five 
animals/group, fixed in formalin and included in paraffin. Paraffin-embedded sections were stained 
for hematoxylin and eosin. Five micrometer-thick sections were processed for the triple-layered 
immunohistochemical PAP (peroxidase anti-peroxidase) method as described above. For negative 
controls, the primary anti-serum was omitted. Lectin staining (1:100, Sigma Aldrich) was used to 
identify capillaries. 
Statistical anlaysis 
All values are presented as mean±SEM. Two-way ANOVA was performed to compare the different 
parameters between the different groups. A P value < 0.05 was considered to be significant. 
Statistics were computed with GraphPad Prism version 5.01 (GraphPad Software). 
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Supplemental Figures 
  
 
Figure S1. Immunohistochemistry analysis of the expression of  TH, DDC, DβH and PNMT in 
BAEC.  
Paraffin embedded sections from adrenal gland and spleen and methanol fixed EC were analyzed by 
immunohistochemistry using the PAP peroxidase anti-peroxidase system. DDC, DβH and PNMT 
are localized in the cytosol of  EC and their expression is enhanced after 16 hours of hypoxia. TH 
present a nuclear localization. Scale bar is 20 µm. Adrenal gland was used as positive control and 
spleen as negative control. A negative control in EC was performed incubating cells with secondary 
antibody only to avoid false positive. Images are representative of 3 independent experiments. 
 
 
 
 
Figure S2: PKA/CREB regulates catecholamines release in the culture medium 
BAEC were transfected with p-CREB and p-PKA or treated with H89 and then incubated in the 
hypoxic chamber for 16 hours. Culture mediums were collected and used for ELISA assay. A-D) 
H89 inhibits catecholamines release induced by hypoxia (A-B). CREB and PKA overexpresion 
increase NE (C) and EPI (D) release respect to basal levels. PKA overexpression further increases 
the response to hypoxia; * p<0.05 vs normoxia, # p<0.05 vs hypoxia. Results are the mean of 5 
independent experiments. 
 
 
 
 
 
 
 
 
Figure S3: EC produce catecholamines in vivo: negative control  
To confirm the specificity of immunohistochemical data about TH, DDC, DβH and PNMT 
expression in BAEC (Fig. 3) we performed a negative control incubating tissues with secondary 
antibody only [femoral arteries (A) and in capillaries (B)]. 
 
Figure S4: EC dependent catecholamines release has a key role in angiogenesis in vitro. 
BAEC were treated with fusaric acid (FA, 10 µM) for 30 min and incubated in the hypoxic chamber 
for 16 hours. A) Cells were plated on matrigel matrix and the formation of network-like structures 
was analyzed by microscopy. FA inhibits hypoxia induced BAEC organization in tubular structures. 
Images are representative of 3 independent experiments. B-C) Cultured mediums were collected 
and used for ELISA assay. FA inhibits hypoxia-induced norepinephrine (NE, B) and epinephrine 
(EPI, C) release. * p<0.05 vs normoxia, # p<0.05 vs hypoxia. Results are the mean of 5 independent 
experiments.  
Letters to the EditorRegarding the impact of left ventricular size on
response to cardiac resynchronization therapy
We read with interest the report by Rickard et al1 in
a recent issue of the journal regarding the impact of left
ventricular size on response to cardiac resynchronization
therapy (CRT).
In this study, the effect of CRT is clearly analyzed in
668 patients with nondilated and severely dilated cardio-
myopathy, 2 underrepresented categories in the medical
literature. The authors show a significant improvement
of cardiac function after CRT in these subjects.
We have 2 main concerns. First, the role of the
different etiology of the cardiomyopathy (ischemic vs
nonischemic) on the reverse ventricular remodeling is
not well addressed. Given the recent findings about
this issue,2-5 an analysis in a large cohort of subjects1
could be of keen relevance to the reader.
Second, prior studies have yielded inconsistent results
regarding the effect of CRT on the incidence of atrial
fibrillation (AF) in patients with heart failure.3,6-9 In the
study by Rickard et al, the development of AF in the
studied groups remains quite unclear. There is a higher
incidence of AF in nondilated patients compared with the
other groups, but the authors do not present data
concerning the relation between CRT and AF. We believe
that this information may be remarkable, especially
because the authors have a large follow-up subgroup
(471 subjects) also with echocardiographic records.
Am Heart J 2012;163:e11.
0002-8703/$ - see front matter
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Letters to the Editor124sistent with previous recently reported ex vivo and in vivo findings
(1–3), we highlight consistently larger LA measurements obtained
with IVUS compared to FD-OCT across all segments, with a
further significant reduction in these luminal measurements when
measured in smaller-sized coronary segments, and when measured
with 3D-QCA. This also supports recent data which has compared
Terumo FD-OCT, IVUS, and conventional QCA measurements
in stented coronary segments (3). Until further validation studies
are conducted, specific lumen-based cut-off values previously vali-
dated with IVUS and currently utilised in contemporary interven-
tional practice should not be arbitrarily translated into the FD-
OCT and 3D QCA hemispheres. (Fig. 1)
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Atrial Function in Patients
Undergoing CRT
We read with great interest the paper by Carluccio et al. (1) regarding
the impact of left ventricular (LV) remodeling on the response to
cardiac resynchronization therapy (CRT). In this elegant study, the
authors performed a comprehensive assessment of LV function,
showing that extensive LV remodeling at baseline is associated with
poor improvement after CRT.
We wish to raise an essential issue, which may be of keen interest
to the readers.
In recent years, there has been growing interest in the potential
impact of CRT on atrial function, but the state of knowledge in this
field is still controversial and unsettled (2–4). In the paper by
Carluccio et al. (1) several baseline data concerning atrial function
are presented (left atrial volume index and mitral regurgitation
severity), but unfortunately there is no information related to CRT
response. We believe that their excellent echocardiographic data
could also be useful to better understand another debated issue (i.e.,
the effect of CRT on the risk of the development of atrial
arrhythmias) that is clearly related to atrial remodeling (4,5).
Gaetano Santulli, MD,* Salvatore D’Ascia, MD,
Vittoria Marino, MD, Cristofaro D’Ascia, MD
*Columbia University Medical Center, College of Physicians & Sur-
geons, St. Nicholas Avenue, New York, New York, 10032. E-mail:
gs2620@columbia.edu.
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R E P L Y
We would like to thank Dr. Santulli et al. (1) for their interest in
our recently published paper. In their letter, they point out an
important issue regarding patients undergoing cardiac resynchroni-
zation therapy (CRT), namely, the consequences of CRT on left
atrial (LA) function and remodeling. Despite extensive evidence of
the benefits of CRT on ventricular function, the impact of CRT on
atrial function and remodeling has not been thoroughly evaluated.
Previous studies demonstrated that in patients in whom left
ventricular remodeling occurs, favorable changes in LA volumes
and LA function can also be seen (2,3). These changes are expected
to translate into reduced incidence of atrial arrhythmias, secondary
to positive LA remodeling (2,4). That may be important as
occurrence of atrial fibrillation is associated with worse prognosis in
heart failure patients (5).
As recently demonstrated through analysis of a large multicenter
trial (2), and single-center experience (4), CRT-defibrillator ther-
apy was associated with pronounced reverse remodeling of the LA.
This beneficial effect on LA volumes was followed by substantial
reduction in the risk of atrial fibrillation. Importantly, patients whoid not report atrial arrhythmias after device implantation showed
significantly lower incidence of heart failure and death (2).
Our study (1) was mainly focused on evaluating the impact of
xtensive left ventricle remodeling on subsequent response to CRT,
n terms of left ventricular ejection fraction improvement and
ccurrence of cardiac events at follow-up. Hence, the study was not
eared to specifically evaluate changes in LA remodeling. However,
A volume index was enlarged at baseline (44  20 ml/m2), and it
was significantly reduced at follow-up after CRT (39.6  15
l/m2, p  0.01), as was mitral regurgitation severity (see Carluc-
cio et al. [1]). Whether these beneficial changes on LA remodeling,
and their relationship with diastolic left ventricle parameters, are
also associated with lower risk of developing atrial arrhythmias
remains the object of future studies.
Erberto Carluccio, MD,* Paolo Biagioli, MD,
Giuseppe Ambrosio, MD, PhD
*Division of Cardiology, University of Perugia, School of Medicine,
Perugia PG 06132, Italy. E-mail: e.carluccio@alice.it
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An emerging and intriguing role of the G protein coupled receptor ki-
nase 2 (GRK2) involves its ability to modulate themetabolic state of the
cell. Little is known about this feature, opposite to the relevance of the ki-
nase in the regulation of the G protein coupled receptor (GPCR) signal-
ing. Indeed, GRK2 belongs to a family of seven serine/threonine protein
kinases, each encoded by a single gene, that speciﬁcally phosphorylates
the activated form of GPCRs, mediating their desensitization [1,2].
The ﬁrst suggestion that GRK2 is involved in the cellular metabo-
lism derives from the observation that insulin [3] and insulin like
growth factor are both able to induce up regulation of the kinase,
which occurs within the time frame of a few minutes. Interestingly,
GRK2 accumulation leads to the shut-off of insulin signaling and in-
hibits glucose extraction [3–5]. Conditions characterized by elevated
GRK2 levels such as hypertension or chronic activation of β adrener-
gic receptor [3], as well as transgenic overexpression of the kinase [6]
present resistance to the metabolic effects on the cell induced by in-
sulin. This evidence suggests a novel role of GRK2 in controlling the
cellular use of glucose and, more in general, the ability of the cell to
master energy production and expenditure.Mitochondria, of course, play an important role in cell energy produc-
tion, given their ability to produce ATP in an oxygen dependent manner.
The mitochondria functional state varies dramatically depending on the
functional andmetabolic state of the cell. Post transductionmodiﬁcation
of mitochondrial proteins and in particular protein phosphorylation ap-
pears to be an important mechanism of mitochondrial function. In the
last few years, different reports [7] conﬁrmed that a series of kinases
(MAPKs, Akt, PKA and PKC) are present in mitochondria, particularly in
the intermembrane space and membranes where they meet mitochon-
drial constitutive upstream activators.
All of the above considerations prompted us to verify the hypothesis
that GRK2 might affect energy cellular production by interfering with
mitochondrial function. Pursuing this aim, we demonstrate that GRK2
has capability to localize in the mitochondrial fraction and profoundly
affect the biology and the production of energy of these organelles.
2. Materials and methods
2.1. Cell culture
HEK-293 cells were cultured in Dulbecco's minimal essential medium
(DMEM) and 25 mMglucose supplementedwith 10% fetal bovine serum
(FBS) at 37 °C in 95% air and 5% CO2.
2.2. Primary cultured mouse aorta cells and infection
Primary cultured cells were prepared with little modiﬁcations
from a previously validated protocol [8] for extraction of cells from
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mozygous GRK2f/f) [9,10]. Brieﬂy, vessels were cut in rings and placed
on Matrigel (BD Technologies), incubated in Dulbecco's minimal es-
sential medium (DMEM) supplemented with 20% fetal bovine
serum (FBS) and incubated at 37 °C in 95% air and 5% CO2. After 5 to
7 days, aortic rings were removed, and the cells remaining on Matri-
gel expanded. To obtain GRK2 knock out cells, we incubated GRK2f/f
primary cultured cells with an adenovirus encoding for Cre recombi-
nase (AdCre, Vector Biolabs) at MOI of 50 particles per cell for 3 h in a
serum free medium. Incubation was repeated after 1 week. GRK2 re-
moval was conﬁrmed by western blot. A similar procedure, using an
empty vector (AdEMPTY, Vector Biolabs) was applied to obtain con-
trol GRK2f/f cells. Cells were studied between passages 7 and 14.
2.3. GRK2 cloning in pcDNA3.1
Using human GRK2 cDNA (GRK2-WT) in pcDNA3.1 [3] as a tem-
plate and the primers which contain consensus sequences for the in-
dicated restriction enzymes (Table 1), we ampliﬁed the N-Terminal
region and catalytic domain, (GRK2 NT-CD, 1–453 amino acids), the
catalytic domain and C-Terminal region (GRK2 CD-CT, 191–689
amino acids), the C-Terminal region (GRK2 CT 454–689 amino
acids) and the RH domain (GRK2 RH, 54–174 amino acids) (Fig. 3A).
These truncated mutants were cloned in pcDNA3.1 (+) Myc/His A
by means of T4 DNA ligase (Promega). The right frame and orienta-
tion were conﬁrmed by restriction analysis and DNA sequencing by
using the above indicated primers (Avant 3100, Applied Biosystem).
2.4. Cell transfections
Cell trasfection was performed with lipotrasfection reagents (lipofec-
tamine 2000, Invitrogen) using 2 μg of plasmid DNA according to manu-
facturer's instructions [3,11]. For stable transfected clone selections, after
24 to 48 h cell medium was supplemented with G418 (500 μg/mL) for
2 weeks. The G418-resistant cells were cultured in medium supplemen-
ted with G418 to a ﬁnal concentration of 250 μg/mL and examined for
overexpression of GRK2 (GRK2-HEK) by western blotting, using speciﬁc
antibodies (Santa Cruz Biotechnology).
2.5. Mitochondria extracts preparation and western blot
Cells were washed in ice-cold phosphate buffer (PBS) and dis-
rupted by dounce homogenization in isolation buffer [IB pH 7.4
200 mM sucrose, 1 mM EGTA-Tris and 10 mM Tris-MOPS]. The ho-
mogenate was spun at 800 g for 10 min; the supernatant was recov-
ered and further centrifuged for 10 min at 8000 g. The resultingTable 1
Primer sequences used for ampliﬁcation of truncated mutants of human GRK2 gene.
Truncated
mutants
Primers Restriction
enzymes
GRK2 NT-CD For: 5′-TAAGCTTGGATGGCGGACCTGGAGGC-
3′
HindIII
Rev: 5′-
CCCTCTAGAGAAAAAGGGGCTCTCTTTC-3′
XbaI
GRK2 CD-CT For: 5′-
TAAGCTTGGATGGAATGACTTCAGCGTGCATC-3′
HindIII
Rev: 5′-
CCCTCTAGAGAGGCCGTTGGCACTGCCGCG-3′
XbaI
GRK2 RH For: 5′-
AAAAGGATCCTGATGACCTTTGAGAAGATC-3′
BamHI
Rev: 5′-
AAAAGATATCTGCAAAACCGTGTGAACTTATC-3′.
EcoRV
GRK2 CT For: 5′-
TAAGCTTGGATGCTCCCTGGACTGGCAGATG -3′,
HindIII
Rev: 5′-
CCCTCTAGAGAGGCCGTTGGCACTGCCGCG- 3′
XbaIpellet (mitochondrial fraction) was collected while the supernatant
was further spun for 30 min at 100,000 g to obtain the cytosolic frac-
tion, spanned again at 100,000 g to further purify the fraction. The mi-
tochondrial fraction was further puriﬁed by centrifuging twice at
8000 g for 10 min. The obtained pellet was puriﬁed by centrifugation
at 95,000 g for 30 min on a 30% Percoll gradient in IB [12]. The
obtained mitochondrial layer was washed free of Percoll and resus-
pended in IB. Protein concentration was determined by bichinconnate
assay (Pierce). Cytosol and mitochondria extracts were conﬁrmed by
western blot using speciﬁc antibodies (Santa Cruz Biotechnology).
Cellular or mitochondria extracts were electrophoresed by SDS/PAGE
and transferred to nitrocellulose; GRK2 was visualized by speciﬁc anti-
body (Santa Cruz Biotechnology), anti-mouseHRP-conjugated secondary
antibody (Santa Cruz Biotechnology) and standard chemiluminescence
(Pierce) on autoradiographic ﬁlm. Images were then digitalized and den-
sitometric analysis was performed (ImageQuant software).
2.6. Overlay assay
Mitochondrial proteins were electrophoresed by SDS/PAGE and
transferred to nitrocellulose. The membrane was incubated with
50 ng of GRK2 puriﬁed protein (Invitrogen) in binding buffer [Hepes
0.25 M; MgCl2 50 mM; DTT 2.5 mM; Na3VO4 5 mM; H20-Tween
0.1%] for 1 h at room temperature. Protein was ﬁxed in 0.5% formalde-
hyde for 5 min and washed with 2% glycine [13]. GRK2 was visualized
by chemiluminescence after incubation with anti-GRK2 antibody
(Santa Cruz Biotechnology).
2.7. Kinase assay
Kinase assay was performed by using mitochondrial extracts. Phos-
phorylation reaction was initiated by adding master mix (Hepes
0.5 M; MgCl2 1 M; DTT 1 M; Na3VO4 1 M; H20-Tween 0.1%), 50 ng of
GRK2 puriﬁed protein (Invitrogen) and [γ-32P]ATP (GE Healthcare)
and prolonged for 30 min at 37 °C. Laemmli buffer was added to stop
the reaction. Then, 30 μl of the reaction mix were resolved on SDS-
PAGE4-12% gradient (Invitrogen), stained with Coomassie blue, de-
stained, vacuum dried, and exposed for autoradiography [14].
2.8. Quantitative analysis of mitochondrial nucleic acids
Cell DNA and total RNAwere isolated using commercially available re-
agents (DNAzol and Trizol, Invitrogen). cDNA was synthesized from RNA
by reverse transcriptase (Invitrogen), following the manufacturer's in-
structions. Real-time quantitative polymerase chain reaction (RT-PCR)
was performed on DNA and cDNA as previously described [11] to amplify
two mitochondrial (cytochrome b, NADHd), and one nuclear (β globin)
genes. The primer sequences used were: [15] cytochrome b: For: 5′-
CCTAGGCGACCCAGACAATTAT; Rev: 5′-TCATTCGGGCTTGATGTGG;
NADHd: For: 5′-CAGCCATTCTCATCCAAACC; Rev: 5′-ATTATGATGC-
GACTGT GAGTGC; β globin: For: 5′-AGCCTGACCAACATGGTGAAAC; Rev:
5′-AGCCACCTGAATAGCTGGGACT. All values obtained were normalized
to the values obtainedwith the β globin primers. The reactionwas visual-
ized by SYBR Green Analysis (Applied Biosystem) on StepOne instrument
(Applied Biosystem). The results are expressed as the relative integrated
intensity.
2.9. Immunoﬂuorescence
HEK-293 and GRK2-HEK cells were incubated for 30 min with 5 nM
mitotracker (Rosamine-basedMitotracker dye-Invitrogen) to identifymi-
tochondria. Then the cellswereﬁxedwith−20 °C coldmethanol/acetone
and permeabilized by incubation in 0.3% Triton X-100 solution for
3 min. Cells were incubated for 1 h at room temperature with mouse
anti-GRK2 Ab (Santa Cruz Biotecnology) in PBS containing 1% BSA
[14]. After two washings in PBS, the cells were incubated for 1 h at
Fig. 1. (A) Cellular and mitochondrial ATP content in HEK-293 and GRK2-HEK cells.
(* pb0.05 vs HEK-293 cells). (B) Infection with AdCRE removes GRK2 gene in GRK2f/f
cells. Recombinant ﬂoxed GRK2 cells were incubated either with adenovirus encoding
for Cre recombinase (AdCRE, Vector Biolabs) or an empty virus (AdEMPTY) at MOI of 50
particles for 3 h in a serum free medium. Cells were then maintained in culture and
GRK2 removalwas conﬁrmedbywesternblot (1: cells treatedwithAdCRE; 2: cells treated
with AdEMPTY). (C) Cellular and mitochondrial ATP content in GRK2f/f and GRK2f/f,CRE
aortas derived cells. (+ pb0.05 vs GRK2f/f cells).
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trogen) in PBS. After washing in PBS, the glass slides were mounted
under a coverslip in a 50% glycerol PBS solution. Images were acquired
with a Zeiss 510 confocal laser scanning microscope.
2.10. Transmission electron microscopy (TEM) and Immunogold staining
Mitochondrial fractionswerewashed in PBS and ﬁxed in 4% parafor-
maldehyde for 4 h at 4 °C. Then samples were incubated with 0.05 M
glicine, dehydrated in graded ethanols and 100% acetone and blocked
in 5% BSA in PBS for 1 h. Mitochondrial fractions were washed in incu-
bation buffer (IB: 0.8% BSA in PBS and 15 mM NaN3), incubated with
anti GRK2 antibody (5 μg/ml) in IB overnight and washed in IB. Subse-
quently, samples were incubated with secondary antibody (Aurion
ultra-small gold reagents) for 1.5 h, washed and incubated with Aurion
R-gent SE-EM, according to manufacturer's instructions. Samples were
then ﬁxed with 2.5% glutaraldehyde, washed in PBS, ﬁxed in osmium
tetroxide, dehydrated in an ethanol series, embedded in epoxy
resin, and then examined under a transmission electron microscope
(JEM-2000EX), at the Federico II facility for advanced imaging (CISME).
2.11. Cytoﬂuorimetry
Cells were incubated for 30 min with 5 nMmitotracker (Rosamine-
basedMitotracker dye-Invitrogen) to identifymitochondria. Thenmito-
tracker stained and unstained control cells were analyzed by ﬂow cyto-
metry (FACSCalibur, BD Biosciences) followed by analysis of mean
ﬂuorescence intensity of 10,000 events by Cellquest software (BD Bio-
sciences) [16].
2.12. Assay for oxidative ATP synthesis
Cellswere harvested, washed twice in PBS, and counted in a Burker's
camera. A replicate for each samplewas prepared that had been treated
for 1 h with 4 μg/ml rotenone (Sigma). The emission recorded from
samples treated with rotenone was deﬁned as baseline luminescence
corresponding to a non mitochondrial source of ATP. Assays were per-
formed using the ATP luminescence assay kit (Sigma) according to
manufacturer's instructions.
2.13. Cell hypoxia
Cell medium was previously saturated for 10 min at 1 atm with 95%
N2 and 5% CO2 mixture, containing (mM) concentrations of 116NaCl,
5.4KCl, 0.8MgSO4, 26.2NaHCO3, 1NaH2PO4, 1.8CaCl2, 0.01glycine and
0.001 (%w/v) phenol red, and placement in an anaerobic chamber (hyp-
oxia chamber) ﬁlledwith the same gasmixture and heated to 37 °C. The
pH, PO2 and PCO2 of the resulting medium were 7.36±0.2, 45.3±
1.2 mmHg, and 35.3±0.8 mm Hg and 7.32±0.9, 32.6±1.1 and
37.9 ±2.1 mm Hg, before and at the end of hypoxia, respectively [17].
2.14. Mouse skeletal muscle infection
Animal studies were carried out on homozygous GRK2f/f mice [9]
(n=23; weight: 26.7±3.1 g) in accordance to Federico II University
guidelines. To obtain GRK2 gene removal, mice were anaesthetized
by vaporized Isoﬂurane 3% and intramuscular injection of AdCre
(109 pfu/ml) were performed into right quadriceps femoris (200 μl)
muscle. GRK2 removal was conﬁrmed by western blot. After 5 days
we performed ischemia/reperfusion.
2.15. Mouse surgery
Mice were anaesthetized by isoﬂurane 4% inhalation and maintained
by mask ventilation (isoﬂurane 2%). A surgical incision was made in the
skin overlying the middle portion of the right hind limb and the rightcommon femoral artery was exposed and isolated, as previously de-
scribed [18], and a slipknotwas placed around the proximal endof the ar-
tery with a 5–0 silk suture, maintained for 1 h to induce hind limb
ischemia. Groups of 3 mice were sacriﬁced at the end of 1 h of ischemia,
after 15 min or 60 min of reperfusion. These mice were compared to
GRK2f/f mice subjected to the same procedures (3 for each time point)
and to sham-operated GRK2f/f (n=3) and GRK2f/f,Cre (n=3).
2.16. Assay for oxidative ATP synthesis in vivo
At sacriﬁce, quadriceps femoris muscles were harvested and
quickly washed in PBS. Assay was performed using the ATP lumines-
cence assay kit (Sigma) according to manufacturer's instructions.
Then, values were normalized according to muscles' weights.
2.17. Statistical analysis
All values are presented as mean±SEM. Two-way ANOVA was
performed to compare the different parameters among the different
groups. Bonferroni post hoc testing was performed where applicable.
A signiﬁcance level of pb0.05 was assumed for all statistical evalua-
tions. Statistics were computed with GraphPad Prism software (San
Diego, California).
3. Results
3.1. GRK2 increases oxidative ATP synthesis
To evaluate the relevance of GRK2 in energy production we mon-
itored whether GRK2 modulates mitochondrial ATP synthesis. Fig. 1A
shows that human embryonic kidney (HEK-293) ﬁbroblasts stably
over expressing a human GRK2 gene (GRK2-HEK) contain higher
471A. Fusco et al. / Cellular Signalling 24 (2012) 468–475levels of total and mitochondrial ATP, compared to control cells. We
also studied primary cultured cells derived from the aortas of recom-
binant mice with both copies of the GRK2 gene ﬂanked by two f-lox
sites (GRK2f/f). When these cells were infected with AdCre to obtain
cellular expression of the bacterial CRE recombinase (GRK2f/f,CRE),
GRK2 protein levels became undetectable (Fig. 1B). At the same
time, in GRK2f/f,Cre cells (Fig. 1C) there is a signiﬁcant reduction of
total and mitochondrial ATP levels, supporting a positive role of
GRK2 in bio-energetic pathway.Fig. 2. (A) Mitochondria were obtained by co-fractionation experiments on a 30% Percoll grad
nogold on mitochondria extracts using anti-GRK2 antibody. (C) GRK2 levels were analyzed in
absence of Histone H3 and Calnexin in puriﬁedmitochondria was conﬁrmed by western blot in
expression of GRK2-WT increases GRK2 levels both in cytosol and mitochondria (*pb0.05 vs H
mitochondrial integrity, triton X-100 (Trit) was added in the digestion buffer. Samples were p
orescence. HEK-293 cells (upper lane) andGRK2-HEK cells (lower lane)were labeled in vivowi
were taken under confocal microscopy. Bars, 10 μm.3.2. GRK2 is located in mitochondria
To clarify the basis for the possible link between GRK2 and the mi-
tochondria, we evaluated the presence of the kinase in the organelles
by co-fractionation experiments on a 30% Percoll gradient. First of all,
to verify that the mitochondrial fraction was free from contaminants
of other compartments, we observed samples from HEK-293 cells
under TEM and conﬁrmed the purity of the mitochondrial fraction
(Fig. 2A). On this fraction, immunogold analysis shows that the kinaseient and observed by electron microscopy. (B) GRK2 localization was observed by immu-
cytosol (Cyt) and mitochondrial (Mit) extracts by western blot in HEK-293 cells. (D) The
HEK-293 cells, using cellular extracts for molecular weight reference. (E) The stable over-
EK-293 cells). (F) Mitochondria were incubated with or without tripsin (Trip). To disrupt
robed for GRK2, Mn SOD and VDAC1. (G) GRK2 localization was analyzed by immunoﬂu-
thmitotracker (red),ﬁxed, and immunostainedwith anti-GRK2 (green) antibody. Pictures
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membranes (Fig. 2B).
Localization of GRK2 on mitochondria was also conﬁrmed on mi-
tochondria and cytosol fractions isolated from HEK-293 cells by west-
ern blot. Fig. 2C shows that endogenous GRK2 partly co-puriﬁed with
the mitochondria-enriched fraction, as did the Mn-dependent Super-
oxide Dismutase (Mn SOD), a protein that resides within mitochon-
drial compartments. We veriﬁed that the puriﬁed mitochondrial
fractions were free from contaminants of the cytosol (actin)
(Fig. 2C), nuclei (Histone H3) and sarcoplasmic reticulum (calnexin)
(Fig. 2D). The speciﬁcity of the antibody for GRK2 is conﬁrmed by
the observation that stable overexpression of GRK2 in HEK-293 cells
increases the levels of the protein both in cytosol and mitochondria
(Fig. 2E).
To conﬁrm the sub-mitochondrial compartment where GRK2 lo-
calizes, we subjected the puriﬁed mitochondrial fraction to a double
treatment with trypsin and triton demonstrating that the kinase tar-
gets to outer membrane (Fig. 2F). Conﬁrmation derives from the evi-
dence that the mitochondrial outer membrane protein VDAC1 but not
the mitochondrial matrix protein MnSOD localizes in the same sub-
mitochondrial fraction as GRK2.
Finally, the ability of GRK2 to co-localize with mitochondria was
also demonstrated by confocal microscopy using immunoﬂuores-
cence (Fig. 2G). In particular, imaging conﬁrms the ubiquitous locali-
zation of GRK2 within the cytosol and the membrane compartments,
but the nucleus. When the GRK2 and mitochondria signals are
merged, it appears clearly that GRK2 can compartmentalize in mito-
chondria. This feature is further highlighted in presence of GRK2
overexpression (Fig. 2G).Fig. 3. (A) GRK2 sequence and truncated mutants cloned in pcDNA3.1 (+) Myc/His A. HEK-
GRK2 CD-CT (D) and GRK2 CT (E).3.3. Two regions within GRK2 sequence show afﬁnity for mitochondria
To map the regions of GRK2 that possess the ability to localize in mi-
tochondria, we generated myc/histidine-tagged, truncated mutants of
GRK2 (Fig. 3A). The aminoacid sequence 1–453 is able to localize tomito-
chondria (Fig. 3B). Within this region, we found that the 120 aminoacids
comprising the RGS homology (GRK2 RH) domain (aminoacids 54–174)
are able to target mitochondria (Fig. 3C). Also, the region 191–689
(Fig. 3D) which comprises the catalytic and carboxyl termini (CT)
domain is able to target the mitochondria. Finally, the CT sequence per
se (495–689, Fig. 3E) cannot bind the organelles.
3.4. GRK2 interacts and phosphorylates unidentiﬁed mitochondrial proteins
To conﬁrm the ability of GRK2 to localize on mitochondria, we
performed an overlay assay with puriﬁed GRK2 as bait on HEK-293
and GRK2-HEK cells mitochondria extracts blotted on nitrocellulose.
This assay conﬁrms the ability of GRK2 to interact with yet unidenti-
ﬁed mitochondrial proteins within the molecular weight range of 30–
60 KDa (Fig. 4A).
Using a similar approach, we performed a kinase assay to verify
whether GRK2 recognizes substrates among the mitochondrial pro-
teins (Fig. 4B). This experiment conﬁrms that GRK2 phosphorylates
mitochondrial proteins within the molecular range of 30–60 KDa.
3.5. GRK2 increases mitochondrial biogenesis
Given the localization of GRK2 on mitochondria, we asked wheth-
er GRK2 promotes mitochondrial DNA accumulation. By quantitative293 cells were transfected with pcDNA3.1 encoding for GRK2 NT-CD (B), GRK2 RH (C),
Fig. 4. (A) Overlay assay with (left blot) or without (right blot) puriﬁed GRK2 as bait in
HEK-293 and GRK2-HEK cells mitochondria blotted on nitrocellulose. (B) Puriﬁed
GRK2 was incubated with HEK-293 and GRK2-HEK mitochondrial extracts blotted on
nitrocellulose in a kinase buffer, in presence of [32P]γ-ATP. The blot was then exten-
sively washed and exposed to autoradiography.
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NADH de-hydrogenase (NADHd) and cytochrome B (Cyt B), using nu-
clear β globin gene as internal control. Fig. 5A shows that GRK2 in-
creased the levels of both mitochondrial genes.
To correlate the increased mitDNA with increased expression of mi-
tochondrial proteins, we monitored the expression levels of NADHd
and cytochrome B mRNA. Total RNA was extracted from cells and sub-
jected to reverse transcription and quantitative RT-PCR analysis. As
shown in Fig. 5B, GRK2 signiﬁcantly up-regulated the levels of NADHd
and cytochrome BmRNAs. Reciprocally, in GRK2f/f,CRE cells, we observed
a reduction in the number of copies and the level of expression of the
NADHd and cytochromeB as compared to GRK2f/f cells (Figs. 5C and 5D).
To assess the actual change in total mitochondrial mass, we loaded
cells with the mitochondrial selective ﬂuorescent dye mitotracker
and analyzed the intensity of ﬂuorescent emission by FACS analysis.
GRK2 overexpression in HEK-293 induced a rightward shift in theemission proﬁle of mitotracker, which increased by a 36% (Fig. 5E).
Reciprocally, in GRK2f/f,Cre cells, we observed a leftward shift com-
pared to GRK2f/f cells, accounting for a decrease of emission intensity
of mitotracker of about 31% (Fig. 5F). These data are compatible with
a positive effect of GRK2 on mitochondrial biogenesis.
3.6. GRK2 protects from hypoxia/reperfusion induced ATP loss
Given the ability of GRK2 to promote ATP production through an in-
crease in mitochondria, we veriﬁed the effects of the kinase in a mito-
chondrial threatening condition, the hypoxia/reperfusion. Acute hypoxia
(1 h) promotes an increase of total and mitochondrion-associated GRK2
levels, as assessed by western blot analysis. The increase of GRK2 levels
in hypoxic conditions was transient, since re-oxygenation for 15 min
and 1 h restored the levels of the kinase to normal oxygen conditions
(Fig. 6A). In control cells, ATP levels decreased during hypoxia and after
oxygen restoration. Over-expression of GRK2 attenuated the loss of ATP
production, compared to controls (Fig. 6B). As expected, in GRK2f/f,CRE
cells ATP levels were severely reduced under both basal and hypoxia con-
ditions, and the recovery following oxygen restoration was impaired
(Fig. 6C).
3.7. Removal of GRK2 gene in GRK2f/f,CRE mice decreases ATP levels
We evaluated the role of GRK2 in the regulation of ATP levels in an
in vivo model of muscle ischemia. We used mutant GRK2f/f mice. In-
tramuscular injection of adenoviral particles (109 pfu/ml) encoding
for Cre recombinase promoted targeted deletion of GRK2 gene, thus
reducing the levels of the kinase by several folds (Fig. 6D). Ischemia
causes GRK2 mitochondrial accumulation in mouse hind limbmuscle.
Ischemia was obtained by ligation of the femoral artery for 1 h, and
reperfusion was applied for 15 min. By western blot, ischemia in-
duces an increase of GRK2, which promptly recovers to basal levels
after 15 min of reperfusion (Fig. 6E). In control GRK2f/f mice, femoral
artery occlusion reduced ATP levels, in quadriceps femoral muscle.
Reperfusion of ischemic muscles for 15 min and 1 h partially restored
muscular ATP levels. In GRK2f/f,CRE muscles, GRK2 removal parallels a
signiﬁcant reduction of ATP levels. GRK2 deletion also attenuated the
recovery of ATP levels following reperfusion of ischemic muscles,
compared to GRK2f/f mice (Fig. 6F).
4. Discussion
This report shows for the ﬁrst time that GRK2 can localize on
the mitochondrial outer membrane. Indeed, until now, the paradigm
indicates that GRK2 shuttles between the cytosol and the plasmamem-
brane, anchoring to the latter through its pleckstrin homology andGβγ
binding domains within the carboxyl terminus [19]. Our data allow us
to indicate that also the mitochondria should be included as a cellular
compartment on which this molecule can be found. Two regions
within the RH and the catalytic domains possess the ability to localize
truncated mutants of GRK2 on these organelles. The most compelling
ﬁnding, though, is that GRK2 modiﬁes the biology of mitochondria.
Indeed, the mitochondrial compartment is more than just a reservoir
for the kinase. We observed consensual changes in mitochondrial
DNA and RNA, as well as mitochondrial mass size, after overexpression
or deletion of GRK2, consistent with the ability of the kinase to pro-
mote mitochondrial biogenesis. Furthermore, these changes are paral-
leled by modiﬁcation of mitochondrial ATP production.
Mitochondria are most important in the settings of the responses
to stress, such as the ischemia/reperfusion [20], and under these con-
ditions we report two striking novel and unexpected observations.
First, ischemia causes acute cellular and mitochondrial accumulation
of GRK2 both in vitro (Fig. 6A) and in vivo (Fig. 6E), an effect reverted
by oxygen restoration. This surprising evidence further strengthens
the physiological role of GRK2 in the mitochondria. Second, a
Fig. 5. (A and B) Quantitative RT-PCR analysis in HEK-293 and GRK2-HEK cells of copy numbers and gene expression of the mitochondrial genes Cytochrome B (Cyt B) and NADHd,
relative to the nuclear gene β globin. (RQ: relative quantities, * pb0.05 vs HEK-293 cells). (C and D) Same as above, in GRK2f/f and GRK2f/f,CRE cells. (RQ: relative quantities,
+ pb0.05 vs GRK2f/f cells). (E) Intensity of ﬂuorescent emission in HEK-293 (green) and GRK2-HEK (red) cells and mitotracker unstained control cells (purple) under FACS analysis.
(F) Same as above, in GRK2f/f(green) and GRK2f/f,CRE(red) cells and mitotracker unstained control cells (purple).
474 A. Fusco et al. / Cellular Signalling 24 (2012) 468–475protective effect of the kinase is revealed, since transgenic overex-
pression causes mitochondrial accumulation of the kinase and pro-
tects ATP production even after hypoxia/reperfusion damage.
Although we do not have evidence regarding the mechanism
through which GRK2 localizes in the mitochondria, it is evident that
within these organelles, the kinase can bind some protein counter-
parts, which can also be phosphorylated by the kinase. It is possible
to speculate that these unknown substrates favors the accumulation
within the mitochondria of GRK2 and in turn get phosphorylated. In-
deed, using a catalytic inactive mutant of GRK2 we can observe mito-
chondrial accumulation, suggesting that the enzymatic activity of the
kinase is not needed for the localization (data not shown). The iden-
tiﬁcation of the mitochondrial partner of GRK2 is actively pursued in
the lab, and will allow to better understand the mechanisms of bio-
genesis and mitochondrial protection induced by the kinase.
The favorable activity of GRK2 within the mitochondria turns out
to be protective, in particular after ischemia/reperfusion. Previous
data in the literature support a protective role of GRK2 for the cell.
First, GRK2 gene deletion is detrimental for embryonic cardiac devel-
opment [21]. Second, in adult life, cardiac selective GRK2 removal al-
ters the cardiac hypertrophy response to chronic β adrenergic
receptor stimulation, leading to an eccentric dilatation of the heart
similar to that observed in intermediate-advanced phases of heart
failure [9]. On the contrary, other data in literature, suggest a detri-
mental effect of increased GRK2 levels for the cell, and may appearin contrast to the present observation. In particular, in mice subjected
to myocardial infarction, the inducible, cardiac speciﬁc removal of
GRK2 through gene deletion results in the amelioration of survival,
reduced “at risk” ischemic area and improved cardiac performance
[22]. This apparent discrepancy could be imputed to differences in
timing and model. Indeed, we applied ischemia reperfusion for 1 h
in the skeletal muscle. It is possible that in more extensive tissue
damage in a more sensitive tissue such as the myocardium, the nega-
tive signaling properties of GRK2 prevail on the protective metabolic
effects of the kinase.
In conclusion, our data add more support to the building of a new
perspective in which GRK2 not only regulates GPCR signaling, but also
coordinates a series of metabolic responses to excessive signaling and
stress, by starting receptor desensitization [19], reducing glucose ex-
traction [3] and metabolism and activating mitochondrial biogenesis.Acknowledgments
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Fig. 6. (A) In cells, GRK2 accumulates during hypoxia and returns to basal levels after oxygen replenishment (1: no hypoxia; 2: 1 h hypoxia; 3: 15 min oxygen replenishment; 4: 1 h
oxygen replenishment). (B) Cellular ATP content in HEK-293 and GRK2-HEK cells during hypoxia (H: hypoxia; O.R.: oxygen restoration; * pb0.05 vs HEK-293 cells). (C) Cellular ATP
in GRK2f/f and GRK2f/f,CRE cells during hypoxia (H: hypoxia; O.R.: oxygen restoration; + pb0.05 vs GRK2f/f cells). (D) In vivo GRK2 expression, in quadriceps femoris muscle from
mice harboring f-loxed GRK2 gene after intramuscular injection of AdCre (109 pfu/ml) (1: AdEMPTY; 2: AdCre). (E) Ischemia induces an increase of GRK2, which promptly recovers
to basal levels after 15 min of reperfusion (1: no ischemia; 2: 1 h ischemia; 3: 15 min). (F) ATP content in quadriceps femoris muscle of mice subjected to hind limb ischemia/reperfusion
(* pb0.05 vs GRK2f/f mice; Control: non ischemic muscle; IS: 1 h ischemia; Rep: reperfusion).
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Canadian Journal of Cardiology xx (2011) xxx www.onlinecjc.caLetter to the EditorDevelopment of Atrial Fibrillation in Recipients
of Cardiac Resynchronization Therapy: The Role
of Atrial Reverse Remodelling
To the Editor:
We congratulate Wilton et al. for their interesting report in a
recent issue of the Canadian Journal of Cardiology, regarding
the role of rate-controlled persistent atrial fibrillation (AF) on
the clinical outcome and ventricular remodelling in patients
receiving cardiac resynchronization therapy (CRT).1
In this post hoc analysis there are follow-up data (2.8 1.4
years) for 86 patients (19 with and 67 without persistent AF).
Using a composite of objective symptomatic improvement and
left ventricular (LV) reverse remodelling, the authors find that
subjects with and without AF have a similar likelihood of re-
sponding to CRT in the first year of treatment. However, those
in the AF group have significantly less improvement in LV
end-systolic volume, with a doubled risk of death or cardiac
transplantation during long-term follow-up.
We have several comments concerning the relationship be-
tween CRT response and the incidence of new-onset AF. Prior
reports have yielded controversial results regarding the effect of
CRT on the incidence of AF.2,3 In the study by Wilton et al.,
18% of patients in the non-AF group developed AF during
follow-up after CRT, but unfortunately there is no informa-
tion about the role of CRT response. It would be interesting to
know how many patients that developed new-onset AF were
“CRT responders” and how many were “nonresponders.” Al-
though LV function was evaluated by multiple gated acquisi-
tion we would like to know if there are also data (simple echo-
cardiography could be enough) regarding atrial dimension and
function,2,3 in order to compare atrial reverse remodelling in
CRT responders and nonresponders.3 Moreover, if possible
the authors might provide an analysis regarding the role of the
etiology of cardiomyopathy (ischemic vs nonischemic) in the
development of AF.3,4
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Editor’s Choice
THROMBOLYSIS OUTCOMES IN ACUTE
ISCHEMIC STROKE PATIENTS WITH PRIOR
STROKE AND DIABETES MELLITUS
Gaetano Santulli, New York: Mishra et al.1 exam-
ined the influence of diabetes mellitus and prior
stroke on the outcomes of patients who received
thrombolysis vs nonthrombolyzed controls. They
found no interaction on outcome between diabetes
and prior stroke with thrombolysis treatment.
These results conflict with the European Medicines
Evaluation Agency’s justification for restricting the use
of IV alteplase. As Dr. Demaerschalk mentioned in the
accompanying editorial,2 recent studies1,3,4 have sug-
gested that thrombolysis can be safely used in several
groups of patients who do not qualify for treatment due
to strict application of exclusion criteria.
In addition, most of the commonly cited thrombo-
lytic exclusion criteria are just consensus-based, not
evidence-based.2,3 It is time to reevaluate the criteria for
thrombolysis, adopting a clinical score to stratify the
risk, similar to those used in acute coronary syndrome.5
A good risk assessment tool will be able to identify a
gradient of mortality risk by using variables that capture
the majority of prognostic information to better evalu-
ate the risk/benefit ratio for each patient.
Copyright © 2012 by AAN Enterprises, Inc.
1. Mishra NK, Ahmed N, Davalos A, et al. Thrombolysis out-
comes in acute ischemic stroke patients with prior stroke and
diabetes mellitus. Neurology 2011;77:1866–1872.
2. Demaerschalk BM. Challenging the validity of imposing
contraindications to thrombolysis for acute ischemic stroke.
Neurology 2011;77:1862–1863.
3. Tong D. Are all IV thrombolysis exclusion criteria necessary?
Being SMART about evidence-based medicine. Neurology
2011;76:1780–1781.
4. Rubiera M, Ribo M, Santamarina E, et al. Is it time to reas-
sess the SITS-MOST criteria for thrombolysis? A compari-
son of patients with and without SITS-MOST exclusion
criteria. Stroke 2009;40:2568–2571.
5. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk
score for ST-elevation myocardial infarction: a convenient,
bedside, clinical score for risk assessment at presentation: an
intravenous nPA for treatment of infarcting myocardium
early II trial substudy. Circulation 2000;102:2031–2037.
A RANDOMIZED TRIAL OF HIGH-DOSE
VITAMIN D2 IN RELAPSING-REMITTING
MULTIPLE SCLEROSIS
Helmut H. Leitner, Vienna: Stein et al.1 compared
high- vs low-dose vitamin D2 treatment in MS with-
out benefit in the high-dose treatment group. Sun-
light exposure and reduced vitamin D3 levels
independently contribute to MS risk. The effect of
sunlight exposure is supported by decreased signs of
actinic skin damage found in MS patients compared
to controls.2 It is difficult to determine which of
these 2 environmental factors is of primary impor-
tance as higher levels of sunlight exposure will en-
hance vitamin D levels.
The incidence of vitamin D–related rickets dis-
ease decreased in the United States and Europe dur-
ing the last century following the discovery that
vitamin D possessed antirachitic properties, whereas
the incidence of MS seemed to increase in the same
population. In the United States, most of the patients
with rickets are African American, whereas the majority
of patients with MS are of European ancestry.3 It seems
improbable that the same environmental factor should
be centrally involved in the etiology of both diseases,
which differ clinically and occur in different popula-
tions living in the same geographic area.
These findings together with those of Stein et al.
do not provide a reason for vitamin D supplementa-
Editors’ Note: Dr. Santulli, citing the findings of Dr. Mishra
et al. that neither diabetes nor prior stroke affected throm-
bolysis outcomes, calls for the reevaluation of thrombolysis
criteria and the adoption of a clinical score, similar to that
used in acute coronary syndrome, to stratify risk. There were
2 WriteClick submissions in reference to the recent article by
Dr. Stein et al. comparing high-dose and low-dose vitamin
D2 supplementation in relapsing-remitting multiple sclerosis.
Dr. Leitner calls attention to the incongruity of epi-
demiologic trends in MS vs another vitamin D–related
illness, rickets, as further reason not to supplement patients
with MS without proven vitamin D deficiency at this time. Dr.
Grimaldi et al. argue that the study was underpowered and
potentially biased. Their own phase II study of high-dose
vitamin D3 supplementation is under way.
Megan Alcauskas, MD, and Robert C. Griggs, MD
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840 Neurology 78 March 13, 2012
Cell & Developmental Biology
Santulli, Cell Dev Biol 2012, 1:1
http://dx.doi.org/10.4172/cdb.1000e103
Volume 1 • Issue 1 • 1000e103
Cell Dev Biol
ISSN:  CDB, an open access journal
Open AccessEditorial
The Ten Commandments of Ethical Publishing
Gaetano Santulli*
Columbia University Medical Center, New York, USA
*Corresponding author: Gaetano Santulli MD, Columbia University Medical 
Center, New York, USA, E-mail:  gs2620@columbia.edu
Received April 18, 2012; Accepted April 19, 2012; Published April 21, 2012
Citation: Santulli G (2012) The Ten Commandments of Ethical Publishing. Cell 
Development Biol 1:e103. doi:10.4172/cdb.1000e103
Copyright: © 2012 Santulli G. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
This article describes the position of the Journal on the major ethical 
principles of academic publishing. Academic publishing depends, to 
a great extent, on trust. Editors trust peer reviewers to provide fair 
assessments, authors trust Editors to select appropriate peer reviewers, 
and readers put their trust in the peer-review process [1,2]. Publication 
of ethically uncertain research occurs albeit well-published guidelines 
set forth in documents such as the Declaration of Helsinki (http://
whqlibdoc.who.int/euro/1994-97/EUR_ICP_CEH_212.pdf). Such 
guidelines exist to aide editorial staff in making decisions regarding 
ethical acceptability of manuscripts submitted for publication, yet 
examples of ethically suspect and uncertain publication exist [3,4]. 
The editor of any medical Journal has to be aware of the ethical and 
legal framework within which medical research is conducted [5]. With 
an Open Access Journal, we are committed to the widest possible 
dissemination of Research outputs observing the highest ethical 
publication practices [6,7,8].
Authors have a number of duties and responsibilities that are 
mirrored by those of editors and publishers. Of particular importance 
are the principles of transparency and integrity. To publish in OMICS 
Journals, the authors have to be sure that: 
1. The corresponding author has the approval of all other listed 
authors for the submission of the manuscript.
2. All people who have a right to be recognized as authors have been 
included on the list of authors and everyone listed as an author 
has made an independent contribution to the manuscript.
The list of authors corresponds to the following criteria: a) 
substantial contributions to conception and design, or acquisition 
of data, or analysis and interpretation of data; b) drafting the article 
or revising it critically for important intellectual content; and c) final 
approval of the version to be published. All authors must meet these 
criteria for authorship and conversely, no-one should be omitted from 
the list if he/she meets these criteria.
3.  The work submitted in the manuscript is original and has 
not been published elsewhere and is not presently under 
consideration of publication by any other Journal.
4.  The material in the manuscript has been acquired according 
to modern ethical standards and does not contain material 
plagiarized from anyone else without their written permission. 
Plagiarism includes both the theft or misappropriation of 
intellectual property and the substantial unattributed textual 
copying of another’s work. The theft or misappropriation of 
intellectual property includes the unauthorized use of ideas or 
unique methods obtained by a privileged communication, such 
as a grant or manuscript review [4]. 
5.  The material that derives from previously published papers is 
properly attributed to the prior publication by proper citation.
6.  The source of the Research funds has been listed on the paper: 
the authors should acknowledge all significant funders of the 
Research pertaining to their article.
7.  All relevant conflicts of interest have been declared. Referees 
are asked to declare their conflicts of interest when returning 
their report on a paper. If a member of the editorial team feels 
a conflict of interest in making a decision on a paper, she/
he should return the paper to the office and request that it is 
transferred to an alternative Editor. 
8.  Concerning studies in humans: the authors must indicate that 
the study was approved by an institutional review committee 
and that the subjects gave written informed consent [9]. All 
studies that involve humans have to adhere to the principles of 
the Declaration of Helsinki (see the link above). 
9.  Concerning studies in experimental animals: the authors must 
indicate that an institutional review committee approved the 
study. All studies in animals should be conducted in accordance 
with the National Institutes of Health (NIH) Guide for the 
Care and Use of Laboratory Animals, or the equivalent. The 
species, strain, number used, and other relevant characteristics 
of the animals should be stated. When describing surgical 
procedures, identify the pre-anesthetic and anesthetic agents 
used and state the amount or concentration and the route and 
frequency of administration for each. Generic names of drugs 
must be given. These details should be included in the Methods 
section of the article [10]. 
10. If any of the statements above ceases to be true the authors 
have a duty to notify the Journal as soon as possible so that 
the manuscript can be withdrawn. Authors must inform the 
Journal promptly should their results be later invalidated, and 
permit inspection or auditing of reports if necessary
References
1. Vlassov V, Groves T (2010) The role of Cochrane Review authors in exposing 
research and publication misconduct. Cochrane Database Syst Rev 8: 
ED000015.
2. Graf C, Wager E, Bowman A, Fiack S, Scott-Lichter D, et al. (2007) Best 
Practice Guidelines on Publication Ethics: a publisher’s perspective. Int J Clin 
Pract Suppl : 1-26.
3. Coats AJ (2009) Ethical authorship and publishing. Int J Cardiol 131: 149-150.
4. Angelski CL, Fernandez CV, Weijer C, Gao J (2012) The publication of ethically 
uncertain research: attitudes and practices of journal editors. BMC Med Ethics 
13: 4.
5. Santulli G (2012) Thrombolysis outcomes in acute ischemic stroke patients with 
prior stroke and diabetes mellitus. Neurology 78: 840.
6. Vita J (2012) JAHA: The American Heart Association’s Open Access Journal. 
Journal of the American Heart Association 1: 1-2.
Citation: Santulli G (2012) The Ten Commandments of Ethical Publishing. Cell Development Biol 1:e103. doi:10.4172/cdb.1000e103
Page  2  of 2
Volume 1 • Issue 1 • 1000e103
Cell Dev Biol
ISSN:  CDB, an open access journal
7. Phelps L, Fox BA, Marincola FM (2012) Supporting the advancement of 
science: open access publishing and the role of mandates. J Transl Med 10: 13.
8. Matarese A, Santulli G (2012) Angiogenesis in Chronic Obstructive Pulmonary 
Disease: A Translational Appraisal. Translational Medicine @ UniSa. 3: 49-56.
9. Santulli G. Coronary heart disease risk factors and mortality. JAMA 307: 1137.
10. Santulli G, Lombardi A, Sorriento D, Anastasio A, Del Giudice C, et al. (2012) 
Age-Related Impairment in Insulin Release: The Essential Role of beta2-
Adrenergic Receptor. Diabetes  61: 692-701. 
Submit your next manuscript and get advantages of 
OMICS Group submissions
Unique features:
User friendly/feasible website-translation of your paper to 50 world’s leading languages
Audio Version of published paper
Digital articles to share and explore
Special features:
200 Open Access Journals
15,000 editorial team
21 days rapid review process
Quality and quick editorial, review and publication processing
Indexing at PubMed (partial), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc
Sharing Option: Social Networking Enabled
Authors, Reviewers and Editors rewarded with online Scientific Credits
Better discount for your subsequent articles
Submit your manuscript at: http://omicsgroup.org/editorialtracking/clinical-trials
RESEARCH PAPERbph_1078 712..721
Impaired neoangiogenesis
in b2–adrenoceptor
gene-deficient mice:
restoration by intravascular
human b2–adrenoceptor
gene transfer and role of
NFkB and CREB
transcription factors
Michele Ciccarelli1,2*, Daniela Sorriento1*, Ersilia Cipolletta1,
Gaetano Santulli1, Anna Fusco1, Rui-Hai Zhou2, Andrea D. Eckhart2,
Karsten Peppel2, Walter J. Koch2, Bruno Trimarco1 and Guido Iaccarino1
1Dipartimento di Medicina Clinica, Scienze Cardiovascolari ed Immunologiche, Università
Federico II, Napoli, Italy, and 2Center for Translational Medicine, Thomas Jefferson University,
Philadelphia, PA, USA
Correspondence
Guido Iaccarino, Medicina
Clinica, Scienze Cardiovascolari
ed Immunologiche, Federico II
University, Via Pansini 5; Edificio
2, 80131 Naples, Italy. E-mail:
guiaccar@unina.it
----------------------------------------------------------------
*These Authors contributed
equally to this paper.
----------------------------------------------------------------
Keywords
adrenergic signalling; gene
therapy; ischaemic hindlimb;
NFkB activity
----------------------------------------------------------------
Received
7 May 2010
Revised
22 September 2010
Accepted
25 September 2010
BACKGROUND AND PURPOSE
There is much evidence supporting the role of b2-adrenoceptors (b2AR) in angiogenesis but the mechanisms underlying their
effects have not been elucidated. Hence, we studied post-ischaemic angiogenesis in the hindlimb (HL) of b2AR knock-out mice
(b2AR-/-) in vivo and explored possible molecular mechanisms in vitro.
EXPERIMENTAL APPROACH
Femoral artery resection (FAR) was performed in wild-type and b2AR-/- mice and adaptive responses to chronic HL ischaemia
were explored; blood flow was measured by ultrasound and perfusion of dyed beads, bone rarefaction, muscle fibrosis and
skin thickness were evaluated by immunoflourescence and morphometric analysis. Intrafemoral delivery of an adenovirus
encoding the human b2AR (ADb2AR) was used to reinstate b2ARs in b2AR-/- mice. Molecular mechanisms were investigated in
mouse-derived aortic endothelial cells (EC) in vitro, focusing on NFkB activation and transcriptional activity.
RESULTS
Angiogenesis was severely impaired in b2AR-/- mice subjected to FAR, but was restored by gene therapy with ADb2AR. The
proangiogenic responses to a variety of stimuli were impaired in b2AR-/- EC in vitro. Moreover, removal of b2ARs impaired the
activation of NFkB, a transcription factor that promotes angiogenesis; neither isoprenaline (stimulates bARs) nor TNFa induced
NFkB activation in b2AR-/- EC. Interestingly, cAMP response element binding protein (CREB), a transcription factor that
counter regulates NFkB, was constitutively increased in b2AR-/- ECs. ADb2AR administration restored b2AR membrane density,
reduced CREB activity and reinstated the NFkB response to isoprenaline and TNFa.
CONCLUSIONS AND IMPLICATIONS
Our results suggest that b2ARs control angiogenesis through the tight regulation of nuclear transcriptional activity.
Abbreviations
ADb2AR, gene therapy with adenovirus encoding the human b2AR; ADU, arbitrary densitometry units; b2AR, b2
adrenoceptor; b2AR-/-, b2AR knock-out mice; BF, blood flow; CREB, cAMP response element binding protein; EC,
endothelial cell; US, ultrasound; VEGF, vascular endothelial growth factor
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Introduction
Little is known about the role of the b2-adrenoceptor (b2AR) in
the vasculature. Recently, our group and others have begun to
elucidate the mechanisms of b2AR control of vascular func-
tions (Lembo et al., 1997; Ferro et al., 1999) and showed that
this receptor can activate eNOS in an Akt-dependent manner
and induce release of nitric oxide (NO) at the endothelium
(Iaccarino et al., 2002; 2004). We have also shown that the
adenoviral-mediated endothelial overexpression of the b2AR
regulates post-ischaemic angiogenesis (Iaccarino et al., 2005),
to the extent that b2ARs can correct impaired angiogenesis in
animal models of cardiovascular disease such as the sponta-
neously hypertensive rat (Iaccarino et al., 2002; 2005). The
mechanisms underlying b2AR-regulated angiogenesis have
still not been elucidated. One possible explanation is that
receptors such as the b2AR are able to regulate the transcrip-
tional activity of the cell, in order to promote the release of
proangiogenic cytokines such as vascular endothelial growth
factor (VEGF). Indeed, b2AR overexpression results in VEGF
accumulation in the culture medium of endothelial cells.
VEGF has a transcriptional regulation that is controlled by
the hypoxia responsive transcription factor-1 (HIF-1), and
also by NFkB, which is known to be activated downstream by
tumour necrosis factor receptors (TNF-R) superfamily-
members and some G protein-coupled, seven transmembrane
(7TM) receptors (GPCRs) (Ye, 2001).
The role of NFkB in angiogenesis is well established, and
is linked to its ability to regulate inflammatory cytokine pro-
duction in many cellular types; these include the endothe-
lium, infiltrating macrophages, vascular smooth muscle cells
and pericytes, and skeletal muscle cells. In this context, recep-
tor and transcription factors are major players, allowing the
finely tuned response of different cell types. Therefore, NFkB
represents a particularly apt subject for our investigation on
the signal transduction mechanisms underlying the proan-
giogenic effects of b2ARs.
The b2AR knock-out (b2AR-/-) mouse model has already
proved useful to unveil specific molecular features of the b2AR
(Chruscinski et al., 1999; Shenoy et al., 2006). We therefore
exploited such a model to investigate the adaptive responses
to chronic hindlimb (HL) ischaemia in a b2AR-negative
(b2AR-/-) situation. Furthermore, using adenoviral-mediated
gene transfer, we reconstituted membrane b2AR expression in
the ischaemic HL. In vitro, we explored the possible mecha-
nisms accounting for b2AR’s beneficial effects on angio-
genesis, focusing particularly on NFkB activation and
transcriptional activity.
Methods
Mouse strain and surgical procedures
Previously described b2AR-/- and b2AR+/+ mice (age 14–18
weeks) were used in this study (Chruscinski et al., 1999).
Founders were provided by courtesy of Brian Kobilka, Stan-
ford University, CA. Mice were bred in heterozygousity and
homozygous b2AR-/- or b2AR+/+ male littermates were used
as the study and control population. All procedures were
approved by the Thomas Jefferson University Institutional
Animal Care and Use Committee and the Federico II Univer-
sity Ethical Committee for Animal Research. Mice were anaes-
thetized with a mixture of ketamine (100 mg·kg-1) and
xylazine (3 mg·kg-1) and the right common femoral artery
was isolated and removed. In a group of b2AR-/- mice (n =
20), we placed a silastic catheter into the femoral artery distal
to the resection, through which a solution containing
1011 tvp of either an adenovirus encoding for LacZ or the
human b2AR gene was infused into the HL and allowed to
remain there for 30 min while the saphenous vein was tem-
porarily occluded (Santulli et al., 2009a). Afterwards, the virus
was removed through the catheter, the common femoral
artery removed and the wound closed in layers. With this
manoeuvre, we ascertained that endothelial cells, vascular
smooth muscle cells and skeletal myocytes of the hindlimb
express the transgene carried by the viral vector, as found
previously (Santulli et al., 2009a). Mice were checked daily for
fur loss, skin lesions (blistering), necrosis, self-inflicted ampu-
tations of the ischaemic hindlimb. Surgical aftercare and dis-
tress surveillance were performed according to institution’s
guidelines.
Blood flow determination
Blood flow (BF) in the posterior tibial artery of ischaemic and
non-ischaemic HL was evaluated by ultrasound (US) (using a
VisualSONICS VeVo 770 imaging system with a 710 MHz
scanhead) in isofluorane-anaesthetized mice (2% v·v-1) imme-
diately after surgery and at days 3, 7, 10 and 14 thereafter. We
measured maximal velocity (Vmax) and maximal diameter of
the vessel. After calculation of the vessel area, BF was calcu-
lated using the formula: BF = Vmax/vessel area (Santulli et al.,
2009a). Data are expressed as ischaemic to non-ischaemic
ratio. Fourteen days after surgery, mice were anaesthetized as
above, and a PE 10 catheter was placed into the abdominal
aorta through the left common carotid, as previously
described (Iaccarino et al., 2002). Maximal vasodilatation was
obtained by administration of nitroglycerin (2 mg i.a.) fol-
lowed by injection of 3 ¥ 106 orange-dyed beads (15 mm
diameter, Triton Technologies, San Diego, CA, USA). Animals
were then killed by cervical dislocation, samples of the gas-
trocnemius muscle from the ischaemic and non-ischaemic
HL were collected and frozen with liquid nitrogen and stored
at -80°C. Next, the samples were homogenized and digested
according to manufacturer protocol; the beads were collected
and suspended in DMTF. The release of dye was assessed by
light absorption at 450 nm (Santulli et al., 2009a). Data are
expressed as ischaemic to non-ischaemic muscle ratio.
Immunofluorescence and morphology
At 14 days, we used B mode US for morphological analysis of
the ischaemic and controlateral hindlimbs. In particular, we
evaluated bone rarefaction, muscle fibrosis and skin thick-
ness, all processes that are associated with HL ischaemia (San-
tulli et al., 2009b).
The anterior tibial muscle was isolated and harvested for
immuonostaining as described previously (Zhou et al., 2003).
Specimens were fixed in 4% paraformaldehyde and then
embedded in paraffin. A series of cross-sections (6 mm) were
obtained. Rat anti-CD31 antibody (1:50, BD Pharmingen, CA)
and rabbit anti-von Willebrand (vW) factor (1:50, DAKO,
BJPb2AR and neoangiogenesis
British Journal of Pharmacology (2011) 162 712–721 713
Carpinteria, CA) were used as primary antibodies for double
staining of endothelial cells. As a negative control, normal rat
and rabbit IgG were used instead of the primary antibody.
The primary antibodies were recognized by Alexa Fluor 594
goat anti-rat (Green) and Alexa Fluor 488 goat anti-rabbit
(Blue) secondary antibodies (1:100), respectively (Molecular
Probes, Eugene, Oregan). Nuclei were counterstained with
VECTASHIELD mounting medium with DAPI (Red) (Vector,
Burlingame, CA). Immunofluorescence was visualized under
a fluorescence microscope (Olympus IX71, Olympus, Center
Valley, CA, USA) and the number of capillaries per 20 fields
was measured on each section by two independent operators
(M.C., R.H.Z.), blinded to treatment. Another series of tissue
sections were stained with haematoxylin/eosin (H&E) for
morphological analysis.
bAR radioligand binding
Membrane fractions were obtained from quadricep muscle
homogenates by centrifugation as previously described (Iac-
carino et al., 1998). Total receptor density was assessed by bAR
radioligand binding studies using the non-selective bAR
antagonist [125I]-cyanopindolol (125I-CYP), as described previ-
ously (Iaccarino et al., 2001b). The percentage of b2ARs was
calculated from the high affinity binding subpopulation
using GraphPad Prism.
Adenoviral constructs
We used adenoviral vectors encoding for the human wild-
type b2AR gene (Adb2AR) and the LacZ (control virus) as
previously described (Iaccarino et al., 2002; 2005; Ciccarelli
et al., 2007).
Cell culture
Aortic endothelial cells (ECs) from b2AR-/- and b2AR+/+ mice
were isolated as previously described (Iaccarino et al., 2002).
Vessels were cut into rings, placed on matrigel, incubated in
DMEM supplemented with 20% FBS and EC growth supple-
ment (10 mg · 100 mL-1), and incubated at 37°C in 5% CO2.
After 7 days, aortic rings were removed, and the ECs remain-
ing on matrigel were expanded in DMEM containing
10% FBS.
Western blotting
Cells were deprived of serum overnight, exposed to agonists
and lysed in RIPA/SDS buffer (50 mmol·L-1 Tris-HCl, pH 7.5,
150 mmol·L-1 NaCl, 1% NP-40, 0.25% deoxycholate,
9.4 mg·50 mL-1 sodium orthovanadate, 20% SDS). Protein
concentration was determined using a BSA assay kit (Pierce,
Thermoscientific, Rockford, IL, USA). IkBa was immunopre-
cipitated from total lysates with anti-IkBa antibody and
protein A/G agarose. Immunocomplexes or total lysates were
electrophoresed by SDS/PAGE and transferred to a nitrocellu-
lose filter. Total IkBa and b2AR were visualized by specific
antibodies (Santacruz, Santa Cruz, CA, USA), anti-rabbit
horseradish peroxidase–conjugated secondary antibody (San-
tacruz) and standard chemiluminescence (Pierce). Autorad-
iographies were then digitalized and densitometry
quantification performed using dedicated software
(ImageQuant, GE HealthCare, Milano, Italy). Data are
presented as arbitrary densitometry units (ADU) after
normalization for actin. In other experiments, cells were
infected with Adb2AR at a rate of 20:1.
VEGF quantification
Aortic ECs from b2AR-/- and b2AR+/+ mice were deprived of
serum overnight and then stimulated with isoprenaline (Iso)
for 6 h. Culture medium was collected and VEGF was immu-
noprecipitated with anti-VEGF antibody (Santacruz) and
protein A/G agarose (Santacruz). After being extensively
washed, the immunocomplexes were electrophoresed by
SDS/PAGE and transferred to nitrocellulose; VEGF was visu-
alized by specific antibody (Santacruz), anti-rabbit HRP-
conjugated secondary antibody (Santacruz) and standard
chemiluminescence (Pierce). For our analysis, we examined
the Western blot band corresponding to VEGF 164 isoform.
Cell transfection and luciferase assay
Transient transfection was performed using Lipofectamine
2000 (Invitrogen, Paisley, UK) according to manufacturer’s
instruction. Aortic ECs from b2AR-/- and b2AR+/+ mice were
transfected with plasmid expression vectors coding cAMP
response element binding protein (CREB) and IkB plasmids
(Sorriento et al., 2009; 2010) used for signal transduction
studies, or with a kB-luciferase reporter and b-galactosidase
for NFkB activity. In this latter case, 24 h after transfection,
cells were deprived of serum overnight and stimulated with
TNFa (20 ng·mL-1), as positive control, and Iso (10-7 mol·L-1)
for 1, 3 and 6 h. Lysates were analysed using the luciferase
assay system with reporter lysis buffer from Promega and
measured in a b-counter. Relative luciferase activity was nor-
malized against the co-expressed b-galactosidase activity to
overcome variations in transfection efficiency between
samples. In other experiments, cells were stimulated with Iso
(10-7 mol·L-1) or TNFa (20 ng·mL-1) for 3 h (Santulli et al.,
2009b).
Tube formation assay
When plated on matrigel (Becton Dickinson, Bedford, MA,
USA), ECs organize themselves into a network-like structure,
resembling sinusoids of immature vessels (Ciccarelli et al.,
2008). Six-well multidishes were coated with growth factor-
reduced matrigel (10 mg·mL-1) according to the manufactur-
er’s instructions. Control and b2AR-/- ECs (2 ¥ 105) were
incubated at 37°C for 12 h in 1 mL of DMEM medium. Tube
formation was defined as a structure exhibiting a length four
times its width. Network formation was observed using an
inverted phase-contrast microscope (ZEISS). Representative
fields were taken, and the average of the total number of
complete tubes formed by cells was counted in 15 random
fields by two independent investigators (D.S and E.C.).
RT PCR
Total RNA was isolated from ECs deprived of serum overnight
or mouse hindlimb muscle using Trizol reagent (Invitrogen)
and cDNA was synthesized by means of Thermo-Script
RT-PCR System (Invitrogen), following the manufacturer’s
instruction. After reverse transcription, real-time quantitative
polymerase chain reaction (RT-PCR) was performed with the
SYBR Green Real Time PCR master mix kit (Applied Biosys-
tems, Carlsbad, CA, USA). The reaction was visualized with
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SYBR Green Analysis (Applied Biosystem) software on a
StepOne thermocycler (Applied Biosystem). Primers for
VEGF-165 and GAPDH gene analysis were as previously
described (Sorriento et al., 2009).
Statistical analysis
Data are presented as mean  SEM. Each experiment was
performed from three to five times. P values were calculated
by Student’s t-test or two-way ANOVA as appropriate. For dis-
tribution statistics, the chi-squared test was performed.
The nomenclature conforms to the British Journal of
Pharmacology’s ‘Guide to Receptors and Channels’ (Alex-
ander et al., 2009).
Results
In vivo post-ischaemic angiogenesis
Blood perfusion evaluation. As shown in Figure 1A, compared
to b2AR proficient controls, hindlimbs from b2AR-/- mice
present a significantly lower bAR membrane-density. Intra-
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Figure 1
b2AR knock-out exacerbated the symptoms of ischaemia and impaired perfusion and angiogenesis in ischaemic hindlimbs of mice. (A) Effects of
adenoviral-mediated gene transfer on bAR levels (*P < 0.05 b2AR-/- vs. b2AR+/+; # P < 0.05, b2AR-/-/ADb2AR vs. b2AR-/-, n = 3 to 5). (B)
Ischaemia-induced skin lesions in b2AR-/- and b2AR+/+ hindlimbs (HLs) (* P < 0.05 b2AR-/- vs. b2AR+/+, c2test, n = 10 per group). (C) HL blood
flow over 14 days in b2AR+/+, b2AR-/-, and Adb2AR-treated b2AR-/- ischaemic HL, as measured by US Doppler. ADb2AR ameliorated blood
perfusion in the ischaemic HL (*P < 0.05 b2AR-/- vs. b2AR+/+; # P < 0.05, ADb2AR vs. b2AR-/-; n = 10 per group). (D) Blood perfusion in the
ischaemic HL as evaluated by dyed beads dilution method (*P < 0.05 b2AR-/- vs. b2AR+/+; # P < 0.05, b2AR-/-/Adb2AR vs. b2AR-/-; n = 10 per
group). (E) HL muscle capillary density. (*P < 0.05 ischaemic vs. non-ischaemic muscle; #P < 0.05 b2AR-/-vs. b2AR+/+; ! P < 0.05, b2AR-/-/Adb2AR
vs. b2AR-/-; n = 5 per each group). (F) VEGF gene expression in ischaemic gastrocnemius muscle 3 days after femoral artery ligation and resection
(* P < 0.05 vs. non-ischaemic, n = 3; ! P < 0.01 vs. non-ischaemic b2AR +/+; # P < 0.01 vs. ischaemic b2AR +/+; n = 3; $ P < 0.01 vs. non-ischaemic
b2AR-/-; @ P < 0.01 vs. ischaemic b2AR-/- alone; n = 3).
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vascular delivery of adenovirus leads to the infections mostly
of vascular cells, including endothelium and VSMC, and
perivascular fibroblasts and skeletal myocytes as shown by
LacZ staining (Figure S1A and B). Administration by this
route of Adb2AR in b2AR-/- mice restores bAR density in the
hindlimb (Figure 1A). Gross morphology and functional
analysis of mice following chronic ischaemia indicate a
higher occurrence of necrosis, autoamputation and limping
in b2AR-/- mice as compared to b2AR+/+ controls (Figure 1B).
b2AR restoration by Adb2AR was also able to prevent this
symptom (Figure 1B). US evaluation of hindlimb perfusion
(blood flow, BF) immediately after femoral artery removal
shows an absence of flow in ischaemic HL in all groups of
mice (data not shown). Over two weeks, BF was partially
restored in b2AR+/+ while no improvement was observed in
b2AR-/- mice (Figure 1C). A similar result was obtained with
the dyed beads perfusion analysis (Figure 1D). As assessed by
both techniques, the Adb2AR restores blood perfusion
through the ischaemic hindlimb (Figure 1C and D). In line
with these results, chronic ischaemia appeared to induce a
capillary rarefaction that was higher in the b2AR-/- compared
to the b2AR+/+ mice, and Adb2AR reversed this effect in the
b2AR-/- (Figure 1E). b1AR mRNA levels were not affected by
the b2AR removal, nor by Adb2AR gene therapy (Figure S1C).
We thus evaluated the production of reactive VEGF in the
ischaemic hindlimb. Consistent with the perfusion data,
VEGF gene expression was upregulated in the ischaemic
hindlimbs of b2AR+/+ mice, while it was blunted in the
b2AR-/- mice both before and after ischaemia (Figure 1F). In
the latter, Adb2AR gene therapy restored the VEGF level in
basal conditions as well during chronic ischaemia (Figure 1F).
Evaluation of angiogenic phenotypes in vitro
Matrigel assay and VEGF production in primary cultures of
ECs. In order to study angiogenesis in vitro, we tested the
ability of mouse EC primary cultures to organize into a
network when plated on a matrigel substrate. b2AR gene dele-
tion inhibited the ability of ECs to form into vascular tubes
compared to wild-type cells (Figure 2A). To verify the rel-
evance of NFkB to the pro-angiogenic phenotype of EC, we
transfected b2AR+/+ cells with the NFkB inhibitor IkB, 48 h
before plating cells on matrigel. As expected, IkB blocked the
tubular formation of b2AR+/+ endothelial cells on matrigel
(Figure 2B). We further investigated the pro-angiogenic phe-
notype of b2AR-/- ECs by evaluating VEGF production in
basal conditions and after isoprenaline treatment. As shown
in Figures 2C and 6 h of stimulation with Iso increased VEGF
levels in b2AR+/+ but not in b2AR-/- EC. A similar result was
obtained when VEGF mRNA levels were determined by
RT-PCR in the same conditions (Figure 2D).
b2AR effects on NFkB signalling. To investigate the ability of
b2ARs to modulate VEGF production and angiogenesis, we
tested the possibility that b2AR may regulate the activity of
the NFkB transcription factor. Indeed, in b2AR+/+ EC, bAR
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stimulation with Iso induced a time-dependent degradation
of the endogenous NFkB inhibitor, IkBa (Figure 3A). Consis-
tent with this result, the luciferase assays demonstrated a
time-dependent increase in NFkB transcriptional activity
after Iso stimulation (Figure 3B). As expected, TNFa also
increased NFkB transcriptional activity in b2AR+/+ EC, and
the overexpression of IkB inhibited the Iso-induced increase
in NFkB activity (Figure 3B).
In ECs, b2AR gene deletion inhibits Iso-induced IkBa
downregulation (Figure 3C), confirming that b2AR may regu-
late NFkB activation in response to Iso. Surprisingly, b2AR
gene deletion also inhibited TNFa-induced IkBa downregu-
lation (Figure 3C). Accordingly, restoration of b2ARs by means
of Adb2AR infection corrected both Iso and TNFa–mediated
IkBa degradation to levels comparable to the ones observed
in b2AR+/+ EC (Figure 3C), confirming the importance of
0' 2' 5' 10' 15' 30' 60'
0
6000
12000
18000
 *  *
IκBα
IκBα
 cellular content
0' 2' 5' 10' 15' 30' 60'ISO
Actin
Isoprenaline, 10-7M
A
D
U
Control TNFa Iso, 1h Iso, 3h Iso, 6h IkB Iso, 3h + IkB
0
20000
40000
60000
80000
 *
Relative NFκB activity
 *
 *
 *
!#
P
ro
te
in
(c
p
m
 m
g
−1
)
P
ro
te
in
(c
p
m
 m
g
−1
)
b2AR +/+ b2AR-/- -/-/Adb2AR
0
5000
10000
15000
20000
 IκBα cellular content
 *
 * *  *
##
A
D
U
b2AR +/+ b2AR -/- b2AR -/-/Adb2AR
0
20000
40000
60000
80000
100000
# # #
*
*
*,#
*
Relative NFκB activity
b2AR +/+ b2AR -/- 2AR -/-/Adb2AR
0
5000
10000
15000
p-CREB/CREB
#
#
#
#,*#,*
***
#
A
D
U
D
F
B
C
E
A
b2AR +/+ b2AR -/- 2AR -/-/Adb2AR
0
2000
4000
6000
p-NFκB/NFκB
# #
*
*
*
*
A
D
U
Control Isoprenaline TNFα
b2AR
Figure 3
Effects of b2AR gene deletion on NFkB signalling. (A) IkBa levels visualized by Western blot in b2AR+/+ ECs. Isoprenaline (Iso, 10-7M) was kept in
the tissue culture medium for the time indicated. Densitometry units (ADU) (results normalized to actin response) are depicted in graphs. (* P <
0.05 vs. control, n = 3). (B) Effects of TNFa (20 ng·mL-1) for 6 h or Iso (10-7M) for 1, 3 and 6 h on NFkB transcription activity in b2AR+/+ EC and
in b2AR+/+ EC transfected with the IkB plasmid (* P < 0.05 vs. control, # P < 0.05 vs. control; ! P < 0.05 Iso + IkB vs. IkB; n = 3 to 5). (C) IkBa
levels assessed by Western blot in b2AR-/- and b2AR+/+ ECs stimulated with Iso (10-7M, 1 h) or TNFa (20 ng·mL-1, 1 h) (* P < 0.05 vs. control;
# P < 0.05 vs. b2AR+/+; n = 3 to 5). (D) NFkB activity in EC induced by Iso (10-7M) and TNFa (20 ng·mL-1) (* P < 0.05 vs. control; # P < 0.05 vs.
b2AR +/+; n = 3 to 5). (E) ECs were stimulated with Iso (10-7M) and TNFa (20 ng·mL-1). CREB phosphorylation was visualized by Western blot,
digitalized and corrected for endogenous CREB. (* P < 0.05 vs. control; # P < 0.05 vs. b2AR +/+, n = 3). (F) EC were stimulated as in (E), and NFkB
phosphorylation was visualized by WB, digitalized and corrected for total NFkB. (* P < 0.05 vs. control; # P < 0.05 vs. b2AR +/+, n = 3).
BJPb2AR and neoangiogenesis
British Journal of Pharmacology (2011) 162 712–721 717
b2ARs in NFkB endothelial signalling. In accord with this, in
b2AR-/- EC, both Iso and TNFa-induced NFkB-activity were
blocked, and Adb2AR restored the responses to both agonists
(Figure 3D). These data suggest that b2AR knock-out may
have a general impact on cytokine transcription.
Recently, CREB, another b2AR-controlled transcription
factor, has been shown to down-regulate the activity of NFkB
(Ye, 2001). Indeed, CREB binding protein (CBP) and the
related cofactor p300 are co-activators able to regulate the
activity of transcription factors, and CREB and NFkB have
been shown to compete for limiting amounts of CBP/p300
(Ye, 2001). In fact, the recruitment of these co-activators by
CREB reduces their availability for NFkB. Thus, we evaluated
CREB and NFkB activation by Western blot in b2AR-/- ECs
stimulated with Iso or TNFa. b2AR gene deletion increased
CREB phosphorylation both in basal conditions and after
stimulation with Iso or TNFa and the restoration of b2ARs by
adenovirus-mediated gene transfer decreased p-CREB levels
(Figure 3E). Reciprocal results were obtained with NFkB.
Indeed, compared to b2AR proficient controls, in b2AR-/- ECs,
Iso and TNFa failed to induce NFkB phosphorylation while
Adb2AR infection restored the responses to both agonists
(Figure 3F).
Identification of signal transduction components. To determine
whether CREB upregulation is a commonmechanism of inhi-
bition for b2AR and TNFR stimulation of NFkB, we assessed
pNFkB after stimulation with Iso or TNFa in b2AR+/+ EC
trasfected with CREB or IkB. Indeed, both substances resulted
in the inhibition of NFkB activation to both agonists
(Figure 4A). Given the ability of the b2AR to couple to both Gs
and Gi, we tested the possibility that Gi is indeed involved in
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Molecular mechanisms involved in b2AR activation of NFkB. (A) Effects of transgenic expression of IkB and CREB in b2AR +/+ EC on NFkB activation
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maintaining low levels of CREB within the cell. To test this
hypothesis, we treated cells with the Gi inhibitor Pertussis
toxin for 18 h and then stimulated b2AR+/+ ECs with Iso. Gi
inhibition was accompanied by the inhibition of Iso-induced
IkB downregulation (Figure 4B) and NFkB phosphorylation
(Figure 4C). Furthermore, PTX increased the basal level of
pCREB and prevented Iso-induced dephosphorylation of
CREB (Figure 4D).
Finally, we have presented these new findings in a cartoon
as shown in Figure 5.
Discussion
The results of our study provide compelling evidence that
the removal of the b2AR impairs angiogenesis both in vitro
and in vivo. This finding extends previous knowledge
regarding the ability of b2AR overexpression to enhance
angiogenesis in vivo, and it further supports the knowledge
of the ability of b2AR to induce VEGF and cytokine produc-
tion. Indeed, our work adds novel findings concerning the
signalling that connects b2ARs and the nuclear transcrip-
tional activity of NFkB.
Evidence has been obtained suggesting that the adrener-
gic system is activated within ischaemic regions (Newton
et al., 1997) but the physiological relevance of this response is
unclear. A teleological explanation would suggest that this
activation is needed to better adapt to the ischaemic stress.
Indeed, the regenerative properties of catecholamines have
been implicated by the observation that catecholamine-
deficient mice undergo inappropriate embryo development
(Zhou et al., 1995). During postnatal life, catecholamines par-
ticipate in cardiac and vascular remodelling and in tissue
regeneration in response to various stresses (Iaccarino et al.,
2001a; Ciccarelli et al., 2008). Adrenoceptors are the effectors
of catecholamines, but their role appears to be redundant,
since correct embryo development occurs in all of the AR
knock-out models, and in adult life, mice with deletion of AR
genes do not present basal phenotypic alterations. Under
stress conditions, though, or in the presence of catechola-
mine challenge, a perturbation in the phenotype of KO mice
has been noted (Rohrer et al., 1999). In particular, previous
studies in bAR-/- mice have shown that b2ARs are mostly
involved in vascular and metabolic mechanisms (Chruscinski
et al., 1999; Rohrer et al., 1999). Our study extends this
notion and is the first to illustrate the requirement for endog-
enous b2ARs in neoangiogenesis following chronic ischaemia,
by providing the following evidence: (i) b2AR-/-mice present
impaired tolerance to chronic ischaemia; (ii) this phenotype
is rescued by the local restoration of b2AR membrane-density,
induced by adenoviral-mediated gene transfer; (iii) a func-
tional relationship appears to exist between the b2AR and
NFkB, the transcription factor involved in ischaemia-induced
cytokine production.
These results accord with our recent observation that
overexpression of the b2AR enhances the adaptive pro-
Figure 5
In the wild-type cell (left), the presence of the b2AR causes a tonic stimulation that fosters the activation of NFkB, which, by translocating to the
nucleus upon activation, competes for CBP with CREB. Furthermore, the b2AR exerts a tonic inhibition on cAMP production, by coupling to Gi.
Once the receptor is removed (right), the inhibitory effect on cAMP is released, unbalancing the nuclear transcription towards CREB, which binds
more CBP, thus making NFkB binding to the same cofactor unlikely to occur. pP65/p50: NFkB; TNFR: TNFa receptor.
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angiogenic response to ischaemia (Iaccarino et al., 2005).
Importantly, the present results add to the hypothesis that
other endogenously expressed bAR subtypes cannot under-
take this role of b2ARs in ischaemic neo-angiogenesis. Inti-
mate differences in the signalling capabilities of this receptor
make it unique, and probably this is the reason for our find-
ings. Removal of this receptor alters the intracellular signal
transduction pathways to such an extent that the trascrip-
tional status of the cell is modified. Our in vitro study revealed
that angiogenesis is impaired in b2AR-/- EC, probably due to
the impaired production of cytokines such as VEGF. The main
transcription factors modulating VEGF expression are
hypoxia-inducible factor-1a (HIF-1a) (Marti et al., 2000) and
NFkB (Kiriakidis et al., 2003). HIF-1a activates the transcrip-
tion of target genes in response to hypoxia and is inactive in
basal conditions due to ubiquitination and degradation.
NFkB, in contrast, can be activated following stimulation of
different receptors. The ability of GPCRs to activate this tran-
scription factor has been established in different cell types,
mainly in the immune system. With regard to the bARs, the
evidence showing that bAR agonists are able to induce NFkB
activation is controversial. In monocytes, Farmer and Pugin
(2000) showed that a number of bAR agonists had inhibitory
effects on LPS-induced TNFa and IL-8 production, and pro-
posed that cAMP through PKA is the mediator of such inhi-
bition (Farmer and Pugin, 2000). In contrast, Chandrasekar
et al. (2004) showed that in cardiac-derived ECs, Iso induces
NFkB promoter activity in a b2AR-dependent manner. These
authors concluded that b2ARs induce NFkB activation in a
cAMP-independent manner, through the activation of Gi,
Pi3K, Akt and IKK with IkBa degradation. Our results accord
with the latter findings, since in b2AR+/+ EC, Iso induced IkBa
degradation and enhanced NFkB transcriptional activity in a
time-dependent manner. Furthermore, our data indicate that
the physical presence of b2ARs is needed to activate NFkB;
indeed, b2AR gene deletion inhibited NFkB activity in
response to both GPCRs and TNF-Rs. Gas and Gai signalling
pathways have opposite effects on NFkB: Gs-dependent sig-
nalling, induces PKA-dependent CREB activation and conse-
quently inhibition of NFkB activity (Ye, 2001). In contrast, Gi
activates NFkB by inhibiting/removing IkB. Our hypothesis is
that the lack of b2ARs that have the ability to couple to Gi
tilts the balance towards Gs-dependent signalling, which
would lead to PKA-induced CREB activation and CBP/p300
recruitment, making the latter unavailable for NFkB activa-
tion (Figure 5). Indeed, validation of such a hypothesis
derives from our studies with the pertussis toxin, showing the
relevance of Gi for b2AR-induced activation of NFkB. Irrespec-
tive of this result, the observation that regardless of its
mechanism of action b2AR influenced not only isoprenaline,
but also TNFa-dependent activation of NFkB is strongly sug-
gestive of a pivotal role played by b2ARs in the instruction of
signals required for the fine-tuning of NFkB transcriptional
activity. We have performed our experiments in the endot-
helial cells, but it is most likely that the b2AR can regulate
NFkB activity also in other cell types. In particular it would be
interesting to evaluate the skeletal muscle, which expresses a
large number of b2ARs and is also an important source of
VEGF.
In conclusion, our data indicate that the b2AR is impor-
tant in mediating production of key pro-angiogenic cytok-
ines, such as VEGF. The impairment of the signal
transduction of this receptor results in imparment of angio-
genesis in response to chronic ischaemia. Our data add a
novel piece to the puzzling paradigm of those pathophysi-
ological conditions that are characterized by increased adr-
energic neural drive, impaired b adrenoceptor signalling and
impaired organ function such as myocardial ischaemia.
Under these conditions, the reduction of b2ARs signalling is
detrimental not only for the cardiac function but also for the
development of an adequate compensatory neoangiogenesis,
which would worsen the blood supply to the ischaemic heart
and accelerate the progression of myocardial dysfunction.
The use of therapeutic strategies aimed at improving bAR
signalling, may therefore achieve double efficacy, by amelio-
rating myocardial function and by hastening compensatory
angiogenesis.
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Cardiac resynchronisation therapy response predicts
occurrence of atrial fibrillation in non-ischaemic dilated
cardiomyopathy
S. L. D’Ascia,1 C. D’Ascia,1 V. Marino,1 A. Lombardi,2 R. Santulli,3 M. Chiariello,1,* G. Santulli1,4
Introduction
Cardiac resynchronisation therapy (CRT) has
emerged as a highly effective treatment for patients
with advanced heart failure (HF) and ventricular
conduction delay (1). Several studies have showed
the haemodynamic and functional improvement
obtained with biventricular pacing, with a subsequent
reduction of hospitalisations and a decrease in mor-
tality (2). Nevertheless, despite the positive effects of
CRT on haemodynamic, functional status and mor-
tality in HF, approximately 30% of patients do not
respond to this therapy, emphasising the need for
better selection criteria (1,2). Furthermore, the pri-
mary cardiac cause of exacerbation of HF is atrial
fibrillation (AF) that is also an independent risk
factor for sudden death. HF and AF often coexist;
both are responsible for increased mortality, more
frequent hospitalisations, reduced exercise capacity
and decreased quality-of-life (QoL). Besides, AF and
HF are believed to directly predispose to each other
(3). In particular, in the setting of advanced HF,
30–40% of patients will develop AF during the
course of the disease. So, if CRT influences the
occurrence of AF, this might influence patient selec-
tion and possibly programming of the device.
On these grounds, the aims of the present study
were: to identify preimplantation characteristics that
best can predict which patients will benefit the
most from biventricular pacing, in order to make
out suitable candidates for CRT (4); to compare the
incidence of new-onset AF after 1, 2 and 3 years of
follow-up in responder and non-responder patients,
so as to assess a possible favourable role of CRT,
through means of an atrial reverse remodelling, on
the prevention of this arrhythmia.
Methods
Study population
This is a single-centre prospective study that
included all the consecutive CRT implants from July
2004 until June 2007 performed at our institution on
patients with non-ischaemic idiopathic-dilated car-
diomyopathy (coronary angiography failed to reveal
stenosis > 30%), following the previously described
eligibility criteria for CRT (5). All patients had New
York Heart Association (NYHA) functional class III
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What’s known
Albeit several studies examined the association
between cardiac resynchronization therapy and
atrial fibrillation in heart failure, results are still
unclear and quite conflicting.
What’s new
In this study we show that in patients with
non-ischemic dilated cardiomyopathy a positive
response to cardiac resynchronization therapy has a
favorable role on the prevention of new-onset atrial
fibrillation.
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or IV symptoms for at least 6 months before enrol-
ment, despite optimal pharmacological treatment
(including b blockers, loop diuretics, vasodilators,
nitrate, digitalis, angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers and spiron-
olactone when tolerated; no antiarrhythmic drugs for
VT were administered to the patients), left ven-
tricular ejection fraction (LVEF) £ 35% and QRS
duration > 120 ms measured on at least three leads
on the surface ECG. Exclusion criteria were: recent
(previous 3 months) acute coronary syndrome or
planned coronary revascularization, previous pace-
maker or implantable cardioverter defibrillator (ICD)
implantation, requirement of continuous intravenous
therapy, a life expectancy of < 1 year due to non-
cardiac diseases, history of AF, patients whose major
echocardiographic parameters could not be obtained
because of poor image quality, systolic blood pres-
sure > 170 or < 80, heart rate > 140 and kidney
failure with serum creatinine levels > 250 lmol ⁄ l (5).
Detailed clinical and instrumental data (ECG,
echocardiogram, QoL evaluation, 6-min walk test,
cardiopulmonary exercise test) were collected, with
scheduled visits, before implantation and at the
1-, 2- and 3-year follow-up. Patients were also given
a diary in which the information of any medical con-
tacts between their follow-up visits was to be
recorded. The detection of AF relied on electrocardi-
ography, 24 h Holter examination and strips from
continuous telemetric control of implanted devices
(every 3 to 6 months, when ICDs were systematically
checked) (6). AF was defined as an episode, with or
without symptoms, lasting at least 10 min (7,8),
similar to a large sub-study of the CARE-HF trial
reported by UC. Hoppe et al. (9). Patients were also
assessed for HF symptoms (NYHA functional class).
QoL was evaluated by the Minnesota Living with HF
questionnaire (scores range from 0 to 105, with
higher scores reflecting a poorer QoL) (10), while
the 6-min walk test was carried out according to
Bittner’s recommendations (11). The 6-min walk
distance and QoL tests were administered by study
nurses who had no knowledge of the patients’ treat-
ment. Coronary angiography was performed prior to
implantation in all patients, also to exclude causes of
HF amenable to surgery or intervention. This study
protocol was designed in compliance with the
Helsinki declaration and approved by the local Ethics
Committee. Written informed consent was obtained
from each participant.
Non-responders were defined after 12 months of
follow-up as patients with at least one of the follow-
ing characteristics: deteriorating function (HF-related
death, need for heart transplantation), increase in
LVEF £ 4 absolute percentage points (12), worsening
in peak oxygen consumption, in QoL score or in the
distance walked in 6 min, as previously described
(13,14).
ICD implantation and optimisation
Patients were implanted with a biventricular ICD
(Contak Renewal 1 or 2; Guidant Inc., part of
Boston Scientific, Natick, MA, USA). All procedures
were performed under local anaesthesia. Three trans-
venous leads were inserted, through the left subcla-
vian vein. The atrial lead was placed in the high
right atrium; the right ventricular lead was posi-
tioned, in the apex or in the high interventricular
septum, as far as possible from the LV lead; LV
pacing was obtained after coronary sinus (CS) angi-
ography, advancing a bipolar lead into the lateral or
posterolateral cardiac vein. The final lead position
was chosen on the basis of visual inspection, assessed
by anteroposterior and lateral chest radiography. The
atrioventricular interval (electrical delay between
atrial and ventricular excitation) was optimised by
Doppler echocardiography 1 day after implantation
to reach maximal transmitral diastolic filling and
maximal biventricular capture and checked every
year. Patients in whom transvenous LV lead implan-
tation was acutely unsuccessful (n = 5), attributable
to several causes [failure to cannulate the CS (n = 2),
high threshold to chronic pacing (n = 1), CS dissec-
tion (n = 1) and impossibility to obtain a stable lead
placement (n = 1)] were obviously excluded from
the study.
Echocardiographic evaluation
A trans-thoracic, two-dimensional echocardiogram
was serially performed in all patients using a Sonos
5500 ultrasound system (Philips, Amsterdam, Neth-
erlands), equipped with a 2.5-MHz transducer. The
examination included two-dimensional, M-mode and
Doppler data. All recordings were made, as previ-
ously described, with the patient in the lateral
recumbent position, according to the American Soci-
ety of Echocardiography recommendations (4). The
following parameters were measured using the differ-
ent axis: LV end-diastolic and end-systolic diameters,
LVEF (biplane LV end-systolic and end-diastolic vol-
umes were calculated from apical views according to
the modified Simpson’s rule), LV end-systolic vol-
ume index, left atrial diastolic and systolic areas,
amount of mitral regurgitation (calculated as the
area of the colour-flow Doppler regurgitant jet
divided by the area of the left atrium in systole, both
in square centimetres). All echocardiographic studies
were performed and analysed by the same study-
independent physicians, blinded to the study proto-
col and to the patients’ status. Echocardiographic
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measurements were systematically averaged in five
consecutive samples (15).
Cardiopulmonary exercise test
Symptom-limited cardiopulmonary exercise testing
(Treadmills ‘Rammill Series’; Morgan Italia, Bologna,
Italy) was performed, conducted on an upright bicy-
cle ergometer with a 10-W ⁄min step protocol, start-
ing with 2 min of unloaded cycling. Measurements
of oxygen consumption (VO2), were taken at rest
and during exercise using a moving average of eight
breaths. During each stage of exercise, data on heart
rate and rhythm and BP were collected. All patients
were encouraged to exercise until they felt unable to
continue because of dyspnoea and ⁄or fatigue. The
ventilatory threshold was measured by the V-slope
method (16). The maximum VO2 was defined as the
highest VO2 value measured (peak VO2).
Statistical analysis
Unless otherwise specified, data are presented as the
mean value ± SD or absolute numbers with percent-
ages for categorical variables, unless otherwise speci-
fied. Data normality was evaluated through the
Kolmogorov–Smirnov test. Comparison of quantita-
tive variables was performed using the Student’s
t-test for paired and unpaired data when appropriate,
with a Bonferroni correction when multiple compari-
sons were made (15). Dichotomous or categorical
data were assessed with the v2 test or Fisher’s exact
test. The non-normally distributed data within
patient groups were compared using the nonpara-
metric Wilcoxon test. Odds ratios were given with
the 95% confidence interval (CI). Differences in
event rates (AF, death) over time were calculated
according to the Kaplan–Meier method and analysed
with the use of Cox proportional hazard models.
Table 1 Baseline characteristics of the patients included in the analysis, then (1-year follow-up) sub-divided in
responders and non-responders
All patients Responders Non-responders
No. 58 42 16
Age (years) 62.5 ± 11.1 62.4 ± 14.2 62.5 ± 11.9
Male sex: No. (%) 37 (63.8) 27 (64.3) 10 (62.5)
Height (cm) 168.41 ± 6.9 167.7 ± 7.38 170.86 ± 4.9
Weight (kg) 72.37 ± 13.6 70.3 ± 13.6 75.65 ± 14.5
Body mass index 25.41 ± 3.92 25.07 ± 3.7 25.8 ± 4.33
Body surface (m2) 1.81 ± 0.18 1.77 ± 0.192 1.86 ± 0.18
Heart rate (bpm) 70.89 ± 5.9 71.5 ± 5.51 72.23 ± 7.8
QRS duration from surface ECG (ms) 170.8 ± 6.1 167.3 ± 20.6 171.2 ± 8.5
Systolic blood pressure (mmHg) 122.7 ± 15.5 122.8 ± 15.9 125.0 ± 17.4
Diastolic blood pressure (mmHg) 74.4 ± 13.4 74.7 ± 14.6 70.1 ± 12.8
Diabetes (%) 31.0 28.6 37.5
Hypertension (%) 24.1 23.8 25.0
Smoking (current or former) (%) 19.0 19.0 18.8
Dyslipidemia (%) 41.5 40.0 45.5
NYHA class 3.19 ± 0.395 3.19 ± 0.397 3.19 ± 0.403
NYHA III: No. (%) 47 (81.0) 34 (81.3) 13 (81.0)
NYHA IV: No. (%) 11 (19.0) 8 (19.0) 3 (18.8)
LVEF (%) 27.6 ± 5.6 27.9 ± 5.5 26.7 ± 5.7
LV end-diastolic diameter (mm) 69.8 ± 6.9 68.1 ± 7.1 73.2 ± 9.1*
LV end-systolic diameter (mm) 57 ± 8.7 56 ± 9.2 59 ± 10.7
LV end-systolic volume index (ml ⁄m2) 121.2 ± 13.2 118.4 ± 13.1 121.3 ± 13.0
LV filling time (s) 0.46 ± 0.04 0.51 ± 0.05 0.45 ± 0.04
Left atrial diastolic area (cm2) 17.8 ± 3.7 17.2 ± 3.8 21.5 ± 4.2
Left atrial systolic area (cm2) 26.9 ± 5.9 26.3 ± 5.4 29.8 ± 5.9
Mitral regurgitation area (% of left atrial systolic area) 0.24 ± 0.02 0.20 ± 0.02 0.28 ± 0.02*
QoL score 39.7 ± 10.8 40.8 ± 10.01 36.6 ± 12.5
Distance walked in 6 min (m) 309.7 ± 5.74 310.2 ± 5.79 308.4 ± 5.52
Oxygen uptake at peak exercise (ml ⁄ kg ⁄min) 12.5 ± 0.73 12.5 ± 0.7 12.3 ± 0.6
Oxygen uptake at anaerobic threshold (ml ⁄ kg ⁄min) 9.43 ± 0.9 9.60 ± 0.9 8.96 ± 0.7
*= p < 0.05 vs. Responders.
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Finally, we performed a linear regression analysis to
characterise the predictors of AF and a subsequent
backward stepwise multivariable analysis, tested for
goodness-of-fit, built using only the variables that
were associated with new-onset FA in the first regres-
sion analysis.
All tests that we performed were two-tailed and a
p-value < 0.05 was considered statistically significant.
All statistical tests were performed with the spss 18.0
statistical package (SPSS Inc., Chicago, IL) and
GraphPad Prism 5.01 (GraphPad software, San
Diego, CA) (17).
Results
Population characteristics
We enrolled 58 Caucasian patients who met the
inclusion ⁄ exclusion criteria. Baseline characteristics
of these subjects are depicted in Table 1. The mean
age was 62.5 ± 11.1 years; there was a male predomi-
nance (63.8%), with a mean LVEF of 27.6 ± 5.6%.
Drug therapy for HF did not change significantly
over the follow-up period, and all patients had stable
biventricular stimulation.
After 1 year, 42 patients (72.4%) were considered
responders to CRT according to the previously
defined criteria. There were 16 non-responders
(27.6%), with 4 HF-related hospitalizations. Two
patients died before the 2-year follow-up visit (one
responder and one non-responder); four patients
died before the 3-year follow-up visit (one responder
and three non-responder). No difference in survival
was evidenced by Kaplan–Meier analysis (Figure 1A).
Clinical outcomes
Our most interesting finding is that, already after
1 year, there is a significant difference in new-onset
AF in non-responder patients (18.2%) vs. responders
(3.3%). These data are confirmed at 2 years (33.3%
vs. 12.2%) and 3 years (50.0% vs. 15.0%) follow-up.
In particular, at 3-year follow-up, non-responders
have a markedly increased risk to develop new-onset
AF (OR = 5.67, 95% CI = 1.36–23.59, p = 0.019).
Hence, this disparity in risk persisted throughout the
3-year follow-up period. Furthermore, Kaplan–Meier
curves showed a significant difference in developing
new-onset AF between the two groups (p < 0.05;
Figure 1B). Finally, the multivariable analysis con-
firmed the non-response to CRT as an additive risk
factor for new onset AF (OR = 4.32, CI = 2.46–9.63,
p < 0.05).
As expected, we observed a favourable improve-
ment of clinical status in the group of CRT respond-
ers, already evidenced at 1-year follow-up, and
supported after 2 and 3 years (Table 2).
Discussion
This is the first study that analyses long-term effects
of CRT in a population of patients with idiopathic-
dilated cardiomyopathy, with a follow-up of 3 years.
The present work confirms the clinical benefit of
treating HF patients with CRT and suggests a role
of this non-pharmacological therapy in prevention of
AF.
The loss of coordination of ventricular contraction
contributes to the pathophysiology of HF, reducing
the already diminished contractile reserve of the
heart. Specifically, dyssynchronous contraction exac-
erbates inefficient use of energy by the heart (mec-
hano-energetic uncoupling). Indeed, the left lateral
wall is activated well after the septum contracts (18).
This leads to contraction of the lateral wall during
relaxation of the septum resulting in marked
mechanical dysfunction. The dyssynchronous failing
heart also exhibits deep alterations in protein expres-
sion (19,20), such as changes in local calcium
handling, as exemplified by a strong decrease of
phospholamban in the delayed activated myocardium
(21). The purpose of CRT is to restore ventricular
relaxation and contraction sequences by simulta-
Figure 1 Kaplan–Meier estimate of time to first onset of
atrial fibrillation (AF). There is no significant difference in
mortality (Panel A), while first onset of AF was
significantly earlier in non-responder patients (dotted line)
than in responders (continuous line) (Panel B)
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neously pacing both ventricles. Numerous studies
have reported positive long-term effects in terms of
symptoms, exercise tolerance, QoL and HF prognosis
after CRT (22,23) and our work corroborates these
findings. A prospective study examining the relation
between CRT and AF using as control a HF popula-
tion that does not receive CRT would be neither
ethical nor practical, given the proven efficacy of this
therapy in treating HF. So, we decide to compare a
homogeneous population of CRT recipients, then
subdivided into responders and non-responders. One
of the most pressing unresolved questions, however,
remained how to identify patients that will not
respond to CRT, and how to define whether or not
response is really central to the entire issue (4,24),
since there is relatively poor correlation between the
various measures of CRT response. Thus, as men-
tioned in methods, we used clear and reproducible
criteria for the definition of non-responder patients,
also to avoid any case of misinterpretation.
We recruited only patients with non-ischaemic-
dilated cardiomyopathy. Indeed, albeit CRT is an
effective alternative therapy in patients with dilated
heart disease whether of ischaemic or non-ischaemic
origin, the response tends to be slightly lower when
the heart disease is ischaemic, maybe because of the
presence of necrotic tissue. This is the first study that
focalizes on this topic, assuring a homogeneous study
population. Indeed, heterogeneity may explain con-
troversial results concerning this issue emerged in
literature.
Another chief issue to discuss in analysing the
occurrence of AF is how the same AF is detected.
We defined AF as an episode, with or without symp-
toms, lasting 10 min or more, identified by electro-
cardiography, Holter examination and using the
Table 2 Characteristics of the patients at follow-up visits
All patients
1 year
Responders
1 year
Non-responders
1 year
Responders
2 years
Non-responders
2 years
Responders
3 years
Non-responders
3 years
No. 58 42 16 41 15 40 12
Age (years) 63.5 ± 11.9 63.5 ± 11.1 63.4 ± 14.2 63.5 ± 10.4 62.9 ± 14.2 64.5 ± 10.4 63.0 ± 14.01
Male sex: No. (%) 37 (63.8) 27 (64.3) 10 (62.5) 26 (63.4) 9 (60.0) 26 (65.0) 8 (66.7)
Height (cm) 168.11 ± 6.9 167.1 ± 7.38 170.86 ± 4.9 167.1 ± 7.41 170.85 ± 4.9 167.1 ± 7.38 170.86 ± 5.0
Weight (kg) 72.39 ± 13.5 70.85 ± 13.01 76.44 ± 14.4 70.4 ± 13.9 76.8 ± 14.62 70.2 ± 14.1 77.95 ± 14.7
Body mass index 25.42 ± 3.9 25.09 ± 3.7 26.2 ± 4.4 25.07 ± 3.8 24.78 ± 7.11 25.0 ± 3.9 25.07 ± 7.32
Body surface (m2) 1.80 ± 0.183 1.78 ± 0.182 1.87 ± 0.18 1.77 ± 0.196 1.88 ± 0.17 1.77 ± 0.197 1.89 ± 0.18
Heart rate (bpm) 68.41 ± 6.5 67.55 ± 6.19 70.69 ± 7.05 68 ± 6.05 68.3 ± 7.01 67.95 ± 7.05 69 ± 7.5
QRS duration from surface ECG (ms) 168.3 ± 18.1 169.9 ± 17.1 172.9 ± 17.7 169.8 ± 16.8 173.4 ± 17.1 169.7 ± 17.2 173.4 ± 17.0
Systolic blood pressure (mmHg) 123 ± 15.1 122 ± 15.2 124 ± 14.7 125 ± 13.6 122 ± 14.3 126 ± 16.2 118 ± 19.5
Diastolic blood pressure (mmHg) 74.0 ± 13.5 74.7 ± 13.7 71.9 ± 12.9 75 ± 14.1 71.1 ± 10.8 75 ± 11.2 71.4 ± 10.9
NYHA class 2.53 ± 0.82 2.38 ± 0.79 2.94 ± 0.77* 2.32 ± 0.79 3.00 ± 0.84*, 2.28 ± 0.81 3.0 ± 0.8*,,
NYHA I: No. (%) 2 (4.8) 2 (4.8) – 3 (7.3) – 4 (10) –
NYHA II: No. (%) 33 (59.6) 28 (66.7) 5 (31.3)* 27 (65.9) 5 (33.3)*, 26 (65) 4 (33.3)*,,
NYHA III: No. (%) 13 (22.4) 6 (14.3) 7 (43.8)* 6 (14.3) 5 (33.3) 5 (12.5) 4 (33.3),
NYHA IV: No. (%) 10 (17.2) 6 (14.3) 4 (25)* 5 (12.2) 5 (33.3) 5 (12.5) 4 (33.3),
LVEF (%) 32.8 ± 6.1 34.3 ± 5.5 28.9 ± 6.0* 33.2 ± 5.2 29.5 ± 5.6*, 34.1 ± 5.2 29.7 ± 5.8*,,
LV end-systolic volume index (ml ⁄m2) 121.2 ± 13.8 117.4 ± 12.9 121.1 ± 13.4 117.1 ± 12.2 121.1 ± 13.1 115.4 ± 13.0 121.8 ± 13.1
LV filling time (s) 0.47 ± 0.05 0.52 ± 0.05 0.45 ± 0.03 0.51 ± 0.04 0.45 ± 0.04 0.52 ± 0.03 0.46 ± 0.03
Left atrial diastolic area (cm2) 17.8 ± 2.5 18.2 ± 2.4 20.5 ± 2.4 18.2 ± 2.4 20.5 ± 2.3 17.6 ± 2.5 23.1 ± 2.4
Left atrial systolic area (cm2) 26.9 ± 2.8 27.3 ± 2.7 28.8 ± 2.7 27.3 ± 2.7 28.8 ± 2.8 27.8 ± 2.8 31.2 ± 3.0
Mitral regurgitation area
(% of left atrial systolic area)
0.24 ± 0.02 0.21 ± 0.02 0.27 ± 0.03* 0.21 ± 0.02 0.27 ± 0.02*, 0.20 ± 0.02 0.28 ± 0.02*,,
QoL score 40 ± 14 34 ± 19 40 ± 16* 33 ± 14 41 ± 15*, 29.5 ± 15 41.3 ± 21*,,
Distance walked in 6 min (m) 305 ± 10 338 ± 11 304 ± 11* 341 ± 13 302 ± 10*, 342 ± 11 302 ± 9*,,
Oxygen uptake at peak
exercise (ml ⁄ kg ⁄min)
12.5 ± 0.73 14.9 ± 0.7 12.5 ± 0.7* 15.2 ± 0.7 12.6 ± 0.7*, 15.7 ± 0.6 12.6 ± 0.8*,,
Oxygen uptake at anaerobic
threshold (ml ⁄ kg ⁄min)
9.43 ± 0.9 11.5 ± 0.6 10.0 ± 0.6* 11.7 ± 0.6 10.0 ± 0.4*, 11.9 ± 0.7 9.9 ± 0.4*,,
New-onset Atrial Fibrillation: No. (%) – 2 (3.3) 4 (18.2)* 4 (9.7) 5 (33.3)*, 6 (15.0) 6 (50.0)*,,
*= p < 0.05 vs. Responders 1 year; = p < 0.05 vs. Responders 2 years; = p < 0.05 vs. Responders 3 years.
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continuous monitoring capability offered by
implanted devices, which were programmed uni-
formly to capture AF episodes (25–27). During fol-
low-up, device interrogation was scheduled every 3–
6 months and all printouts were carefully checked
for new-onset AF episodes. Other studies have used
a variety of different definitions for AF, also relied
on symptoms, which appear clearly inadequate in
assessing overall AF burden.
Despite the extensive evidence of the benefits of
CRT on ventricular function, data about the effects
of CRT on atrial function and on incidence of new-
onset AF are conflicting (2,7,28). Post hoc analysis of
the CARE-HF trial suggested that CRT had no
favourable impact on the incidence of AF compared
with medical therapy alone, but many of these
patients (19%) already had a history of AF (9). A
study by the group of JJ. Bax confirmed the clinical
importance of new-onset AF after CRT, showing that
recipients of CRT who develop new-onset AF have
less echocardiographic response to CRT and more
cardiac adverse events during follow-up (28).
Another recent article described, consistently with
our findings, that more than 20% of the overall HF
patient population treated with CRT suffered
episodes of paroxysmal atrial tachycardia (25).
Anyway, the potential mechanisms to take into
account for the effect attributed to CRT in the pre-
vention of AF could be related to an improvement in
left ventricular systolic function and a decrease of the
degree of mitral regurgitation, with a reduction of
structural atrial remodelling of the electrophysiologi-
cal substrate responsible for the initiation ⁄ triggers of
atrial arrhythmias (29). Anyway, non-responders have
larger atriae, larger ventricles and more mitral regur-
gitation already at baseline. So we cannot exclude
these parameters predicting AF independent of sup-
posed non-response to CRT. Indeed, the fact that
after 3-year follow-up non-responder patients show
an increased left atrial diastolic area than responders
is a strong evidence for supporting the hypothesis
that CRT may prevent AF through atrial reverse
remodelling (29), probably as a result of a reduction
of the overload in the atria (18). What is more, as
shown in a previous study by JW. Fung and coll.
(30), we also noted a trend of a greater left atrial dia-
stolic area in patients who developed AF. Neverthe-
less, atrial function is relatively complex, and more
quantitative methods are needed to better explore
atrial functional improvement. Moreover, because
patients with HF who develop AF have a worse out-
come (3), it could be interesting to know whether or
not the outcome might be improved by CRT.
Our study is limited by the relatively small num-
ber of subjects, although they constitute a remarkable
patient population, because of selective inclusion and
exclusion criteria. The percentage of patients who
developed new-onset AF although reach statistical
significance when analysed, the absolute number is
small. Another limitation is the non-randomised nat-
ure of the study. Thus, the results must be inter-
preted cautiously and further randomised studies,
pooling data from multiple centres, are needed to
confirm our findings and to assess their clinical
impact.
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mG Protein-Coupled Receptor Kinase 2 in Patients With Acute
Myocardial Infarction
Gaetano Santulli, MDa,b,†, Alfonso Campanile, MDc,†, Letizia Spinelli, MDb,c,
Emiliano Assante di Panzillo, MDb,c, Michele Ciccarelli, MD, PhDa, Bruno Trimarco, MDa,b, and
Guido Iaccarino, MD, PhDa,b,*
Lymphocyte G protein–coupled receptor kinase 2 (GRK2) levels are increased in patients
with chronic heart failure, and in this condition, they correlate with cardiac function. The
aim of this study was to assess the prognostic role of GRK2 during acute cardiac dysfunc-
tion in humans. A study was designed to investigate the role of GRK2 levels in patients
with acute coronary syndromes. Lymphocyte GRK2 levels were examined at admission and
after 24 and 48 hours in 42 patients with acute coronary syndromes, 32 with ST-segment
elevation myocardial infarction and 10 with unstable angina as a control group. Echocar-
diographic parameters of systolic and diastolic function and left ventricular remodeling
were evaluated at admission and after 2 years. GRK2 levels increased during ST-segment
elevation myocardial infarction and were associated with worse systolic and diastolic
function. This association held at 2-year follow-up, when GRK2 was correlated with the
ejection fraction and end-systolic volume, indicating a prognostic value for GRK2 levels
during acute ST-segment elevation myocardial infarction. In conclusion, lymphocyte
GRK2 levels increase during acute myocardial infarction and are associated with worse
cardiac function. Taken together, these data indicate that GRK2 could be predictive of
ventricular remodeling after myocardial infarction and could facilitate the tailoring of
appropriate therapy for high-risk patients. © 2011 Elsevier Inc. All rights reserved. (Am
J Cardiol 2011;107:1125–1130)
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mIn recent years, the overall prevalence of heart failure
(HF) has increased.1 Ischemic heart disease represents a
eading cause of HF, and a plethora of studies have assessed
he clinical evolution of ST-segment elevation myocardial
nfarction (STEMI) toward HF.2–6 Given the complexity of
HF, interest has intensified in developing biologic markers
to provide prognostic information about the disease.7 In-
eed, several multivariate prognostic models have been
eveloped to allow risk stratification.6,8 Because biomarkers
ay reflect various pathophysiologic processes,7 the use of
a multimarker approach has been suggested to better iden-
tify patients who are at high risk,9 paving the way for more
accurate treatment.3–5 A candidate biomarker in cardiovas-
cular scenario is the G protein–coupled receptor kinase 2
(GRK2).10 This protein is involved in the desensitization
and downregulation of G protein–coupled receptors, such
as the -adrenergic receptor, and is the most important G
protein–coupled receptor kinase expressed in the heart. In-
creased cardiac GRK2 levels have been described in chronic
HF and are associated with elevated sympathetic nervous
system activity.11–13 We previously showed that increased
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doi:10.1016/j.amjcard.2010.12.006ardiac GRK2 levels are associated with the impairment of
ardiac function and that cardiac protein levels can be mon-
tored using peripheral lymphocytes, thus circumventing the
roblem of tissue sampling.14 Nevertheless, the role of
GRK2 as a marker for HF progression after acute myocar-
dial infarction (MI) remains to be clarified. Thus, we de-
signed a study to investigate GRK2 levels during the early
phases of MI to define its relevance as a biomarker in the
evolution toward HF.
Methods
We enrolled 32 patients consecutively admitted to the
Coronary Care Unit of “Federico II” University with a
diagnosis of acute (24-hour) STEMI, defined by typical
chest pain and persistent ST-segment elevation on electro-
cardiography.15,16 MI was confirmed by increased serum
reatine kinase and assessed by cardiac ultrasound using the
all motion score index. We also recruited 10 age-matched
atients with unstable angina pectoris as a control group.3
Angiography was performed in all patients according to
standard indications.15 GRK2 levels were evaluated at ad-
ission and after 24 hours. All patients provided written
nformed consent. The study was approved by the ethics
ommittee of “Federico II” University. We used a database
eporting characteristics of each patient, including clinical,
iochemical, and echocardiographic data and anthropomor-
hic parameters including age, gender, height, weight, body
ass index, and body surface area (BSA). Patients werehen reexamined at 2-year follow-up. Outcome variables
www.ajconline.org
pG
c
c
t
s
b
s
N
r
e
t
t
D
nous fl
1126 The American Journal of Cardiology (www.ajconline.org)analyzed during this examination were echocardiographic
(systolic and diastolic function, MI size, and ventricular
remodeling) and clinical (compliance with therapy, rehos-
pitalization).
Patients’ lymphocytes were extracted from 20-ml blood
samples, as previously described, by means of Ficoll puri-
fication using Histopaque-1077 (Sigma Aldrich, St. Louis,
Missouri) at admission and after 24 and 48 hours.14,17 Sam-
les thus obtained were frozen and stored at 80°C.
We performed immunodetection of lymphocyte levels of
RK2 and actin using detergent-solubilized cell extracts or
ytosol fractions obtained by centrifugation, using poly-
lonal anti-GRK2 and antiactin antibodies (Santa Cruz Bio-
echnology, Santa Cruz, California), as previously de-
cribed.11,14 The proteins were visualized using standard
enhanced chemiluminescence (ECL Kit; Amersham Biosci-
ences, Piscataway, New Jersey).17,18 Quantization was done
Table 1
Baseline clinical characteristics of patients at admission
Variable Patients With UAP Patients With STEMI
(n  10) (n  32)
Men/women 7/3 30/2
Age (years) 60.9  3.1 59.9  1.9
Weight (kg) 75.7  4.6 76.3  1.7
Height (cm) 164.6  1.6 162.3  5.3
Body mass index (kg/m2) 23.4  3.3 27.17  0.59
BSA (m2) 1.8  0.1 1.85  0.1
Systolic blood pressure
(mm Hg)
133.1  6.0 119.8  3.9
Diastolic blood pressure
(mm Hg)
76.9  4.0 72.9  2.3
Heart rate (beats/min) 70.5  3.8 72.6  2.1
* p 0.05.
UAP  unstable angina pectoris.
Table 2
Echocardiographic parameters of patients with ST-segment elevation myo
Variable Patients With STEMI High
(n  32) (n 
Systolic parameters
Ejection fraction (%) 43.2  1.4 43.9
Shortening fraction (%) 27.7  1.1 29.1
Stroke volume (ml) 40.1  1.7 36.5
Cardiac output (L/min) 3.0  0.1 2.8
Cardiac index (L/min/m2) 1.6  0.1 1.5
Wall motion score index 1.9  0.1 1.9
iastolic parameters
E (cm/s) 66.6  3.4 68.7
A (cm/s) 68.1  2.8 69.7
E/A ratio 1.0  0.1 1.0
Deceleration time (ms) 163.9  9.7 143.5
Isovolumic relaxation time (ms) 92.2  2.8 91.7
PVs (cm/s) 47.5  1.9 51.7
PVd (cm/s) 40.5  2.4 38.4
PVs/PVd ratio 1.3  0.1 1.4
E= (cm/s) 5.7  0.5 6.2
E/E= ratio 13.9  1.1 13.6
* p 0.05.
PVd  diastolic pulmonary venous flow; PVs  systolic pulmonary vey scanning the autoradiographic film and using dedicatedoftware (ImageQuant; Molecular Dynamics, Piscataway,
ew Jersey). GRK2 levels indicate GRK2 expression cor-
ected by actin expression and by lymphocyte levels for
ach patient (in corrected densitometry units). All labora-
ory work was performed in blinded fashion with respect to
he identity of the samples.17–19
Cardiac ultrasound evaluation was performed using
Vivid 7 (GE Healthcare, Milwaukee, Wisconsin) by the
same operator (L.S.) in the enrollment phase and at 2-year
follow-up. Systolic functional parameters including the
ejection fraction, shortening fraction, cardiac output, stroke
volume, and cardiac index were analyzed. We also evalu-
ated diastolic functional parameters including E-wave ve-
locity (E), A-wave velocity (A), the E/A ratio, deceleration
time, systolic and diastolic pulmonary venous flow, isovolu-
metric relaxation time, mitral annular motion velocity (E=)
with Doppler tissue imaging, and the E/E= ratio. Infarct size
h GRK2 Low GRK2 -Blocker Therapy No -Blocker Therapy
 15) (n  17) (n  24) (n  8)
13/2 17/0 22/2 8/0
.7  3.3 61.8  2.3 58.4  2.7 63.9  3.2
.1  2.8 77.4  2.2 77.1  1.7 73.9  4.9
.8  1.4 158.3  9.9 160.8  7 166.9  2.2
.1  0.9 27.3  0.7 27.4  0.6 26.5  1.6
.8  0.3 1.86  0.4 1.8  0.03 1.8  0.1
.7  4.8 116.5  5.9 119.4  4 121.2  8.3
5  2.8 71.2  3.6 73.3  2.7 71.9  4.8
0  2.8 71.65  3.1 75.2  2.2 64.6  3.9*
infarction
Low GRK2 -Blocker Therapy No -Blocker Therapy
(n  17) (n  24) (n  8)
41.2  2 41.4  2.7 45.1  1.9
26.5  1.2 26.8  2.1 31.1  2.2
43.3  2.9* 40.9  2.2 37.6  2.3
3.17  0.1* 3.1  0.2 2.6  0.2
1.71  0.1 1.7  0.1 1.4  0.1
1.91  0.1 2.0  0.1 1.8  0.1
64.8  5.1 64.62  3.8 72.6  7.5
66.6  4.0 64.8  2.9 77.9  6.3*
1.0  0.1 1.1  0.2 1.0  0.1
183  15.1* 168.2  11.7 149.1  17
92.8  5.9 90.3  3.9 98.2  5.5
44.3  2.9 46.6  2.3 50.4  4.1
42.1  3.7 39.9  3.1 42.6  3.8
1.2  0.1 1.3  0.1 1.3  0.2
5.3  1.3 5.44  0.6 6.6  1.05
14.2  1.3 13.96  1.1 13.7  3.3
ow.Hig
(n
57
75
166
27
1
123
7
73.6cardial
GRK2
15)
 1.7
 1.9
 1.2
 0.1
 0.1
 0.1
 4.45
 4.13
 0.1
 10.4
 2.3
 2.2
 3.1
 0.1
 0.8
 2.01was assessed using the wall motion score index. Left ven-
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1127Coronary Artery Disease/GRK2 Levels in STEMItricular remodeling was assessed by measuring end-systolic
volume (ESV) and its long-term variation corrected by BSA
(%-ESV/BSA).8,20
Statistical analysis was performed using SPSS version
18.0 (SPSS, Inc., Chicago, Illinois) and GraphPad Prism
version 5.01 (GraphPad Software, San Diego, California).
Data are expressed as mean SE. We performed chi-square
tests to compare categorical variables and independent-sam-
ples Student’s t tests for continuous variables. All analyses
were performed using a 2-sided model. A p value 0.05
was considered significant. Some continuous variables were
transformed into categorical variables using the median
values as cutoffs. In particular, we divided our population
according to GRK2 level at admission into 2 groups using a
cut-off value of 0.47 corrected densitometry units: elevated
GRK2 and low GRK2. Moreover, we studied the effects of
-blocker therapy and revascularization on GRK2 levels.
Indeed, we subdivided our STEMI population into patients
treated with  blockers and those who did not receive 
blockers because of contraindications. Similarly, to inves-
tigate whether time of revascularization could affect GRK2
Figure 1. Determinants of GRK2 levels at admission. (A) Western blot
analysis of GRK2 on lymphocytes showed that peripheral GRK2 levels
were higher in patients with STEMI than in controls with unstable angina
pectoris (UAP). (B) Of interest, in patients with STEMI, treatment affected
RK2 levels, as higher GRK2 levels were observed in patients receiving
rimary percutaneous transluminal coronary angioplasty (PTCA) com-
ared with those receiving late elective PTCA. (C) Furthermore, patients
receiving  blockers (Bs) had lower levels of GRK2 than patients not
eceiving Bs. CDU  corrected densitometry units. *p 0.05 (indepen-
dent-samples Student’s t test); #p 0.01 (independent-samples Student’s t
test).levels, we subdivided our population into patients treatedwith early percutaneous transluminal coronary angioplasty,
defined as angioplasty performed on the infarct-related ves-
sel during the first 24 hours of an acute MI,15 and late
ercutaneous transluminal coronary angioplasty (patients
ho received medical therapy and were referred later [24
ours] to coronary intervention).3 We also performed inde-
endent-samples Student’s t tests, Pearson’s correlations,
nd linear regressions between GRK2 levels at admission
nd echocardiographic variables considered at 2-year fol-
ow-up. In this case, we considered as continues variables
ot only the absolute value of ultrasound parameters but
lso their variations from admission values. Finally, we
erformed a linear regression analysis to characterize the
ost significant variables at admission associated with %-
SV/BSA and a back-step multiple regression analysis to
efine the best predictive model of %-ESV/BSA.20
Results
Clinical characteristics of patients are listed in Table 1.
As expected, patients with STEMI presented with impaired
cardiac function, as indicated by the ultrasound parameters
listed in Table 2. GRK2 levels at admission were higher in
patients with STEMI than in those with unstable angina
pectoris (Figure 1). Two pivotal determinants of GRK2
levels were treatment and time. In particular, early revas-
cularization and -blocker therapy clearly affected GRK2
evels. Indeed, GRK2 levels were higher in patients treated
ith early percutaneous transluminal coronary angioplasty
han in those who received late percutaneous transluminal
oronary angioplasty (Figure 1). This finding could be re-
ated to the reperfusion injury, consistent with previous
eports.13,21 Also, patients treated with  blockers had lower
RK2 levels compared with those who did not receive 
blockers (Figure 1).
Time also affected GRK2 levels. In particular, during the
Figure 2. Determinants of GRK2 levels on the second day. (A) In patients
with STEMI, GRK2 levels were reduced on the second day of observation.
(B) This reduction was particularly observed in patients receiving  block-
ers (Bs), whereas those not receiving Bs did not have reduced GRK2
evels. CDU  corrected densitometry units. *p 0.05 (independent-
amples Student’s t test); #p 0.01 (independent-samples Student’s t test).second day of observation, GRK2 levels decreased (Figure 2),
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1128 The American Journal of Cardiology (www.ajconline.org)and this trend was more evident in patients who received 
blockers (Figure 2). Furthermore, when we considered the
-blocker group (n  24 [75%]), some patients had reduc-
tions of GRK2 levels (responders, 62.5% [n  15]),
whereas others did not have reduced GRK2 levels after
treatment (nonresponders, 37.5% [n 9]) during the 2 days
f observation. Of interest, nonresponders had worse wall
otion score indexes (2.27  0.23 vs 1.81  0.1) than
Figure 3. GRK2 levels and cardiac function. (A) Patients with high GRK2
evels had worse systolic function as assessed by stroke volume compared
o those with low GRK2 levels (independent-samples Student’s t test). (B)
RK2 levels were also associated with worse diastolic function, assessed
y deceleration time (DT) (independent-samples Student’s t test).
Figure 4. GRK2 levels and outcomes. (A) After 2 years, patients with
higher GRK2 levels at admission had worse systolic function, with lower
stroke volumes, than those with low GRK2 levels (independent-samples
Student’s t test). (B) Also, cardiac remodeling, assessed by the change in
ESV after 2 years of follow-up (%-ESV/BSA) was correlated with GRK2
level at admission (r2  0.25, p 0.05).esponders.We found a relation between GRK2 levels at admission
nd stroke volume, a parameter of systolic function. Patients
ith high GRK2 levels had worse cardiac function, with
ower stroke volumes, than those with low GRK2 levels
Figure 3). Furthermore, we found a relation between periph-
ral GRK2 levels and diastolic functional parameters such as
eceleration time and the E/E= ratio. Indeed, at admission,
atients with high GRK2 levels had lower deceleration times
han those with low GRK2 levels (Figure 3).
Twenty-six patients (81.25%) completed 2-year follow-
p. We found a relation between GRK2 levels on the first
ay of analysis and stroke volume. Indeed, after 2 years,
atients with high GRK2 levels had worse cardiac function,
ith lower stroke volumes, than those with low GRK2
evels (Figure 4). Furthermore, we observed a correlation
nd a linear regression between admission GRK2 level and
%-ESV/BSA (Figure 4). The most important admission
ariables associated with %-ESV/BSA were shortening
raction, stroke volume, wall motion score index, E/E= ratio,
reatine kinase, and GRK2 level (Table 3). Multiple regres-
ion analysis conducted using a backward stepwise method
ncluding variables showing significant associations on uni-
ariate analysis (p 0.05) revealed that admission GRK2
evel (p  0.011) was the best predictor of %-ESV/BSA.
iscussion
The present investigation sheds light on the role of
RK2 in acute MI. The first compelling evidence is that
RK2 increases quickly after STEMI. This increase had
lready been shown in experimental models of myocardial
schemia in the rat.12 The deleterious effect of this kinase on
-adrenergic receptor signaling has been also explored in
mice, showing that GRK2 gene deletion could prevent the
development of post-MI HF and restore heart function.13
Another major finding of our work concenrs the deter-
minants affecting the increase in GRK2, in particular an-
gioplasty and -blocker therapy. To the best of our knowl-
edge, this is the first study reporting that early reperfusion
causes an increase in GRK2 level. Furthermore, the obser-
vation that  blockers are able to reduce GRK2 levels is
omewhat consistent with previous reports,10,22,23 but we
extend it to 2 essential novelties. First, GRK2 level at
admission was associated with worse cardiac function
acutely and after 2 years. Indeed, we found that patients
with high GRK2 levels had worse systolic and diastolic
function acutely and after 2 years. At 2-year follow-up, we
found that patients with high GRK2 levels had lower stroke
able 3
dmission variables associated with long-term variation of end-systolic
olume corrected by body surface area
Independent Variable at Admission r2 p Value
Shortening fraction 0.1636 0.045
Stroke volume 0.1885 0.030
Wall motion score index 0.2283 0.016
E/E= ratio 0.1611 0.047
Creatine kinase 0.4837 0.000
GRK2 level 0.2547 0.012volumes and also increases in %-ESV/BSA (Figure 4)
b
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1129Coronary Artery Disease/GRK2 Levels in STEMIcompared to those with low GRK2 levels. These results can
be justified by the negative inotropic implications of ele-
vated GRK2 levels.10–14 Second, in our STEMI population,
not all patients showed reduced GRK2 levels in response to
-blocker therapy, and interestingly, nonresponders had
worse cardiac performance, suggesting the importance of
early therapy with  blockers in patients with acute coro-
nary syndromes.
Altogether, our results indicate that GRK2 is strictly
associated with cardiac remodeling. Indeed, the implica-
tions of neurohormonal mechanisms in the progression of
left ventricular remodeling have been extensively stud-
ied.5,24–26 It is well known that this process starts rapidly
after MI, usually within the first few hours, sustained by
activation of the sympathetic activity adrenergic response
that, at least initially, provides support for the failing myo-
cardium.5,24 Continuous activation of neurohormonal sys-
tems and adrenergic response, leading to excessive vaso-
constriction and volume expansion, becomes deleterious to
the heart, with progressive deterioration of cardiac func-
tion.27 Classic measures to assess left ventricular remodel-
ing include heart size, shape, and mass; ejection fraction;
shortening fraction; and ESV. A recent study demonstrated
that ESV is the strongest indicator of HF hospitalization in
patients with coronary heart disease, being statistically su-
perior to other echocardiographic measures of ventricular
enlargement and systolic function such as the ejection frac-
tion and shortening fraction.8 The close statistical relation
etween GRK2 and ESV supports the prognostic role of
eripheral GRK2 levels. Therapeutic agents, such as 
blockers, are superior to other classes of drugs to induce
reverse remodeling, with a stronger correlation between
dose and effect.28,29 It is therefore remarkable to note that
-blocker therapy can reduce GRK2 levels and that this
phenomenon is associated with better cardiac function.22
Thus, GRK2 levels in the early stages of STEMI could
provide valuable information about ventricular remodeling
and progression toward HF.1,30 They may also constitute a
valid tool to assess and monitor the efficacy of  blockers in
patients with acute coronary syndromes, detecting those
patients in need of more intensive treatment to improve their
outcomes.28,30
The most important limitation of this study was the small
sample size, which prevented us from performing a statis-
tical analysis on the basis of a hard end point (death or
revascularization). A larger study would also have allowed
stratification of the outcome according to -blocker therapy.
Moreover, we have no data on GRK2 levels at 2-year
follow-up, and we did not perform a crossover analysis
between patients treated with  blockers and those not
treated. Further studies with larger populations are needed
to validate our analysis. This task must be addressed
through the development of a rapid bench test to quantify
GRK2 levels in humans. Peripheral GRK levels could be
used as a biomarker for monitoring prognosis and effective-
ness of treatment in patients with STEMI. Indeed, biomark-
ers linked to mechanisms involved in the development of
HF, such as GRK2, seem best suited for serving as early
biologic markers to select therapy or assess progression.
Further studies ongoing in our laboratory are actively pur-
suing this issue. Randomized trials are needed to addressthis translational gap before the use of novel biomarkers
becomes common practice to facilitate tailored treatment
after an acute coronary event.
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Abstract
Background: Integrins are heterodimeric receptors that play a critical role in cell-cell and cell-matrix adhesion
processes. Among them, aVb3 integrin, that recognizes the aminoacidic RGD triad, is reported to be involved in
angiogenesis, tissue repair and tumor growth. We have recently synthesized a new and selective ligand of aVb3
receptor, referred to as RGDechiHCit, that contains a cyclic RGD motif and two echistatin moieties.
Methods: The aim of this study is to evaluate in vitro and in vivo the effects of RGDechiHCit. Therefore, we
assessed its properties in cellular (endothelial cells [EC], and vascular smooth muscle cells [VSMC]) and animal
models (Wistar Kyoto rats and c57Bl/6 mice) of angiogenesis.
Results: In EC, but not VSMC, RGDechiHCit inhibits intracellular mitogenic signaling and cell proliferation.
Furthermore, RGDechiHCit blocks the ability of EC to form tubes on Matrigel. In vivo, wound healing is delayed in
presence of RGDechiHCit. Similarly, Matrigel plugs demonstrate an antiangiogenic effect of RGDechiHCit.
Conclusions: Our data indicate the importance of RGDechiHCit in the selective inhibition of endothelial aVb3
integrin in vitro and in vivo. Such inhibition opens new fields of investigation on the mechanisms of angiogenesis,
offering clinical implications for treatment of pathophysiological conditions such as cancer, proliferative retinopathy
and inflammatory disease.
Introduction
Angiogenesis is a complex multistep phenomenon con-
sisting of the sprouting and the growth of new capillary
blood vessels starting from the pre-existing ones. It
requires the cooperation of several cell types such as
endothelial cells (ECs), vascular smooth muscle cells
(VSMCs), macrophages, which should be activated, pro-
liferate and migrate to invade the extracellular matrix
and cause vascular remodeling [1,2]. The angiogenic
process is finely tuned by a precise balance of growth
and inhibitory factors and in mammalians it is normally
dormant except for some physiological conditions, such
as wound healing and ovulation. When this balance is
altered, excessive or defective angiogenesis occur and
the process becomes pathological. Excessive angiogen-
esis gives also rise to different dysfunctions, including
cancer, eye diseases, rheumatoid arthritis, atherosclero-
sis, diabetic nephropathy, inflammatory bowel disease,
psoriasis, endometriosis, vasculitis, and vascular malfor-
mations [3]. Therefore the discovery of angiogenesis
inhibitors would contribute to the development of thera-
peutic treatments for these diseases.
The integrins are cell adhesion receptors that mediate
cell-cell and cell-matrix interactions and coordinate sig-
naling allowing a close regulation of physiological phe-
nomena including cellular migration, proliferation and
differentiation. In particular, the aV integrins, combined
with distinct b subunits, participate in the angiogenic
process. An extensively studied member of this receptor
class is integrin aVb3, that is strongly overexpressed in
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activated EC, melanoma, glioblastoma and prostate can-
cers and in granulation tissue, whereas is not detectable
in quiescent blood vessels or in the dermis and epithe-
lium of normal skin [4-6]. This integrin participates in
the activation of vascular endothelial growth factor
receptor-2 (VEGFR-2), providing a survival signal to the
proliferating vascular cells during new vessel growth
[7,8] and also seems to be essential in the step of vacuo-
lation and lumen formation [9]. It has been also
reported that aVb3 is under the tight control of VEGF:
this integrin is not expressed in quiescent vessels [10],
but VEGF induces aVb3 expression in vitro and, inter-
estingly, the VEGF and aVb3 integrin expression are
highly correlated in vivo [11,12]. Therefore, aVb3
should be considered a tumor and activated endothe-
lium marker.
aVb3 is able of recognizing many proteins of the
extracellular matrix, bearing an exposed Arg-Gly-Asp
(RGD) tripeptide [5,13,14]. Even if different integrins
recognize different proteins containing the RGD triad,
many studies have demonstrated that the aminoacids
flanking the RGD sequence of high-affinity ligands
appear to be critical in modulating their specificity of
interaction with integrin complexes [15,16].
Several molecules including peptides containing
RGD motif [11] have been recently developed as inhi-
bitors of aVb3 integrin, in experiments concerning
tumor angiogenesis, showing a reduction of functional
vessel density associated with retardation of tumor
growth and metastasis formation [6,17]. So far, the
pentapeptide c(RGDf[NMe]V), also known as cilengi-
tide (EMD 121974), is the most active avb3/avb5
antagonist reported in literature [18,19] and is in
phase III clinical trials as antiangiogenic drug for glio-
blastoma therapy [15]. The development of more
selective antiangiogenic molecule would help to mini-
mize the side-effects and increase the therapeutic
effectiveness.
We have recently designed and synthesized a novel
and selective peptide antagonist, referred to as RGDe-
chiHCit, to visualize aVb3 receptor on tumour cells [20].
It is a chimeric peptide containing a cyclic RGD motif
and two echistatin C-terminal moieties covalently linked
by spacer sequence. Cell adhesion assays have shown
that RGDechiHCit selectively binds aVb3 integrin and
does not cross-react with aVb5 and aIIbb3 integrins [20].
Furthermore, PET and SPECT imaging studies have
confirmed that the peptide localizes on aVb3 expressing
tumor cells in xenograft animal model [21]. Since aVb3
is also a marker of activated endothelium, the main pur-
pose of this study was to evaluate in vitro and in vivo
effects of RGDechiHCit on neovascularization. Thus, we
first assessed the in vitro peptide properties on bovine
aortic ECs, and then in vivo, in Wistar Kyoto (WKY)
rats and c57BL/6 mice, the ability of this cyclic peptide
to inhibit angiogenesis.
Methods
Peptides
RGDechiHCit was prepared for the in vitro and in vivo
studies as previously described [20]. To test the biologi-
cal effects of RGDechiHCit, we synthesized the cyclic
pentapeptide c(RGDf[NMe]V), also known as cilengitide
or EMD 121974 [14,19]. We also investigated RGDe-
chiHCit and c(RGDf[NMe]V) peptides degradation in
serum. Both peptides were incubated and the resulting
solutions were analyzed by liquid chromatography/mass
spectrometry (LC/MS) at different times. 20μL of
human serum (Lonza, Basel, Switzerland) were added to
8 μL of a 1 mg/ml solution of either RGDechiHCit or c
(RGDf[NMe]V) at 37°C. After 1, 2, 4 and 24h, samples
were centrifuged for 1min at 10000g. Solutions were
analyzed by LCQ Deca XP Max LC/MS system
equipped with a diode-array detector combined with an
elctrospray ion source and ion trap mass analyzer (Ther-
moFinnigan, San Jose, CA, USA), using a Phenomenex
C18 column (250× 2 mm; 5μm; 300 Ǻ) and a linear gra-
dient of H2O (0.1%TFA)/CH3CN (0.1%TFA) from 10 to
80% of CH3CN (0.1%TFA) in 30 min at flow rate of
200μL/min.
In vitro studies
In vitro studies were performed on cell cultures of ECs
or VSMCs, cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Sigma-Aldrich, Milan, Italy) as pre-
viously described and validated [22,23]. Cell culture
plates were filled with 10 μg/cm2 of human fibronectin
(hFN, Millipore®, Bedford, MA, USA) as described [24].
All experiments were performed in triplicate with cells
between passages 5 and 9.
Cell proliferation assay
Cell cultures were prepared as previously described [25].
Briefly, cells were seeded at density of 100000 per well
in six-well plates, serum starved, pre-incubated at 37°C
for 30’ with c(RGDf[NMe]V) or RGDechiHCit (10-6 M).
Proliferation was induced using hFN (100 μg/ml). Cell
number was measured at 3, 6 and 20 h after stimulation
as previously described [26,27].
DNA synthesis
DNA synthesis was assessed as previously described
[27]. Briefly, cells were serum-starved for 24 h and then
incubated in DMEM with [3H]thymidine and 5% FBS.
After 3, 6 and 20 h, cells were fixed with trichloracetic
acid (0.05%) and dissolved in 1M NaOH. Scintillation
Santulli et al. Journal of Translational Medicine 2011, 9:7
http://www.translational-medicine.com/content/9/1/7
Page 2 of 10
liquid was added and [3H]thymidine incorporation was
assessed as previously described [27].
VEGF quantification
VEGF production was measured as previously described
[26]. Briefly, ECs were seeded at a density of 600000 per
well in six well plates, serum starved overnight, seeded
with c(RGDf[NMe]V) or RGDechiHCit (10-6 M) and
then stimulated with hFN for 6 hours. Cultured medium
was collected and VEGF production was revealed by
western blot.
Endothelial Matrigel assay
The formation of network-like structures by ECs on an
extracellular matrix (ECM)-like 3D gel consisting of
Matrigel® (BD Biosciences, Bedford, MA, USA), was
performed as previously described and validated [27,28].
The six-well multidishes were coated with growth fac-
tor-reduced Matrigel in according to the manufacturer’s
instructions. ECs (5×104) were seeded with c(RGDf
[NMe]V) or RGDechiHCit (10-6 M), in the absence
(negative control) or presence (100 μg/ml) of hFN [24].
Cells were incubated at 37°C for 24h in 1 ml of DMEM.
After incubation, ECs underwent differentiation into
capillary-like tube structures. Tubule formation was
defined as a structure exhibiting a length four times its
width [27]. Network formation was observed using an
inverted phase-contrast microscope (Zeiss). Representa-
tive fields were taken, and the average of the total num-
ber of complete tubes formed by cells was counted in
15 random fields by two independent investigators.
Western blot
Immunoblot analyses were performed as previously
described and validated [23,28]. Mouse monoclonal
antibodies to extracellular signal regulated kinase
(ERK2) and phospho-ERK, anti-rabbit VEGF and actin
were from Santa Cruz Biotecnology (Santa Cruz, CA,
USA). Levels of VEGF were determined using an anti-
body raised against VEGF-165 (Santa Cruz Biotechnol-
ogy) [26]. Experiments were performed in triplicate to
ensure reproducibility. Data are presented as arbitrary
densitometry units (ADU) after normalization for the
total corresponding protein or actin as internal control
[24].
In vivo studies
Wound healing assay was performed on 14-week-old
(weight 293 ± 21 g) normotensive WKY male rats
(Charles River Laboratories, Calco (LC), Italy; n = 18),
and Matrigel plugs experiments were carried out on 16-
week-old (weight 33 ± 4 g) c57BL/6 mice (Charles River
Laboratories, Milan, Italy; n = 13). All animal proce-
dures were performed in accordance with the Guide for
the Care and Use of Laboratory Animals published by
the National Institutes of Health in the United States
(NIH Publication No. 85- 23, revised 1996) and
approved by the Ethics Committee for the Use of Ani-
mals in Research of “Federico II” University [23].
Wound Healing
The rats (n = 18) were anesthetized using vaporized iso-
flurane (4%, Abbott) and maintained by mask ventila-
tion (isoflurane 1.8%) [29]. The dorsum was shaved by
applying a depilatory creme (Veet, Reckitt-Benckiser,
Milano, Italy) and disinfected with povidone iodine
scrub. A 20 mm diameter open wound was excised
through the entire thickness of the skin, including the
panniculus carnosus layer, as described and validated
[1,28]. Pluronic gel (30%) containing (10-6 M) c(RGDf
[NMe]V) (n = 6), RGDechiHCit (n = 7), or saline (n = 5)
was placed daily directly onto open wounds, then cov-
ered with a sterile dressing. Two operators blinded to the
identity of the sample examined and measured wound
areas every day, for 8 days. Direct measurements of
wound region were determined by digital planimetry
(pixel area), and subsequent analysis was performed
using a computer-assisted image analyzer (ImageJ soft-
ware, version 1.41, National Institutes of Health,
Bethesda, MD, USA). Wound healing was quantified as a
percentage of the original injury size. Eight days after
wounding, rats were euthanized. Wounds did not show
sign of infection. The lesion and adiacent normal skin
were excised, fixed by immersion in phosphate buffered
saline (PBS, 0.01 M, pH 7.2-7.4)/formalin and then
embedded in paraffin to be processed for immunohistol-
ogy, as described [1].
Matrigel Plugs
Mice (n = 13), anesthetized as described above, were
subcutaneously injected midway on the dorsal side,
using sterile conditions, with 0.2 ml of Matrigel® base-
ment matrix, pre-mixed with 10-6M VEGF and 10-5M c
(RGDf[NMe]V) (n = 4), 10-6M VEGF and 10-5M RGDe-
chiHCit (n = 5), or 10-6M VEGF alone (n = 4). After
seven days, mice were euthanized and the implanted
plugs were harvested from underneath the skin, fixed in
10% neutral-buffered formalin solution and then
embedded in paraffin. Invading ECs were identified and
quantified by analysis of lectin immunostained sections,
as described [1,2].
Histology
All tissues were cut in 5 μm sections and slides were
counterstained with a standard mixture of hematoxylin
and eosin. For Masson’s trichrome staining of collagen
fibers, useful to assess the scar tissue formation, slides
were stained with Weigert Hematoxylin (Sigma-Aldrich,
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St. Louis, MO, USA) for 10 minutes, rinsed in PBS
(Invitrogen) and then stained with Biebrich scarlet-acid
fuchsin (Sigma-Aldrich) for 5 minutes. Slides were
rinsed in PBS and stained with phosphomolybdic/phos-
photungstic acid solution (Sigma-Aldrich) for 5 minutes
then stained with light green (Sigma-Aldrich) for 5 min-
utes [30]. ECs were identified by lectin immunohisto-
chemical staining (Sigma-Aldrich) [2] and quantitative
analysis was performed using digitized representative
high resolution photographic images, with a dedicated
software (Image Pro Plus; Media Cybernetics, Bethesda,
MD, USA) as previously described [28].
Data presentation and statistical analysis
All data are presented as the mean value ± SEM. Statis-
tical differences were determined by one-way or two-
way ANOVA and Bonferroni post hoc testing was per-
formed where applicable. A p value less than 0.05 was
considered to be significant. All the statistical analysis
and the evaluation of data were performed using Graph-
Pad Prism version 5.01 (GraphPad Software, San Diego,
CA, USA).
Results
Peptides
RGDechiHCit and c(RGDf[NMe]V) peptides stabilities
were evaluated in serum. The degradation of the pep-
tides were followed by LC/MS. The reversed-phase high
performance liquid chromatography (RP-HPLC) of
RGDechiHCit before the serum incubation showed a
single peak at tr = 11.82 min corresponding to the com-
plete sequence (theoretical MW = 2100.1 g mol-1) as
indicated by the [M+H]+, [M+2H]2+ and [M+3H]+3
molecular ion adducts in the MS spectrum (Figure 1A).
After 1h, chromatography showed two peaks, ascribable
to RGDechiHCit and to a fragment of the complete
sequence (theoretical MW = 1929.1 g mol-1), respec-
tively, as confirmed by MS spectrum. Finally, after 24h a
further peak at tr = 10.93 min corresponding to another
RGDechiHCit degradation product (theoretical MW =
1775.8 g mol-1) appeared, as indicated by the molecular
ion adducts in the MS spectrum, although the peaks
attributed to the RGDechiHCit and to the first fragment
were still present (Figure 1B).
In contrast with RGDechiHCit, c(RGDf[NMe]V)
showed high stability in serum. The RP-HPLC profile of
the peptide before the incubation showed a single peak
at tr = 16.64 min, ascribable to the complete sequence
by the MS spectrum (Figure 1C). After 24h of incuba-
tion chromatogram and mass profiles failed to identify
any degradation product (Figure 1D).
Since RGDechiHCit showed a low stability, we replen-
ished antagonists every six hours in experiments invol-
ving chronic exposure.
In vitro experiments
Cell proliferation and DNA synthesis
Because angiogenesis is intimately associated to EC pro-
liferation, we explored the effects of RGDechiHCit and c
(RGDf[NMe]V) on hFN-stimulated EC. In this cellular
setting, after 6 hours, both avb3 integrin antagonists
inhibited in a comparable way the ability of hFN to
induce proliferation (hFN: +1.98 ± 0.6; hFN+RGDechiH-
Cit: +0.58 ± 0.24; hFN+c(RGDf[NMe]V): +0.6 ± 0.38
fold over basal; p < 0.05, ANOVA) as depicted in Figure
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Figure 1 Reversed-phase high performance liquid
chromatography (RP-HPLC) chromatograms and mass spectra
at t = 0 and t = 24 h for RGDechiHCit (A and B) and c(RGDf
[NMe]V) (C and D), respectively. In panel B the chromatographic
peaks at tr = 11.70 (Black Star), 12.04 (Black Square) and 10.93 min
(Black Circle) are marked.
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2A. After 20 hours such inhibitory effect was less
marked (Figure 2A). In VSMC there was only a trend of
an anti-proliferative effect for these peptides, due to the
less evident action of hFN in this specific cellular setting
(hFN: +1.21 ± 0.1; hFN+RGDechiHCit: +0.93 ± 0.07;
hFN+c(RGDf[NMe]V): +0.9 ± 0.09 fold over basal; NS;
Figure 3A).
The effects of RGDechiHCit and c(RGDf[NMe]V) on
EC and VSMC proliferation were also measured by asses-
sing the incorporation of [3H]Thymidine in response to
hFN. This assay confirmed the anti-proliferative action of
both these peptides, which is more evident after 6 hours
and in ECs (hFN: +1.84 ± 0.24; hFN+RGDechiHCit: +
1.02 ± 0.2; hFN+c(RGDf[NMe]V): + 1.09 ± 0.07 fold over
basal; p < 0.05, ANOVA; Figure 2B). On the contrary,
the effect of RGDechiHCit on VSMC did not reach sta-
tistical significance in comparison to the c(RGDf[NMe]V)
used as control (Figure 3B).
Effects on cellular signal transduction
Since hFN-mediated activation of ERK2 is linked to
angiogenesis [16,24,31], we analyzed the ability of
RGDechiHCit and c(RGDf[NMe]V) to inhibit hFN-
induced phosphorylation of ERK2 in EC and VSMC. In
accordance with the results on cell proliferation and
[3H]Thymidine incorporation, in EC both RGDechiHCit
and c(RGDf[NMe]V) significantly inhibited the hFN-
induced phosphorylation of mitogen-activated protein
ERK2 (Figure 2C). Also, in VSMC, there was no signifi-
cant inhibition of ERK2 phosphorylation by the RGDe-
chiHCit compund c(RGDf[NMe]V) (Figure 3C).
Evaluation of VEGF expression
Angiogenesis is largely dependent on ERK2 activation,
which in turn promotes cellular proliferation and
expression of VEGF. This cytokine promotes infiltration
of inflammatory cells, proliferation of ECs and VSMCs
and sustains the proangiogenic phenotype [12]. The
early release (6 hours) of the cytokine is therefore an
important readout when studying angiogenesis in vitro.
On these grounds, we assessed the expression levels of
this pivotal proangiogenetic factor in EC after 6 hours
of stimulation with hFN. hFN induces VEGF release
and such response was blunted by incubation with
either integrin antagonist, as depicted in Figure 4
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Figure 2 In vitro effects of c(RGDf[NMe]V) and RGDechiHCit on
cell proliferation (Panel A) and DNA synthesis assessed by [3H]
thymidine incorporation (Panel B) in bovine aortic endothelial
cells (EC). Given alone, c(RGDf[NMe]V) or RGDechiHCit did not
affect EC proliferation. Neverteless, incubation with these aVb3
integrin antagonists inhibited in a comparable way EC proliferation
in response to the mitogenic stimulus, hFN. All experiments
depicted in this figure were performed from three to six times in
duplicate (* = p < 0.05 vs Basal, # = p < 0.05 vs hFN). Panel C. In
vitro effects of c(RGDf[NMe]V) and RGDechiHCit on EC signal
transduction. Extracellular signal regulated kinase (ERK)/mitogen-
activated protein kinase activation: western blot of activated
(phosphorylated: pERK) ERK2 after hFN-stimulation. Equal amounts
of proteins were confirmed via blotting for total ERK. Densitometric
analysis (bar graph) showed that hFN stimulation caused ERK
activation (* = p < 0.05 vs Basal) and that treatment with aVb3
antagonists blunted such activation (# = p < 0.05 vs hFN). Error bars
show SEM. Representative blots are shown in the inset.
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Figure 3 In vitro effects of c(RGDf[NME]V) and RGDechiHCit on
vascular smooth muscle cell (VSMC) cell proliferation (Panel A)
and DNA synthesis assayed by [3H]thymidine incorporation
(Panel B). In this cellular setting, hFN induced a mitogenic stimulus,
appreciable especially at 20h. c(RGDf[NMe]V) but not RGDechiHCit
at that time-point induced an attenuation of such proliferative
response. All experiments were performed from three to five times
in triplicate (* = p < 0.05 vs Basal; # = p < 0.05 vs hFN). In vitro
effects of c(RGDf[NMe]V) and RGDechiHCit on VSMC signal
transduction were represented in Panel C. Extracellular signal
regulated kinase (ERK)/mitogen-activated protein kinase activation:
western blot of activated (phosphorylated: pERK) ERK2 after hFN-
stimulation. Blots were then stripped and reprobed for either total
ERK as a loading control. Densitometric analysis (bar graph) showed
that hFN induced ERK phosphorylation (* = p < 0.05 vs Basal) and
that treatment with c(RGDf[NMe]V) but not RGDechiHCit decreased
such activation (# = p < 0.05 vs hFN). Error bars show SEM.
Representative blots are presented in the inset.
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(hFN: +18.9 ± 1.02; hFN+RGDechiHCit: +2.44 ± 0.76;
hFN+c(RGDf[NMe]V): +3.19 ± 0.73 fold over basal,
ADU; p < 0.05, ANOVA).
Endothelial Matrigel assay
The formation of capillary-like tube structures in the
ECM by ECs is a pivotal step in angiogenesis and is also
involved in cell migration and invasion [26]. To evaluate
any potential antiangiogenic activity of our novel integ-
rin antagonist, in vitro angiogenesis assays were con-
ducted by evaluating hFN-induced angiogenesis of ECs
on Matrigel.
As shown in Figure 5, when ECs were plated on wells
coated with Matrigel without the addition of hFN, they
showed formation of only a few spontaneous tube struc-
tures (17.4 ± 1.2 branches per 10000 μm2). On the
other hand, when the cells were plated on Matrigel with
the addiction of hFN, cells formed a characteristic
capillary-like network (42.8 ± 4.4 branches per 10000
μm2; p < 0.05 vs Basal, ANOVA). In the presence
of RGDechiHCit or c(RGDf[NMe]V), the extent of
tube formation hFN-induced was significantly reduced
(10.03 ± 1.44; 14.11 ± 3.9, respectively; p < 0.05 vs hFN
alone, ANOVA; Figure 5).
In vivo experiments
Wound healing
The examination of full-thickness wounds in the back
skin showed that both RGDechiHCit and c(RGDf
[NMe]V) slowed down healing (Figure 6). At a macro-
scopic observation, the delay in the wound healing in
treated rats was evident, with raised margins, more
extensive wound debris and scab, that persisted for at
least 7 days after surgery. Moreover, histological
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Figure 4 VEGF production in bovine aortic endothelial cells
(ECs) measured by Western blot (inset). Shown are VEGF levels
after 6 hours of serum starvation. Equal amount of proteins were
verified by blotting for actin. Quantification of western blot from all
experiments demonstrated that hFN was able to increase VEGF
production (* = p < 0.05 vs Basal), while after c(RGDf[NMe]V) or
RGDechiHCit treatment VEGF levels returned to basal conditions (#
= p < 0.05 vs hFN). All data derived from three different
experiments performed in duplicate. The results were expressed as
fold increased with respect to the basal condition in untreated
samples. Error bars show SEM.
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Figure 5 Representative phase contrast photomicrographs of
bovine aortic endothelial cells (ECs) are shown plated on
Matrigel. Both c(RGDf[NMe]V) and RGDechiHCit inhibited hFN-
induced tube formation. Microscopy revealed numbers of network
projections (branches) formed in each group after 12 h of
incubation. Data from three experiments in triplicate are
summarized in the graph (* = p < 0.05 vs Basal; # = p < 0.05 vs
hFN). Error bars show SEM. The black bar corresponds to 100 μm.
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Figure 6 Both c(RGDf[NMe]V) and RGDechiHCit slowed down the closure of full thickness punch biopsy wounds. Three to five rats were
analyzed at each time point. Gross appearance (representative digital photographs, light blue bar: 1 cm) after 5 days of the wound treated with
pluronic gel containing c(RGDf-[NMe]V), RGDechiHCit (10-6M) or saline. Diagram of the kinetics of wound closure; * = p < 0.05 vs Control; # =
p < 0.05 vs c(RGDf-[NMe]V, ANOVA). Error bars show SEM. Representative sections (5 μm) of wounds excised 8 days after surgery (see Methods):
Hematoxylin & Eosin, Lectin immunohistochemistry, Masson’s trichrome; black bar: 100 μm. Histological analysis revealed a retarded repair
pattern in treated rats, which is consistent with inhibition of angiogenesis in the granulation tissue. In particular, in control animals, epidermal
cell growth achieved complete re-epitalization (green arrowheads) and there was a well defined and organized fibrous core of scar tissue. Both
in c(RGDf[NMe]V) and RGDechiHCit treated rats there was a chronic inflammatory infiltrate (red arrows) and lectin staining showed (in brown)
the presence of vessels in the granulation tissue.
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analysis showed that while control rats presented a
dermal scar tissue consisting of a well defined and
organized fibrous core with minimal chronic inflam-
matory cells, skin wounds exposed to RGDechiHCit or
c(RGDf[NMe]V) exhibited a retarded repair pattern.
Indeed, there was an intense inflammatory infiltrate,
extended from the wound margin into the region of
the panniculus carnosus muscle and hypodermis. More-
over, the basal epidermis was disorganized and epidermal
cell growth failed to achieve re-epithelialization, as shown
in Figure 6.
Matrigel plugs
After injection, Matrigel implants containing the angio-
genic stimulant VEGF (10-5 M) formed a plug into
which ECs can migrate. Matrigel pellets evidenced a sig-
nificant lower EC infiltration, identified through means
of immunohistological lectin staining, in c(RGDf[NMe]
V) and RGDechiHCit treated plugs respect to VEGF
alone (VEGF+RGDechiHCit: 0.211 ± 0.034; VEGF+c
(RGDf[NMe]V): 0.185 ± 0.027 fold over VEGF alone;
p < 0.05, ANOVA), as depicted in Figure 7.
Discussion
In the present study, we evaluated the anti-angiogenic
properties of RGDechiHCit peptide in vitro on EC and
VSMC cells and in vivo on animal models of rats and
mice. The data here reported recapitulate the well-
known antiangiogenic properties of c(RGDf[NMe]V),
that was used as control. We previously described the
design and synthesis of RGDechiHCit, a novel and selec-
tive ligand for aVb3 integrin, containing a cyclic RGD
motif and two echistatin C-terminal moieties [20]. In
vitro studies showed that this molecule is able to selec-
tively bind aVb3 integrin and not to cross-react with
other type of integrins. Furthermore, PET and SPECT
imaging studies have confirmed that the peptide loca-
lizes on aVb3 expressing tumor cells in xenograft animal
model [21]. Given the presence in the molecule of the
RGD sequence it was obvious to speculate that RGDe-
chiHCit acted as an antagonist. Our report is the first
evidence that our peptide acts as antagonist for aVb3
integrin. Its ability to inhibit hFN-induced cell prolifera-
tion is comparable to that of c(RGDf[NMe]V), although
the half-life is quite reduced.
A major evidence that is brought up by our results is
the peculiar selectivity of RGDechiHCit towards EC, as
compared to c(RGDf[NMe]V). Indeed, RGDechiHCit
fails to inhibit VSMC proliferation in vitro, opposite to c
(RGDf[NMe]V). We believe that this feature is due to
the selectivity of such a novel compound toward aVb3.
Indeed, VSMCs express aVb3 only during embryogenesis
[31], but express other integrins which may be blocked
by c(RGDf[NMe]V). On the contrary, aVb3 is expressed
by ECs [8], thus conferring RGDechiHCit selectivity
toward this cell type. This issue is relevant cause the
effect in vivo is similar between the two antagonists on
wound healing and Matrigel plugs invasion. Indeed, our
data suggest that inhibition of the endothelial integrin
system is sufficient to inhibit angiogenesis. It is possible
to speculate that the higher specificity of RGDechiHCit
for the endothelium would result in a lower occurrence
of side effects than the use of less selective inhibitors.
This is only an indirect evidence, that needs further
investigation in more specific experimental setups.
Indeed, of the wide spectrum of integrins that are
expressed on the surface of ECs, aVb3 receptor has been
identified as having an especially interesting expression
pattern among vascular cells during angiogenesis, vascu-
lar remodeling, tumor progression and metastasis
[6,32,33]. What is more, two pathways of angiogenesis
have been recently identified based on the related
but distinct integrins aVb3 and aVb5 [4]. In particular,
aVb3 integrin activates VEGF receptors and inhibition
of b3 subunit has been shown to reduce phosphorylation
of VEGF receptors [7], thereby limiting the biological
Figure 7 Representative immunohistochemical sections (5 μm)
of subcutaneously injected Matrigel plugs. ECs were identified
(light blue arrowheads) by lectin staining, which gave a brown
reaction product, as described in Methods. Both c(RGDf[NMe]V) and
RGDechiHCit treatment reduced the number of invading cells from
the edge (black arrows) to the core of implanted Matrigel plug.
Analysis was conducted in 20 randomly chosen cross-sections
per each group. Bar: 400 nm. * = p < 0.05 vs VEGF. Error bars
show SEM.
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effects of VEGF [1]. Further, Mahabeleshwar and cowor-
kers have shown the intimate interaction occurring
between aVb3 integrin and the VEGFR-2 in primary
human EC [12]. The relevance of this molecule to
angiogenesis and its potential as a therapeutic target
has, therefore, been well established [34,35] and in this
report we show that its activity is highly critical for both
hFN or VEGF-stimulated ECs proliferation.
Our results concerning RGDechiHCit in angiogenic
processes are of immediate translational importance,
because deregulation of angiogenesis is involved in sev-
eral clinical conditions including cancer, ischemic, and
inflammatory diseases (atherosclerosis, rheumatoid
arthritis, or age-related macular degeneration) [34-36].
Therefore, the research for drugs able to modulate
angiogenesis constitutes a crucial investigation field.
Since RGDechiHCit is rapidly removed in serum it is
possible to increase its effect by engineering the mole-
cule to elongate its lifespan. In the present paper we cir-
cumvented this issue by increasing the times of
application of the drug both in vitro and in vivo, or by
reducing the times of observation. This issue can be
solved by the use of a more stable aromatic pharmaco-
phore that recapitulates the binding properties of RGDe-
chiHCit. Clearly, further investigations are also needed
to fully understand the basic cell biological mechanisms
underlying growth factor receptors and integrin function
during angiogenesis. The knowledge of molecular basis
of this complex mechanism remains a challenge of fasci-
nating interest, with clinical implications for treatment
of a large number of pathophysiological conditions
including but not limited to solid tumors [17,37], dia-
betic retinopathy [38,39] and inflammatory disease [36].
Conclusions
The present study indicates the importance of RGDe-
chiHCit in the selective inhibition of endothelial aVb3
integrin. Such inhibition opens new fields of investiga-
tion on the mechanisms of angiogenesis, offering clinical
implications for the treatment of several conditions such
as proliferative retinopathy, inflammatory disease and
cancer.
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DOI 10.1016/j.molcel.2011.01.030SUMMARY enylyl cyclase, thus leading to the activation of protein kinaseAdrenergic stimulation of the heart engages cAMP
and phosphoinositide second messenger signaling
cascades. Cardiac phosphoinositide 3-kinase
p110g participates in these processes by sustaining
b-adrenergic receptor internalization through its
catalytic function and by controlling phosphodies-
terase 3B (PDE3B) activity via an unknown kinase-
independent mechanism. We have discovered that
p110g anchors protein kinase A (PKA) through
a site in its N-terminal region. Anchored PKA
activates PDE3B to enhance cAMP degradation
and phosphorylates p110g to inhibit PIP3 production.
This provides local feedback control of PIP3 and
cAMP signaling events. In congestive heart failure,
p110g is upregulated and escapes PKA-mediated
inhibition, contributing to a reduction in b-adrenergic
receptor density. Pharmacological inhibition of
p110g normalizes b-adrenergic receptor density
and improves contractility in failing hearts.
INTRODUCTION
In cardiomyocytes, stimulation of G protein-coupled b-adren-
ergic receptors (b-ARs) by catecholamines engages tandem
signaling pathways that utilize the second messengers cyclic
AMP (cAMP) and phosphatidylinositol(3,4,5)-trisphosphate
(PtdIns(3,4,5)P3 or PIP3) (Rockman et al., 2002). cAMP is gener-
ated upon engagement of b-AR/Gs-triggered stimulation of ad-84 Molecular Cell 42, 84–95, April 8, 2011 ª2011 Elsevier Inc.A (PKA), which in turn controls myocardial contractility (Xiang
and Kobilka, 2003). Instead, PtdIns(3,4,5)P3 is produced from
PtdIns(4,5)P2 by the main G protein-coupled phosphoinositide
3-kinases (PI3Ks), PI3Kb and g (Guillermet-Guibert et al., 2008;
Hirsch et al., 2000).
Signals processed throughmyocardial cAMP/PKA and PI3Kg/
PtdIns(3,4,5)P3 pathways are tightly coupled, thus generating
intracellular sites for crosstalk between the cAMP and PtdIns
(3,4,5)P3 responsive enzymes. For instance, PI3Kg cooperates
with b-ARK1 to dampen cAMP signaling by promoting desensi-
tization and downregulation of b-ARs (Naga Prasad et al., 2001).
Additionally, PtdIns(3,4,5)P3 is needed for AP-2 adaptor recruit-
ment at the plasmamembrane and for the consequent organiza-
tion of clathrin-coated pits (Naga Prasad et al., 2002). This mech-
anism contributes to the pathological decrease in myocardial
b-AR density and function during the natural history of heart
failure (Bristow et al., 1982; Nienaber et al., 2003; Perrino et al.,
2007). PI3Kg also attenuates the cAMP/PKA pathway by
working as an activator of the phosphodiesterases PDE3B and
PDE4, which hydrolyze cAMP to 50-AMP (Conti and Beavo,
2007; Kerfant et al., 2007; Patrucco et al., 2004). Although little
is known about the regulation of PDE3B by PI3Kg, previous
reports have demonstrated that this is operated within a macro-
molecular complex including both the catalytic (p110g) and the
adaptor (p84/87) subunits of PI3Kg (Patrucco et al., 2004; Voigt
et al., 2006). Importantly, the functional interaction between
p110g and PDE3B does not involve the kinase activity of p110g,
which instead acts as a scaffold for PDE3B (Hirsch et al., 2009).
As a result, mice lacking p110g exhibit decreased myocardial
PDE3B activity and elevated cAMP, while PDE3B function and
cAMP levels are normal in mice expressing a kinase-inactive
p110g. In p110g nullmice subjected to cardiac pressure overload
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uncontrolled, thus leading to cardiomyopathy and heart failure
(Crackower et al., 2002; Patrucco et al., 2004).
Therefore, p110gmight constitute a molecular hub connecting
the cAMP and PtdIns(3,4,5)P3 signaling axes in cardiomyocytes.
However, the molecular mechanisms operating this interplay
remain unclear. We show herein that crosstalk between myocar-
dial cAMP and PtdIns(3,4,5)P3 signaling pathways is mediated
by the formation of a previously unidentifiedmultiprotein complex
that couples p110g to PDE3B activation. Within this complex,
p110g acts as an A-kinase anchoring protein (AKAP) tethering
the phosphodiesterase near its activator, PKA. Functional studies
further confirm that anchoring of PKA to p110g inhibits its lipid
kinase activity in a phosphorylation-dependentmanner. Coupling
of cAMP and PtdIns(3,4,5)P3 signalingmediated by the anchoring
function of p110g is perturbed in mouse models of congestive
heart failure, leading to b-AR downregulation. Inhibition of p110g
can restore compromised b-AR density and improve contractility,
highlighting the potential for therapeutic interventions.
RESULTS
p110g Activates PDE3B in a PKA-Dependent Manner
To elucidate the mechanisms linking PDE3B activity to p110g,
these proteins were overexpressed in HEK293T cells. p110g
and PDE3B could be coimmunoprecipitated in this cell type as
in mouse cardiomyocytes (Figures 1A, lane 3, and 1B, lane 1).
The cotransfection of p110g wild-type or p110g kinase-dead
with PDE3B resulted in a higher phosphodiesterase activity
than in cells expressing PDE3B alone (Figures 1C, column 3,
and S1A). This confirmed that p110g activates PDE3B in
a kinase-independent manner. One interpretation was that
p110g may associate with an activator of PDE3B, and PKA
appeared as a likely candidate (Degerman et al., 1998). Indeed,
recombinant PKA phosphorylated PDE3B in vitro (Figure S1B).
Furthermore, cAMP/PKA-mediated phosphorylation of PDE3B
was enhanced in the presence of p110g (Figure S1C). Treatment
with PKA inhibitors H89 or PKI blunted the increase in PDE3B-
mediated cAMP hydrolysis (Figures 1C, column 4, and 1D,
column 2). Taken together, our results imply that PKA residing
in the p110g-PDE3B complex enhances the activity of PDE3B.
Further support for this model was provided by evidence that
p110g copurified with PKA activity (Figure 1E, column 1). Addi-
tional experiments demonstrated the copurification of p110g
and PDE3B with the regulatory (RIIa) and catalytic (C) subunits
of PKA (Figure 1F, lane 1). In contrast, other class I PI3Ks
expressed in the heart, p110a and p110b, did not associate
with PKA and PDE3B (Figures S1D and S1E). Interestingly,
p110g was found to associate with the PKA regulatory subunit
RIIa but not with the RIa isoform (Figure S1F). In this complex,
we could also detect the p110g regulatory subunit p84/87, but
not p101 (Figure 1G, lane 1).
Further characterization of the p110g-PKA complex was con-
ducted in the mouse heart. Coimmunoprecipitation confirmed
the interaction of p110g with PKA in the myocardium (Figures
S2A and S2B). Immunofluorescence staining further illustrated
that p110g, RIIa, and PDE3B signals overlapped in mouse adult
cardiomyocytes (Figures 1H, S2C, and S2D). More stringentbiochemical analyses showed that, in myocardial lysates, RIIa
coimmunoprecipitates with PDE3B, the catalytic subunit of
PKA, as well as the p110g and p84/87 subunits of PI3Kg (Fig-
ure 1I, lane 1). Additional control experiments established that
the p101 subunit of PI3Kg was not present in this signaling
complex. These results establish p110g as the key element in
a PI3Kg/PDE3B/PKA ternary complex controlling PDE3B activity
through PKA.
p110g Acts as an A-Kinase Anchoring Protein
A critical role for p110g as a scaffold protein in the complex
suggests that p110g could act as an AKAP. AKAPs directly
bind the regulatory subunits of PKA to orchestrate the compart-
mentalization of cAMP/PKA signaling through association with
target effectors, substrates, and signal terminators (Carr et al.,
1991; Scott and Pawson, 2009). Accordingly, recombinant RIIa
subunits of PKA copurified with recombinant p110g in an
in vitro pull-down experiment (Figure 2A, lane 1). Further support
for this interaction was provided by surface plasmon resonance
measurements, which calculated a dissociation constant (KD) of
1.86 ± 0.01 mM for the interaction of p110g with RIIa (Figure 2B).
RII overlay experiments detected a binding band of 116 kDa in
p110g immunoprecipitates (Figure 2C, lane 1, upper panel).
This RII-binding band was absent in control blots pretreated
with the PKA anchoring inhibitor peptide, AKAP-IS (Figure 2C,
lane 1, lower panel). Immunoblot analysis of PKA RIIa immuno-
precipitates established that treatment with AKAP-IS could
disrupt the RIIa-p110g interaction (Figures 2D, lane 2, and 2E,
column 2). Control experiments indicated that other AKAPs
expressed in cardiomyocytes, including AKAP18a, AKAP79,
and AKAP-Lbc, do not coimmunoprecipitatewith p110g (Figures
S3A–S3C). Mapping studies have revealed that residues 1–45 of
RIIa form a docking and dimerization domain that serves as
a binding surface for AKAPs (Gold et al., 2006; Hausken et al.,
1994). RIIa fragments lacking this region (PKA RIIa D1–45) did
not bind p110g, as assessed by coprecipitation (Figure 2F,
lane 2), indicating that the N terminus of PKA RIIa is essential
for the interaction with p110g. Collectively, these results show
that p110g is a bona fide AKAP.
Mapping of the p110g-PKA RIIa Interaction
Mapping studies in HEK293T cells using a series of p110g dele-
tion fragments (Figure S4A) revealed that RIIa interacts with an
amino-terminal portion of p110g spanning residues 114–280
(Figure 3A, lane 2). Further investigation with a solid-phase
peptide array located the RIIa binding determinants between
residues 126 and 150 of p110g (Figure S4B). These results
were independently confirmed when a peptide encompassing
these residues of p110g selectively disrupted the RIIa-p110g
interaction in a dose-dependent manner (Figures 3B, lanes 2
and 3, and 3C, columns 2 and 3). Importantly, loss of PKA
anchoring led to a concomitant decrease in p110g-associated
PDE3B activity (Figure S4C).
More definitive analysis of the p110g 126–150 peptide re-
vealed that N-terminal residues are required for the binding to
PKA RIIa (Figure S4D). In addition, spot array analysis of
C-terminal truncations indicated that the exposure of charged
or hydrophobic residues flanking this region blunted the bindingMolecular Cell 42, 84–95, April 8, 2011 ª2011 Elsevier Inc. 85
Figure 1. p110g Activates PDE3B through PKA within a PI3Kg-PKA-PDE3B Complex
(A) Coimmunoprecipitation of PDE3B with p110g in HEK293T cells transfected with p110g and PDE3B-Flag.
(B) Coimmunoprecipitation of p110g with PDE3B in wild-type (p110g+/+) but not in p110g knockout (p110g/) mouse neonatal cardiomyocytes.
(C) Phosphodiesterase activity in PDE3B immunoprecipitates upon transfection of HEK293T cells with PDE3B-Flag (PDE3B) or with PDE3B-Flag and p110g.
Cells were treated with PKA inhibitor H89 (5 mM, 10 min) or vehicle as indicated. PDE activity (%) was calculated relative to the activity of single PDE3B
transfectants.
(D) Phosphodiesterase activity (%) of double p110g, PDE3B-Flag transfectants treated with PKA inhibitor Myr-PKI (5 mM, 10 min) or vehicle.
(E) PKA activity (cpm) in a p110g immunoprecipitate from transfected HEK293T cells.
(F) Coimmunoprecipitation of transfected p110g, PDE3B-Flag, PKA RIIa-ECFP (PKA RIIa), and PKA CAT-YFP (PKA C) from HEK293T extracts.
(G) Coimmunoprecipitation of p110g and p84/p87, but not p101, with PKA RIIa from HEK293T transfected cells.
(H) Colocalization (yellow spots) of p110g (green) and PKA RIIa (red) by immunofluorescence in mouse adult cardiomyocytes. Longitudinal and transverse
sections are shown in the upper and right panels, respectively. Single p110g and PKA RIIa localizations are presented in the lower panels.
(I) PDE3B, p110g, p84/p87, and PKA CAT (PKA C), but not p101, coimmunoprecipitate with PKA RIIa in myocardial tissue extracts of wild-type mice. A
representative immunoprecipitation is presented in (A)–(G) and (I). For all bar graphs, values represent mean ± SEM of a minimum of four independent experi-
ments. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figures S1 and S2.
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that while single point mutations did not disrupt the binding
(data not shown), the substitution of basic residues 126 (K) and
130 (R) with A abolished the interaction with RIIa (Figure 3D).
Cell-based analyses confirmed that a p110g K126A,R130A
mutant exhibited a reduced ability to copurify with the PKA holo-
enzyme (Figure 3E, lane 3). Moreover, this PKA-anchoring defec-
tive p110g mutant failed to increase PDE3B activity (Figures 3F,
column 3 and S4F). Thus, association of PKA with p110g allows
PKA to modulate PDE3B activity, thereby suppressing local
accumulation of cAMP.86 Molecular Cell 42, 84–95, April 8, 2011 ª2011 Elsevier Inc.PKA Phosphorylates p110g and Inhibits p110g Lipid
Kinase Activity
We further reasoned that anchored PKA might phosphorylate
p110g to modulate its catalytic activity. Indeed, recombinant
PKAmediated the incorporation of 32P into p110g, and this effect
was blocked in the presence of the specific PKA inhibitor peptide
PKI (Figures 4A and S5A). Studies in cultured cells indicated
that the forskolin-evoked accumulation of intracellular cAMP
induced the phosphorylation of p110g by PKA (Figure 4B,
lane 2). Conversely, PKA failed to phosphorylate the p110g
K126A,R130A mutant that does not bind PKA RIIa (Figures 4C,
Figure 2. p110g Is a Bona Fide AKAP
(A) In vitro copurification of p110g-GST and PKA RIIa-6His in a GST pull-down assay.
(B) Direct interaction of p110g and PKA RIIa in a surface plasmon resonance assay. p110g was immobilized on the chip, and PKA RIIa was injected at three
different concentrations.
(C) Binding of 32P-labeled PKA RIIa to immunoprecipitated p110g in the presence of AKAP-IS scrambled peptide but not in the presence of AKAP-IS peptide.
(D) Competition of the p110g-PKA RIIa coimmunoprecipitation with AKAP-IS peptide.
(E) Quantitative densitometry of the competition experiment represented in (D). Values represent mean ± SEM of four independent experiments. *p < 0.05.
(F) Loss of the coimmunoprecipitation of PKA RIIa with p110g by truncation of the 1–45 amino acids of RIIa-ECFP (PKA RIIa D1–45). A representative assay is
presented in all figures. See also Figure S3.
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phosphorylation site on p110g using sequential bioinformatic,
biochemical, and functional approaches. Bioinformatic
screening of the p110g sequence indentified a number of puta-
tive PKA phosphorylation sites (Table S1). However, only two
of them (S400 and T1024) (1) appeared conserved among
different species and (2) contained an R side chain at the 3
position, which is optimal for PKA substrate recognition (Fig-
ure S5B). Peptides containing these residues were not covered
in a phosphoproteomic analysis, but peptide arrays of p110g
phosphorylated by PKA showed a signal in two overlapping
peptides containing T1024 but not in sequences containing
S400 (Figure S5C). Most relevantly, only the T1024D and the
T1024A mutations, but not S400A, resulted in a significant
decrease in the phosphorylation of p110g by PKA (Figures 4E,
lane 4, 4F, column 2, and S5D), indicating that T1024 represents
the main phosphorylation site of p110g by PKA. It is worthy to
note that the T1024 is conserved in p110g orthologs and is not
present in the other class I PI3Ks (Figure S5E).
Lipid kinase assays showed that the incubation of PKAwith re-
combinant p110g reduced the kinase activity of p110g on both
PtdIns and PtdIns(4,5)P2 (Figures 4G, lane 2, and S6A). Yet treat-
ment with the PKI peptide abolished this effect (Figure S6B), thus
demonstrating that PKA negatively regulates the lipid kinase
activity of p110g. Similarly, cell-based studies demonstrated
that forskolin-dependent activation of PKA resulted in a decrease
in p110g lipid kinase activity, which was blocked by PKI (Fig-
ure 4H, lanes 3 and 4). Forskolin treatment also significantlyreduced, by 28.9%, PtdIns(3,4,5)P3 production in cells stimu-
lated with PGE2, a G protein-coupled receptor agonist activating
p110g (Figure 4I, column 3). Collectively, these observations
establish that PKA inhibits p110g through direct phosphoryla-
tion. Of note, the phosphomimetic T1024D mutant showed
reduced lipid kinase activity compared to wild-type p110g (Fig-
ure 4J, lane 2), indicating that the phosphorylation of p110g by
PKA on T1024 represents a crucial mechanism controlling
p110g lipid kinase activity.
p110g Is Inhibited by PKA in Cardiomyocytes
Next, the functional interaction between p110g and PKA was
explored in vivo. Wild-type mouse hearts stimulated with b-AR
agonist isoproterenol, which triggers the PKA axis, showed
a rapid inhibition of the lipid kinase activity of p110g (Figure 5A).
Although this is apparently in contrast with the notion that b-AR
activation triggers the PI3K/Akt pathway (Jo et al., 2002; Leblais
et al., 2004), isoproterenol induced PtdIns(3,4,5)P3 rise and Akt
phosphorylation in p110g kinase-dead mice (Figures 5B,
columns 3 and 4, and 5C, columns 4–6). Adrenergic-evoked
response was instead lost in p110b kinase-dead mice (Figures
5B, columns 5 and 6, and 5C, columns 7–9), supporting the
view that only p110g activity is repressed upon b-AR activation.
The inhibition of p110gwas further confirmed in ex vivo Langen-
dorff perfused hearts, where isoproterenol blunted p110g
activity by 77.3% ± 12%, while coperfusion with the PKA inhib-
itor H89 left p110g activity unchanged compared to control
hearts (Figure 5D, lanes 2 and 3). Moreover, in isolated adultMolecular Cell 42, 84–95, April 8, 2011 ª2011 Elsevier Inc. 87
Figure 3. Mapping of the p110g-PKA RIIa Interaction
(A) Loss of the coimmunoprecipitation of p110g-Myc with PKA RIIa by deletion of amino acids 114–280 (p110g D114–280) but not by deletion of the Ras-binding
domain (p110g DRBD) or the PIK domain (p110g DPIK) of p110g-Myc.
(B) Sequence of the 126–150 peptide is represented on a scheme of p110g. In dose-dependent competition experiments, the 126–150 peptide, but not
a scrambled control peptide, antagonized the p110g-RIIa protein-protein interaction.
(C) Quantitative densitometry of the competition experiment represented in (B).
(D) Binding of PKA RIIa to a set of alanine mutant 126–150 p110g peptides in a solid-phase peptide array.
(E) Mutation of K126 and R130 of p110g to A (p110g K126A,R130A) blunts coimmunoprecipitation of p110g with PKA RIIa in transfected HEK293T cells. Values
were obtained by quantitative densitometry and normalized over control.
(F) Phosphodiesterase activity (%) of PDE3B immunoprecipitates upon transfection of HEK293T cells with PDE3B-Flag alone or with PDE3B-Flag and either
wild-type or mutant p110g (p110g K126A,R130A). A representative immunoprecipitation is provided for (A), (B), (E), and (F). For all bar graphs, values represent
mean ± SEM of a minimum of four independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S4.
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activity of p110g by 53.3% ± 7% (Figure 5E, lane 2). Inhibition
of PKA with PKI restored p110g activity (Figure 5E, lane 3). We
then investigated the in vivo regulation of p110g activity by
PKA in a mouse model of cardiac pressure overload character-
ized by endogenous adrenergic stimulation of the myocardium
as well as compensatory hypertrophy (Figure 5F, insets). After
1 week of transverse aortic constriction (TAC), the p110g lipid
kinase activity was markedly reduced, by 50% ± 7%, when
compared to sham-operated mice (Figure 5F, lane 2). Taken
together, these findings show that signaling by the b-AR/
cAMP/PKA pathway inhibits cardiac p110g.
Regulation of p110g Kinase Activity by PKA Impacts
on b-Adrenergic Density
The kinase activity of p110g is known to reducemyocardial b-AR
density (Nienaber et al., 2003; Perrino et al., 2007). We thus
hypothesized that the regulation of p110g by PKA could88 Molecular Cell 42, 84–95, April 8, 2011 ª2011 Elsevier Inc.contribute to this process by mediating a feedback loop control-
ling b-AR cell surface expression. Therefore, b-AR density was
measured in wild-type, p110b kinase-dead (p110bKD/KD),
p110g knockout (p110g/), and p110g kinase-dead
(p110gKD/KD) hearts. The loss of p110g but not of p110b activity
was associated with a significant increase in b-AR density
(p110g/ + 36.4% and p110gKD/KD + 25.8% versus wild-type
controls) (Figure 6A, columns 3 and 4). Similarly, treatment of
wild-type mice with a selective p110g inhibitor (AS605240)
determined a significant 28.1% upregulation of cardiac b-AR
density, while AS605240 did not modify b-AR density in
p110gKD/KD hearts, indicating that this compound is specific
for p110g (Figure S7A).
A reduction of cell surface b-ARs is a key trait of heart failure
(Bristow et al., 1982, 1990; Denniss et al., 1989; Engelhardt
et al., 1996). This prompted us to investigate whether abnormal
regulation of p110g activity might be involved in this pathological
condition. We thus examined b-AR surface expression and
Figure 4. PKA Phosphorylates and Inhibits p110g
(A) Phosphorylation of p110g immunoprecipitated from transfected HEK293T cells in the presence of recombinant PKA C, 32P-ATP, and PKA inhibitor PKI (1 mM)
or vehicle.
(B) PKA-mediated phosphorylation of p110g immunoprecipitated from HEK293T cells upon stimulation with forskolin (FSK 20 mM, 5 min).
(C) PKA-mediated phosphorylation of p110g or p110gK126A,R130A immunoprecipitated fromHEK293T cells upon stimulation with forskolin (FSK 20 mM, 5min).
(D) Quantitative densitometry of the experiment represented in (C).
(E) PKA-mediated phosphorylation of p110g or p110g T1024D mutant immunoprecipitated from HEK293T cells and incubated or not with active PKA (30 min).
(F) Quantitative densitometry of PKA phosphorylation (background subtracted) of the experiment represented in (E).
(G) Lipid kinase activity of recombinant p110g-GST incubated in vitro with or without recombinant PKA C (30 min).
(H) Lipid kinase activity of p110g immunoprecipitated from transfected HEK293T cells treated with vehicle, pan-p110 inhibitor LY-294002 (LY, 20 mM, 15 min),
forskolin (FSK, 20 mM, 5 min) or FSK plus PKA inhibitor Myr-PKI (1 mM).
(I) Measurement of cellular PtdIns(3,4,5)P3 (pmol PIP3) levels in transfected HEK293T treated with the GPCR agonist PGE2 (100 nM, 10 min) alone or in
combination with FSK (50 mM, 3 min).
(J) Lipid kinase activity of p110g wild-type or p110g T1024D mutant immunoprecipitated from transfected HEK293T cells. In lipid kinase assays (G, H, J), the
ability of p110g to phosphorylate phosphoinositide was detected by autoradiography following incubation with 32P-ATP substrate. A representative assay is
presented in all figures. For all bar graphs, values represent mean ± SEM of a minimum of four independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. See
also Figures S5 and S6.
Molecular Cell
Kinase and Scaffolding Functions of Cardiac p110gp110g lipid kinase activity in hearts isolated from mice after
20 weeks of TAC, a time sufficient to develop a hypokinetic dila-
tive cardiomyopathy (left ventricle fractional shortening <30%).
At this stage, wild-type animals presented a 58.4% reduction
in b-AR density compared to sham controls (Figure 6B, column
2). In contrast, b-AR membrane density remained normal when
p110gKD/KD mice were subjected to 20 weeks of aortic banding(Figure 6B, column 4). This indicated that p110g stimulates b-AR
downregulation in the myocardium. Since PtdIns(3,4,5)P3 is crit-
ical in this process (Naga Prasad et al., 2001), PtdIns(3,4,5)P3
levels were measured after 20 week TAC. In p110gKD/KD hearts,
PtdIns(3,4,5)P3 was 39% lower than in wild-types (Figure 6C,
column 3). This paralleled a 37.5% ± 6% increase in p110g
activity in 20 week TAC-treated wild-type mice compared toMolecular Cell 42, 84–95, April 8, 2011 ª2011 Elsevier Inc. 89
Figure 5. PKA Inhibits the Lipid Kinase Activity of p110g in the Myocardium
(A) Lipid kinase activity of p110g immunoprecipitated from myocardial tissue lysates following treatment of wild-type (p110g+/+) or p110g knockout mice
(p110g/) with b-AR agonist isoproterenol (ISO, 1.25 mg/kg i.p. for 5 or 15 min) or vehicle.
(B) Measurement of myocardial PtdIns(3,4,5)P3 (pmol PIP3) levels in wild-type (p110g
+/+), p110g kinase-dead (p110gKD/KD), and p110b kinase-dead (p110bKD/KD)
mice treated with isoproterenol (ISO, 1.25 mg/kg i.p. for 5 min) or vehicle.
(C) Phospho-Akt (P-Akt) and total Akt (Akt) levels in myocardial tissue lysates following treatment of wild-type (p110g+/+), p110g kinase-dead (p110gKD/KD), and
p110b kinase-dead (p110bKD/KD) mice with b-AR agonist isoproterenol (ISO, 1.25 mg/kg i.p. for 5 or 15 min) or vehicle.
(D) Lipid kinase activity of p110g immunoprecipitated from myocardial tissue lysates following ex vivo cardiac Langendorff perfusion (5 min) with vehicle,
isoproterenol (ISO 10 mM), or ISO plus PKA inhibitor H89 (10 mM).
(E) Lipid kinase activity of p110g immunoprecipitated from rat adult cardiomyocytes treated with isoproterenol (ISO, 1 mM, 3min), ISO plus PKA inhibitor Myr-PKI
(1 mM, 5 min), or vehicle.
(F) Lipid kinase activity of p110g immunoprecipitated frommyocardial tissue lysates ofmice subjected to transverse aortic constriction for 1week (TAC 1week) or
to sham operation. Insets are representative hematoxylin and eosin stainings of left ventricular sections from sham-operated and 1 week TAC mice. A repre-
sentative assay is presented in all figures. For all bar graphs, values, obtained by quantitative densitometry and normalized over control, represent mean ± SEM of
a minimum of five mice per group. *p < 0.05, **p < 0.01.
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heart failure, p110g-dependent PtdIns(3,4,5)P3 might become
independent from PKA-mediated restrain. Consistently, after
20 weeks of TAC, p110g levels rose significantly while PKA
RIIa and PKA C expression remained unaltered (Figure 6E and
6F). Furthermore, proportionally less PKA copurified with
p110g isolated from these hearts (Figure 6E, column 2). Ratio
of densitometry of p110g and the coimmunoprecipitated PKA
C from the same blots showed that exposure to prolonged pres-
sure overload evoked a 56.4%± 9%decrease in the detection of
PKA catalytic subunit anchored to p110g (Figure 6E, column 2).90 Molecular Cell 42, 84–95, April 8, 2011 ª2011 Elsevier Inc.This was further supported by the finding that, during heart
failure, expression of PI3Kg adaptor subunits is altered. While
p84/87 remained constant, p101, the adaptor excluded from
the PKA-containing complex, followed p110g upregulation at
both mRNA and protein level (Figures 6F, S7B, and 6G). As
a consequence of this modulation, the association of p110g
with p84/87 did not change (Figures 6H, lane 2, and S7C). In
contrast, p110g association with p101 significantly increased
in failing hearts (Figure 6I, lane 2), resulting in an unphysiological
balance between p110g and its adaptors. Thus, the functional
consequence of this pathological reorganization of PI3Kg
Figure 6. Modulation of p110g Lipid Kinase Activity by PKA Affects b-AR Density
(A) Myocardial b-AR density in wild-type (p110g+/+), p110b kinase-dead (p110bKD/KD), p110g knockout (p110g/), and p110g kinase-dead (p110gKD/KD) mice.
(B) Myocardial b-AR density of p110g+/+ and p110gKD/KD mice subjected to sham operation or to aortic constriction for 20 weeks (TAC 20 weeks).
(C) Myocardial PtdIns(3,4,5)P3 (pmol PIP3) levels in hearts obtained from sham-operated mice or from 20 week TAC-treated wild-type or p110g
KD/KD mice.
(D) Lipid kinase activity of p110g immunoprecipitated from myocardial tissue lysates of sham-operated or 20 week TAC-treated mice. Values were obtained by
quantitative densitometry and normalized over control.
(E) Coimmunoprecipitation of p110g and PKA C from myocardial lysates from mice subjected to pressure overload for 20 weeks or to sham operation. After
quantitative densitometry, p110g-bound PKA was expressed as the ratio of coimmunoprecipitated PKA C over immunoprecipitated p110g.
(F) Total levels of the indicated proteins in myocardial tissue lysates from sham-operated mice or from mice subjected to pressure overload for 20 weeks.
(G) mRNA levels of p110g, p101, and p84/p87 in hearts from sham-operated mice or mice subjected to 20 weeks of TAC.
(H) Coimmunoprecipitation of p110g with p84/87 from myocardial lysates of mice subjected to pressure overload for 20 weeks or to sham operation.
(I) Coimmunoprecipitation of p110gwith p101 frommyocardial lysates of mice subjected to pressure overload for 20 weeks or to sham operation. In b-AR density
measurements (A and B), receptor density is expressed as the Bmax after saturation binding using
125I-labeled cyanopindolol ligand (fmol/mg protein).
A representative assay is presented in (D)–(I). For all bar graphs, values represent mean ± SEM of a minimum of four independent experiments or six mice per
group. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S7.
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lipid kinase activity.
Inhibition of p110g Kinase Activity Improves Cardiac
Function in Heart Failure
Patients with severe aortic stenosis, similar to mice subjected to
TAC, showed an increase in p110gprotein expression (Figure 7A,
right panel, and Table S2). This is in line with a previous study
conducted on patients with end-stage heart failure (Perrino
et al., 2007).We thus hypothesized that the development of heart
failure involves the aberrant activation of p110g. We tested thismodel by treating aortic banded mice with failing hearts (frac-
tional shortening <30%) for 1 week with the selective p110g
inhibitor AS605240. Indeed, AS605240 restored a significant
proportion of myocardial b-ARs on the plasma membrane
(37.2%) when compared to vehicle-treated controls (Figure 7B,
column 3). Accordingly, echocardiographic measurements
detected a significant increase (27.7%) in left ventricular frac-
tional shortening after treatment with AS605240 (Figures 7C,
column 2, and S7D and Table S3). The p110g inhibitor restored
fractional shortening to that of p110gKD/KD mice subjected to
20 weeks of aortic banding (Figure 7C, column 3). These findingsMolecular Cell 42, 84–95, April 8, 2011 ª2011 Elsevier Inc. 91
Figure 7. p110g Inhibition Restores b-AR Density and Cardiac Function in Heart Failure
(A) Immunohistochemistry for p110g in human hearts from healthy control patients or patients with aortic stenosis. Bar graph is 25 mm. Representative images are
presented.
(B) Myocardial b-AR density of wild-type mice with heart failure (obtained by 20 weeks of pressure overload) treated with selective p110g inhibitor AS605240
(AS 10 mg/kg i.p. q.d. for 1 week) or vehicle.
(C) Left ventricular fractional shortening of wild-type mice with heart failure treated with AS605240 (10 mg/kg i.p. q.d. for 1 week) or vehicle or of p110gKD/KD mice
subjected to aortic constriction for 20 weeks. Representative M-mode echocardiographic snapshots are presented (right). For all bar graphs, values represent
mean ± SEM of eight mice per group. *p < 0.05, **p < 0.01.
(D) Schematic representation of the diverse function of p110g and p110b in cardiac physiology and pathology. See also Figure S7.
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acts the reduction in b-AR density in failing hearts, thus
preserving physiological adrenergic signaling and protecting
the myocardium from the deterioration of the systolic function
in heart failure.
DISCUSSION
Our results establish that myocardial p110g physically and func-
tionally interacts with PKA. We provide evidence that p110g
orchestrates a physiological crosstalk between cAMP and
PtdIns(3,4,5)P3 pathways, modulating PDE3B activity and b-AR
internalization. In heart failure, this functional coupling operated
by p110g is perturbed, leading to impaired contractility.
While we previously reported that the loss of p110g results in
a defective activity of PDE3B (Patrucco et al., 2004), the molec-
ular mechanism of p110g-dependent regulation of PDE3B has
remained elusive. We now establish that p110g directly binds
PKA, a recognized activator of PDE3B, and that the phosphory-92 Molecular Cell 42, 84–95, April 8, 2011 ª2011 Elsevier Inc.lation of PDE3B by PKA is favored when both the kinase and the
phosphodiesterase are tethered to p110g. Whereas the associ-
ation of p110g with PKA is direct, the interaction with PDE3B is
mediated by the p84/87 PI3Kg regulatory subunit (Voigt et al.,
2006). This supports the selective involvement of p84/87, and
not of p101, in constraining the assembly of this ternary complex.
A broader implication of our results is that multiprotein assem-
blies involving p84/87/p110g, PDE3B, and PKA coordinate the
spatial and temporal modulation of cAMP signaling in the
myocardium, acting in a manner similar to other AKAPs such
as mAKAP, AKAP350, and gravin (Dodge et al., 2001; Taske´n
et al., 2001; Willoughby et al., 2006). These signaling complexes
tether PKA in proximity to PDEs to locally modulate cAMP
signaling, thereby optimizing signal termination. In respect to
what has been shown for other AKAPs, an important finding of
the present study is that we provide evidence of the colocaliza-
tion of PKA and PDE3B in a macromolecular complex. By inter-
acting with PKA and PDE3B, the p84/87/p110g heterodimer
appears involved in a crucial negative feedback controlling the
Molecular Cell
Kinase and Scaffolding Functions of Cardiac p110gcAMPpathway. In p110g-deficient animals, loss of this feedback
leads to cAMP accumulation in resting conditions (Crackower
et al., 2002) and to cAMP-mediated cardiac damage under
stress (Patrucco et al., 2004).
While p110g appears to behave like an AKAP in that it directly
binds the RIIa subunit, its PKA-anchoring site appears to be
atypical. Classical AKAPs bind to PKA RIIa through a conserved
amphipathic helix (Carr et al., 1991), and their association can be
disrupted by synthetic peptides designed to reproduce this
helical structure (Alto et al., 2003; Gold et al., 2006). As expected,
the p110g/PKA RIIa interaction could also be disrupted by
AKAP-IS, a consensus RII-anchoring disruptor peptide (Alto
et al., 2003). However, the p110g sequence defined by the
peptide array is not predicted to form a helical domain, and the
interaction with RIIa appears to rely on two positively charged
residues. Nonetheless, these findings are in line with the notion
that the family of AKAPs, which currently includes 45 genes
and their splice variants, exhibits substantial heterogeneity in
sequence, yet always featuring the ability to tether PKA at
subcellular locations.
The PKA associated with p110g not only influences the cata-
lytic activity of PDE3B, but also modulates the lipid kinase
activity of p110g itself. Indeed, the proximity of PKA and
p110g within the same macromolecular complex allows active
PKA to phosphorylate both PDE3B and p110g. The phosphory-
lation of p110g by PKA on T1024 results in a negativemodulation
of p110g kinase activity. T1024 resides in an a helix situated in
close proximity to the ATP-binding pocket, and therefore the
functional effects of this phosphorylation on the kinase activity
of p110g may derive from a conformational change disturbing
the catalytic pocket. This mechanism is supported by our find-
ings with the phosphomimetic T1024D mutant, which resulted
in decreased lipid kinase activity. T1024 of p110g is highly
conserved among species and is not represented in the other
class I PI3K isoforms, which are, however, inhibited by their
autophosphorylation within the catalytic domain (Czupalla
et al., 2003).
Modulation of p110g by PKA has relevant functional implica-
tions in vivo in the myocardium. While the b-AR/cAMP pathway
that activates PKA also triggers the PI3K pathway (Jo et al.,
2002; Leblais et al., 2004), our results indicate that in physiolog-
ical conditions, p110g activity is negligible, owing to its low
expression levels and to the inhibitory phosphorylation by PKA.
Instead, other G protein-coupled p110 isoforms, such as
p110b (Ciraolo et al., 2008; Guillermet-Guibert et al., 2008; Jia
et al., 2008), appear to be the main PI3K catalytic subunits
responsible for the production of PtdIns(3,4,5)P3 and the conse-
quent activation of Akt upon b-AR stimulation. Our findings are in
line with the view that, in physiological conditions, p110g activity
undergoes a delicate negative regulation in response to cAMP
production and PKA activation. This inhibitory effect can be
linked to the well-established view that, while class IA exerts
beneficial effects on the myocardium (Oudit and Penninger,
2009), p110g function is associated with detrimental responses
to cardiac stress (Crackower et al., 2002; Rockman et al.,
2002). In heart failure, p110g is upregulated, and due to defective
PKA-mediated inhibition, its activity is significantly enhanced.
Of note, PtdIns(3,4,5)P3 measurement in TAC-treated heartsshowed that only in p110gKD/KD and not in p110bKD/KD hearts
(data not shown) is PtdIns(3,4,5)P3 lower than in wild-type
controls, thus confirming a prominent role of the p110g isoform
in heart failure (Figure 7D).
The negative influence exerted by p110g catalytic activity on
the development of heart failure appears to be related to its
impact on b-AR pathway, a key regulator of heart contractility
(Rockman et al., 2002). Indeed, p110g promotes the desensitiza-
tion and downregulation of b-ARs through its interaction with
b-ARK1 (Naga Prasad et al., 2001) and through the recruitment
of PH domain-containing proteins such as AP-2 (Naga Prasad
et al., 2002), required for the assembly of b-AR downregulation
machinery. Consistent with these observations, genetic ablation
of p110g, expression of a catalytically inactive p110g, or admin-
istration of a selective p110g inhibitor to wild-type mice slightly
but significantly increased cardiac b-AR density. A trend toward
elevated b-AR surface expression has been already reported in
a previous study conducted on p110g-deficient mice (Nienaber
et al., 2003). In our hands, while basal myocardial b-AR expres-
sion was only marginally affected by the inactivation of p110g,
the effect of p110g on b-AR downregulation appeared prominent
during adrenergic stress and pressure overload-induced heart
failure. Consistently, in failing hearts, p110g catalytic activity
appeared significantly enhanced and occurred in a context
where expression of p110g and its adaptor p101 was dramati-
cally upregulated. This effect limited the organization of
complexes with p84/87 and PKA, thus reducing PKA-mediated
inactivation of p110g. In agreement, blockade of p110g activity
either genetically or pharmacologically led to a renormalization
of b-AR density in heart failure, improving compromised cardiac
contractility.
In summary, our results establish that myocardial p110g
connects the PtdIns(3,4,5)P3 and cAMP signaling pathways.
We show that anchored PKA is the key regulator of enzymes in
this macromolecular complex and that PKA locally controls
PDE3B activity, reducing cAMP levels. This finding provides an
explanation for the longstanding conundrum of how the p110g
kinase-independent function can promote cAMP degradation
(Patrucco et al., 2004). On the other hand, PKA inhibits p110g
activity to maintain myocardial b-ARs on the cell surface. In heart
failure, uncoupling of p110g from its negative regulator PKA
results in b-AR downregulation. Pharmacological inhibition of
p110g restores the physiological condition, with beneficial
effects on b-AR density and, ultimately, on cardiac contractility,
thus establishing p110g targeting as a potential treatment for
heart failure.EXPERIMENTAL PROCEDURES
Mice
p110g knockout (Hirsch et al., 2000), p110g kinase-dead (Patrucco et al.,
2004), and p110b kinase-dead mice (Ciraolo et al., 2008) are all in a C57BL/
6J background. C57BL/6J wild-type mice were used as controls.
Hearts and Cell Lysis, Protein Immunoprecipitation,
and Western Blotting
Hearts, adult rat cardiomyocytes, and HEK293T cells were homogenized in
1% Triton X-100 buffer with protease and phosphatase inhibitors. Lysates
were cleared by centrifugation at 13,000 rpm for 15 min at 4C. SupernatantsMolecular Cell 42, 84–95, April 8, 2011 ª2011 Elsevier Inc. 93
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cated antibodies.
Lipid Kinase Assay
Immunoprecipitated p110g was incubated in lipid kinase buffer containing
phosphatidylinositol, phosphatidylserine, ATP, and 5 mCi of 32P-ATP for
10 min at 30C at 1200 rpm. The reaction was stopped by addition of HCl,
and lipids were extracted using chloroform/methanol. The organic phase
was spotted on thin-layer chromatography plates and resolved with chloro-
form/methanol/ammonium hydroxide/water. Dried plates were exposed for
autoradiography.
Transverse Aortic Constriction and AS605240 Treatment
In vivo pressure overload was imposed on the left ventricle by surgical banding
of the transverse aorta, as previously described (Patrucco et al., 2004). Sham-
operated animals underwent the same surgical procedure without TAC. 2D
guided M-mode echocardiography was performed in anesthetized mice to
assess cardiac function. Fractional shortening (FS) lower than 30% was
used as a threshold to discriminate between compensated and decompen-
sated hearts. Mice displaying a 25%–30% FS were injected i.p. daily for
1 week with either 10 mg/kg AS605240 or vehicle.
b-AR Density Measurement
Mouse hearts were homogenized in 250 mM sucrose, 5 mM EDTA, 5 mM Tris-
HCl (pH 7.5), 2 mM leupeptin, 100 mM benzamidine, and 100 mM PMSF and
centrifuged at 800 g for 15 min at 4C. Supernatants were filtered and centri-
fuged at 25,000 g for 30 min at 4C. The pelleted membranes were washed in
acidified ice-cold binding buffer before being resuspended in binding buffer.
Total b-AR density was determined by incubation of membrane proteins
with a saturating concentration of 125I-labeled cyanopindolol. Nonspecific
binding was determined as previously described (Ciccarelli et al., 2008). Reac-
tions were conducted at 37C for 1 hr and terminated by vacuum filtration.
After ice-cold washing, bound radioactivity was assessed on a gamma
counter. All assays were performed in triplicate, and receptor density (femto-
moles) was normalized to milligrams of membrane protein.
Data and Statistical Analyses
Prism software (GraphPad) was used for statistical analysis. All data were ex-
pressed as mean ± SEM. P values were calculated by using Student’s t test
and one-way ANOVA test, followed by Bonferroni’s post hoc analysis when
appropriate. p < 0.05 was considered significant (*), p < 0.01 was considered
very significant (**), and p < 0.001 was considered extremely significant (***).
See Supplemental Experimental Procedures for details and for remaining
procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, seven figures, and three tables and can be found
with this article online at doi:10.1016/j.molcel.2011.01.030.
ACKNOWLEDGMENTS
We would like to thank M. Zaccolo (University of Glasgow), J. Beavo (Univer-
sity of Washington), J. Hamm (University of Torino), and all the members of
E.H.’s lab. This work was supported by grants from Fondation Leducq
(06CDV02 to E.H., J.D.S., G.S.B., and M.D.H.), the European Union Sixth
Framework Program EuGeneHeart (E.H.), Telethon (E.H.), Regione Piemonte
(E.H.), University of Torino (E.H.), AIRC (E.H.), NIH (grant HL08836 to J.D.S.),
and Medical Research Council UK (G0600675 to G.S.B. and M.D.H.).
Received: September 14, 2010
Revised: December 20, 2010
Accepted: January 24, 2011
Published: April 7, 201194 Molecular Cell 42, 84–95, April 8, 2011 ª2011 Elsevier Inc.REFERENCES
Alto, N.M., Soderling, S.H., Hoshi, N., Langeberg, L.K., Fayos, R., Jennings,
P.A., and Scott, J.D. (2003). Bioinformatic design of A-kinase anchoring
protein-in silico: a potent and selective peptide antagonist of type II protein
kinase A anchoring. Proc. Natl. Acad. Sci. USA 100, 4445–4450.
Bristow, M.R., Ginsburg, R., Minobe, W., Cubicciotti, R.S., Sageman, W.S.,
Lurie, K., Billingham, M.E., Harrison, D.C., and Stinson, E.B. (1982).
Decreased catecholamine sensitivity and beta-adrenergic-receptor density
in failing human hearts. N. Engl. J. Med. 307, 205–211.
Bristow, M.R., Hershberger, R.E., Port, J.D., Gilbert, E.M., Sandoval, A.,
Rasmussen, R., Cates, A.E., and Feldman, A.M. (1990). Beta-adrenergic path-
ways in nonfailing and failing human ventricular myocardium. Circulation 82 (2,
Suppl), I12–I25.
Carr, D.W., Stofko-Hahn, R.E., Fraser, I.D., Bishop, S.M., Acott, T.S., Brennan,
R.G., and Scott, J.D. (1991). Interaction of the regulatory subunit (RII) of cAMP-
dependent protein kinase with RII-anchoring proteins occurs through an
amphipathic helix binding motif. J. Biol. Chem. 266, 14188–14192.
Ciccarelli, M., Santulli, G., Campanile, A., Galasso, G., Cerve`ro, P., Altobelli,
G.G., Cimini, V., Pastore, L., Piscione, F., Trimarco, B., and Iaccarino, G.
(2008). Endothelial alpha1-adrenoceptors regulate neo-angiogenesis. Br. J.
Pharmacol. 153, 936–946.
Ciraolo, E., Iezzi, M., Marone, R., Marengo, S., Curcio, C., Costa, C., Azzolino,
O., Gonella, C., Rubinetto, C., Wu, H., et al. (2008). Phosphoinositide 3-kinase
p110beta activity: key role in metabolism and mammary gland cancer but not
development. Sci. Signal. 1, ra3.
Conti, M., and Beavo, J. (2007). Biochemistry and physiology of cyclic nucle-
otide phosphodiesterases: essential components in cyclic nucleotide
signaling. Annu. Rev. Biochem. 76, 481–511.
Crackower, M.A., Oudit, G.Y., Kozieradzki, I., Sarao, R., Sun, H., Sasaki, T.,
Hirsch, E., Suzuki, A., Shioi, T., Irie-Sasaki, J., et al. (2002). Regulation of
myocardial contractility and cell size by distinct PI3K-PTEN signaling path-
ways. Cell 110, 737–749.
Czupalla, C., Culo, M., Mu¨ller, E.C., Brock, C., Reusch, H.P., Spicher, K.,
Krause, E., and Nu¨rnberg, B. (2003). Identification and characterization of
the autophosphorylation sites of phosphoinositide 3-kinase isoforms beta
and gamma. J. Biol. Chem. 278, 11536–11545.
Degerman, E., Landstro¨m, T.R., Wijkander, J., Holst, L.S., Ahmad, F., Belfrage,
P., and Manganiello, V. (1998). Phosphorylation and activation of hormone-
sensitive adipocyte phosphodiesterase type 3B. Methods 14, 43–53.
Denniss, A.R., Marsh, J.D., Quigg, R.J., Gordon, J.B., and Colucci, W.S.
(1989). Beta-adrenergic receptor number and adenylate cyclase function in
denervated transplanted and cardiomyopathic human hearts. Circulation 79,
1028–1034.
Dodge, K.L., Khouangsathiene, S., Kapiloff, M.S., Mouton, R., Hill, E.V.,
Houslay, M.D., Langeberg, L.K., and Scott, J.D. (2001). mAKAP assembles
a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO
J. 20, 1921–1930.
Engelhardt, S., Bo¨hm, M., Erdmann, E., and Lohse, M.J. (1996). Analysis of
beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens
by quantitative polymerase chain reactions: progressive reduction of beta
1-adrenergic receptor mRNA in heart failure. J. Am. Coll. Cardiol. 27, 146–154.
Gold, M.G., Lygren, B., Dokurno, P., Hoshi, N., McConnachie, G., Taske´n, K.,
Carlson, C.R., Scott, J.D., and Barford, D. (2006). Molecular basis of AKAP
specificity for PKA regulatory subunits. Mol. Cell 24, 383–395.
Guillermet-Guibert, J., Bjorklof, K., Salpekar, A., Gonella, C., Ramadani, F.,
Bilancio, A., Meek, S., Smith, A.J., Okkenhaug, K., and Vanhaesebroeck, B.
(2008). The p110beta isoform of phosphoinositide 3-kinase signals down-
stream of G protein-coupled receptors and is functionally redundant with
p110gamma. Proc. Natl. Acad. Sci. USA 105, 8292–8297.
Hausken, Z.E., Coghlan, V.M., Hastings, C.A., Reimann, E.M., and Scott, J.D.
(1994). Type II regulatory subunit (RII) of the cAMP-dependent protein kinase
Molecular Cell
Kinase and Scaffolding Functions of Cardiac p110ginteraction with A-kinase anchor proteins requires isoleucines 3 and 5. J. Biol.
Chem. 269, 24245–24251.
Hirsch, E., Katanaev, V.L., Garlanda, C., Azzolino, O., Pirola, L., Silengo, L.,
Sozzani, S., Mantovani, A., Altruda, F., and Wymann, M.P. (2000). Central
role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation.
Science 287, 1049–1053.
Hirsch, E., Braccini, L., Ciraolo, E., Morello, F., and Perino, A. (2009). Twice
upon a time: PI3K’s secret double life exposed. Trends Biochem. Sci. 34,
244–248.
Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S.H., Zhang, J., Signoretti, S.,
Loda, M., Roberts, T.M., and Zhao, J.J. (2008). Essential roles of PI(3)K-
p110beta in cell growth, metabolism and tumorigenesis. Nature 454, 776–779.
Jo, S.H., Leblais, V., Wang, P.H., Crow, M.T., and Xiao, R.P. (2002).
Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent
G(s) signaling during beta2-adrenergic stimulation. Circ. Res. 91, 46–53.
Kerfant, B.G., Zhao, D., Lorenzen-Schmidt, I., Wilson, L.S., Cai, S., Chen, S.R.,
Maurice, D.H., and Backx, P.H. (2007). PI3Kgamma is required for PDE4, not
PDE3, activity in subcellular microdomains containing the sarcoplasmic retic-
ular calcium ATPase in cardiomyocytes. Circ. Res. 101, 400–408.
Leblais, V., Jo, S.H., Chakir, K., Maltsev, V., Zheng, M., Crow, M.T., Wang, W.,
Lakatta, E.G., and Xiao, R.P. (2004). Phosphatidylinositol 3-kinase offsets
cAMP-mediated positive inotropic effect via inhibiting Ca2+ influx in cardio-
myocytes. Circ. Res. 95, 1183–1190.
Naga Prasad, S.V., Barak, L.S., Rapacciuolo, A., Caron, M.G., and Rockman,
H.A. (2001). Agonist-dependent recruitment of phosphoinositide 3-kinase to
the membrane by beta-adrenergic receptor kinase 1. A role in receptor
sequestration. J. Biol. Chem. 276, 18953–18959.
Naga Prasad, S.V., Laporte, S.A., Chamberlain, D., Caron, M.G., Barak, L., and
Rockman, H.A. (2002). Phosphoinositide 3-kinase regulates beta2-adrenergic
receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin
complex. J. Cell Biol. 158, 563–575.Nienaber, J.J., Tachibana, H., Naga Prasad, S.V., Esposito, G., Wu, D., Mao,
L., and Rockman, H.A. (2003). Inhibition of receptor-localized PI3K preserves
cardiac beta-adrenergic receptor function and ameliorates pressure overload
heart failure. J. Clin. Invest. 112, 1067–1079.
Oudit, G.Y., and Penninger, J.M. (2009). Cardiac regulation by phosphoinosi-
tide 3-kinases and PTEN. Cardiovasc. Res. 82, 250–260.
Patrucco, E., Notte, A., Barberis, L., Selvetella, G., Maffei, A., Brancaccio, M.,
Marengo, S., Russo, G., Azzolino, O., Rybalkin, S.D., et al. (2004). PI3Kgamma
modulates the cardiac response to chronic pressure overload by distinct
kinase-dependent and -independent effects. Cell 118, 375–387.
Perrino, C., Schroder, J.N., Lima, B., Villamizar, N., Nienaber, J.J., Milano,
C.A., and Naga Prasad, S.V. (2007). Dynamic regulation of phosphoinositide
3-kinase-gamma activity and beta-adrenergic receptor trafficking in end-
stage human heart failure. Circulation 116, 2571–2579.
Rockman, H.A., Koch, W.J., and Lefkowitz, R.J. (2002). Seven-transmem-
brane-spanning receptors and heart function. Nature 415, 206–212.
Scott, J.D., and Pawson, T. (2009). Cell signaling in space and time: where
proteins come together and when they’re apart. Science 326, 1220–1224.
Taske´n, K.A., Collas, P., Kemmner, W.A., Witczak, O., Conti, M., and Taske´n,
K. (2001). Phosphodiesterase 4D and protein kinase a type II constitute
a signaling unit in the centrosomal area. J. Biol. Chem. 276, 21999–22002.
Voigt, P., Dorner, M.B., and Schaefer, M. (2006). Characterization of
p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma
that is highly expressed in heart and interacts with PDE3B. J. Biol. Chem.
281, 9977–9986.
Willoughby, D., Wong, W., Schaack, J., Scott, J.D., and Cooper, D.M. (2006).
An anchored PKA and PDE4 complex regulates subplasmalemmal cAMP
dynamics. EMBO J. 25, 2051–2061.
Xiang, Y., and Kobilka, B.K. (2003). Myocyte adrenoceptor signaling path-
ways. Science 300, 1530–1532.Molecular Cell 42, 84–95, April 8, 2011 ª2011 Elsevier Inc. 95
RESEARCH ARTICLE Open Access
The GPIIIA PlA2 polymorphism is associated with
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Abstract
Background: The clinical impact of PlA2 polymorphism has been investigated in several diseases, but the
definition of its specific role on thrombotic cardiovascular complications has been challenging. We aimed to
explore the effect of PlA2 polymorphism on outcome in patients with atherosclerosis.
Methods: We studied 400 consecutive patients with coronary artery disease (CAD) undergoing percutaneous
coronary intervention. A replication study was conducted in 74 hypertensive patients with cerebrovascular events
while a group of 100 healthy subjects was included as control population. PlA genotype was determined by PCR-
RFLP on genomic DNA from peripheral blood cells. Major adverse cardiac events (MACE), were considered as end
points, and recorded at a mean follow up of 24 ± 4.3 months.
Results: The frequencies of PlA2 polymorphism was similar between groups and genotype distribution was in
Hardy-Weinberg equilibrium. In patients with CAD, the presence of PlA2 allele was associated with higher
incidence of cardiac death (13.1% vs. 1.5%, p = 0.0001), myocardial infarction (10.7% vs. 2.6%, p = 0.004) and needs
of new revascularization (34.8% vs. 17.7%, p = 0.010). Accordingly, the Kaplan-Meier analysis for event free survival
in patients harboring the PlA2 allele showed worse long-term outcome for these patients (p = 0.015). Cox
regression analysis identified the presence of PlA2 as an independent predictor of cardiac death (OR: 9.594, 95% CI:
2.6 to 35.3, p = 0.002) and overall MACE (OR: 1.829, 95% CI: 1.054 to 3.176, p = 0.032). In the replication study, the
PlA2 polymorphism increased the risk of stroke (OR: 4.1, 95% CI: 1.63-12.4, p = 0.02) over TIA and was identified as
an independent risk factor for stroke (B:-1.39; Wald: 7.15; p = 0.001).
Conclusions: Our study demonstrates that in patients with severe atherosclerosis the presence of PlA2 allele is
associated with thrombotic cardiovascular complications.
Background
Atherosclerosis manifesting as myocardial infarction,
angina pectoris, cerebral ischemia and peripheral artery
disease is a multifactorial disease with the environment
and genetics contributing to its pathogenesis. During
the last decade several genes involved in the athero-
sclerotic process and their polymorphisms have been
suspected to increase the thrombotic predisposition and
to influence the risk for acute coronary syndromes.
Among these genes, polymorphisms of those involved in
platelet function have been extensively studied. Indeed,
platelets play a pivotal role in atherothrombosis [1] and
their function is strongly related to the interactions of
the glycoprotein IIb/IIIa receptor (GP IIb/IIIa) and the
von Willebrand factor, as well as fibrinogen, leading to
platelets aggregation [2-4]. GP IIIa is a high poly-
morphic protein with platelet antigen 1 (PlA1) and 2
(PlA2) as the most common allelic isoforms [5]. In the
PlA2 allele, cytosine is substituted for thymidine in exon
2, which is phenotypically translated in the substitution
of proline for leucine at position 33 of the mature GP
IIIa [6]. A previous in vitro study demonstrates that the
PlA2 variant enhances the binding of the GPIIb/IIIa
receptor to fibrinogen and therefore increases the plate-
let aggregation induced by agonists [7]. The clinical
impact of PlA2 polymorphism has been investigated in
several diseases, in which thrombus formation is a key
pathogenetic factor, but the definition of the specific
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role of such polymorphisms on thrombotic coronary
and cerebrovascular complications has been challenging.
Weiss et al. [8] observed a strong association between
the PlA2 polymorphism of the GP IIIa gene and acute
coronary thrombosis, and this association was strongest
in patients who had had coronary events before the age
of 60 years, suggesting this polymorphism as an inher-
ited risk factor for coronary thrombosis. These findings
were further expanded on peripheral artery disease by
Mikkelson [9] who reported an association between
PlA2 variant and the progression of atherosclerosis in
the abdominal aorta. Similarly, in the Copenhagen City
Heart Study, a prospective study with 9,149 subjects,
there was a three-fold and four-fold risk of ischemic car-
diovascular disease and MI in men <40 years homozy-
gous for PlA2 polymorphism [10]. On the other hand,
several studies failed to confirm this association; indeed
a metanalysis of 23 of such negative studies, showed the
lack of association between the PlA2 allele and the risk
of myocardial infarction and this negative result per-
sisted even after subgroup analyses [11]. Therefore, up
to date, available data are hugely uncertain and still
debated. Several issues common to epidemiologic risk
factor studies can be accountable for the difficulty
encountered in reproducing the results of genetic asso-
ciation studies. Among these limitations there is inaccu-
rate phenotyping [12]. In particular, atherosclerotic
disease may present with different clinical manifesta-
tions. It is therefore pivotal to accurately select the clini-
cal phenotype that can be affected by the genetic
variability. To address this issue, and therefore gain
more inside on the role of PlA2 polymorphism on
atherothrombotic disease, we performed a prospective
study in a cohort of patients selected for angiography
documented severe coronary artery disease (CAD),
which needed percutaneous coronary intervention (PCI).
Moreover, to assess the role of this polymorphism on
cerebrovascular disease, a replication study was per-
formed in an independent population of hypertensive
subjects, screened for large vessel atherosclerotic disease,
and previous ischemic cerebrovascular events, namely
stroke or transient ischemic attack (TIA). Finally, a
group of 100 healthy subjects was included as control
population of our study.
Methods
Patients
To assess the role of PlA2 polymorphism on cardiovas-
cular disease we analyzed the incidence of this gene var-
iant in a total of 574 unrelated individuals. A first group
was constituted by 400 consecutive patients (mean age
60.5 ± 10, 83% male) undergoing elective or urgent PCI
for CAD documented by a positive stress test or by Tl
single photon emission computed tomography. To
perform a replication analysis we selected an indepen-
dent population of patients with cerebrovascular disease.
Therefore, a population of 74 unrelated patients (mean
age 61.58 ± 2, 63% male) with cerebrovascular events
was examinated, recruited from those admitted to the
Hypertension Diagnosis and Care Outpatient Clinic of
“Federico II” University of Naples and participating in
the ‘Campania Salute Project’ [13]. Finally, to identify
normal distribution of the PlA genotype, we enrolled a
control population of 100 gender- and age-matched
healthy unrelated individuals (60 ± 10 years, 83% male),
recruited from blood donors of our blood bank. Con-
trols were free from heart disease, medication use, and
cardiovascular risk factors, except for smoking habits.
To help to diminish the likelihood of bias and reduce
population stratification case and controls individuals
were drawn from the same geographic region (Campa-
nia, Southern Italy) and matched for age, sex and race.
All clinical data and biochemical features of enrolled
patients were stored in a computerized database. A writ-
ten informed consent was obtained from all patients
according to the Ethics Committee of the “Federico II”
University of Naples School of Medicine. The Ethic
Committee regulations of our Institution approved the
study protocol.
Percutaneous coronary intervention
PCI was performed according to the American Heart
Association/American College of Cardiology guidelines
[14]. Antegrade perfusion was graded by Thrombolysis
In Myocardial Infarction (TIMI) criteria [15]. Angio-
graphic lesion morphology was classified according to
American Heart Association/American College of Cardi-
ology classification [16]. Stenoses >50% were considered
significant. Bare-metal stents (BMS) were used in the
80% of patients, while drug-eluting stent (DES) in the
remaining 20%. Glycoprotein IIb/IIIa inhibitors were
used in 30% of patients. After the procedures, all
patients were on dual antiplatelet therapy with aspirin
and clopidogrel for at least 30 days after BMS implanta-
tion and for 12 months after DES. Other cardioactive
drugs for long-term medical treatment were left to the
discretion of the attending cardiologists.
Outcome evaluation
In the evaluation of long-term clinical outcome, major
adverse cardiac events (MACE) were considered as end
points, including cardiac death, acute myocardial infarc-
tion (AMI), and needs of any new myocardial revascu-
larization (considering re-PCI or coronary artery by-pass
graft). All deaths were considered as cardiac, unless it
was unequivocally proven non-cardiac. AMI was defined
as recurrent chest pain with ST-segment or T-wave
changes and recurrent elevation of cardiac enzyme
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levels. The follow-up was based on a direct systematic
review of all patients’ clinical files for a mean study per-
iod of 24 ± 4.3 months, contacting relatives or a
patient’s physician when necessary. Follow-up was com-
pleted in all patients and data stored in a computerized
database. A second population was identified among the
hypertensive cohort of patients afferent to the ‘Campa-
nia Salute Project’ [13]. We selected 74 patients affected
by cerebrovascular events, either TIA or stroke. In parti-
cular, the diagnosis of TIA or stroke was confirmed by
neurological evaluation according to current standards
for care [17]. This included patient personal and family
history, physical examination, computed tomography or
magnetic resonance imaging, and laboratory testing. The
diagnosis of stroke was based on WHO criteria, con-
firmed by TC or MR, when needed. The cause of stroke
was identified in large-vessel disease, according to the
clinical features and results of the diagnostic workup,
based on TOAST pathophysiological classification [18].
TIA was defined as an episode of focal neurological
symptoms with abrupt onset and rapid resolution lasting
<24 hours that is due to altered circulation to a loca-
lized portion of the brain [19].
GpIIIa genotyping
Using a commercially available kit (Midiprep DNA, Qia-
gen, Valencia, California), genomic deoxyribonucleic
acid (DNA) was isolated from 2 ml of the peripheral
blood samples. PlA2 polymorphism was studied using
combined polymerase chain reaction (PCR) and restric-
tion fragment length polymorphism technique (RFLP)
on PCR amplified products using PCR conditions and
primers on a Thermocycler (MJ Research, St. Bruno,
Canada) and DNA polymerase (TAQ, Qiagen) as pre-
viously reported [20,21].
Statistical Analysis
Continuous variables are presented as mean ± SD and
categorical variables as absolute number and percentage
value. Differences between groups were assessed using
univariate analysis of variance for continuous variables,
with a Bonferroni post-hoc test for evaluation of multi-
ple comparisons. Categorical variables were analyzed by
chi-square test, and odds ratio (OR) with 95% confi-
dence intervals (CIs) or by the Fisher exact test when
the expected values in any of the cells of the test, given
the frequencies and the overall sample size, was below
10; p value <0.05 was considered significant. Difference
in event-free survival between groups were evaluated by
the Kaplan-Meier method, comparisons were made
using log-rank test. A Cox regression analysis was con-
ducted for the PlA2 polymorphism considering age, car-
diovascular risk factors, medication use, left ventricular
ejection fraction, angiographic characteristics, and
interaction of the PlA2 polymorphism in both the study
populations. The software used was SPSS 16 (SPSS Inc.,
Chicago, Illinois).
Results
Frequencies of PlA2 polymorphism in study population
As reported in Table 1, the frequencies of PlA2 poly-
morphism was similar between study and control group.
The genotype distribution was in Hardy-Weinberg equi-
librium. The allele frequency for PlA1 and PlA2 was,
respectively, 84% and 16% in patients with CAD, 82.3%
and 17.7% in hypertensive subjects with cerebrovascular
events, and 84.5% and 15.5% in the control healthy
group.
Clinical and angiographic characteristics in patients with
coronary artery disease
Accordingly to the allelic distribution of the PlA2 allele
we divided patients with CAD into 2 groups: group 1
(300 patients, PlA1/PlA1 genotype; 90% male, mean age
60 ± 10 years) and group 2 (100 patients, PlA1/PlA2
and PlA2/PlA2 genotypes; 81% male, mean age 62.1 ±
8.6 years). As reported in tables, no differences were
noted between the two groups regarding baseline clini-
cal (table 2) and angiographic (table 3) features.
Table 1 Genotype distribution of PlA2 polymorphism in
study populations
Genotype CAD
patients
Hypertensive
patients
Control
population
P
PlA1/A1 70.4 67.8 72 0.79
PlA1/A2 27 29.1 25 0.91
PlA2/A2 2.6 3.1 3 0.81
CAD: Coronary artery disease
Table 2 Clinical characteristics of CAD patients
Variable PlA1
(n = 300)
PlA2
(n = 100)
p
Value
Age 60 ± 10 62.1 ± 8.6 0.72
Male sex (%) 90 81 0.03
Hypertension (%) 56 57 0.82
Diabetes (%) 29.3 19.4 0.11
Smoking (%) 58.6 53.8 0.45
Dyslipidemia (%) 55.2 53.8 0.81
Obesity (%) 9.5 7.7 0.89
Family history of CAD (%) 38.2 33.4 0.37
Previous AMI (%) 10.9 15.4 0.35
Previous PCI (%) 10.9 15.4 0.35
Previous CABG (%) 9.1 3.8 0.15
LVEF prior to PCI, mean ± SD 47 ± 10 51 ± 8 0.06
PCI: Percutaneous coronary intervention
LVEF: Left ventricular ejection fraction
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Medication use
There were no differences between groups regarding
medication use at the time of PCI and during follow-up
time. In particular, at follow-up time both groups were
similarly treated, using dual antiplatelet therapy (99% vs.
98% group 2, p = NS), calcium antagonist (19% vs. 18%
group 2, p = NS), beta-blockers (45% vs. 47% group 2,
p = NS), angiotensin-converting enzyme inhibitors
(36% vs. 34% group 2, p = NS), and statins (42% vs.
40% group 2, p = NS).
Long-term follow-up
There were no significant differences between groups
regarding MACE incidence during hospitalization.
Interestingly, at long-term follow-up, the rates of
MACE were significantly higher in PlA2 group com-
pared to PlA1 (43.5% vs 25.8%, p 0.018). In particular,
patients with PlA2 allele showed a significant increased
rate of cardiac death (14.6% vs 5.3%, p = 0.025), AMI
(12% vs 4.5%, p = 0.043) and new myocardial revascu-
larization (34.8% vs 17.7%, p = 0.010). Accordingly, the
Kaplan-Meier analysis for event free survival in
patients harboring the PlA2 allele (Figure 1) showed
worse long-term outcome for these patients (p =
0.015). Cox regression analysis identified the presence
of PlA2 allele as an independent predictor for cardiac
death (OR: 9.594, 95% CI: 2.6 to 35.3, p = 0.002) and
overall MACE (OR: 1.973, 95% CI: 1.039 to 3.747, p =
0.036). There were no interactions noted for this rela-
tionship when considering age, sex, risk factors for
CAD, multivessel disease, previous myocardial revascu-
larization, number of treated lesions, and basal left
ventricular ejection fraction.
Effect of PlA2 polymorphism on cerebrovascular events in
hypertensive patients
To analyze in a different population the impact of this
polymorphism on atherothrombotic events we analyzed
the impact of PlA2 in hypertensive patients with history
of cerebrovascular events according to the level of cere-
bral damage (TIA or stroke). The characteristics of
these patients are depicted in table 4. Both the TIA and
stroke groups presented with an elevated cardiovascular
risk due to the presence of many risk factors which dis-
tribution did not differ between the two groups. Inter-
estingly, PlA2 allele was significantly more represented
among patients with stroke than patients with TIA
(stroke:46.4%; TIA:17.4%; p = 0.01). This polymorphism
indeed increased the risk of stroke in this high risk
population (OR: 4.1, 95% CI: 1.63-12.4, p = 0.02) over
TIA. Finally, a multiple regression analysis corrected by
common risk factors for cerebrovascular events, showed
that PlA2 allele as an independent risk factor for stroke
(B:-1.39; Wald: 7.15; p = 0.001).
Discussion
The main finding of this study is the relationship
between the PlA2 gene variant and the incidence of
major adverse cardiovascular events in patients harbour-
ing the PlA2 gene polymorphism. Indeed, in patients
with CAD undergoing PCI we found that the presence of
PlA2 allele associated with a significantly worse prognosis
with a higher incidence of cardiac death, AMI, and new
myocardial revascularization. Moreover, in an indepen-
dent population of hypertensive patients with large vessel
atherosclerosis and previous cerebrovascular events,
patients harbouring the PlA2 gene polymorphism
Table 3 Angiographic characteristics of CAD patients
Variable PlA1
(n = 300)
PlA2
(n = 100)
p Value
Coronary artery disease (%)
LAD 61.9 50 0.27
Cx 33.6 29 0.37
Dx 45 50 0.30
Multivessel Disease (%) 28 30 0.49
Lesion type, B2/C (%) 78 85 0.55
BMS (%) 74 66 0.56
DES (%) 26 34 0.57
TIMI 3 post PCI (%) 97.5 98 0.89
cTFC post (mean ± SD) 15.10 ± 6 14.25 ± 8 0.76
Lesion length (mm) 15.54 ± 6.59 16.48 ± 8.74 0.13
Preprocedural stenosis (%) 86.55 ± 10.19 85.05 ± 11.48 0.11
Stent/patient (n) 1.08 ± 0.32 1.07 ± 0.26 0.74
BMS: Bare metal stent, Cx: Left circumflex coronary artery, DES: Drug eluting
stent, Dx: Right coronary artery, LAD: Left anterior descending coronary artery.
Figure 1 Observed event free survival curve at follow up:
Patients with coronary artery disease harbouring the PlA2 allele of
the GP III a gene (group 2) had a higher incidence of MACE with
reduced event free follow up time as indicated by the Kaplan Meier
analysis.
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presented with a significantly higher incidence of stroke
over TIA. Taken together these data suggest an effect for
the PlA2 gene polymorphism in the development of
more severe thrombotic complications in high risk
patients.
Since the original report from Weiss et al. [8] indicat-
ing PlA2 polymorphism as a risk factor for myocardial
infarction or unstable angina, several studies have investi-
gated this polymorphism in the effort to discover a novel
thrombogenic risk factor but to date results have been
inconclusive and often controversial [8,11,22]. The incon-
sistence of findings in literature can be mostly attributed
to differences in the design as well as to the choice of the
control group and the endpoint of the studies. Moreover,
studies differ in the variation of environmental factors
and ethnicity, present biases in the selection of patients
and controls and often aim to different clinical endpoints.
Since atherosclerosis is a multifactorial disease, it would
be too simplistic to explain interindividual variations
based on genetic inheritance alone. Indeed several chal-
lenges exist in identifying the genetic determinants of
such a complex disease including genetic heterogeneity,
gene-gene and gene-environment interactions [12].
Furthermore, interaction of multiple genes that are in
linkage disequilibrium and simultaneous studies of sev-
eral genes may reveal associations that at present seem to
be weak. Nevertheless, such approaches are costly, and
impose the use of large populations and heavy statistic
modeling in order to carefully peruse small impact of sin-
gle gene variants on multifactorial disease [12]. There is
still room for candidate gene association study that can
be performed in relatively small populations, that are
carefully characterized and selected for homogeneity
[12]. We also have recently underlined the need for accu-
rately selection of patients in association studies in order
to identify the populations in which single gene poly-
morphisms may be more determinant in complex pheno-
types such as atherosclerosis [20,21]. Therefore, since
platelets play a major role in the development of
atherosclerotic thrombosis and acute ischemic events, we
investigated the role of the PlA2 gene polymorphism in
higher risk populations such as patients with severe CAD
requiring mechanical revascularization and hypertensive
patients with previous cerebrovascular events. Interest-
ingly, in the CAD population, we observed that the pre-
sence of PlA2 patients was associated with a 3 times
higher risk of death or 2.8 increased risk of AMI. Note-
worthy, patients harbouring the PlA2 allele presented an
higher risk of needing new revascularization at follow up
with 50% of patients undergoing new PCI for the occur-
rence of a new myocardial infarction. This is consistent
with data by Kastrati et al [23] reporting a higher risk of
restenosis after coronary stent placement in these
patients. Moreover, in an independent population of
hypertensive patients with cerebrovascular events, the
presence of the PlA2 allele was associated with a 4.1
higher risk to develop stroke rather than TIA. Thus,
these data suggest that, in a high risk clinical scenario
represented by patients with a greater prevalence of
atherothrombotic risk factors, the presence of PlA2 is
associated with a more aggressive disease leading to an
higher incidence of major ischemic events and to an
unfavourable outcome. Our results only apparently differ
from the finding observed in a subgroup analysis of the
Physicians’ health study (PHS) [24] by Ridker et al. [25]
which prospectively studied the risk associated with the
PlA2 polymorphism for myocardial infarction, stroke or
venous thromboses and reported no associations between
PlA2 polymorphism and the relative risk to develop any
cardiac or cerebro-vascular event. Indeed, as already
remarked by previous studies [26,27], the PHS was con-
ducted in a very healthy population, with an event rate 4
times less than general population, and therefore with a
very low risk of cardiovascular events. Also, our analysis
focused on the outcome and the incidence of MACE in
patients that already had a clinical manifestation of the
disease, while the PHS aimed to the occurrence of the
first event.
Table 4 Characteristics of hypertensive patients
Variable Hypertensives with TIA (n = 46) Hypertensives with stroke (n = 28) P value
Age (years) 62.06 ± 1.63 61.1 ± 2.60 0.77
Male sex (%) 54.3 71.4 0.15
Diabetes (%) 9.7 10.6 0.88
Smoking (%) 55.3 58.1 0.75
Dyslipidemia (%) 51.1 51.6 0.95
SBP (mmHg) 150.08 ± 3.23 147.5 ± 2.88 0.42
DBP (mmHg) 87.94 ± 1.78 88.83 ± 2.16 0.97
LVMI (g/m2) 127.09 ± 3.64 127.82 ± 2.68 0.98
DBP: Diastolic blood pressure
LVMI: Left Ventricle Mass Index
SBP: Systolic blood pressure
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Limitations of our study include those inherent to any
prospective but observational study. Moreover, since this
is an association study, we cannot rule out the presence
of a possible linkage disequilibrium with other neighbor-
ing genes that might explain the significant association
with atherosclerotic phenotype or adverse prognosis.
The study was conducted in patients with severe CAD
undergoing PCI while the replication study was per-
formed in hypertensive patients with previous cerebro-
vascular events; therefore, our findings need to be
confirmed in further larger patient populations. Never-
theless, recent studies [20,21] underlines the need for
selection of patients in association studies in order to
identify the populations in which single gene poly-
morphisms may be more determinant in complex phe-
notypes such as CAD.
Conclusions and clinical implications
Our study suggests that the PlA2 polymorphism is asso-
ciated with a more aggressive atherothrombotic disease
and adversely affects the prognosis in these high risk
patients. Indeed, in patients with severe CAD under-
going PCI the presence of PlA2 allele is associated with
increased risk of death, myocardial infarction and new
myocardial revascularization. Moreover, high risk hyper-
tension patients harbouring the PlA2 allele show an
increased risk to develop severe cerebral damage. There-
fore considering the atherothrombotic disease, the PlA2
genotype could be useful to physicians in targeting
antithrombotic strategies and therapeutic options. Since
atherosclerosis is a multifactorial disease, future studies
on interactions between environmental factors, common
cardiovascular risk factors and platelet associated genetic
determinants are warranted.
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Advanced algorithms can lead to electrocardiographic misinterpretations
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We observed a patient with syncope, who implanted a pacemaker with advanced algorithms such as “atrial-tachy response” and “dynamic
atrio-ventricular delay”. After one year, conventional ECG Holter showed pacemaker malfunction, wrongly attributed to exposure to
electromagnetic field. In fact, telemetry revealed an inappropriate programming and solved our case. Holter monitoring is commonly
performed in the evaluation of pacemaker malfunction, albeit it remains a quite shallow diagnostic method especially to detect electro-
magnetic interferences. New algorithms seem important, but it is reasonable to obtain more suitable analytical tools, too.
© 2008 Elsevier Ireland Ltd. All rights reserved.Keywords: Pacemaker malfunction; Holter monitoring; Electromagnetism; Atrial-tachy response; Atrio-ventricular delay1. Introduction
It is common knowledge that the presence of electro-
magnetic interferences is involved in a wide range of devices
dysfunction [1–3]. Specific settings of pacemaker (PM) are
required in order to reduce interference. However, the
interference is identifiable only by endocardial signal (EGM)
tracing with a typical morphology that could be lacking
when the interference is present exclusively in the electronic
circuit. Moreover, PM malfunction could be present only
when the subject is exposed to electromagnetic field. New
generation algorithms offer tailored program settings, albeit
both devices' reduced memory and few number of telemetric
controls often require a traditional 24 h ECG Holter
recording system [4] at follow-up.⁎ Corresponding author. Department of Clinical Medicine, Cardiovascular
and Immunologic Sciences, Via Sergio Pansini, 5-Ed. 2; 80131 Naples, Italy.
Tel./fax: +39 081 7463075.
E-mail address: gaetanosantulli@libero.it (C. D'Ascia).
1 Postal Address: Dipartimento di Medicina Clinica, Scienze Cardiovas-
colari ed Immunologiche, Università degli Studi di Napoli “Federico II”. Via
Pansini no. 5, Ed. 2; 80131 Naples, Italy.
0167-5273/$ - see front matter © 2008 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.ijcard.2008.11.1442. Clinical case
A70 years oldwomanwas admitted to our hospital because
of a syncope. The ECG revealed a second degree type 2
atrioventricular block. The woman was not affected by docu-
mented hypertension, coronary artery disease or diabetes
evaluated by standard methods. Subsequently, a dual chamber
device “Discovery 2” DDD Guidant with bipolar endocardial
catheters (all parameters are depicted in Table 1) was im-
planted [5]. No adverse events took place during surgical
intervention or hospitalization. In order to assess device
function during daily activities, the patient underwent Holter
monitoring, performed 1 year after implantation.
The patient lived in a house placed near a mobile phone
radio antenna and consequently probably subjected to an
intensive electromagnetic field. This fact was not known at
the moment of implantation.
Holter analysis showed both atrial tachyarrhythmia and
atrial fibrillation. In the first case, an inappropriate ventric-
ular tracking not stopped by atrial-tachy response (ATR)
algorithm occurred (Fig. 1A); in the second case, an atrial
undersensing determined a useless DDD stimulation with
frequent fusions (Fig. 1B).
Table 1
Setting parameters of pacemaker device.
Mode: DDD
Electro catheter configuration: bipolar
Ventricular and atrial sensing and output: standard
Ventricular Atrial
Impedance: 800 Ω Impedance: 796 Ω
Amplitude: 7 mV Amplitude: 3.1 mV
Threshold: 0.8 V at 0.5 ms; 3 mV at
0.5 ms
Threshold: 0.6 Vat 0.5 ms; 2.6 mVat
0.5 ms
Lower rate: 60 bpm
Frequency hysteresis: OFF
AV delay: DYNAMIC (80 ms at max rate–150 ms at minimum rate)
Maximum tracking rate (MTR): 120 bpm
Atrial-tachy response (ATR): on
Fig. 1. (A) Missed intervention of ATR algorithm: AF triggered in Ventricle.
(B) Inadequate DDD stimulation due to atrial undersensing. (C) Dynamic
AV delay previous-cycle-dependent.
e35S.L. D'Ascia et al. / International Journal of Cardiology 141 (2010) e34–e36Besides, the atrio-ventricular delay (AVD) programmed in
DYNAMIC mode, was shorter than the expected one. We
highlight that the DYNAMIC AVD provides a physiologic
replay of the cardiac frequency variation, so that the AVDused
at 60 bpm (lower ratio) is 150 ms (high), while at 100 bpm the
AVD is 80 ms (low), with a linear correlation for the inter-
mediate frequencies. Anyway, Holter documented cardiac
cycles at 60 bpm in which AVD was shorter than expected.
3. Discussion
How to explain PM malfunction? The first hypothesis
was an abnormality linked to patient's exposure to electro-
magnetic interferences [1,4–6]. Pacing, sensing and impe-
dances tested by telemetry were found to be in normal range
(Table 1), with no matching with the observed abnormalities.
The second hypothesis was that the device had been
reprogrammed by other physicians in another medical center.
Indeed, the patient referred about several previous cardiologic
visits, but she was not informed about re-programming and did
not exhibit any documentation. Our interpretation of Holter
monitoring [4,6] was that PM had been re-programmed in the
ATR OFF mode. This fact was then confirmed by telemetric
interrogation.
About the variability ofAVD,we saw that this phenomenon
used to happen always after a cycle preceding the maximum
tracking rate (MTR), most likely a premature atrial contraction
triggered to the ventricle. The presence of this dependence
from the preceding cycle has been confirmed by device
producers. Analysis of a particular Holter strip confirmed our
theory: in fact, ECG showed a cycle at MTR followed by
stimulation at lower rate. The first beat at lower rate is at AVD
of 80 ms, while the subsequent beats are at AVD of 150 ms,
related to the previous long cycle (Fig. 1C).
4. Conclusions
The present case-report highlights that PM settings have
both electrophysiological and clinical relevance [5]. ATR andDYNAMIC-AVD are advanced algorithms of a considerable
clinical impact albeit an adequate knowledge is the funda-
mental premise for their use. The risk of electromagnetic
interference, permanent or intermittent, needs to be checked in
any case, possibly in the same setting where the interference
seems to be present [5,6]. Nevertheless, because of the
e36 S.L. D'Ascia et al. / International Journal of Cardiology 141 (2010) e34–e36underlined problem, it should be desirable to plan an increased
number of telemetric controls, also using on-line systems.
From a technical point of view, we evidence that these devices
don't keep either the date of the last programming change or
the operator that reprogrammed the device, but there is only the
most recent interrogation date. Therefore, it would be pref-
erable to have in all devices a list of programming changes,
with the possibility to identify any operator. In this way,
interpretation of PM behavior could become easier, enabling a
reliable assessment of the appropriateness of special pacing
algorithms, in order to improve the detection of PM dys-
functions due to inappropriate programming [4]. In fact, with
increasing automation, analysis of the ambulatory tracing
becomes very difficult without access to the internal operation
of the PM.
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Intracardiac Injection of AdGRK5-NT Reduces Left
Ventricular Hypertrophy by Inhibiting NF-B–Dependent
Hypertrophic Gene Expression
Daniela Sorriento, Gaetano Santulli, Anna Fusco, Antonio Anastasio, Bruno Trimarco, Guido Iaccarino
Abstract—Several studies underline the role of the transcription factor NF-B in the development of left cardiac
hypertrophy (LVH). We have demonstrated recently that the RGS homology domain within the amino terminus of
GRK5 (GRK5-NT) is able to inhibit NF-B transcription activity and its associated phenotypes. The aim of this study
was to evaluate the ability of GRK5-NT to regulate LVH through the inhibition of NF-B both in vitro and in vivo. In
cardiomyoblasts, GRK5-NT inhibits phenylephrine-induced transcription of both NF-B and atrial natriuretic factor
promoters, assessed by luciferase assay, thus confirming a role for this protein in the regulation of cardiomyocyte
hypertrophy. In vivo, we explored 2 rat models of LVH, the spontaneously hypertensive rat and the normotensive Wistar
Kyoto rat exposed to chronic administration of phenylephrine. Intracardiac injection of an adenovirus encoding for
GRK5-NT reduces cardiac mass in spontaneously hypertensive rats and prevents the development of phenylephrine-
induced LVH in Wistar Kyoto rats. This associates with inhibition of NF-B signaling (assessed by NF-B levels),
transcriptional activity and phenotypes (fibrosis and apoptosis). Such phenomenon is independent from hemodynamic
changes, because adenovirus encoding for GRK5-NT did not reduce blood pressure levels in spontaneously hypertensive
rats or in Wistar Kyoto rats. In conclusion, our study supports the regulation of LVH based on the GRK5-NT inhibition
of the NF-B transduction signaling. (Hypertension. 2010;56:696-704.)
Key Words: cardiac hypertrophy  intracardiac injection  spontaneously hypertensive rats
 NF-B  transcription factors
NF-B is an ubiquitously expressed transcription factorthat modulates the expression of genes involved in the
regulation of cell functions, such as survival, apoptosis,
growth, division, innate immunity, differentiation, and cellu-
lar responses to stress, hypoxia, and ischemia.1–4 The classic
cellular model in which this factor is studied is the immune
system for its central role in cytokine production.4,5 It has
been reported recently that NF-B is relevant in the devel-
opment of left ventricular hypertrophy (LVH) and remodel-
ing through mechanisms independent from inflammation.
NF-B mediates hypertrophic growth of cardiomyocytes in
response to G protein–coupled receptor agonists, including
norepinephrine, endothelin 1, and angiotensin II.6,7 Also,
NF-B inhibition attenuates LVH in different animal models
of disease.8,9 This evidence suggests that NF-B blockade
may be an effective strategy to inhibit LVH and remodeling.
The family of G protein–coupled receptor kinases (GRKs)
and, in particular GRK2 and GRK5, possesses the ability to
bind both NF-B and its inhibitor, IB.10,11 In particular,
GRK5, by means of its RGS homology (RH) domain within
the amino terminus, interacts with IB leading to the
stabilization and accumulation of the IB/NF-B complex
in the nucleus and, consequently, to the inhibition of NF-B
transcriptional activity.11 This feature of the RH domain of
GRK5 leads to the hypothesis that the use of peptides that are
designed and engineered on this sequence of the kinase may
induce NF-B inhibition. When applied to cardiac myocytes,
this strategy could efficiently reduce hypertrophic responses. To
test this hypothesis, we evaluated whether an adenovirus that
encodes for the RH domain within the amino terminal of GRK5
(AdGRK5-NT) is able to regulate hypertrophic responses of the
cardiac myocyte, both in vitro and in vivo, by means of its ability
to inhibit NF-B transcription activity.
Methods
Cell Culture
A cell line of cardiac myoblasts (H9C2) was maintained in culture in
DMEM supplemented with 10% FBS at 37°C in 95% air-5% CO2.
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Luciferase Assay
Cells were transfected with plasmid expression vectors containing
the luciferase reporter gene linked to 5 repeats of an NF-B binding
site (B-Luc) or atrial natriuretic factor (ANF) promoter and infected
with 1010 pfu/mL of an adenovirus encoding the amino-terminal
region of GRK5 (AdGRK5-NT) that comprises the RH domain.
AdGRK5-NT was a kind gift of Prof Walter J. Koch (Thomas
Jefferson University).12 Transient transfection was performed using
the Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instruction. Cells were stimulated with the alpha 1 adrenergic
receptor agonist phenylephrine (PE; 107 M) for 24 hours. Lysates
were analyzed using the luciferase assay system with reporter lysis
buffer from Promega and measured by liquid scintillation. Luciferase
activity was normalized against the coexpressed -galactosidase
activity to overcome variations in transfection efficiency between
samples.
In Vivo Study
Experiments were carried out in accordance with the Federico II
University Ethical committee on 12-week–old normotensive Wistar
Kyoto (WKY; n13, subdivided as follows: untreated n4, PE
n3, PEAdLac-Z n3, and PEAdGRK5-NT n3) and sponta-
neously hypertensive (SHR; n12, subdivided as follows: untreated
n3, AdLac-Z n3, and AdGRK5-NT n6) male rats (Charles
River, Calco, LC, Italy), which had access to water and food ad
libitum. The animals were anesthetized by vaporized isoflurane
(4%). After the induction of anesthesia, rats were orotracheally
intubated, the inhaled concentration of isoflurane was reduced to
1.8%, and lungs were mechanically ventilated (New England Med-
ical Instruments Scientific, Inc) as described previously.13 The chest
was opened under sterile conditions through a right parasternal
minithoracotomy to expose the heart. Then, we performed 4 injec-
tions (50 L each) of AdGRK5-NT (1010 pfu/mL) or AdLac-Z (1010
pfu/mL), as control, into the cardiac wall (anterior, lateral, posterior,
and apical). Finally, the chest wall was quickly closed in layers using
3-0 silk suture, and animals were observed and monitored until
recovery. In the WKY group, we implanted under the skin a
miniosmotic pump (ALZET 2004) releasing PE (100 mg/kg).14
Echocardiography
Transthoracic echocardiography was performed at days 0, 7, 14, and
28 after surgery using a dedicated small-animal high-resolution
imaging system (VeVo 770, Visualsonics, Inc) equipped with a
17.5-MHz transducer (RMV-716). The rats were anesthetized by
isoflurane (4%) inhalation and maintained by mask ventilation
(isoflurane 2%). The chest was shaved with a depilatory cream
(Veet, Reckitt-Benckiser).15 Left ventricular (LV) end-diastolic and
LV end-systolic diameters (LVEDD and LVESD, respectively) were
measured at the level of the papillary muscles from the parasternal
short-axis view as recommended.16 Intraventricular septal (IVS) and
LV posterior wall thickness (PW) were measured at end diastole. LV
fractional shortening (LVFS) was calculated as follows: LVFS
(LVEDDLVESD)/LVEDD100. LV ejection fraction (LVEF)
was calculated using a built-in software for the VeVo770.13 LV mass
(LVM) was calculated according to the following formula, representing
the M-mode cubic method: LVM1.05[(IVSLVEDDLVPW)3
(LVEDD)3]; LVM was corrected by body weight. All of the measure-
ments were averaged on 5 consecutive cardiac cycles and analyzed by
2 experienced investigators blinded to treatment (G.S. and A.A.).
Blood Pressure Measurement and Evaluation of
Cardiac Performance
Blood pressure (BP) was measured as described previously,17,18 and
the record of both systolic (SBP) and diastolic (DBP) BPs was taken
using a pressure transducer catheter (Mikro-Tip, Millar Instruments,
Inc). The catheters already placed in the ascending aorta were then
advanced further into LV to record the maximal and minimal first
derivatives of pressure over time (dP/dt maximum and dP/dt mini-
mum), as indices of global cardiac contractility and relaxation.19 To
include the effects of differences of SBP on cardiac contractility, we
also corrected dP/dt maximum by peak systolic pressure (dP/dt
maximum/SBP), as described previously.20 These maneuvers were
performed at week 4 after surgery.
Histology
Four weeks after AdGRK5-NT or AdLac-Z intracardiac injection,
the hearts were immersion fixed in 10% buffered paraformaldehyde.
The tissues were embedded in paraffin, cut at 5 m, and processed.
For Masson’s trichrome staining of collagen fibers, slides were
stained with Weigert hematoxylin (Sigma-Aldrich) for 10 minutes,
rinsed in PBS (Invitrogen), and then stained with Biebrich scarlet-
acid fuchsin (Sigma-Aldrich) for 5 minutes. Slides were rinsed in
PBS and stained with phosphomolybdic/phosphotungstic acid solu-
tion (Sigma-Aldrich) for 5 minutes, then stained with light green
(Sigma-Aldrich) for 5 minutes. Slides were rinsed in distilled water,
dehydrated with 95% and absolute alcohol, and a coverslip was
placed. To evaluate adenovirus expression, paraffined sections were
analyzed directly at fluorescent microscopy or the green fluorescent
protein (GFP) tag was evaluated by immunohistochemistry, as
previously described.12 For the analysis of cardiomyocytes size,
Masson’s trichrome staining sections were used.21 The areas
(squared micrometers) of 100 cardiac myocytes per heart were
measured with the public domain Java image processing program
ImageJ.22
Western Blot
The experiments were performed as described previously.11 The
antibodies anti-IB, actin, and histone 3 were from Santa Cruz
Biotechnology, Inc; anticleaved caspase 3, NF-B, p-NFB (p65),
and phospho-cAMP responsive element binding (p-CREB) antibod-
ies were from Cell Signaling Technology. Densitometric analysis
was performed using Image Quant software (Molecular Dynamics,
Inc). Blots from 3 independent experiments were quantified and
corrected for appropriate loading control. Densitometric analysis was
adapted to fit a graph scale between 0 and 10 000 arbitrary
densitometric units (ADUs). Results are reported as meanSEM.
Real-Time PCR
Total RNA was isolated using TRIzol reagent (Invitrogen), and
cDNA was synthesized by means of a Thermo-Script RT-PCR
System (Invitrogen), following the manufacturer’s instruction. After
reverse transcription, real-time quantitative PCR was performed with
the SYBR Green real-time PCR master mix kit (Applied Biosystems)
and quantified by built-in SYBR Green Analysis (Applied Bio-
system) on a StepOne instrument (Applied Biosystem). Primers
for gene analysis were as follows: ANF: forward 5cgtgccccgac-
ccacgccagcatgggctcc3, reverse 5ggctccgagggccagcgagcagagc-
cctca3; tumor necrosis factor alpha (TNF-): forward 5ccag-
gagaaagtcagcctcct3, reverse 5cgataaaggggtcagagtaat3; and 18S:
forward 5gtaacccgttgaacccatt3, reverse 5ccatccaatcggtagtagcg3.
Electrophoretic Mobility-Shift Assay
Nuclear proteins were isolated from heart samples, and NF-B
binding activity was examined by electrophoretic mobility-shift
assay, as described previously.11 For the competition, assay nuclear
extracts were incubated with a 50-fold excess of unlabeled oligos for
20 minutes before adding the labeled oligo. Electrophoretic mobility-
shift assay for organic cation transporter 1 (OCT-1) binding was
performed as a loading control (5tgtcgaatgcaaatcctctcctt3).
Statistical Analysis
For each parameter we compared the values observed in the
AdGRK5-NT–treated SHRs (n6) with a control SHR group, which
was composed of untreated (n3) and AdLacZ-treated (n3) SHRs.
This was possible because within these groups there was no
statistical difference. For the same reason, in WKY rats we compared
the effect of PE between AdGRK5-NT–treated rats (n3) with a
control WKY PE group, composed of PE-treated (n3) and PE/
AdLac-Z-treated (n3) rats. Both SHRs and PE-treated WKY rats
were compared with untreated WKY rats (n4). All values are
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presented as meanSEM. Two-way ANOVA was performed to
compare the different parameters between the different groups. A P
value 0.05 was considered to be significant. Statistics were
computed with GraphPad Prism version 5.01 (GraphPad Software).
Results
In Vitro Study
We evaluated in vitro the effect of GRK5-NT, comprising the
RH domain, on the regulation of NF-B signaling and
transcriptional activity. In H9C2 cardiomyoblasts, AdGRK5-NT
caused an increase of total IB levels (Figure 1A), analyzed
by Western blot, as described previously in other cellular
types.11,12 The effect of GRK5-NT on NF-B activity was
evaluated by luciferase assay. PE increased NF-B transcrip-
tion activity, and the overexpression of GRK5-NT reduced
such effect both in basal conditions and after PE stimulation
(Figure 1B), suggesting that NF-B is induced by hypertro-
phic stimuli in cardiac cells and that GRK5-NT is able to
inhibit such phenomenon. To assess the ability of GRK5-NT
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Figure 1. The effect of AdGRK5-NT on hypertrophy in vitro. A, In H9C2 cardiomyoblasts, GRK5-NT overexpression was induced by
adenovirus-mediated gene transfer (AdGRK5-NT), and total IB levels were analyzed by Western blot. GRK5-NT causes an increase
of IB levels. AdLac-Z and noninfected cells were used as controls. The graph shows densitometric analysis after normalization
according to Methods from 3 independent experiments expressed in ADUs; *P0.05 vs control. B, H9C2s were infected with
AdGRK5-NT and stimulated with PE. NF-B activity was evaluated by luciferase assay and normalized according to the Methods sec-
tion. PE increases NF-B activity, and AdGRK5-NT inhibits this activity both in basal condition and after PE stimulation (*P0.05 vs
basal, #P0.05 vs control). Results are expressed as meanSEM from 5 independent experiments. C, H9C2s were infected with
AdGRK5-NT and stimulated with PE. ANF promoter activity was evaluated by luciferase assay and normalized as indicated in the Meth-
ods section. PE induces ANF promoter activity. and AdGRK5-NT inhibits such response (*P0.05 vs Basal, #P0.05 vs Control). Results are
expressed as meanSEM from 5 independent experiments. D, H9C2s were transfected with either GRK5-NT or IB and stimulated with PE.
Control cells were transfected with an empty plasmid. p65 and CREB phosphorylations were evaluated by Western blot. Overexpression of
either GRK5-NT or IB inhibits NF-B but not CREB activation. Actin was used as loading control. The graph shows the densitometric analy-
sis after normalization according to methods of 3 independent experiments (*P0.05 vs basal, #P0.05 vs PE).
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to modulate hypertrophy in vitro, we performed an ANF
promoter-driven luciferase assay. Figure 1C shows that
GRK5-NT overexpression inhibits PE-induced ANF pro-
moter activity. These in vitro data suggest that GRK5-NT can
regulate the expression of hypertrophic genes by modulating
NF-B activity. To evaluate whether GRK5-NT effect is
selective for NF-B signaling, we assessed its ability to
regulate an NF-B–independent transcription factor, CREB,
by Western blot. We overexpressed in cardiomyoblasts
GRK5-NT or the main inhibitor of NF-B, IB, by transient
transfection. Control cells were transfected with an empty
plasmid. The overexpression of either GRK5-NT or IB
inhibited NF-B phosphorylation but did not affect CREB
activation both in basal condition and after stimulation with
PE (Figure 1D). These results indicate that GRK5-NT selec-
tively inhibits NF-B signaling and does not affect the
signaling of other transcription factors.
In Vivo Study in SHRs
Echocardiographic Parameters
To confirm the role of GRK5-NT in the regulation of LVH,
we analyzed in vivo the SHR, an animal model of
hypertension-induced LVH. AdGRK5-NT or AdLac-Z was
injected in the cardiac wall of the SHR. LVH was evaluated
weekly for 4 weeks by echocardiography. AdGRK5-NT
treatment efficiently reduced IVS and PW thickness (Figure
2A), LVM/body weight (BW; Figure 2B) and the heart
weight (HW)/BW ratio (Figure 2C). Cardiac function as-
sessed by ultrasound changed accordingly. Indeed, LV ejec-
tion fraction and LVFS, which are depressed in the SHR
control group with respect to the WKY rat, returned to the
levels of normotensive rats in the AdGRK5-NT–treated
SHRs (Figure 2D). To rule out changes in hemodynamics as
a possible mechanism of regulation of LVH, we measured BP
in rats at 4 weeks. BP was slightly but significantly increased
in AdGRK5-NT–treated rats with respect to controls (Figure
2E). This phenomenon might be attributed to an amelioration
of LV dysfunction observed by cardiac ultrasounds and also
Table. Cardiac Contractility Assessed In Vivo
Group
dP/dt
Maximum
dP/dt
Minimum
dP/dt
Maximum/SBP
WKY control (n4) 7989486 6728452 59.359.84
SHR control (n6) 4187296* 4761398* 24.025.08*
SHR AdGRK5-NT (n6) 7543683† 6754554† 41.878.13†
Cardiac contractility was assessed by intra-LV positioning through the
carotid artery of a pressure transducer catheter. WKY control indicates
untreated WKY rats; SHR control, SHR control group; SHR AdGRK5-NT, SHR
hearts infected with the adenovirus encoding for the amino-terminus region of
GRK5. Data are meanSEM.
*P0.05 vs WKY.
†P0.05 vs SHR control.
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Figure 2. The effect of intracardiac injection of AdGRK5-NT in vivo in SHRs. A through C, Cardiac hypertrophy was evaluated by echo-
cardiography in 4 untreated WKY rats, 6 AdGRK5-NT SHRs, and 6 control SHRs, as indicated in the Methods section. Four weeks
after injection, a reduction of IVS and PW (A), LVM/BW ratio (B), and HW/BW ratio (C) was found in AdGRK5-NT versus SHR control
hearts (*P0.05 vs WKY; #P0.05 vs SHR control). D, Interestingly, LVFS and LVEF were also ameliorated in SHRs by AdGRK5-NT as
compared with SHR control (*P0.05 vs WKY; #P0.05 vs SHR control). E, To exclude the involvement of BP values in GRK5-NT–de-
pendent regulation of cardiac hypertrophy, we assessed in treated rats SBP and DBP values. AdGRK5-NT–treated rats had higher SBP
and DBP than SHR controls (*P0.05 vs WKY; #P0.05 vs SHR Control). F, The ability of AdGRK5-NT to reduce LVH was further con-
firmed on myocardial samples by a reduction of ANF and TNF- gene expression evaluated by real-time PCR. The values found in
AdGRK5-NT–treated LVs were corrected by those found in the SHR control and expressed as the percentage of SHR control at 1 week
and 4 weeks from starting treatment (*P0.05 vs 1 week). Results are expressed as meanSEM from 3 to 5 independent experiments.
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Figure 3. Evaluation of AdGRK5-NT treatment on NF-B signaling. A, AdGRK5-NT expression in treated hearts was evaluated by GFP
expression by both immunohistochemistry (IHC) and fluorescence (F) 1 week and 4 weeks from injection. In the top lane, IHC shows
that GFP is homogeneously diffused in the whole heart at 1 week, and its expression is decreased but still present at 4 weeks from
intracardiac injection. In the middle lane, panels show an upper magnification of IHC. In the bottom lane, panels show that also by fluo-
rescence the distribution of the GFP localizes to the cardiac myocytes after 1 week and 4 weeks. Images are representative of 3 inde-
pendent experiments. B, Paraffin-embedded sections of control and treated hearts were stained by trichrome staining to evaluate colla-
gen fibers. AdGRK5-NT treatment reduces fibrosis compared with SHR control. Cardiomyocytes size was measured by means of
ImageJ software, and means of areas are showed in the histogram (*P0.05 vs SHR control). Images are representative of 3 indepen-
dent experiments. C, In LV whole extracts, IB and cleaved caspase 3 levels were evaluated by Western blot. Four weeks after injec-
tion, AdGRK5-NT treatment increases the levels of IB and reduces apoptosis with respect to controls (*P0.05 vs SHR control).
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confirmed by invasive hemodynamics, which showed the
hastening of both systolic and diastolic performance: indeed,
both positive and negative dP/dt were ameliorated by
AdGRK5-NT (Table). Biochemical analysis confirmed the
reduction of LVH. We evaluated the expression of the
hypertrophy marker gene ANF and the inflammation marker
gene TNF- by means of real-time PCR in rat hearts. After 1
week, ANF expression was significantly reduced in
AdGRK5-NT–treated hearts, and after 4 weeks a further
reduction was observed (Figure 2F). A similar pattern is
shown for the TNF- gene expression (Figure 2F).
Histological Analysis
At 1 or 4 weeks from injection, hearts were harvested, and
AdGRK5-NT expression was assessed by histological anal-
ysis. GRK5-NT was homogeneously expressed in the heart at
1 week and, although decreased, was still expressed at 4
weeks from injection as assessed by both immunohistochem-
istry and fluorescence analysis (Figure 3A). LVH caused by
chronic hypertension is accompanied by 2 key pathological
processes, myocyte hypertrophy, because of increased cell
size, and fibrosis. Thus, to confirm the inhibitory effect of
GRK5-NT on LVH, we analyzed cardiomyocyte size and
fibrosis by immunohistochemistry. Both myocyte size and
collagen fiber staining were reduced in AdGRK5-NT versus
SHR control hearts (Figure 3B).
NF-B Signaling
We have shown previously that GRK5-NT causes cellular
and nuclear accumulation of the negative regulator of NF-B
signaling, IB.11 To verify the ability of AdGRK5-NT to
induce the same phenomenon also in the hypertrophic SHR
heart, we analyzed IB levels both in whole and nuclear
extracts by Western blot. AdGRK5-NT increased cellular
(Figure 3C) and nuclear (Figure 3D) IB levels with respect
to the SHR control group. The regulation of apoptosis is an
event under the control of NF-B activity. Although NF-B
is commonly found to be cytoprotective, there are a number
of instances, depending on stimuli and cell context, where it
is proapoptotic. LVH is such an example.23 Thus, we evalu-
ated apoptosis in hypertrophic hearts by analyzing cleaved
caspase 3 levels. In agreement with the inhibition of NF-B,
we found that AdGRK5-NT reduced apoptosis in hypertro-
phic SHR hearts (Figure 3C). To demonstrate that IB
accumulation results in the inhibition of NF-B, we assessed
NF-B nuclear localization by Western blot. NF-B levels in
the nucleus were increased both in SHR control and
AdGRK5-NT hearts, but the activated form of NF-B (phos-
phorylated p65) was reduced only in the latter, suggesting
that NF-B accumulates in the nucleus with IB but cannot
activate gene transcription. To confirm such a result, we
evaluated NF-B transcriptional activity by electrophoretic
mobility-shift assay. NF-B activity was enhanced in hyper-
trophic SHR hearts with respect to nonhypertrophic WKY
rats. AdGRK5-NT, on the contrary, reduces NF-B activity at
1 week from starting treatment, and prolonged treatments
further decreased such activity (Figure 3E). To assess the
specificity of NF-B binding, a competition assay was
performed. The DNA binding of NF-B was reduced by
10-fold excess of unlabeled oligos, and it was completely
inhibited by 20-fold excess (Figure 3F).
In Vivo Study in WKY Rats
We then verified whether AdGRK5-NT was able to prevent
the development of LVH. To this aim, we chronically (14
days) injected PE in WKY rats infected previously with
AdGRK5-NT (n3) or AdLac-Z (n3) in the left ventricle.
As a control we used untreated WKY rats (n4). Cardiac
remodeling was evaluated by echocardiographic analysis
once a week for 2 weeks. AdGRK5-NT significantly pre-
vented the development of PE-induced LVH, because we
found a smaller increase of IVS (Figure 4A), LVM/BW
(Figure 4B), and HW/BW (Figure 4C). This finding is
associated with a reduction of ANF gene expression, evalu-
ated by real-time PCR (Figure 4D).
Discussion
In the present study we offer the compelling evidence that the
RH domain within GRK5-NT inhibits LVH in 2 animal
models of the disease. This effect is attributed to the sterical
inhibition of NF-B activity in the cardiac myocyte through
means of the stabilization of IB. Indeed, GRK5-NT con-
tains the kinase RH domain, which is sufficient for GRK5-NT
effects12 but lacks both the catalytic domain and the nuclear
localization sequence of GRK5. Thus, this mutant cannot
participate in the regulation of hypertrophy that depends on
GRK5-mediated phosphorylative events.24 Rather, we show
NF-B inhibition induced by IB accumulation in cardiac
myocytes, a mechanism demonstrated previously in other cell
types.11,12 In the in vivo study, we used a genetic model of
LVH, the SHR, in which LVH is sustained by high BP levels.
It has been described that the inhibition of NF-B reduces
LVH in SHRs in a BP-independent manner.25 Indeed, the
antihypertensive drug hydralazine has no effect on cardiac
mass or NF-B activity in hypertrophic SHRs.25 On the
contrary, the pharmacological inhibition of NF-B with
pyrrolidine dithiocarbamate or the treatment with an angio-
tensin-converting enzyme inhibitor (captopril) significantly
reduces heart size and inhibits NF-B activity.25 Our present
data are, therefore, in agreement with the literature, because
we found that GRK5-NT is able to inhibit NF-B activity
Figure 3 (Continued). Graph summarizes normalized ADUs from 3 independent experiments. D, In nuclear extracts, 4 weeks after
injection AdGRK5-NT causes accumulation of IB. NF-B levels in the nucleus are increased both in controls and treated hearts, but
the phosphorylated, active form of p65 is reduced in GRK5-NT–treated hearts (*P0.05 vs SHR control). Histone 3 (H3) was used as
loading control. Graph summarizes normalized ADUs from 3 independent experiments. E, NF-B activity was evaluated by electro-
phoretic mobility-shift assay in control and treated hearts. NF-B activity is enhanced in hypertrophic SHR hearts with respect to non-
hypertrophic WKY rats; GRK5-NT treatment reduces such activity in a time-dependent manner. Organic cation transporter 1 was used
as the loading control. Images are representative of 3 independent experiments. F, A competition assay was performed adding unla-
beled oligos. A 10-fold excess of unlabeled oligos reduced and a 20-fold excess completely inhibited binding of NF-B. Lane (Ln) 1,
empty; Ln 2, no unlabeled oligos; Ln 3, 10-fold excess of unlabeled oligos; Ln 4, 20-fold excess of unlabeled oligo. Images are repre-
sentative of 3 independent experiments.
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and, consequently, to reduce LVH without reducing BP
levels. Indeed, GRK5-NT effect on LVH in SHRs does not
associate with a reduction but rather causes a slight increase
of BP levels. Although we do not have a direct proof of it, we
believe that the increased BP is the result of the ameliorated
cardiac contractility, as shown by dP/dt maximum and LV
ejection fraction, which occurs without modification of total
peripheral resistance.26–28 Total peripheral resistances are
increased by the hypertensive status and are a hallmark of
SHRs, and our treatment, being localized in the heart, cannot
affect them. Therefore, increased systolic function in the
presence of unchanged total peripheral resistances, results in
increased systolic BP. In turn, the ameliorated cardiac con-
tractility can be the result of reduced cardiac fibrosis and
hastened diastolic dysfunction typical of the SHR.19,28 As a
consequence, GRK5-NT–induced inhibition of LVH does not
depend on systemic hemodynamics but rather is an effect of
myocyte biology and intracellular signal transduction. We
also performed a confirmatory in vivo study in a different
animal model, the WKY rats, in which LVH was induced
pharmacologically by means of chronic PE administration.
This model differs from the SHR because it is not genetically
determined, and the phenotype is acutely induced by treat-
ment. Also in this model, AdGRK5-NT is able to reduce the
development of LVH by inhibiting NF-B activity. Thus, our
data demonstrate that GRK5-NT exerts its effect on cardiac
LVH independently from the animal model and that NF-B
activation is an intrinsic determinant of the cardiac hypertro-
phic response. We also showed that GRK5-NT inhibition of
LVH is attributed to the inhibition of apoptosis and fibrosis
that characterize the hypertrophic phenotype. This could
appear in contrast with our previous data, when we demon-
strated that GRK5-NT–dependent inhibition of NFB causes
an increase of apoptosis both in endothelial and tumor
cells.11,12 In fact, NF-B has contradictory effects on apopto-
sis and cell survival that largely depend on cell type.29 In
particular, NF-B is antiapoptotic in tumor cells30 and pro-
apoptotic in cardiac cells.23 Therefore, the different reported
effects of GRK5-NT on apoptosis can be ascribed to differ-
ences in cell types.29
LVH is a complex event that depends on the activation of
different signaling pathways.31 Several mechanisms are in-
volved in this response, including cardiomyocyte stretching,
as well as circulating neurohormones, such as catechol-
amines, endothelin 1, angiotensin II, insulin and growth
factors, and cytokines released locally by the myocardial
cells.32–34 These, in turn, activate second messengers that
regulate nuclear transcription factors activity (NF-B, CREB,
NFAT, and GATA-4) modifying the expression of hypertro-
phic genes.35,36 Our data support the relevance of NF-B to
the hypertrophic phenotype. This further underlines the gen-
eral application of GRK5-NT treatment versus a transduction
signaling that is involved not only in LVH but also in other
physiological and pathological conditions in different tissues.
From our data, we cannot exclude the possibility that
GRK5-NT could have multiple cellular targets and that its
effect on LVH could also involve other signaling pathways.37
We, therefore, tested the effects of GRK5-NT on CREB, a
transcription factor activated by cAMP signaling that is
involved in the development of LVH by enhancing the
expression of pivotal genes for efficient oxidative capacity
and resistance to apoptosis.38 Because AdGRK5-NT does not
change on CREB activation, we can rule out that the effect on
NF-B is attributable to a nonspecific inhibition of nuclear
transcriptional activity. Rather, AdGRK5-NT is selective in
its inhibition of NF-B.
For the in vivo study, we used the intracardiac injection of
the adenovirus AdGRK5-NT. We opted for adenovirus-
mediated gene delivery to obtain GRK5-NT expression in the
heart, because the adenovirus homogenously diffuses
throughout the treated tissue, also far from directly injected
sites,39 and is maintained for as long as 30 days.40 One way
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Figure 4. The effect of AdGRK5-NT
treatment on PE-induced cardiac hyper-
trophy was evaluated in WKY rats. We
studied a group of WKY PEAdGRK5-
NT–treated rats (n3) and a group of
WKY PE-treated rats (n6), as indicated
in the Methods section. As control we
used untreated WKY (n4). After 2
weeks, AdGRK5-NT treatment causes a
reduction of IVS (A), LVM/BW ratio (B),
and HW/BW ratio (C). Accordingly, we
found a reduction of ANF gene expres-
sion evaluated by real-time PCR (D)
(*P0.05 vs WKY control; #P0.05 vs
WKY PE).
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of directly obtaining cardiac delivery is the intracoronary
way,13 but it causes high mortality and is not easily achiev-
able in small animals, such as the rat. Otherwise, the systemic
administration through the intravenous route does not guar-
antee a good expression of a protein in the heart, because, in
large part, the adenovirus targets other organs and tissues.
Moreover, systemic treatment could be toxic for animals. The
advantage of the intracardiac injection directly into the wall is
that this maneuver is less toxic for the whole body and leads
to a selective localization of the adenovirus throughout the
heart to obtain a specific overexpression of the encoded
protein in the cardiac tissue.
In conclusion, our study demonstrates the ability of
GRK5-NT to reduce myocardial NF-B activity and LVH.
Moreover, our data suggest the efficiency of such a mecha-
nism of regulation of LVH based on the inhibition of a
specific transduction signaling that is independent from BP
overload, the main stimulus for LVH.
Perspectives
Our data suggest NF-B as a target for LVH. This inhibition
could be used in combination with BP-lowering strategies to
better achieve the target of organ protection in hypertensive
states. Furthermore, it is possible that, in other conditions
with reduced cardiac performance, such as heart failure, it
may be useful to increase cardiac contractility and reduce
adverse remodeling. Further studies need to confirm this
hypothesis.
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